Toll-like receptors in the endangered Tasmanian devil and devil facial tumour disease by Patchett, AL
  
 
 
Toll-like receptors in the endangered Tasmanian devil 
and devil facial tumour disease
 
 
Amanda Louise Patchett 
BMedRes(Hons) 
 
 
Submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
University of Tasmania 
March, 2018
Declaration of Originality 
This thesis contains no material which has been accepted for a degree or diploma by the 
University or any other institution, except by way of background information and duly 
acknowledged in the thesis, and to the best of my knowledge and belief no material previously 
published or written by another person except where due acknowledgement is made in the text 
of the thesis, nor does the thesis contain any material that infringes copyright. 
Amanda Louise Patchett 
01/03/2018 
II 
Authority of Access 
This thesis may be made available for loan and limited copying and communication in 
accordance with the Copyright Act 1968. 
Amanda Louise Patchett 
01/03/2018 
III 
Statement regarding published work contained in this thesis 
The publishers of the papers comprising parts of Chapters 3 to 5 hold the copyright for that 
content, and access to the material should be sought from the respective journals. The remaining 
non-published content of this thesis may be made available for loan and limited copying and 
communication in accordance with the Copyright Act 1968. 
Amanda Louise Patchett 
01/03/2018 
IV 
 
V 
Statement of Co-Authorship 
This following people and institutions contributed to the publication of work undertaken as part 
of this thesis: 
Candidate: Amanda L. Patchett, Menzies Institute for Medical Research, University of Tasmania. 
Author 2: Gregory M. Woods, Menzies Institute for Medical Research, University of Tasmania; 
School of Medicine, University of Tasmania. 
Author 3: A. Bruce Lyons, School of Medicine, University of Tasmania. 
Author 4: Cesar Tovar, Menzies Institute for Medical Research, University of Tasmania. 
Author 5: Roger Latham, School of Medicine, University of Tasmania. 
Author 6: Kate H. Brettingham-Moore, School of Medicine, University of Tasmania. 
Author 7: Jocelyn M. Darby, Menzies Institute for Medical Research, University of Tasmania. 
Author 8: Lynn M. Corcoran, The Walter and Eliza Hall Institute of Medical Research; 
Department of Medical Biology, The University of Melbourne. 
Author 9: Ruth Pye, Menzies Institute for Medical Research, University of Tasmania. 
Author 10: Elspeth McLennan, School of Life and Environmental Sciences, The University of 
Sydney. 
Author 11: Russell Thomson, School of Computing, Engineering and Mathematics, Western 
Sydney University. 
Author 12: Scott Carver, School of Biological Sciences, University of Tasmania. 
Author 13: Samantha Fox, Save the Tasmanian Devil Program, Tasmanian Department of Primary 
Industries, Parks, Water and the Environment. 
Author 14: David Pemberton, Save the Tasmanian Devil Program, Tasmanian Department of 
Primary Industries, Parks, Water and the Environment. 
Author 15: Alexandre Kreiss, Menzies Institute for Medical Research, University of Tasmania. 
Author 16: Adriana Baz Morelli, CSL Ltd. 
Author 17: Anabel Silva, CSL Ltd. 
Author 18: Martin J. Pearse, CSL Ltd. 
Author 19: Katherine Belov, School of Life and Environmental Sciences, The University of 
Sydney. 
Author 20: Carolyn J. Hogg, School of Life and Environmental Sciences, The University of 
Sydney. 
Author 21: Richard Wilson, Central Science Laboratory, University of Tasmania. 
Author 22: Jac Charlesworth, Menzies Institute for Medical Research, University of Tasmania. 
Author 23: Anthony Papenfuss, The Walter and Eliza Hall Institute of Medical Research; 
Department of Medical Biology, The University of Melbourne; Division of Cancer 
Research, Peter McCallum Cancer Centre; Sir Peter McCallum Department of Oncology, 
University of Melbourne. 
 
 
VI 
Paper 1 
Toll-like receptor signalling is functional in immune cells of the endangered Tasmanian devil, 
Developmental and Comparative Immunology, 2015; 53(1): 123-133. 
Located in chapters 3 and 5 of this thesis. 
The candidate (60%) was the primary author and contributed to laboratory work, data analysis 
and manuscript preparation. 
Author 2 (corresponding author) (15%), author 3 (10%) and author 4 (5%) contributed to the 
formulisation and development of the project, and data interpretation. 
Author 5 (5%) and author 6 (5%) assisted with data analysis and interpretation. 
All authors contributed to manuscript refinement and presentation. 
 
Paper 2 
The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial 
Tumour Cell Lines, PLoS One, 2016; 11(12): e168068. 
Located in chapter 5 of this thesis. 
The candidate (60%) was the primary and corresponding author and contributed to the 
formulisation of the project, laboratory work, data analysis and manuscript preparation. 
Author 2 (10%), author 3 (10%) and author 4 (10%) contributed to the formulisation and 
development of the project, and data interpretation. 
Author 7 (10%) contributed to laboratory work. 
All authors contributed to manuscript refinement and presentation. 
 
Paper 3 
The toll-like receptor ligands Hiltonol (polyICLC) and imiquimod effectively activate 
antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii), 
Developmental and Comparative Immunology, 2017; 76: 352-360. 
Located in chapter 4 of this thesis. 
The candidate (60%) was the primary and corresponding author and contributed to the 
formulisation and development of the project, laboratory work, data analysis and manuscript 
preparation. 
 
VII 
Author 2 (15%), author 3 (10%) and author 4 (10%) contributed to the formulisation and 
development of the project, and data interpretation. 
Author 8 (5%) contributed to reagent development for this project. 
All authors contributed to manuscript refinement and presentation. 
 
Paper 4 
 
Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial 
Tumour Disease in the Majority of Tasmanian Devils Destined for Wild Release, Frontiers in 
Immunology, 2018, 9(259): https://doi.org/10.3389/fimmu.2018.00259. 
 
Located in chapter 4 of this thesis. 
 
The candidate (25%) was the second author and contributed to the forumlisation and 
development of the project, laboratory work, data analysis and manuscript preparation. 
Author 9 (corresponding author) (50%) contributed to the forumlisation and development of 
the project, field work, laboratory work, data analysis and manuscript preparation. 
Author 2 (5%), author 3 (5%), author 8 (1%), author 13 (1%), author 14 (1%), author 15 
(1%), author 16 (1%), author 17 (1%) and author 18 (1%) contributed to the forumlisation and 
development of the project and data interpretation. 
Author 12 (2%), author 11 (2%), author 10 (2%), author 19 (1%) and author 20 (1%) 
contributed to laboratory work and data analysis. 
All authors contribute to manuscript refinement and presentation. 
 
Paper 5 
 
Transcriptome and proteome profiling reveals stress-induced expression signatures of 
imiquimod-treated Tasmanian devil facial tumour disease (DFTD) cells, Oncotarget, 2018. 
*Paper in press at time of thesis publication. 
 
Located in chapter 6 of this thesis. 
 
The Candidate (60%) was the primary and corresponding author and contributed to the 
formulisation and development of the project, laboratory work, data analysis and 
interpretation and manuscript preparation. 
Author 4 (10%), author 2 (5%) and author 3 (5%) contributed to the formulisation and 
development of the project and data interpretation. 
Author 21 (5%), author 22 (5%), author 23 (5%) and author 8 (5%) contributed to laboratory 
work and data analysis. 
All authors contributed to manuscript refinement and presentation. 
We the undersigned agree with the above stated "proportion of work undertaken" for each of 
the above published (or submitted) peer-reviewed manuscripts contributing to this thesis: 
Signed: 
Date: 
Professor Gregory Woods 
Primary supervisor 
Menzies Institute for Medical Research 
University of Tasmania 
VIII 
Statement of Ethical Conduct 
The research associated with this thesis abides by the international and Australian codes on 
human and animal experimentation, the guidelines by the Australian Government's Office of 
the Gene Technology Regulator and the rulings of the Safety, Ethics and Institutional Biosafety 
Committees of the University. 
Amanda Louise Patchett 
01/03/2018 
IX 
X 
Publications 
(Available in Appendix 5) 
Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, Woods GM (2015). 
Toll-like receptor signalling is functional in immune cells of the endangered Tasmanian devil. 
Developmental and Comparative Immunology, vol. 53, no. 1, pp. 123-133. 
Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM (2016). The Immunomodulatory 
Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines. PLoS One, 
vol. 11, no. 12, p. e0168068. 
Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM (2017). The toll-like receptor 
ligands Hiltonol and imiquimod effectively activate antigen-specific immune responses in 
Tasmanian devils (Sarcophilus harrisii). Developmental and Comparative Immunology, vol. 
76, pp. 352-360. 
Pye R, Patchett AL, McLennan E, Thomson R, Carver S, Fox S, Pemberton D, Kreiss A, Baz 
Morelli A, Silva A, Pearse MJ, Corcoran LM, Belov K, Hogg CJ, Woods GM, Lyons AB 
(2018). Immunization Strategies Producing a Humoral IgG Immune Response against Devil 
Facial Tumour Disease in the Majority of Tasmanian Devils Destined for Wild Release, 
Frontiers in Immunology, vol. 9 no. 259, https://doi.org/10.3389/fimmu.2018.00259. 
Patchett AL, Wilson R, Charlesworth J, Corcoran LM, Papenfuss AT, Lyons AB, Woods GM, 
Tovar C (2018). Transcriptome and proteome profiling reveals stress-induced expression 
signatures of imiquimod-treated Tasmanian devil facial tumour disease (DFTD) cells, 
Oncotarget, 2018. *Paper in press at time of thesis publication. 
XI 
Conference Presentations and Invited Talks 
Patchett AL. Vaccine development in Tasmanian devil facial tumour disease (DFTD). Invited 
speaker. Environmental Health Australia National Conference, November 2016, Hobart, 
Australia. 
Patchett AL, Wilson R, Papenfuss T, Tovar C, Lyons AB, Woods GM. Imiquimod initiates 
tumour specific overload of the ER stress response in Tasmanian devil facial cancer cells. Poster 
presentation. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, 
September 2016, New York, USA. 
Patchett AL, Tovar C, Lyons, AB, Woods GM. Toll-like receptor ligands as vaccine adjuvants 
in the endangered Tasmanian devil. Poster presentation. International Congress of 
Immunology, August 2016, Melbourne, Australia. 
Patchett AL. Toll-like receptors as adjuvant targets in the endangered Tasmanian devil. Invited 
speaker. June 2016, Anhui Medical University, Hefei, China. 
Patchett AL, Tovar C, Lyons, AB, Woods GM. Toll-like receptors as adjuvant targets in the 
endangered Tasmanian devil. Oral presentation. International Student Research Forum, June 
2016, University of Chinese Academy of Sciences, Beijing, China. 
Patchett AL, Tovar C, Lyons, AB, Woods GM. Toll-like receptors as adjuvant targets in the 
endangered Tasmanian devil. Poster presentation. Australasian Society for Immunology 
Annual Scientific Meeting, November 2015, Canberra, Australia. 
Patchett AL, Tovar C, Lyons, AB, Woods GM. Effects of the TLR7 agonist imiquimod in 
devil facial tumour disease (DFTD). Oral presentation. Molecular & Experimental Pathology 
Society of Australasia Annual Scientific Meeting, November 2015, Hobart, Australia. 
Patchett AL, Tovar C, Lyons, AB, Woods GM. Toll-like receptors as adjuvant targets in devil 
facial tumour disease. Oral presentation. Molecular & Experimental Pathology Society of 
Australasia Annual Scientific Meeting, Australian Health and Medical Research Congress, 
November 2014, Melbourne, Australia. 
Patchett AL, Tovar C, Lyons, AB, Woods GM. Toll-like receptor agonists as vaccine 
adjuvants in devil facial tumour disease. Oral presentation. Tasmanian Haematology, 
Immunology and Neoplasia Group Annual Scientific Meeting, April 2014, White Sands Estate, 
Australia. 
XII 
Acknowledgements 
First and foremost, I wish to thank my primary supervisor Professor Greg Woods for his unwavering 
support, guidance and expertise throughout my PhD. Thank you for passing on your wisdom and passion 
for immunology, I am sincerely grateful to have worked on such a fascinating project. To my co-
supervisors Dr Bruce Lyons and Dr Cesar Tovar, thank you for your advice and dedication. I have been 
fortunate to have such a knowledgeable and encouraging supervisory team for my PhD. 
To all past and present members of the devil/immunology groups, in particular Jocelyn, Ruth, Alex, 
Andy, Terry, Gina, Shanshan, Amy, Guna, Silvana, Patrick, Chrissie, Camilla and Ginger. It’s been a 
privilege to work among so many great scientists, thank you for your encouragement, friendship and 
ideas. A special thank you to Ruth and Alex for being so willing to immunise and collect samples for 
my project whenever they were needed. This PhD would not have been possible without you. 
To Dr Tony Papenfuss, Professor Lynn Corcoran, Dr Jac Charlesworth and Dr Richard Wilson, I am 
particularly grateful for your bioinformatics support throughout the project. Thank you to Roger 
Latham, Kate Brettingham-Moore and Mark Cozens for your analytical guidance. 
To the Save the Tasmanian Devil Program and the Tasmanian Department of Primary Industry, Parks, 
Water and Environment, thank you for your collaboration and continued support of DFTD vaccine 
research. A special thank you to Bonorong Wildlife Sanctuary for providing Tasmanian devils for 
sampling, and to our devil keepers, particularly Ginny Ralph, for your expert animal care. 
To our fellow devil researchers and collaborators at the University of Tasmania and many other institutes 
worldwide, we are appreciative of your valuable advice, sharing of ideas and provision of valuable 
reagents. To Dr Andres Salazar of Oncovir Inc. thank you for your kind provision of Hiltonol, a 
reagent of much benefit to this project and DFTD immunisations. 
To the Save the Tasmanian Devil Appeal and donors, thank you for your ongoing financial support of 
our efforts to understand and prevent DFTD.  
To my fellow PhD students, thank you for friendship. In particular to Rachel, Megan and Macarena, 
who have been on this journey through university from the beginning. Thank you for your 
companionship and encouragement, I wish you all the luck for your futures. 
Lastly, to my amazing network of friends and family outside of work, thank you for your love and 
support. In particular to my wonderful partner Kyle, who believed in me from the start. I am so grateful 
that I got to share this experience with you. Thank you. 
XIII 
Abstract 
Devil facial tumour disease (DFTD) describes two genetically distinct transmissible cancers 
threatening the survival of the world’s largest carnivorous marsupial, the Tasmanian devil 
(Sarcophilus harrisii). Denoted DFT1 and DFT2, these aggressive cancers successfully evade 
immune detection to be transferred as clonal allografts via biting behaviours of the devil. A 
prophylactic DFTD vaccine will protect Tasmanian devils from transmission of DFT1 and 
DFT2. As with other vaccines, its success will depend upon the activation of effective immune 
responses. In human cancer studies, ligands of toll-like receptors (TLRs) are incorporated into 
immunotherapies and vaccines to provide potent immune stimulation. Conserved TLR genes 
have been identified in the genome of the Tasmanian devil, and as such TLR ligands could be 
effective vaccine adjuvants in DFTD. Analysis of TLR signalling in the Tasmanian devil is 
required to determine whether this is the case, as TLR function has not previously been 
investigated in any marsupial species.  
In this thesis, the role of TLRs in immune activation in the Tasmanian devil has been assessed 
using gene expression assays, in vitro mononuclear cell (MNC) stimulations and in vivo 
immunisation trials. Furthermore, the response of DFTD tumour cells to TLR ligands in vitro 
has also been investigated, as tumour cells frequently express TLRs with a range of anti- and 
pro-tumoural functions. These analyses revealed that Tasmanian devil MNCs express genes 
encoding homologues of human TLRs 2, 3, 4, 5, 6, 7, 8, 9, 10 and 13. Stimulation of these cells 
with ligands of TLRs increased expression of inflammatory cytokines including interleukin-1α 
and interleukin-6, indicating that TLR signalling is functional in the immune system of the 
Tasmanian devil. In particular, a combination of the TLR ligands poly-ICLC (TLR3) and 
imiquimod (TLR7) significantly increased the expression of inflammatory cytokines and 
production of interferon-γ from devil MNCs, suggesting that these ligands may be effective 
adjuvants in a DFTD vaccine. To confirm this finding, immunisation trials were performed in 
Tasmanian devils using both model and DFTD antigens. These immunisations revealed that the 
combination of poly-ICLC and imiquimod activates potent antigen-specific immune responses 
in Tasmanian devils that are both more rapid and long-lived than responses activated by 
previously used DFTD vaccine adjuvants. Importantly, this finding reduces the current DFTD 
immunisation protocol in Tasmanian devils from four to two immunisations. This shorter 
immunisation protocol will allow for more feasible delivery of DFTD vaccines to affected wild 
Tasmanian devil populations. 
XIV 
Analysis of the response of DFTD cells to in vitro stimulation with TLR ligands revealed a 
variety of anti- and pro-tumoural functions. In particular, stimulation of the gram-positive 
bacterial sensor TLR2/6 increased the expression of both angiogenic and immunosuppressive 
cytokines from DFT1 cells in culture, highlighting a novel mechanism of immune evasion in 
DFTD. In comparison, other TLR ligands including poly-IC (TLR3) suppressed DFTD cell 
proliferation, while imiquimod (TLR7) was demonstrated to be a potent inducer of apoptosis 
in DFTD cell lines. RNA sequencing and proteomic mass spectrometry analysis of the 
mechanisms by which imiquimod deregulated DFTD survival demonstrated activation and 
subsequent overload of oxidative and ER stress responses via TLR7-independent pathways. 
These findings highlight the potential of stress responses as therapeutic targets in DFTD, and 
provide the first whole transcriptome and proteome analysis of imiquimod action in any 
mammalian tumour cell line. 
This thesis has expanded the current knowledge of the Tasmanian devil’s immune system by 
verifying that devils have functional TLRs that respond to a range of prototypic TLR ligands. 
This is the first description of functional TLRs in any marsupial species, contributing to our 
understanding of marsupial immunology and the evolution of TLR signalling. This thesis has 
also identified the TLR ligands poly-ICLC and imiquimod as potent immunostimulatory agents 
in the Tasmanian devil, and demonstrated that in combination these ligands induce rapid and 
long-lived antigen-specific responses to DFTD immunisation. These ligands also exhibit anti-
tumour effects in DFTD, suggesting that they may have additional uses as immunomodulatory 
agents for therapeutic application. This study provides the first analysis of candidate DFTD 
vaccine adjuvants in Tasmanian devils. Future DFTD vaccines will be formulated with poly-
ICLC and imiquimod as adjuvants for improved vaccine efficacy and DFTD protection. 
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1.1. Introduction 
The mammalian immune system is a complex and highly conserved network of soluble factors, 
cells, barriers and organs with the principal function of protection against disease (reviewed by 
(Parkin et al. 2001)). The occurrence of infection, cancer, hypersensitivity and autoimmunity 
when the immune system becomes ineffective or overactive emphasises the importance of this 
vital system. Cancer develops when cells of the body accumulate certain mutations in the 
coding and noncoding regions of oncogenes and tumour suppressor genes, leading to altered 
gene expression or function. Together, these changes enable the uncontrolled growth and 
survival of the cells, forming a cancer (Hanahan et al. 2000). A key hallmark of cancer 
formation is the ability of the cells to grow irrespective of external cues and restraints, including 
the immune system (Hanahan et al. 2011). Cancer immunotherapies attempt to reverse this 
immune evasion and allow the cancer to be fought by the body’s natural immune response. 
Ongoing research in this field holds great promise, with newly developed immunotherapies 
offering much greater efficacy in the treatment of previously difficult-to-treat tumours (Bloy et 
al. 2014; Buque et al. 2015; Pol et al. 2016).  
In very rare cases, where an appropriate route of transfer exists and ‘non-self’ immune defences 
fail, cancer cells have the ability to be transmitted between individuals as an infectious disease. 
An example of this is devil facial tumour disease (DFTD), which describes two genetically 
distinct transmissible cancers (DFT1 and DFT2) threatening the survival of the world’s largest 
carnivorous marsupial, the Tasmanian devil (Sarcophilus harrisii) (Hawkins et al. 2006; Pye et 
al. 2016b). DFTD is transferred between Tasmanian devils by contact and has resulted in a total 
population decline of up to eighty percent across the devil’s geographical range (Hollings et al. 
2014; Pearse et al. 2006). Conservation targets include the development of a prophylactic 
DFTD vaccine (Kreiss et al. 2015; Tovar et al. 2017). A thorough understanding of the devil’s 
immune system and DFTD will be required for such a vaccine to be successful.  
In humans, adjuvants are frequently used in combination with vaccines and immunotherapies 
to provide stimulatory signals to immune cells. Toll-like receptor (TLR) ligands are a class of 
adjuvants that have been widely investigated for use in human cancer therapy in combination 
with other agents and as direct in situ treatments (Galluzzi et al. 2012a; Vacchelli et al. 2012). 
There are thirteen known mammalian TLRs, which engage with various pathogen and tissue 
damage associated molecules to activate and enhance innate and adaptive immune responses 
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(Pandey et al. 2014). They are highly conserved across mammalian species (Roach et al. 2005), 
and as a result could be effective adjuvant targets in the Tasmanian devil. In this review, the 
roles of TLRs in the immune system are discussed with a focus on cancer onset, treatment and 
prevention. The Tasmanian devil and current knowledge of DFTD are also discussed, including 
approaches to protecting the species from extinction. A greater understanding of DFTD and 
immune function in the Tasmanian devil will reveal more appropriate targets for DFTD 
treatment and prevention. 
1.2. Toll-like receptors in cancer, infection and immunity 
1.2.1. Toll-like receptors: An overview 
The recognition of invading threats by the immune system is critical to the development of any 
immune response. This recognition frequently occurs via pattern recognition receptors (PRRs), 
which are sensors of specific microbial components known as pathogen-associated molecular 
patterns (PAMPs) (Akira et al. 2001). A number of PRR families have been identified in 
mammalian immune cells, including TLRs, NOD-like receptors (NODs) and RIG-1-like 
receptors (RLRs) (Chaudhary et al. 1998; Inohara et al. 2001; Yoneyama et al. 2004). TLRs 
were the first of these families to be identified and are consequently well characterized and 
understood. In addition to PAMP recognition, PRRs recognise damage-associated molecular 
patterns (DAMPs) that are released from stressed and damaged tissues (Bianchi 2007). Recent 
evidence suggests that DAMP recognition is crucial for distinguishing non-pathogenic 
microbiota from tissue-damaging pathogenic bacteria. In the absence of stress-associated 
DAMPs, innate cells may promote immune tolerance to prevent the destruction of commensal 
bacteria (Land 2015). 
TLRs were named for their structural homology to ‘Toll’, a transmembrane receptor involved 
in immune activation within the fruit fly Drosophila melanogaster (Medzhitov et al. 1997; 
Rock et al. 1998). Toll was discovered in the mid-1980s and was shown to control dorsal-
ventral patterning during neural tube development in the Drosophila embryo (Anderson et al. 
1985; Morisato et al. 1994). Similarities between Toll signalling and signalling via the 
mammalian interleukin-1 receptor (IL-1R) were observed in the early 1990s, enabling the 
discovery of a second key function of Toll, immune activation in the Drosophila adult (Gay et 
al. 1991; Lemaitre et al. 1996; Rosetto et al. 1995). During 1997, a human homologue of Toll 
was discovered (Medzhitov et al. 1997). Now known as TLR4, this receptor was demonstrated 
5 
to induce innate and adaptive immune responses via the transcription factor nuclear factor 
kappa-B (NFκB) (Medzhitov et al. 1997; Rock et al. 1998). Phylogenetic analysis has since 
identified conserved TLR homologues in species of fish, amphibians, birds and mammals 
(Roach et al. 2005). In total, thirteen highly conserved TLRs have been identified in mammalian 
species, and can be categorised into six TLR families based on PAMP recognition and 
homology. These include the lipopeptide TLR1 subfamily (TLRs 1, 2, 6 and 10), the double-
stranded ribonucleic acid (dsRNA) TLR3 subfamily (TLR3), the lipopolysaccharide (LPS) 
TLR4 subfamily (TLR4), the flagellin TLR5 subfamily (TLR5), the nucleic acid TLR7 
subfamily (TLRs 7, 8 and 9) and the TLR11 subfamily (TLRs 11, 12 and 13). The TLR11 
family has been functionally lost from the genomes of many mammals including humans, and 
is represented by a pseudogene (Roach et al. 2005).  
All thirteen mammalian TLRs are expressed across countless tissue types, where they engage 
with PAMPs and DAMPs to warn the immune system of impending threats (Bianchi 2007; 
Hornung et al. 2002; Zarember et al. 2002). Accurate identification of these TLR ligands can 
be challenging, as contaminating LPS in samples can inadvertently activate TLR signalling 
pathways (Mancek-Keber et al. 2015). TLRs are located on plasma membranes of cells or 
intracellular endosomal compartments and endoplasmic reticulum (ER) membranes depending 
on the type of molecule they detect (Pandey et al. 2014). Subsequent to PAMP/DAMP 
recognition, signalling cascades stimulate transcription factors that alter the expression of genes 
involved in the immune response (Kawai et al. 2001; Medzhitov et al. 1997). Subsets of 
immune cells express distinct combinations of TLRs to aid their specific function (Kadowaki 
et al. 2001; Muzio et al. 2000). In addition, different TLRs activate different subsets of genes 
depending on the specific signalling pathways and transcription factors that are stimulated 
(Yamamoto et al. 2002). While most play a pro-inflammatory role, recent evidence suggests 
that TLR10 may be anti-inflammatory via negative regulation of TLR signalling pathways 
(Hess et al. 2017; Jiang et al. 2016b; Oosting et al. 2014). The ligands and properties of each 
TLR complex have been summarized (Table 1-1). 
TLRs are involved in a variety of immune functions. Innate responses are activated by TLR-
mediated production of inflammatory factors from both immune and non-immune cells 
(Medzhitov et al. 1997; Ozato et al. 2002). TLR ligands also stimulate up-regulation of 
molecules required for presentation of antigen to the adaptive immune system by antigen- 
presenting cells (APCs) (Krutzik et al. 2005; Medzhitov et al. 1997). In T cells and B cells,  
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7 
TLR signalling synergises with antigen dependent and independent stimuli to promote cell 
maturation, proliferation and function (Rubtsova et al. 2016; Tabiasco et al. 2006). In 
comparison, the functions of regulatory T cells (Tregs) are suppressed by many TLR ligands 
(Voo et al. 2014). The exception to this is TLR2 and TLR5 ligands, which have been reported 
to stimulate the suppressive function of Tregs (Crellin et al. 2005; Zanin-Zhorov et al. 2006). 
TLR ligands can also stimulate delayed expression of interleukin (IL) -10 from APCs, enabling 
controlled and appropriate immune responses (Liu et al. 2014; Samarasinghe et al. 2006). In 
addition, TLR9, which is typically an intracellular TLR, has been found at the cell surface in B 
cells where it may detect self-deoxyribonucleic acid (DNA) and suppress immune responses to 
prevent auto-reactivity (Guerrier et al. 2014). The integration of TLR signalling in different 
immune cell types supports a response that is most fitting for clearance of the detected 
pathogen. 
1.2.2. Toll-like receptor signalling pathways 
TLRs activate immune responses via highly conserved signalling pathways. Each TLR is a 
type-1 transmembrane glycoprotein located on the extracellular plasma membrane, or on 
intracellular membranes such as endosomes, lysosomes or the ER (Botos et al. 2011). Most 
TLRs must form homodimers to be functional. Exceptions to this include TLR1 and TLR6, 
which form heterodimers with TLR2 (Ozinsky et al. 2000), and TLR11 and TLR12, which can 
function as hetero- or homodimers (Koblansky et al. 2013). The TLR4 homodimer requires the 
co-receptor MD2 to form a stable complex with its ligands (Kim et al. 2007).  
TLR signalling begins with the binding of a specific ligand to leucine-rich repeats in the 
extracellular domain of the TLR (Matsushima et al. 2007). Transmembrane and intracellular 
Toll-interleukin-1 receptor (TIR) domains transmit the signal by recruiting specific adaptor 
molecules that provide specificity to TLR signalling pathways. Myeloid differentiation primary 
response 88 (MyD88) is an adaptor molecule recruited to all TLRs but TLR3 (MyD88 
dependent TLR signalling) (Fig. 1.1-A) (Medzhitov et al. 1998). TIR-domain-containing 
adaptor-inducing interferon-β (TRIF) is recruited only to TLR3 and TLR4 (TRIF dependent 
TLR signalling) (Fig. 1.1-B) (Muzio et al. 1998; Yamamoto et al. 2003; Yamamoto et al. 2002). 
Other adaptor molecules include TIR domain containing adaptor protein (TIRAP/MAL) (TLRs 
1/2, 2, 2/6 and 4) and TRIF-related adaptor molecule (TRAM) (MyD88 independent TLR4 
pathway) (Fitzgerald et al. 2003; Horng et al. 2002; Horng et al. 2001). A fifth adaptor 
molecule, sterile-alpha and armadillo motif containing protein (SARM), has also been  
 
8 
 
 
 
Figure 1-1. Mammalian toll-like receptor signalling pathways. A) MyD88 dependent activation of 
inflammatory cytokine expression via TLR1/2, TLR2/6, TLR4, TLR5 and TLR11/12. B) TRIF 
dependent activation of type I interferon and inflammatory cytokine expression via TLR3 and TLR4. 
C) MyD88 dependent activation of type I interferon and inflammatory cytokine expression via TLR7, 
TLR8, TLR9 and TLR13. Image adapted from O’Neill et al, 2013. 
 
9 
identified as a negative regulator of TRIF mediated signalling (Carty et al. 2006). The MyD88 
and TRIF signalling pathways are described in detail below. 
MyD88-dependent TLR signalling 
The initiation of signalling through the MyD88 adaptor molecule results in the recruitment and 
activation of the IL-1 receptor-associated kinases (IRAK) 4, 1 and 2 (Li et al. 2002). These 
recruit and activate TNF receptor-associated factor 6 (TRAF6), which self-polyubiquitinates to 
create Lys63-linked ubiquitin chains (Deng et al. 2000). The poly-ubiquitin chains of TRAF6 
bind to TAK1-binding protein (TAB) 2 and 3, which are in a complex with TGF-beta-activated 
kinase 1 (TAK1) (Qian et al. 2001; Wang et al. 2001). The activation of TAK1 leads to 
stimulation of mitogen-activated protein kinase (MAPK) and NFκB signalling pathways. 
MAPK signalling pathways are activated through mitogen-activated protein kinase kinases 
(MKKs), which stimulate p38, c-Jun N-terminal kinases (JNKs) and extracellular signal-
regulated kinases (ERKs) for activation of transcription factors such as cAMP response 
element-binding protein (CREB) and activator protein-1 (AP-1) (Wang et al. 2001). The NFκB 
signalling pathway is activated after phosphorylation of IκB kinase-β (IKKβ) by TAK1. IκB 
proteins are degraded in response to phosphorylation, resulting in activation of NFκB 
(Ninomiya-Tsuji et al. 1999). Within all cells, TLR mediated activation of NFκB activates the 
expression of genes involved in inflammation, including the cytokines tumour necrosis factor-
alpha (TNFα), IL-1 and IL-6 (Medzhitov et al. 1997; Ozato et al. 2002). 
An alternative MyD88-dependent pathway is stimulated in plasmacytoid dendritic cells (pDCs) 
through engagement of endosomal TLRs (Fig. 1.1-C) (Ito et al. 2005). In this pathway, a large 
complex is formed between MyD88, TRAF3, TRAF6, and IKKα, among other subunits. This 
leads to phosphorylation of the transcription factor interferon-regulatory factor (IRF) 7. The 
activated IRF7 translocates to the nucleus where it stimulates expression of genes involved in 
the anti-viral response, including the type-1 interferons (IFN), IFNα and IFNβ (Honda et al. 
2004; Kawai et al. 2004).  
TRIF-dependent TLR Signalling 
TRIF-dependent TLR signalling activates inflammatory responses and type-1 IFN mediated 
anti-viral responses via TLR3 and TLR4 (Yamamoto et al. 2003). For the activation of the 
inflammatory response, TRIF interacts with the molecules TRAF6 and receptor-interacting 
protein kinase 1 (RIP1). This results in the activation of TRAF6 and the stimulation of MAPK 
 
10 
and NFκB pathways, as described for MyD88 dependent signalling (Cusson-Hermance et al. 
2005; Jiang et al. 2004). For anti-viral responses, TRIF stimulates TNF-receptor associated 
factor 3 (TRAF3), which in turn activates TANK-binding kinase 1 (TBK1) and IKKε. TBK1 
and IKKε catalyse the phosphorylation of the transcription factor IRF3, which translocates to 
the nucleus and activates expression of genes involved in the anti-viral response. These include 
the type-1 IFNs, IFNα and IFNβ (Oganesyan et al. 2006). 
1.2.3. Toll-like receptors in cancer immunosurveillance 
Cancer immunosurveillance involves the innate and adaptive arms of the immune system, 
which integrate to detect and produce effective responses against aberrant and neoplastic cells. 
During cancer immunosurveillance, immune cells recognise cells displaying immunogenic 
epitopes on mutant proteins (neoantigens) and target these for destruction (Dunn et al. 2004). 
Although TLRs are sensors of pathogenic infection, they can play indirect roles in cancer 
immunosurveillance through the detection of endogenous DAMPs released from cells in the 
tumour microenvironment. These processes are not well understood, with passive DAMP 
release during stress and injury frequently correlated with tumour-promoting inflammation and 
poor prognosis (Yu et al. 2010). Conversely, mice with mutant TLR4 were more susceptible to 
tumour development, suggesting a key role for TLR signalling in immunosurveillance (Yusuf 
et al. 2008). Specifically, active release of DAMPs during certain forms of tumour cell 
apoptosis, autophagy and necrosis/necroptosis is closely associated with immune activation via 
TLR signalling (Krysko et al. 2011; Thorburn et al. 2009; Yu et al. 2013). Signalling via the 
TNF receptor during anti-tumour responses activates these necroptotic pathways via RIP1 and 
RIP3 (Zhang et al. 2009). Similarly, certain chemotherapies, radiotherapies and oncolytic 
viruses can stimulate immunogenic autophagic and apoptotic pathways through a process called 
immunogenic cell death (ICD) (Inoue et al. 2014). ER-stress mediated release of TLR ligands 
such as heat shock proteins (HSPs) and high mobility group box 1 (HMGB1) is required for 
increased tumour immunogenicity during ICD (Apetoh et al. 2007; Inoue et al. 2014). The 
principal cell types involved in immunosurveillance and the TLRs that they express have been 
summarized (Table 1-2). 
Immunosurveillance is also important for cancer immunotherapies, which aim to reverse 
immune evasion and reinstate natural immune responses against tumour cells. TLR ligands are 
frequently given as adjuvants in combination with cancer vaccinations and immunotherapies 
for their ability to promote immune cell activation and tumour antigen presentation (Galluzzi  
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et al. 2012a). Several TLR ligands have also been explored for their immunotherapeutic 
potential as stand-alone agents, and Bacillus Calmette-Guérin (BCG) (TLR2) and imiquimod 
(TLR7) have been approved by the US Food and Drug Administration (FDA) for the treatment 
of superficial bladder carcinoma and basal cell carcinoma, respectively (Vacchelli et al. 2012). 
The benefits of TLR ligands as immunotherapeutic agents extend beyond stimulation of 
inflammatory cells. In situ, ligands of several TLRs (including TLRs 2, 4 and 9) can decrease 
the frequencies and function of Tregs and myeloid derived suppressor cells (MDSCs) in the 
tumour microenvironment (Li et al. 2015; Naseemuddin et al. 2012; Sato et al. 2015). 
Conversion of suppressive myeloid cells to an anti-tumoural M1 phenotype has also been 
demonstrated in response to TLR3 ligands in clinical studies (Forghani et al. 2015; Shime et al. 
2012). Tumour cells also express TLRs, and their stimulation during therapy can inhibit cell 
proliferation and activate tumour necrosis or apoptosis (TLRs 3, 5 and 9), thereby promoting 
tumour clearance (Brignole et al. 2010; Cai et al. 2011b; Takemura et al. 2015). 
1.2.4. Immune evasion and toll-like receptors 
Cancer occurs when cells accumulate heritable genetic or epigenetic changes, resulting in their 
continuous proliferation irrespective of external cues and restraints. Some of these changes 
allow the cell to evade immune detection, naturally selecting it to survive and divide in a process 
called immunoselection (Zitvogel et al. 2006). Cancer cells evade immune detection by 
controlling their own immunogenicity, and by regulating the functions of other cells in the 
tumour microenvironment. There are many known mechanisms of tumour immune evasion 
(Table 1-3). TLRs have been implicated in several of these, and as such are often described as 
a double-edged sword in cancer progression (Dajon et al. 2017). Careful selection of TLR 
ligands for cancer immunotherapy is important for avoiding unwanted stimulation of tumour 
growth. 
The contribution of TLR signalling to tumour survival depends on the repertoire of TLRs that 
are expressed in the tumour microenvironment and the cell types that are stimulated. Ligands 
of several TLRs (including TLRs 4, 5 and 7) can stimulate expression of immunoregulatory 
cytokines such as IL-6, IL-8 and transforming growth factor-beta (TGFβ) from tumour cells 
(Jego et al. 2006; Park et al. 2011; Szczepanski et al. 2009). TLRs (including TLRs 2 and 4) 
have also been demonstrated to stimulate expression of the angiogenic cytokine vascular 
endothelial growth factor A (VEGFA), resulting in tumour vasculogenesis and improved  
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Table 1-3. Common mechanisms of cancer immune escape. 
Primary Mechanism Examples Refs. 
Modulation of 
antigenicity 
Down-regulation/loss of expression of neoantigens. Shedding of neoantigens 
from cell surface. Selective expression of non-immunogenic neoantigens. 
(Khong 
et al. 
2002) 
Defective antigen 
presentation 
Down-regulation/loss of expression of MHCI. Down-regulation/loss of 
expression of proteins in the antigen processing pathway including β2M and 
TAP1/2. 
(Leone 
et al. 
2013) 
Immune checkpoint 
inhibitors 
Expression of PD-L1/L2 for inhibition and exhaustion of T cells via PD1. 
Expression of CTLA-4 for for inhibition of APCs via CD80/86. Expression 
of 'don't eat me' signals such as CD47 and CD200 for inhibition of 
phagocytosis. Expression of non-classical MHCI molecules for inhibition of 
NK cells via inhibitory receptors. 
(Postow 
et al. 
2015) 
Defective cell death 
pathways 
Inhibition of death-receptor pathways stimulated by NK cells and CD8+ T 
cells including TNF, FasL, TRAIL, complement and granzyme mediated 
pathways. Up-regulation of anti-apoptotic proteins including BCL2, MCL1, 
XIAP and A20. 
(Koff et 
al. 
2015) 
Immunosuppressive 
cytokines 
Production of immunosuppressive cytokines including IL-10, TGFβ, IL-6 
and VEGF, which inactivate cells participating in cancer 
immunosurveillance, and activate immunosuppressive cells. 
(Lindau 
et al. 
2013) 
Immunosuppressive 
cells 
Recruitment and activation of Tregs and MDSCs by chemokines/cytokines 
produced in the tumour microenvironment by tumour and supporting cells. 
Regulation of APC and T cell function. 
(Lindau 
et al. 
2013) 
Tumour-promoting 
inflammation 
Recruitment and activation of TANs and TAMs in the tumour 
microenvironment in response to chemokines, cytokines and DAMPs. 
Provides an environment supportive of tumour growth through the release of 
growth factors, angiogenic factors and granule proteins. 
(Elinav 
et al. 
2013) 
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oxygen supply (Farnebo et al. 2015; Szczepanski et al. 2009). Several studies have reported 
increased expression of programmed death ligand 1 (PDL1) and other immune checkpoint 
molecules in TLR-stimulated tumour cells (Berthon et al. 2010; Qian et al. 2008). These 
molecules can also be up-regulated by pro-inflammatory cytokines such as IFNγ, which may 
be released by TLR stimulated immune cells in the tumour microenvironment (Berthon et al. 
2010). Tumour cells stimulated with TLR ligands have also demonstrated resistance to 
apoptosis, with increased expression of anti-apoptotic factors and down-regulation of FAS both 
reported (Cherfils-Vicini et al. 2010; Huang et al. 2005). In some cases, these changes can 
enable tumour resistance to chemotherapeutic agents (Cherfils-Vicini et al. 2010). TLR ligands 
can also induce expression of oncogenic factors in tumour cells, promoting tumour survival, 
migration and proliferation (Ochi et al. 2012; Park et al. 2011). 
TLR signalling can also drive tumour-promoting inflammation, which is linked to poor 
prognosis in many cancers. Production of inflammatory chemokines and cytokines by DAMP 
stimulated cells in the tumour microenvironment can drive the accumulation of tumour-
associated macrophages (TAMs) (usually M2 macrophages) and tumour-associated neutrophils 
(TANs) (He et al. 2013; Hernandez et al. 2016; Orlova et al. 2007). The recruitment and 
activation of these cells promotes a situation analogous to wound healing, with improved 
angiogenesis and production of growth factors favouring tumour progression (Barbera-Guillem 
et al. 2002; Goswami et al. 2005). The Th2-type environment of tumour-promoting 
inflammation also allows the recruitment and activation of Tregs and MDSCs. Tregs have been 
shown to express TLRs 2 and 5, and their functions may be stimulated by DAMPs in the tumour 
microenvironment (Crellin et al. 2005; Yamazaki et al. 2011). Activated Tregs induce T cell 
apoptosis via granzyme release, promote T cell anergy via binding of CD2, and inhibit APCs 
through cytotoxic T lymphocyte associated protein 4 (CTLA4) expression (Grossman et al. 
2004; Manzotti et al. 2002; Wakkach et al. 2001). MDSCs promote immune-suppression in the 
tumour microenvironment via release of soluble factors such as arginase, inducible nitric oxide 
synthase (iNOS) and reactive oxygen species (ROS). Functions disrupted by MDSCs include 
TCR signalling, T cell activation, T cell infiltration and T cell homing to the lymph node 
(Molon et al. 2011; Nagaraj et al. 2010; Srivastava et al. 2010). The suppressive environment 
created by these cells can also reprogram anti-tumour M1 macrophages to suppressive M2 
macrophages and prevent the maturation of immature DCs, further promoting tumour tolerance 
(Ostrand-Rosenberg et al. 2012).  
 
15 
1.3. The immune system and toll-like receptors in cancer therapy 
and prevention 
1.3.1. Cancer immunotherapy and vaccination 
The survival of a cancer relies on its ability to avoid destruction by the immune system. 
Immunotherapy attempts to overcome immune tolerance of cancer to restore the host’s natural 
anti-tumour immune response. The practice of treating cancer through activation of the immune 
system was first explored as early as the 17th century AD (Hobohm 2001). Although the 
immune mechanisms involved were not understood at this time, it was observed that 
spontaneous cancer regressions in patients frequently coincided with infection. Treatments for 
cancer throughout the 17th, 18th and 19th centuries included infecting patients with bacterial 
infections such as syphilis, and applying dressings from septic patients to ulcerated tumours 
(Hobohm 2001; Hoption Cann et al. 2003). During the late 19th century, a surgical oncologist, 
William Coley, began to explore the treatment of cancer with vaccines containing infective 
agents. He had linked a case where a patient was completely cured of sarcoma to a concurrent 
infection with erysipelas (Streptococcus pyogenes), and began to infect his cancer patients with 
this organism (Hobohm 2001; Hoption Cann et al. 2003). His technique was problematic, as 
inducing erysipelas could be difficult, and many patients would succumb to the infection. 
Recognising that an acute fever was important for cancer regression, Coley developed a mixture 
of killed Streptococcus pyogenes and Serratia marcescens that he could intravenously inject 
into patients to induce fever without negative side effects (Bickels et al. 2002; Hobohm 2001). 
Now known that Coley’s toxins, this mixture was acting through bacteria-sensing PRRs 
including TLR2 and TLR4 to stimulate pro-inflammatory responses and tumour regression 
(Maletzki et al. 2012). At the time there was much scepticism of the role of the immune system 
in tumour surveillance, and newly developed chemotherapies and radiotherapies were of more 
interest for cancer treatment (Hoption Cann et al. 2003). Following the controversial 
Thalidomide case in the 1960s, the FDA listed Coley’s toxin as a ‘new drug’, preventing its use 
for immunotherapy without extensive trials (Hobohm 2001). 
Today, with significant improvement in our understanding of the immune system, interest in 
harnessing immunology to treat cancer has been revived. Common immunotherapeutic 
strategies involve vaccination with tumour antigens, adoptive transfer of immune effectors, and 
modulation of immunoregulatory factors in the tumour environment (Makkouk et al. 2015). 
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Studies have highlighted the importance of combining these immunotherapeutic strategies in 
order to achieve optimal responses and overcome mechanisms of resistance (Ott et al. 2017). 
Growing evidence also suggests that immunotherapies can synergise with traditional radiation 
and chemotherapies to stimulate successful anti-cancer responses (Bracci et al. 2014; Vacchelli 
et al. 2016). The mechanistic identification of new immunotherapies and therapeutic 
combinations will translate to improved cancer survival in the clinic. 
Cancer Vaccination 
Vaccination involves the delivery of specific antigens to the immune system, in order to prime 
the response for future encounters with the same antigen (Makkouk et al. 2015; Pol et al. 2015). 
Prophylactic vaccinations against cancers are challenging, as heterogeneity in neoantigens 
among tumours prevents the production of a one-size-fits-all immunisation. In comparison, 
therapeutic cancer vaccinations are more achievable, as expressed neoantigens can be identified 
in diagnosed individuals prior to treatment (Pol et al. 2015; Tureci et al. 2016). The enhanced 
capabilities and reduced costs of sequencing technology have improved the feasibility of these 
‘personalised’ cancer vaccines, but prediction of immunogenic neoantigens on a case-to-case 
basis remains difficult. Vaccines produced using common tumour antigens can overcome this 
need for personalised neoantigen identification (Makkouk et al. 2015; Pol et al. 2015). The 
mucin 1 (MUC1) antigen, which is found on the surface of a myriad of cancers, is one such 
tumour antigen that is being experimented with as an antigen for therapeutic cancer vaccination 
(Kaiser et al. 2010; Lakshminarayanan et al. 2012). 
Therapeutic cancer vaccines can be produced using whole tumour cells, tumour lysates, 
antigenic peptides or viral vectors expressing neoantigens. In particular, antigenic peptides have 
demonstrated success in cancer vaccines, as these bind directly to major histocompatibility 
complex (MHC) molecules without the need for antigen processing (Pol et al. 2015). A major 
challenge of therapeutic cancer vaccination involves breaking existing immune tolerance 
against neoantigens and tumour antigens (Higgins et al. 2009). As such, cancer vaccinations 
are often more effective in combination with immunomodulatory or immunostimulatory agents 
that alter this tolerance. Monoclonal antibodies, cytokines, TLR ligands and other strong 
adjuvants are examples of agents that promote anti-tumour responses in combination with 
cancer vaccines (Burkhardt et al. 2012; Cho et al. 2013; Moeini et al. 2017).  
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Another form of therapeutic cancer vaccination involves the administration of antigen pulsed 
DCs to patients (Bloy et al. 2014). DC vaccines follow the same principles as normal 
vaccinations, but DC antigen loading and maturation occurs ex vivo. Patient DC precursors are 
matured using cytokines and growth factors, stimulated with tumour antigen and re-implanted 
into the host. These activated DCs have the capacity to stimulate adaptive responses and 
promote tumour clearance (Bloy et al. 2014; Makkouk et al. 2015). In 2010, the DC vaccine 
Sipuleucel-T (Provenge®) became the only cancer vaccine to be FDA approved to date. 
Sipuleucel-T treats minimally symptomatic metastatic castration-resistant prostate cancer by 
targeting prostate acid phosphatase (PAP), a tumour antigen highly expressed in prostate 
cancer. A fusion protein containing recombinant PAP and GM-CSF is incubated in vitro with 
autologous PBMNC, which are re-implanted into the patient (Kantoff et al. 2010).  
Therapeutic Adoptive Transfer  
Adoptive transfer involves the administration of tumour-specific immune effectors such as 
monoclonal antibodies and activated T cells, to cancer patients. As these effectors are produced 
ex vivo, adoptive transfer surpasses processes such as antigen-presentation and effector 
maturation, which are heavily affected by additional factors. This allows the immune effectors 
to be produced in larger quantities than is possible in an in vitro system (Makkouk et al. 2015). 
Monoclonal antibodies are generated against an array of oncogenic and immunomodulatory 
targets. Their effects range from alteration of signalling cascades, disruption of receptor-ligand 
binding and modulation of cell-stromal interactions, to promotion of anti-tumour immune 
responses via antibody-dependent cell mediated cytoxicity and phagocytosis (Buque et al. 
2015; Xin et al. 2013). They can also be conjugated with cancer drugs and radioisotopes to 
localise tumour treatment and reduce off-target effects (Jiang et al. 2016c; Song et al. 2014). In 
1997, Rituximab (Rituxan®) became the first monoclonal antibody to be approved by the FDA 
for cancer treatment. Generated against the B cell antigen CD20, Rituximab was approved for 
the treatment of non-Hodgkin lymphoma (Anderson et al. 1997). 
Adoptive T cell transfer involves the ex vivo expansion of patient-derived T cells for host re-
implantation. This strategy assumes that T cells taken from the patient are rich in anti-tumour 
clones, and as such ex vivo expansion will dramatically increase the population of T cells 
primed for attack (Aranda et al. 2015; Makkouk et al. 2015). Another benefit of adoptive T cell 
transfer is that the cells can be modified to improve tumour targeting prior to re-infusion into 
patients. Chimeric antigen receptor (CAR) T cells are an example of modified T cells. Through 
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genetic transfer, CAR T cells are engineered to express a complementarity-determining region 
(CDR) derived from a neoantigen-specific antibody and fused to a T cell receptor (TCR) 
signalling domain (Makkouk et al. 2015). The interaction of CAR T cells with their specific 
antigen in cancer patients results in the activation of T cell proliferation, effector functions and 
the development of immunological memory. CAR T cell therapies have shown promise in the 
treatment of CD19-expressing B cell malignancies (Kochenderfer et al. 2017; Sommermeyer 
et al. 2017). Complications involving cytokine storm and auto-reactivity have thus far 
prevented these therapies from obtaining clinical approval (Makkouk et al. 2015).  
Immune Modulation 
Immunomodulatory therapies provide stimulatory signals or inhibit suppressive signals in the 
tumour microenvironment. As they target immune-regulatory processes, these therapies are 
frequently used in combination with other more directed treatments (Makkouk et al. 2015). 
Common immunomodulatory agents include cytokines, TLR ligands and monoclonal 
antibodies. Interleukins, such as IL-2, IL-12 and IL-15 are often used as stimulatory signals for 
their ability to promote cell-mediated immune responses (Kermer et al. 2014; Klevorn et al. 
2016; Zhang et al. 2015). In situ, TLR ligands including the TLR7 ligand imiquimod, can be 
administered to promote anti-tumour immune cell infiltration (Huang et al. 2009). Similarly, 
monoclonal antibodies directed at co-stimulatory molecules including CD40 and 4-1BB can 
promote T cell activation in the absence of ‘true’ co-stimulation, allowing anti-tumour 
responses to progress (Kermer et al. 2014; Wennhold et al. 2016).  
Checkpoint blockade is another popular immunomodulatory strategy. T cell surface molecules 
such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) exhaust 
T cells and inhibit anti-tumour responses. Tumour cells and Tregs express ligands of these 
receptors to dampen anti-tumour responses (Postow et al. 2015). Monoclonal antibodies reverse 
these effects by binding and preventing receptor-ligand interactions. In 2011, the anti-CTLA4 
antibody Ipilimumab (Yervoy®) was the first checkpoint inhibitor to be approved by the FDA 
(metastatic melanoma) (Culver et al. 2011). Several anti-PD1 monoclonal antibodies have now 
also been approved, and in 2015, Ipilimumab and the anti-PD1 antibody nivolumab (Opdivo®) 
were approved as a combination treatment for advanced melanoma. With greatly improved 
patient responses compared to Ipilimumab alone, this approval highlighted the potential for 
combining existing therapies for better patient outcome (Hodi et al. 2016; Ott et al. 2017).  
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Tumour cells are also targets of immunomodulatory therapies. Numerous anti-cancer drugs 
induce ICD in cancer cells, which greatly increases tumour immunogenicity (Inoue et al. 2014). 
During ICD, pathways involving ROS production and ER stress lead to release of immunogenic 
DAMPs, including the pro-phagocytic HSP calreticulin, the TLR4 ligand HMGB1 and the 
inflammatory mediator adenosine triphosphate (ATP) (Garg et al. 2012; Kepp et al. 2011; 
Obeid et al. 2007). These factors stimulate APC activation and neoantigen presentation to the 
adaptive system (Kepp et al. 2011). Oncolytic viruses provide another vector by which ICD can 
be induced in tumour cells. These engineered viruses are designed to proliferate in tumour cells 
and disrupt oncogenic pathways, leading to tumour cell oncolysis and DAMP release (Bartlett 
et al. 2013). In 2015, taimogene laherparepvec (Lmlygic®), an engineered herpes simplex virus 
I virus, was approved for the treatment of advanced melanoma. Taimogene laherparepvec is 
engineered to express granulocyte macrophage colony-stimulating factor (GM-CSF), which 
promotes APC maturation upon tumour oncolysis (Kohlhapp et al. 2016). 
1.3.2. Targeting TLRs for cancer immunotherapy and vaccination 
Successful immunotherapies and vaccines against cancer require adjuvants to activate potent 
tumour-specific immune responses. Adjuvants lower the threshold of immune activation and 
reprogram the immune response to overcome mechanisms of pathogen-associated immune 
evasion, leading to more rapid and robust immune responses against fewer or lower doses of 
antigen (Morelli et al. 2012). As TLRs play key roles in immune activation, their ligands can 
be used to promote these responses. Many TLR ligands have reached clinical trials in cancer 
therapy, but today only the TLR2 ligand BCG, the TLR4 ligand Monophosphoryl lipid A 
(MPL) and the TLR7 ligand imiquimod are FDA approved. Other TLR ligands, particularly 
those targeting TLRs 2, 3, 4, 7, 8 and 9, have been extensively trialled in cancer vaccines and 
immunotherapies (Galluzzi et al. 2012a). Concerns of pro-tumour effects, toxicities and lack of 
efficacy have prevented their approval as therapies without extensive testing. The current usage 
of TLR ligands in human cancer immunotherapy is outlined below. 
TLR2 and TLR4 ligands 
TLR2 and TLR4 recognise components of gram-positive and gram-negative bacteria, 
respectively (Takeuchi et al. 1999). Ligands of these receptors, such as LPS and BCG, were 
some of the earliest adjuvants to be explored for therapeutic application (Mizuno et al. 1968; 
Zbar et al. 1971). BCG, an attenuated strain of Mycobacterium bovis, was developed as a 
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tuberculosis vaccine in the 1920s (Vacchelli et al. 2012). The anti-cancer properties of BCG 
were recognised during the 1960s and 1970s, with a wave of trials investigating its efficacy in 
the treatment of various solid tumours (Vacchelli et al. 2012; Zbar et al. 1971). Inconsistent 
outcomes of BCG therapy meant that it struggled to gain therapeutic approval for cancer 
treatment. The exception was superficial bladder carcinoma, which frequently regressed after 
BCG therapy (Khanna et al. 1991; Melekos 1990). BCG was approved by the FDA for the 
treatment of this cancer in 1990, and is still frequently used today (Vacchelli et al. 2012). Other 
TLR2 ligands have demonstrated limited success in the treatment of cancer, perhaps because 
they promote Treg infiltration and IL-10 production (Yamazaki et al. 2011; Zanin-Zhorov et al. 
2006). 
LPS has also undergone extensive testing as an adjuvant in human cancer therapy since the 
1960s. Many studies show that LPS is very effective at inducing tumour regression, but its 
safety as an adjuvant is of concern (Engelhardt et al. 1991; Otto et al. 1996). High doses of LPS 
induce endotoxic shock, while low doses activate substantial inflammatory responses 
(Copeland et al. 2005; Mackensen et al. 1991). MPL, a less toxic derivative of the lipid A 
component of LPS, has replaced the use of LPS in cancer therapy with less-side effects 
observed (Cluff 2010; Kiener et al. 1988). Cervarix®, a prophylactic vaccine approved by the 
FDA for the prevention of cervical cancer causing strains of Human Papilloma Virus (HPV) in 
2009, includes MPL as an adjuvant (Vacchelli et al. 2012).  
TLR3 ligands 
TLR3 interacts with the sugar phosphate backbone of viral dsRNA molecules (Alexopoulou et 
al. 2001). TLR3 ligands are potent inducers of T helper (Th)-1 responses via TRIF dependent 
pathways, making them ideal adjuvants for stimulation of anti-tumour responses (Yamamoto 
et al. 2003). As in situ agents, TLR3 ligands promote tumour regression via immune cell 
recruitment, depletion of suppressive MDSCs, and activation of tumour cell death (Forghani et 
al. 2015; Nomi et al. 2010; Takemura et al. 2015). Despite these effects, there are yet to be any 
TLR3 ligands approved for cancer therapy. Ampligen® and Hiltonol® are two popular TLR3 
ligands used in human trials (Galluzzi et al. 2012a). Both adjuvants are composed of the 
synthetic dsRNA molecule polyinosinic:polycytidylic acid (poly-IC), and Hiltonol® (poly-
ICLC) is stabilised with carboxymethylcellulose and poly-L-lysine. These stabilising agents 
improve the resistance of Hiltonol® to RNase degradation, resulting in greater efficacy 
(Galluzzi et al. 2012a; Levy et al. 1975). Clinical testing has confirmed that there are no 
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substantial toxicities in patients given Hiltonol® (Galluzzi et al. 2012a). The suitability of this 
adjuvant for cancer therapy will be elucidated by ongoing trials.  
TLR7 and TLR8 ligands 
TLR7 and TLR8 bind viral single stranded ribonucleic acid (ssRNA) molecules that are 
distinguishable from ‘self’ ssRNA due to high uridine and guanosine content (Heil et al. 2004). 
Activation of these TLRs produces potent anti-viral and Th1 responses, with pDCs playing a 
key role through type-1 IFN production (Gibson et al. 2002; Ito et al. 2005; Wagner et al. 1999). 
Immunotherapeutic TLR7/8 ligands are synthetic imidazoquinoline analogues of guanosine 
(Lee et al. 2003b). The TLR7 agonist imiquimod and the TLR7/8 agonist resiquimod are the 
most widely used imidazoquinolines in clinical trials, with imiquimod approved by the FDA as 
a stand-alone treatment for external genital and perianal warts (1997), and actinic keratosis and 
basal cell carcinoma (2004) (Vacchelli et al. 2012). Successful treatment of viral and neoplastic 
lesions with topical imiquimod results in substantial immune cell infiltration, increased IFNγ 
production and initiation of CD8+ T cell cytotoxicity (Barnetson et al. 2004; Huang et al. 2009; 
Soong et al. 2014). Imiquimod also directly stimulates NLRP3-mediated inflammasome 
activation via TLR7 independent stimulation of ROS production, and antagonises 
immunoregulatory adenosine receptor signalling pathways (Gross et al. 2016; Schon et al. 
2006). Stress-mediated suppression of tumour growth and activation of apoptosis and 
autophagy has also been reported in response to imiquimod treatment numerous cancers 
(Almomen et al. 2016; El-Khattouti et al. 2015; Huang et al. 2010). This ability of imiquimod 
to act in the tumour environment at multiple levels perhaps accounts for its success as an 
immunotherapeutic agent. 
TLR9 ligands 
TLR9 ligands are bacterial and viral DNA molecules that are distinguishable from ‘self’ DNA 
due to a high unmethylated CpG content (Hemmi et al. 2000; Rutz et al. 2004). They induce 
potent Th1 immune responses via pDC activation and can also directly stimulate B cell 
proliferation and differentiation (Bernasconi et al. 2003; Ito et al. 2005). Agonists of TLR9 can 
be classified into three classes depending on their cellular targets and modes of immune 
activation. Class A oligodeoxynucleotides (ODNs) strongly stimulate pDCs, while class B 
ODNs activate B cells and macrophages. Class C ODNs have the combined properties of class 
A and B (Vollmer et al. 2004). A number of TLR9 ligands have entered clinical trials as cancer 
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immunotherapies. The success of these ligands as stand-alone agents has been limited, and as 
a result they are generally used in combination with other immunotherapies or 
radio/chemotherapies (Galluzzi et al. 2012a). CpG-7909 (Agatolimid®), a class B ODN, is 
perhaps the most investigated of these (Galluzzi et al. 2012a). CpG-7909 potently stimulates 
Th1-type immune responses, leading to effective anti-tumour immunity (Krieg et al. 2004). It 
also activates cell death pathways in certain tumour cell types including malignant B cells 
(Brignole et al. 2010; Liang et al. 2010). Moderate anti-cancer effects and limited side effects 
are observed in cancer therapy trials involving CpG-7909 (Galluzzi et al. 2012a).  
1.3.3. Developing effective adjuvants from TLR ligands 
TLR ligands have demonstrated varied successes in cancer immunotherapy and vaccination due 
to inconsistent efficacies and safety concerns. Chemical modification, conjugation and 
combination are strategies by which TLR ligands can be improved for enhanced 
immunotherapies and vaccinations (Cluff 2010; Hu et al. 2016; Lakshminarayanan et al. 2012). 
Chemical modification alters unfavourable properties of TLR ligands to improve their potential 
as adjuvants. The TLR4 agonist LPS is not compatible for human use due to its potent 
inflammatory properties (Kiener et al. 1988; Mackensen et al. 1991). In comparison, the 
modified LPS lipid A derivative MPL maintains the immunostimulatory profile of LPS but with 
at least 100-fold less toxicity (Cluff 2010; Kiener et al. 1988). Another chemically modified 
TLR ligand is the poly-IC derivative poly-ICLC (Hiltonol®). Stabilised with poly-l-lysine, 
poly-ICLC is less prone to RNase degradation and as such offers greater longevity and 
improved immune-stimulation in vivo compared to poly-IC (Levy et al. 1975). 
Another strategy for improving TLR-mediated immune activation involves the chemical 
conjugation of TLR ligands to tumour antigen. DCs must interact with both adjuvant and 
antigen to effectively activate tumour-specific responses. Co-delivery of tumour antigen and 
TLR ligands through conjugation ensures that DCs are exposed to both vaccine components, 
preventing induction of immune tolerance and inappropriate responses against other antigens 
(Kreutz et al. 2012). Although TLR conjugate vaccines are yet to reach clinical trials in humans, 
they have shown proficiency in animal models. In particular, vaccines containing the aberrantly 
glycosylated tumour antigen MUC1 conjugated to TLR2 ligands significantly increased the 
magnitude of the immune response generated compared to the two delivered as a mixture (Cai 
et al. 2011a; Lakshminarayanan et al. 2012). Antigens and TLR ligands can also be co-delivered 
to the immune system encapsulated by nanoparticles such as liposomes (Bayyurt et al. 2017). 
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These are effectively taken up and broken down by DCs, and are efficient triggers of antigen 
cross-presentation to the adaptive immune system (Gao et al. 2017).  
TLR-mediated immune activation can also be improved through the co-stimulation of multiple 
TLRs. This promotes synergistic interactions between signalling pathways, providing a more 
robust immune response (Ouyang et al. 2007). In particular, simultaneous stimulation of 
MyD88 and TRIF dependent pathways induces effective immunity via cooperation of 
inflammatory and anti-viral responses (Bagchi et al. 2007; Ouyang et al. 2007). Different TLR 
ligands can be mechanistically paired together to target these pathways and activate specific 
cell types. An example of TLR synergy involves TLR3 and TLR7 ligands, which directly 
activate conventional DCs (cDCs) and pDCs, respectively. When used in combination, type 1 
IFN released through TLR7 pDC stimulation up-regulates expression of TLR7 in cDCs (Hu et 
al. 2016). Synergistic interaction of TLR3 and TLR7 signalling pathways in these cells 
enhances antigen presentation and results in improved Th1 responses (Hu et al. 2016; 
Napolitani et al. 2005).  
1.4. Devil facial tumour disease 
1.4.1. The Tasmanian devil and devil facial tumour disease 
The Tasmanian devil (Sarcophilus harrisii) is a non-territorial marsupial scavenger and hunter 
native to Australia. Although only the size of a small dog, the devil is world’s largest living 
marsupial carnivore (Fig. 1.2-A) (Hawkins et al. 2006; Pemberton 1990). Today, the Tasmanian 
devil is found only on the island state of Tasmania, having become extinct from mainland 
Australia during the late Holocene due to environmental changes, influence of man and 
competition from the dingo (Hawkins et al. 2006; Johnson et al. 2003). Historical population 
fluctuations have also occurred across Tasmania due to environmental factors, culling by white 
settlers, secondary poisoning from rabbit control and disease (Bruniche-Olsen et al. 2014; 
Hawkins et al. 2006; Statham 2005). Following the extinction of the Tasmanian Tiger 
(Thylacinus cyanocephalus) in the 20th century, the devil became the top native mammalian 
predator in Tasmania (Hawkins et al. 2006). It was legally protected in 1941, and estimations 
indicate that the population size was around 150 000 by the early 1990s (McCallum et al. 2007).  
In 1996 a photographer imaged devils with large facial tumours at Mount William National 
Park (wukalina) in Tasmania’s northeast. Although these tumours were never pathologically  
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Figure 1-2. Gross appearance of DFTD tumours and geographical sites of relevance. A) Healthy Tasmanian 
devil. B) Tasmanian devil with advanced DFT1. C) Gross appearance of DFT1 tumours. D) Gross appearance of 
DFT2 tumours. E) Map of Tasmania displaying locations of relevance to this review including sites of DFT1 and 
DFT2 origin (red), disease-free insurance populations (purple), wild-recovery release sites (yellow), other 
discussed sites (blue) and the DFT1 disease front (dashed line). 
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examined, it is believed these were the first recorded sighting of an aggressive and fatal 
transmissible tumour named DFTD (Fig. 1.2-B and 1.2-C) (Hawkins et al. 2006). Found 
predominately as large masses on the face and neck, it was hypothesised that DFTD tumours 
were passed between animals via direct transfer of rogue cells through biting, a characteristic 
behaviour of Tasmanian devils (Hamede et al. 2013; Loh et al. 2006a; Pearse et al. 2006). 
Metastases to internal organs were common, and fatalities usually occurred within 6 months of 
lesion appearance (Pyecroft et al. 2007). Over twenty years, DFTD would spread from east to 
west across Tasmania producing an estimated total population decline of around 80% (Hollings 
et al. 2014). Initial spread was rapid, with greater than 51% of the population estimated to be 
affected by mid-2005 (Hawkins et al. 2006). Today, only the far northwest of Tasmania is 
believed to be DFTD free (Fig. 1.2-E), and severely affected areas have experienced up to 95% 
decreases in population numbers (Hollings et al. 2014). It was hypothesized in 2009 that DFTD 
could lead to extinction of the Tasmanian devil (McCallum et al. 2009). This is yet to occur in 
any affected populations. 
More recently in 2014, routine euthanasia of a severely diseased Tasmanian devil from the 
D’Entrecasteaux Channel region of Tasmania revealed a tumour with the gross appearance of 
DFTD, but negative for typical diagnostic markers (Fig. 1.2-D). Karyotypic analysis of the 
tumour and others from the region revealed a second transmissible tumour (Pye et al. 2016b). 
DFTD and the new tumour were denoted DFT1 and DFT2, respectively, with DFTD used as 
an umbrella term to describe both tumours. Diagnosed cases of DFT2 are thus far confined to 
the Channel region and numbers are low (21 cases in early 2017) [R. Hamede, personal 
communication], although the disease appears to be persisting. The impact of DFT2 on 
Tasmanian devil populations remains unseen at this early stage. 
1.4.2. DFTD transmission and clonality 
Naturally occurring transmissible cancers are rare, with only three documented in animal 
species. These include an ancient venereal sarcoma in dogs known as Canine Transmissible 
Venereal Tumour (CTVT), a recently discovered transmissible leukaemia in certain species of 
soft-shell clams, and DFTD (Metzger et al. 2015; Murgia et al. 2006; Pearse et al. 2006). 
Transmissible tumours represent rogue clonal cell lines that develop in a single animal, and 
move as allografts between individuals via an effective route of transmission (coitus in dogs, 
filter feeding in clams, biting in devils) (Hamede et al. 2013; Metzger et al. 2015; Murgia et al. 
2006). The rogue cells must avoid both ‘non-self’ and anti-cancer immune defences to survive 
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in new hosts. Both clam leukaemia and DFTD are fatal, and have produced severe population 
declines in their respective species (Hawkins et al. 2006; Metzger et al. 2015). Comparatively, 
CTVT, which has affected canines for more than 11 000 years, is rarely fatal and can be easily 
treated with Vincristine (Amber et al. 1990; Murchison et al. 2014). As CTVT is a much older 
disease, host-disease evolutionary processes have likely reduced the aggressiveness of this 
tumour allowing for host survival (Ujvari et al. 2016). 
The allograft theory of DFTD was first suggested in 2006 (Pearse et al. 2006). Analysis of 
DFT1 karyotypes identified complex chromosomal abnormalities that were identical across 
every facial tumour tested. To further support this theory, one host devil was observed to have 
a pericentric inversion of chromosome 5, an abnormality that was not found in its tumour. It 
was impossible for this tumour to have been derived from host tissue considering it did not 
share the same chromosomal abnormality (Pearse et al. 2006). Further proof for the allograft 
theory of DFTD transmission was generated through subsequent studies. Analyses of MHC 
class I and class II loci revealed that DFT1 tumours have identical genotypes that in many cases 
are distinct from host genotype (Siddle et al. 2007). Genotypes at microsatellite loci are also 
identical between tumours but different from host tissue (Murchison et al. 2010; Siddle et al. 
2007). Similarly, DFT2 tumours exhibit identical microsatellite genotypes that are distinct from 
host. Both microsatellite and MHC genotype in DFT2 tumours were distinct from DFT1 
tumours, suggesting that the two tumours arose independently (Pye et al. 2016b). 
The normal Tasmanian devil karyotype consists of 14 chromosomes, including 6 pairs of 
autosomes and a pair of sex chromosomes (Fig. 1.3-A). Cytogenetic analysis of DFT1 tumours 
revealed a clonal and stable but vastly abnormal karyotype with missing chromosome 2 
homologues and sex chromosomes (Fig. 1.3-B) (Deakin et al. 2012; Pearse et al. 2012). 
Chromosomal painting revealed complex rearrangements of two X chromosomes in the DFT1 
genome, suggesting that the founder devil was female (Murchison et al. 2012; Pye et al. 2016b). 
The missing chromosomes from the DFT1 karyotype have been rearranged to create five 
marker chromosomes designated M1-5 (Deakin et al. 2012; Pearse et al. 2012). Small 
differences in the rearrangements of chromosomes and markers distinguish four distinct DFT1 
strains, with either strain 1 or 2 representing the original clonal cell line. Since the mid-2000s, 
strain 2 has become the dominant strain across Tasmania, perhaps because this clone is slower 
growing allowing greater time for tumour transmission prior to host death (Pearse et al. 2012). 
DFT1 exists as diploid and tetraploid sub-clones. Diploid clones have been associated with the  
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Figure 1-3. Representative karyotypes of DFT1 and DFT2 tumours. A) Karyotype of a normal male 
Tasmanian devil. B) Karyotype of a DFT1 tumour. C) Karyotype of a DFT2 tumour. Cytogenetic abnormalities 
in DFT1 and DFT2 tumours are marked by red arrows. Image adapted from Pye et al, 2016.  
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severe population collapses that were seen in eastern Tasmania, while tetraploid clones are 
associated with the increased longevity and reduced disease impacts that have been observed 
further west (Hamede et al. 2015; Pearse et al. 2012). 
The karyotype of DFT2 tumours is vastly different from DFT1 tumours, giving further evidence 
that DFT2 arose independently of DFT1. DFT2 karyotypes are monosomal at chromosome 6 
and sex chromosomes are present (Fig. 1.3-C). The DFT2 karyotype also shares vastly different 
chromosomal additions and deletions than the DFT1 karyotype, with chromosomes 1, 2 and 4 
exhibiting additional material. The Y chromosome is present in these tumours irrespective of 
the sex of the host, suggesting that these tumours arose from a male devil (Pye et al. 2016b). 
Early immunohistochemical characterization of DFT1 tumours proposed a neuroectodermal 
origin of the clonal cell lineage (Loh et al. 2006b). This hypothesis was confirmed by miRNA 
and messenger ribonucleic acid (mRNA) tumour profiling, which demonstrated expression 
patterns consistent with a neurological origin (Murchison et al. 2010). In particular, DFT1 
highly expressed proteins associated with myelination, indicating that the tumour was of 
Schwann cell origin. The myelin protein periaxin was expressed strongly and specifically in 
DFT1 cells, and is now used as a diagnostic marker for DFT1 tumours (Murchison et al. 2010; 
Tovar et al. 2011). Periaxin expression is absent in DFT2 tumours (Pye et al. 2016b), but at this 
stage the cellular origin of the lineage remains unknown.  
1.4.3. The immune system and DFTD 
In order to be transmissible, a cancer must evade both immunosurveillance and allograft 
rejection. Several theories could account for DFTD transmission, including a failure of the 
immune system to recognise ‘non-self’ due to low genetic diversity, an inability of the immune 
system to fight cancer due to inherent immune dysfunction or insufficiency, or an absence of 
an immune response against DFTD cells due to tumour-specific aberrations and mutations 
(Kreiss et al. 2011; Kreiss et al. 2008; Siddle et al. 2013). The evidence for and against each of 
these theories is discussed below. 
Low genetic diversity 
A failure of the immune system to reject allografts has been observed in the cheetah, which 
suffered severe inbreeding and reduced genetic diversity following a previous population 
bottleneck (O'Brien et al. 1985). Similar population bottlenecks may have introduced low 
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genetic diversity into the Tasmanian devil population, reducing their ability to recognise 
allogeneic tissues (Hawkins et al. 2006). Analysis of MHC class I and II loci in the Tasmanian 
devil confirmed that genetic diversity is low (Siddle et al. 2007). In addition, lymphocytes from 
eastern Tasmanian devils were unable to induce allogeneic responses against each other through 
mixed lymphocyte reactions (Cheng et al. 2012; Siddle et al. 2007; Siddle et al. 2010). Further 
analysis of genetic variation at the whole genome level, and in other immune related gene 
families such as TLRs and cytokines, has confirmed the low genetic diversity of Tasmanian 
devils (Miller et al. 2011; Morris et al. 2015). Examination of MHC in historical samples 
demonstrated that this low diversity dates as far back as the mid-Holocene, and perhaps explains 
a susceptibility of the Tasmanian devil to disease-induced population collapses (Morris et al. 
2013a). To understand whether low diversity accounts for DFTD transmission, allogeneic skin 
transplants were performed and monitored for signs of immune rejection. Within two weeks all 
allografts displayed extensive immune infiltration and were subsequently rejected despite a lack 
of MHC diversity between the animals (Kreiss et al. 2011). These findings demonstrated 
convincingly that Tasmanian devils are capable of allorecognition, and that a lack of genetic 
diversity could not fully account for DFTD transmission.  
In 2012 it was observed that devils from West Pencil Pine, a population lying between areas of 
low and high MHCI variation in the east and west respectively, had lower infection rates than 
other devil populations. This was the most eastward population with MHCI genotypes differing 
from the tumour, suggesting that MHC diversity could account for the slower disease 
progression in this region (Hamede et al. 2012). In support of this, it had been demonstrated 
that mixed lymphocyte reactions could be consistently generated if samples were taken from 
geographically separate populations, suggesting that genetic diversity was required (Kreiss et 
al. 2011). Despite this, no predictable differences in genetic variation at the MHC loci could be 
correlated with DFTD susceptibility in this population (Lane et al. 2012). It was later discovered 
that reduced disease impacts at West Pencil Pine occurred due to the dominant clone being the 
slower growing tetraploid strain. A subsequent change in the dominant clone to the diploid 
variant corresponded with an increase in disease impacts and a population collapse at this site 
(Hamede et al. 2015). 
Immune insufficiency 
A susceptibility of Tasmanian devils to neoplasms has been recognised for some time, with 
devils at the San Diego Zoo in 1979 reported to develop spontaneous tumours at a greater 
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frequency than other mammals (Griner 1979). It has also been suggested that marsupials are 
immunologically lazy, with weak mixed lymphocyte responses documented in the short-tailed 
opossum (Monodelphis domestica), and poor antigen-specific responses in the koala 
(Phascolarctos cinereus) (Stone et al. 1998; Wilkinson et al. 1992a). With transmissible 
cancers so rare, it would seem likely that the Tasmanian devil would have an inherent immune 
insufficiency allowing for the development of both DFT1 and DFT2. Many aspects of the 
Tasmanian devil immune system have now been studied, and are outlined below. 
Tasmanian devils have all expected primary and secondary lymphoid organs, with a structure 
and cellular makeup similar to that seen in eutherian mammals (Howson et al. 2014; Kreiss et 
al. 2009a; Woods et al. 2007). They have CD4+ and CD8+ T cells, IgM and IgG-producing B 
cells and dendritic cells (DCs) throughout lymphoid tissues. They also display a full 
complement of leukocytes in the blood and exhibit competent neutrophil phagocytosis 
(Howson et al. 2014; Kreiss et al. 2008; Woods et al. 2007). Evidence for antibody-dependent 
natural killer (NK) cell cytoxicity and direct peripheral blood mononuclear cell (PBMNC) 
killing of DFTD cells in response to mitogens suggests that NK cells are functional (Brown et 
al. 2011; Brown et al. 2016). PBMNCs were also proliferative in response to mitogens including 
concanavalin A (ConA), phytohaemagglutinin (PHA) and pokeweed mitogen (PWM), although 
high doses were required (Kreiss et al. 2008; Stewart et al. 2008; Woods et al. 2007). 
Immunisation of devils with horse red blood cells demonstrated that devils develop prominent 
primary, secondary and memory humoral responses, suggesting that adaptive immunity also is 
intact (Kreiss et al. 2009b).  
Recent observations have revealed a small number of wild Tasmanian devils with natural serum 
antibody against DFT1. In some cases, this antibody correlated with tumour regression (Pye et 
al. 2016a). These findings provide the first evidence that the devil’s natural immune response 
can overcome immune evasion by DFT1, suggesting that an immune insufficiency does not 
fully account for DFT1 transmission in Tasmanian devils. 
Immune evasion 
With adequate genetic diversity and an immune system capable of rejecting allografts, the 
transmissibility of DFTD cells among Tasmanian devils could be explained by their 
aberrancies. In support of this, established DFT1 tumours display little immune cell infiltration, 
suggesting that the cells are ‘invisible’ to the immune system (Howson et al. 2014). Foreign 
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MHCI recognition plays a key role in allograft rejection and is frequently deregulated in cancer 
to prevent presentation of neoantigens to the immune system (Leone et al. 2013). Analysis of 
MHCI in DFT1 cells suggested that these mechanisms account for DFT1 immune evasion, with 
MHCI protein absent at the cell surface despite high expression at the transcriptional level 
(Siddle et al. 2007; Siddle et al. 2013). Surface MHCI was suppressed by epigenetic 
deacetylation and subsequent silencing of genes required for antigen processing, including β2-
microglobulin (β2m) and the transporters associated with antigen processing (TAP) -1 and -2. 
Treatment of DFT1 cells with IFNγ reversed these epigenetic modifications and reinstated 
MHCI on the DFTD cell surface (Siddle et al. 2013).  
Although MHCI silencing prevents recognition of DFT1 cells by the adaptive immune system, 
additional mechanisms of immune evasion must exist to allow evasion of NK cell defences 
against absent MHCI. These mechanisms are not yet fully elucidated. Analysis of 
immunosuppressive cytokine expression demonstrated that IL-6, IL-10, TGFβ and VEGFA are 
expressed in DFT1 tumours at levels comparable to normal control tissues. This suggests that 
these cytokines are not aberrantly expressed in DFT1, but could play a role in tumourigenesis 
(Morris et al. 2013b). The immune inhibitory axis PD1:PDL1 has also been investigated in 
DFT1. Although PDL1 is not expressed constitutively on DFT1 cells, it was strongly up-
regulated by IFNγ (Flies et al. 2016). During an immune response against DFT1, IFNγ-induced 
PDL1 expression may provoke T cell exhaustion via PD1 receptors. Mechanisms of immune 
evasion have not yet been fully explored in DFT2. 
1.4.4. Preservation of the Tasmanian devil  
As the top mammalian predator in Tasmania, a demise of the Tasmanian devil could have 
severe consequences for the balance and control of introduced predators and native species in 
the state. These effects are already evident in areas devastated by disease, with increases in 
invasive feral cat and black rat numbers and population changes to wild carnivore and herbivore 
species (Hollings et al. 2014, 2016). The Tasmanian devil has been listed on the International 
Union for Conservation of Nature’s (IUCN) Red List of threatened species to educate and 
prioritise conservation and research into DFTD (Hawkins et al. 2008). Ongoing research hopes 
to improve the current understanding of DFTD and to develop strategies for prevention and 
protection of Tasmanian devils from both forms of the disease. DFTD also presents a unique 
opportunity to study neoplasia and graft transplantation for human application, providing a 
‘natural’ cancer model for mechanistic and therapeutic investigation.  
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Recent discoveries of devils with DFT1-specific disease regression and observations of 
persisting populations in areas devastated by disease have created new hope for the survival of 
the Tasmanian devil (Hamede et al. 2015; Pye et al. 2016a). At the molecular level, two 
genomic regions containing immune and cancer related genes have displayed strong selection 
since the arrival of DFT1, providing evidence for host-disease co-evolution (Epstein et al. 
2016). In addition, variants in host PAX3 and TLL1 genes have been associated with cases of 
spontaneous DFT1 regression (Wright et al. 2017). The functional relevance of these genes 
remains unknown, and as such strategies for the protection of devils are required for 
maintenance of remaining genetic diversity, population structure and habitual balance. 
Additionally, the impending spread of DFT2 outward from the D’Entrecasteaux Channel region 
could have devastating impacts on already vulnerable populations, warranting continued 
investigation into preservation of the Tasmanian devil.  
A priority for the protection of Tasmanian devils from DFTD was the establishment of disease-
free captive and wild insurance populations in Tasmania and mainland Australia. These 
populations were created to represent as much genetic variation as possible, in order to ensure 
the maintenance of population diversity in the long-term (Wright et al. 2015). One such 
insurance population was established on Maria Island on the East-Coast of Tasmania with the 
release of 15 disease-free devils in 2012 (Thalmann et al. 2016). Further releases and successful 
breeding has meant that these populations have thrived, and cohorts are now available for re-
population trails in areas of mainland Tasmania. Two such wild recovery areas included 
Narawntapu National Park in 2015 and Stony Head in 2016, regions where DFT1 is prevalent 
(Save The Tasmanian Devil Program 2017). Another release area was the Forestier Peninsula, 
an isolated area of South-East Tasmania. Infected devils were removed from the Forestier 
Peninsula from 2006 to 2010 as part of a disease suppression trial. With no slowing of disease 
progression in this area, the trial was ceased (Ujvari et al. 2014). The area was subsequently 
depopulated of Tasmanian devils, and repopulated in 2015 with healthy devils to create a new 
insurance population (Save The Tasmanian Devil Program 2017).  
Another priority for the protection of Tasmanian devils from DFTD is the development of a 
prophylactic DFTD vaccine. If successful, such a vaccine could be given routinely to re-wilded 
insurance devils and trapped wild devils to promote herd immunity in affected populations. 
Early immunisation trials in captive Tasmanian devils have utilised cultured DFT1 cells treated 
with IFNγ to up-regulate MHCI, and inactivated by methods of freeze-thawing, irradiation or 
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sonication (Kreiss et al. 2015; Tovar et al. 2017). Subcutaneous immunisations were given as 
these demonstrated superior secondary responses in devils when compared to other 
immunisation strategies (Kreiss et al. 2009b). Immunisation trials in small numbers of devils 
demonstrated some success, with one individual protected from immune-challenge with live 
DFT1 cells for more than a year after immunisation (Kreiss et al. 2015). Other non-protected 
immunised devils responded to therapeutic DFT1 immunisations with full tumour regression 
(Tovar et al. 2017). Although further improvements to DFTD vaccines are required, these 
studies provide the evidence that DFTD immunisations can prime tumour-specific immunity in 
Tasmanian devils. Re-wilding trials will provide opportunities for larger DFTD immunisation 
cohorts in the future. 
As with other vaccines, a successful DFTD immunisation will require a potent immune 
adjuvant. Combinations of the adjuvants Montanide, ISCOMATRIX® and the TLR ligands 
CpG and poly-IC were included in previous DFTD immunisation trials, but their efficacy as 
adjuvants in the devil was not tested (Kreiss et al. 2015; Tovar et al. 2017). With potent cell-
mediated responses required to induce protective anti-tumour immunity, proper assessment of 
adjuvant efficacy in the Tasmanian devil is required for a DFTD vaccine to be successful.  
1.5. Toll-like receptors in the Tasmanian devil and research aims 
TLR signalling pathways are popular adjuvant targets in both human and animal studies due to 
their high evolutionary conservation and potent immunomodulatory properties. TLR expression 
has been studied in many mammals (Flies et al. 2014; Tirumurugaan et al. 2010; Vahanan et al. 
2008), but has not yet been thoroughly investigated in any marsupial species. Analysis of the 
function of TLR genes in the Tasmanian devil will assist the identification of appropriate 
immune adjuvants for DFTD immunisations, and will improve our current understanding of 
marsupial immunology. Previous analysis of the Tasmanian devil genome revealed ten full-
length TLR genes with intact extracellular, transmembrane and intracellular domains (Cui et 
al. 2015a). These genes include homologues to the mammalian TLRs 2, 3, 4, 5, 6, 7, 8, 9 and 
10. The tenth TLR gene in the devil genome is a homologue of the mammalian TLR11 
subfamily. This gene has been denoted TLR13-like (TLR13L) in this thesis. As scavengers of 
carrion, Tasmanian devils are exposed to a myriad of pathogens and would require a 
sophisticated innate immune system. As such, we hypothesise that toll-like receptors are 
functional in the Tasmanian devil and can be stimulated by conventional ligands to enhance 
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DFTD vaccinations. The following research aims will address this hypothesis. 
Aim 1: To analyse the function of TLRs in the Tasmanian devil immune system 
The highly conserved nature of TLR signalling across mammalian species means that TLR 
ligands are attractive adjuvant targets in the Tasmanian devil. Analysis of TLR function in the 
devil immune system will reveal potential adjuvant targets for improved DFTD vaccinations. 
This is the first investigation of TLR function in any marsupial, providing insight into the innate 
immune system of these species. 
Chapter 3 investigates the response of Tasmanian devil immune cells to conventional TLR 
ligands through in vitro stimulation and gene expression assays.  
Aim 2: To determine the effects of TLR stimulation on DFTD survival and growth 
Tumour cells can also express a range of TLRs. The treatment of tumour cells with TLR ligands 
has a range of pro- and anti-cancer effects from inhibition of cell death and induction of 
apoptosis, to stimulation of proliferation, migration and survival. Investigation of the response 
of DFTD cells to TLR ligands will determine whether TLR signalling plays a pro-survival role 
in DFTD. Appropriate choice of TLR ligands for use in the Tasmanian devil could be important 
for avoiding adverse effects on DFTD growth and survival in vivo. 
Chapter 5 evaluates the response of DFT1 and DFT2 tumour cells to conventional TLR ligands 
through in vitro stimulation and functional assays.  
Aim 3: To investigate strategies for DFTD treatment and prevention using TLR ligands 
TLR ligands are used in human trials as both vaccine adjuvants and stand-alone therapeutic 
agents. Further investigation of the effects of TLR ligands with potential in the treatment and 
prevention of DFTD will reveal strategies for their use in the Tasmanian devil. 
Chapter 4 incorporates findings from chapter 3 to analyse the efficacy of TLR ligands as 
adjuvants using in vivo immunisation trials. 
Chapter 6 incorporates findings from chapter 4 to further investigate the effects of the TLR7 
ligand imiquimod in DFT1 cell lines using a whole transcriptome and proteome approach. 
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2.1. Reagents, consumables and equipment 
2.1.1. Reagents 
Table 2.1. Reagents used for experimentation 
Reagent Supplier 
Catalogue 
Number 
2.3 mm zirconia beads BioSpec Products 11079125z 
2-Mercaptoethanol Sigma-Aldrich M6250 
4’6-Diamidono-2-Phenylindole 
Dihydrochloride (DAPI) 
Sigma-Aldrich D9542 
Acetic Acid Sigma-Aldrich ARK2183 
Agarose Sigma-Aldrich A9539 
Ammonium bicarbonate Sigma-Aldrich 09830 
AmnioMAXTM-II complete medium Thermo Fisher Scientific 11269016 
Annexin V cell death assay Miltenyi Biotech 130-097-928 
Antibiotic-Antimycotic Thermo Fisher Scientific 15240-062 
Apo-ONE Homogeneous Caspase 3/7 assay Promega G7792 
BD Cytofix/CytopermTM 
Fixation/Permeabilization Solution Kit 
BD Biosciences BD554714 
BD GolgiStopTM BD Biosciences BDB554724 
Bovine Serum Albumin Sigma-Aldrich A9418 
Camptothecin BioVision 1039 
Cell counting kit-8 Sigma-Aldrich 96992 
CellTraceTM violet cell proliferation kit Thermo Fisher Scientific C34557 
Chloroform Merck Millipore 102445 
Digoxin GlaxoSmithKline - 
Dimethyl Sulphoxide (DMSO) Sigma-Aldrich D2650 
Disodium phosphate Merck Millipore 1065860500 
Dithiothreitol Bio-Rad 1610611 
EDTA disodium salt Thermo Fisher Scientific AJA180 
Endotoxin-free KLH Merck Millipore 374825 
Ethanol Fronine JJ0072P 
EZQ protein quantification kit Thermo Fisher Scientific R33200 
Foetal Calf Serum Thermo Fisher Scientific 16000-036 
GlutaMAXTM Thermo Fisher Scientific 35050-061 
Glycine Sigma-Aldrich G7126 
GoScriptTM Reverse Transcription System Promega A5003 
Halt protease inhibitor cocktail (100X) Thermo Fisher Scientific 87786 
HEPES Thermo Fisher Scientific 15630080 
Histopaque®-1077 Sigma-Aldrich 10771 
Hydrochloric acid VWR 20252 
ImmoMixTM Red Bioline BIO-25022 
Iodoacetemide Sigma-Aldrich 57670 
ISCOMATRIX CSL Ltd. - 
Isofluorane Abbot Australasia Pty Ltd. - 
Isopropanol Merck Millipore 109634 
Light Cycler 480 SYBR Green I Master Roche Applied Sciences 04707516001 
LIVE/DEAD Fixable Near-IR Dead Cell 
Stain 
Thermo Fisher Scientific L10119 
Methanol Merck Millipore 4102322500 
Milli-Q® Water Merck Millipore ZR0Q00800 
Monopotassium phosphate Sigma-Aldrich P5655 
Normal goat serum Thermo Fisher Scientific 31873 
Phenol red-free DMEM Thermo Fisher Scientific 31053028 
Phosphate Buffered Saline Thermo Fisher Scientific BR0014G 
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Potassium chloride Sigma-Aldrich P9333 
Propidium Iodide Sigma-Aldrich P4864 
Quick-Load 100 Base pair DNA ladder New England Biolabs N0467S 
Rabbit Immunoglobulin Fraction (Normal) Dako X090302-8 
Recombinant devil interferon-gamma 
Walter and Eliza Hall Institute of Medical 
Research 
- 
Recombinant devil interleukin 2 
Walter and Eliza Hall Institute of Medical 
Research 
- 
RNAlater Thermo Fisher Scientific AM7020 
RNase A Thermo Fisher Scientific AM2270 
RNeasy Mini Kit QIAGEN Bioinformatics 74104 
RPMI 1640 Medium Thermo Fisher Scientific 11875-093 
Sodium Azide Sigma-Aldrich S2002 
Sodium bicarbonate Sigma-Aldrich S5761 
Sodium carbonate Sigma-Aldrich 451614 
Sodium chloride Sigma-Aldrich S5886 
Sodium di-hydrogen orthophosphate Thermo Fisher Scientific 471 
Sucrose Sigma-Aldrich S8501 
SYBR® Safe DNA Gel Stain Thermo Fisher Scientific S33102 
Thiourea Sigma-Aldrich T8656 
TMB peroxidase substrate Rockland Immunochemicals Inc. TMBE-100 
TriReagent Sigma-Aldrich T9424 
Tris/Acetic acid/EDTA Buffer Bio-Rad #161-0743EDU 
Tris/EDTA Buffer Thermo Fisher Scientific 12090-015 
Tris HCL Merck Millipore 108291000 
Triton-X-100 VWR 30632 
Trypan Blue Sigma-Aldrich T6146 
Trypsin from porcine pancreas Sigma-Aldrich T6567 
TURBO DNA-freeTM Kit Thermo Fisher Scientific AM1907 
TWEEN 20 Sigma-Aldrich P9416 
UltraPureTM Distilled Water Thermo Fisher Scientific 10977-023 
Urea Spectrum Chemical U1015 
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2.1.2. Toll-like receptor ligands 
Table 2.2. TLR ligands used for experimentation  
TLR  Ligand Supplier 
Catalogue 
No./Lot 
Preparation 
TLR2 FSL-1 
AdipoGen, San 
Deigo, USA 
AG-CP3-0009 
Reconstituted to 1 
g/ml in sterile water 
TLR3 
Polyinosinic:polycytidylic Acid 
(Poly-IC) 
Sigma-Aldrich, St 
Louis, USA 
P0913 
Reconstituted to 1 
mg/ml in sterile water 
TLR3 Poly-ICLC (Hiltonol®) 
Kindly provided by 
Dr Andres Salazar, 
Oncovir Inc., 
Washington DC, 
USA 
lot PJ215-1-10-
01 
No preparation 
required 
TLR4 
Lipopolysaccharide (Escherichia 
coli) (LPS) 
Sigma-Aldrich, St 
Louis, USA 
L2645 
Reconstituted to 1 
mg/ml in sterile water 
TLR5 Flagellin 
AdipoGen, San 
Diego, USA 
AG-40B-0095-
C100 
Reconstituted to 1 
g/ml in sterile water 
TLR7 Imiquimod 
Sigma-Aldrich, St 
Louis, USA 
I5159 
Reconstituted to 4 
mg/ml in DMSO and 
further diluted in 
sterile water 
TLR9 
CpG-ODN-1585 (sequence: 5’-
GGGGTCAACGTTGAGGGGGG-3’) 
Geneworks, 
Adelaide, Australia 
- 
Reconstituted to 1 
mg/ml in sterile water 
TLR9 
CpG-ODN-2395 (sequence: 5’-
TCGTCGTTTTCGGCGCGCGCCG-3’) 
Geneworks, 
Adelaide, Australia 
- 
Reconstituted to 1 
mg/ml in sterile water 
TLR11 Profilin (Toxoplasma gondii) 
Enzo Life Sciences, 
Farmingdale, USA 
ALX-522-093-
C010 
Reconstituted to 1 
g/ml in sterile water 
 
2.1.3. Oligonucleotides and PCR primers 
Primers for reverse transcriptase polymerase chain reaction (RT-PCR) were designed with the 
NCBI PrimerBLAST tool using gene transcripts identified in the Tasmanian devil reference 
genome Devil7.0 assembly GCA_000189315.1 (Table 2.3.). Primers were synthesised by 
GeneWorks (Adelaide, Australia). 
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Table 2.3. Primers used for RT-PCR and qRT-PCR 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
RPS18 TCGGGACTGCTCTACAAACG ACCCTTGATGGCTGTGATGG 
A20 TAACCAGAAAGAGCAGGACCAC ATCAGACAGAGCTCACAAGGTG 
2M TGTGCATCCTTCCCTACCTGGAGG CATTGTTGAAAGACAGATCGGACCGC 
BAD ATGAGCGACGAGTTCCACTG CAAATTCCGCCCGAACCAAG 
BAK CTACCGGCTGGCACTATATGTT AATGGAGTTGTTGGAGAGGTCC 
BCL2 GCGGATTGTGGCCTTCTTTG AGTCATCCACAGGGCTATGC 
BCLXL AGAATCCACCCTCGGAAACC CAGGAATGGGCTGATCCAGT 
BID CAGCCCAGCTTGGTGGATAA GGATGGGGCATGGGTCATAA 
BIM CGTTTGCTACCAGATCCCCA CACAACTCATAGGCGCTGGA 
CD19 AGGGCAGCTATCCTCTTTGC CAGAGGTAGAAGCCCCCAGA 
CD3e TTCTCCCATGTCCCCACTCA AGGTTCCAGGGCTTTTGGTT 
CD86 GCTTGGTACAGACACAGGAG CCCAAGAATCAGGAGGTTGC 
CSF1R ACATCTTTGGAGTGTCCCCATC GTTTCTCTCCAGGGATGCTGAA 
DDIT3 CCAGCTAGAAATCGGAAGCAAAG GTCAATCGCTCGATCTCTCTCTT 
HSPA5 AGCGACCTCTGACCAAGGAT AGCGGTGACCCGAAGAATAC 
IFN AGGGATCTGGAAGTCCATTCTG TGAAGAGAGCATCCAGCATC 
IL1α ACACTCACCACGTCTCATCG TGTCCAAATTGCTGCCAACG 
IL6 GAGCATGTGCGACAATAGCAG ACTCGGCTAGTTGAGTCGTG 
IL10 GGCAGAGAATGAAACGGAG ACTTCACAAGGCAGGAATCTGT 
IL12A AGTTGCCTGGATTCCAAAGAG GCAAGAGTTTCCTCGACCAC 
MCL1 AGTTGTACGGGCAGTCCTTG CCCCGTCACTGAACACATGA 
MHCI CAGATTTCCCGAGTGGAC GTCGTAGGCGAACTGAAG 
TAP1 TGCCTCAGTACTAGCACCGGTATCTGC CTTCCATGACCTCCTCTAGCTCTGG 
TAP2 TGTGGGCTAAGGCAGATTCTGGCAGGG TCCCAGGAGGAGCTAAGCGTGG 
TLR2 GTGTCTCCACAAACGGGACT TTGCTGAGCTTCATCCCTGG 
TLR3 TCTTCTCGGGCATGGACCACA TGCTCCCTGCAAAGATAGTGCCC 
TLR4 TGGGTGAGGAAGGAATTGGTG GTTGGCAGCAATAGCCACAC 
TLR5 GATGGCTGGTGCATTGAAGC TCAGGTATGGTTGCCTCTGC 
TLR6 AGCAGGAGCTGATTCCCAAC ATGGTGCACTGAGGGATTGG 
TLR7 CAGGACCAGGAGCACACAAA TCTGGTGAAACTAGGCGCTG  
TLR8 GGCAACCGCCTAGACATCTT GGAATCCTGTGGAGCCTGTT 
TLR9 TTGTCCCTCCGAGACTTTGC TTCTCGCTGAGGTCCAACAC 
TLR10 GCCAGAAACGCTCTCTACCA ATGGGTTGCCTCCTGCTTTT 
TLR13L AGCCTGGTGCTTGCAACTAT GCTCATCAGCGGCATTGAAG 
TGF TATGGACATTAGTGGTGAGTG AAGGACGGTTCTGGTTCT 
VEGFA ACGGAAATCGAATGAAGTG CTGGATATTCTTGGAAGATGTC 
XBP1 TGAATGATGTCCGGTTGGTGG CAACACAGTCAGAATCCACAGG 
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2.1.4. Antibodies 
Table 2.4. Antibodies used for experimentation 
Antibody 
Catalogue 
Number/Lot 
Target 
Working 
Concentration 
Supplier 
Alexa Fluor-647 monoclonal 
mouse anti-devil CD4 
15/14-7H9-19-1 devil CD4 0.25 μg/ml 
WEHI, Melbourne, 
Australia 
Polyclonal rabbit anti-human 
CD3 
A0452 
/20011828 
devil CD3 3 μg/ml 
Agilent, Santa Clara, 
USA 
R-phycoerythrin goat anti-rabbit 
IgG (H+L)  
P-2771MP 
/1463195 
rabbit IgG 2 μg/ml 
Thermo Fisher Scientific, 
Waltham, USA 
FITC monoclonal mouse anti-
IFNγ [CC302] 
ab27865/ 
GR195750-4 
devil IFNγ  2 μg/ml Abcam, Cambridge, UK 
Monoclonal mouse anti-
Tasmanian devil IgG  
A4D1 devil IgG 10 μg/ml 
WEHI, Melbourne, 
Australia 
Goat anti-mouse 
immunoglobulin-HRP  
P0447/ 
01117102 
mouse IgG 25 μM 
Agilent, Santa Clara, 
USA 
Polyclonal rabbit anti-
Tasmanian devil Ig 
clones 61dW and 
60dB  
devil Ig 
1/15000 for 
proliferation assays 
1/1000 for B cell 
isolations 
- 
Polyclonal mouse anti-
Tasmanian devil β2m 
- devil β2m 1/200 
Kindly provided by Dr 
Hannah Siddle, 
University of 
Southampton, UK. 
Alexa Fluor-647 goat anti-
mouse IgG (H+L) 
A21235 mouse IgG 2 μg/ml 
Thermo Fisher Scientific, 
Waltham, USA 
Monoclonal rabbit anti-
calreticulin antibody [EPR3924] 
ab92516 devil CALR 1.58 μg/ml Abcam, Cambridge, UK 
Alexa Fluor 488 goat anti-rabbit 
IgG (H+L) 
A11034 rabbit IgG 5 μg/ml 
Thermo Fisher Scientific, 
Waltham, USA 
WEHI, Walter and Eliza Hall Institute of Medical Research.  
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2.1.5. Cell lines 
Table 2.5. Cell lines used for experimentation 
Cell line Cell type Source 
C5065 DFT1 strain 3 DPIPWE 
1426 DFT1 strain 2 DPIPWE 
4906 DFT1 strain 4 DPIPWE 
Half-pea DFT1 strain 3 DPIPWE 
RV DFT2 Menzies Institute for Medical Research 
TD344 FBB Tasmanian devil fibroblasts Menzies Institute for Medical Research 
   
 
2.1.6. Solution recipes 
1.5 % Agarose gel 
 10 ml 10X Tris/Acetic acid/EDTA (TAE) buffer (Bio-Rad, Hercules, USA) 
 90 ml Milli-Q® water (Merck Millipore, Billerica, USA) 
 1.5 g (1.5%) agarose (Sigma-Aldrich, St Louis, USA) 
 10 μl SYBR Safe DNA Gel Stain (Thermo Fisher Scientific, Waltham, USA) 
A 1X solution of TAE buffer was prepared by mixing buffer with water. Agarose powder was 
added to the buffer and dissolved by heating in a microwave. SYBR safe DNA Gel Stain was 
mixed through the gel while still hot. The gel was stored for extended periods of time protected 
from light at room temperature. The gel was heated prior to use to re-melt the agarose.  
Carbonate coating buffer (pH 9.5) 
 4.2 g (10 mM) sodium bicarbonate (NaHCO3) (Sigma-Aldrich, St Louis, USA) 
 1.8 g (34 mM) sodium carbonate (Na2CO3) (Sigma-Aldrich, St Louis, USA) 
 Milli-Q® water (Merck Millipore, Billerica, USA) to 500 ml 
Reagents were dissolved in 400 ml of water and pH was adjusted to 9.5. The solution was 
topped up to 500 ml with water and stored at room temperature. 
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Cell culture freezing medium 
 40 ml (40 %) heat-inactivated foetal calf serum (HI-FCS) (Thermo Fisher Scientific, 
Waltham, USA) (inactivated at 56°C for 30 min) 
 20 ml (20 %) dimethyl sulphoxide (DMSO) (Sigma-Aldrich, St Louis, USA) 
 40 ml (40 %) RPMI 1640 Medium (Thermo Fisher Scientific, Waltham, USA) 
Reagents were combined under sterile conditions and stored in the dark at 4°C. 
DNA extraction buffer 
 192 ml 0.2 M disodium phosphate (Merck Millipore, Billerica, USA) 
 8 ml triton X-100 (VWR, Radnor, USA) 
Reagents were mixed thoroughly and the solution was stored at room temperature. 
DNA staining solution 
 200 μg propidium iodide (PI) (Sigma-Aldrich, St Louis, USA) 
 2 mg RNase A (Thermo Fisher Scientific, Waltham, USA) 
 10 ml phosphate buffered saline (PBS) (section 2.1.6.) 
Reagents were thoroughly mixed immediately before use. 
ELISA blocking buffer  
 5 ml (1%) HI-FCS (Thermo Fisher Scientific, Waltham, USA) 
 500 mg (0.1%) bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, USA)  
 2.5 ml 5% sodium azide (0.025%) (Sigma-Aldrich, St Louis, USA) 
 500 ml PBS (section 2.1.6.) 
Reagents were mixed with PBS and stored at 4°C. 
ELISA wash buffer 
 500 μl (0.05%) TWEEN 20 (Sigma-Aldrich, St Louis, USA) 
 1 L PBS (section 2.1.6.) 
TWEEN 20 was dissolved in PBS and stored at room temperature. 
Fluorescence-activated cell sorting (FACS) buffer 
 1 g (1%) BSA (Sigma-Aldrich, St Louis, USA) 
 10 mg (0.1%) sodium azide (Sigma-Aldrich, St Louis, USA) 
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 100 ml PBS  
BSA and sodium azide were dissolved in PBS. The solution was filtered and stored at 4°C for 
extended periods. 
Phosphate buffered saline (PBS) (for cell culture) 
 1 tablet phosphate buffered saline (Thermo Fisher Scientific, Waltham, USA) 
 100 ml Milli-Q® water (Merck Millipore, Billerica, USA) 
One PBS tablet was dissolved per 100 ml of water. The solution was autoclaved and stored at 
room temperature.  
Phosphate buffered saline (PBS) (for regular use) 
 8 g sodium chloride (Sigma-Aldrich, St Louis, USA) 
 0.2 g potassium chloride (Sigma-Aldrich, St Louis, USA) 
 1.44 g disodium phosphate (Merck Millipore, Billerica, USA) 
 0.24 g monopotassium phosphate (Sigma-Aldrich, St Louis, USA) 
 Milli-Q® water (Merck Millipore, Billerica, USA) to 1 L 
Reagents were thoroughly dissolved in 800 ml of water and pH was adjusted to 7.4. The 
solution was topped up to 1 L with water and stored at room temperature. 
Protein extraction digest buffer 
 21.02 g urea (Spectrum Chemical, New Brunswick, USA) 
 7.61 g thiourea (Sigma-Aldrich, St Louis, USA) 
 0.18 g tris (Merck Millipore, Billerica, USA) 
 Milli-Q® water (Merck Millipore, Billerica, USA) to 50 ml 
All reagents were thoroughly dissolved in 40 ml of water and pH was adjusted to 8.0. The 
solution was topped up to 50 ml with water and stored at room temperature.  
Protein extraction lysis buffer 
 100 μl Halt protease inhibitor cocktail (100X) (Thermo Fisher Scientific, Waltham, USA) 
 10 ml protein extraction digest buffer (section 2.1.6.) 
Protease inhibitor was added to protein extraction digest buffer immediately before use. 
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Protein quantification rinse buffer 
 100 ml methanol (Merck Millipore, Billerica, USA) 
 70 ml acetic acid (Sigma-Aldrich, St Louis, USA) 
 830 ml Milli-Q® water (Merck Millipore, Billerica, USA) 
All reagents were mixed together and stored at room temperature. 
RPMI/10FCS cell culture medium 
 450 ml RPMI 1640 Medium (Thermo Fisher Scientific, Waltham, USA) 
 50 ml (10 %) HI-FCS (Thermo Fisher Scientific, Waltham, USA) 
 5 ml  (1 %) Antibiotic-Antimycotic (Anti-Anti) (Thermo Fisher Scientific, Waltham, USA) 
 5 ml (1 %) GlutaMAXTM (Thermo Fisher Scientific, Waltham, USA) 
Reagents were combined under sterile conditions. The medium was stored in the dark at 4°C. 
T cell medium (TCM) 
 50 ml RPMI/10 FCS cell culture medium 
 120 mg (10 mM) HEPES (Thermo Fisher Scientific, Waltham, USA) 
 0.2 μl (50 μM) 2-Mercaptoethanol (Sigma-Aldrich, St Louis, USA) 
Reagents were combined under sterile conditions. The medium was stored in the dark at 4°C. 
Tissue Transport Medium 
 10 ml (2 %) Anti-Anti (Thermo Fisher Scientific, Waltham, USA) 
 490 ml RPMI 1640 Medium (Thermo Fisher Scientific, Waltham, USA) 
The reagents were combined under sterile conditions and stored in the dark at 4°C.
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2.1.7. Consumables 
Table 2.6. Laboratory consumables used for experimentation 
Consumable Supplier 
Catalogue 
Number 
0.2 ml Thin-Wall Clear PCR Tubes Axygen 321-02-051 
0.6 ml Microcentrifuge Tube Flat Cap Quality Scientific Plastics 10290659 
1.7 ml Ultra Clear Microtubes Axygen 311-04-051 
10 ml Centrifuge Tube Techno Plas S10316SU 
10 ml Pipette BD Falcon 357551 
15 ml Centrifuge Tube Corning #430052 
2 ml Cryogenic Vial Iwaki 2732-002 
2 ml Screw Cap Micro Tubes Thermo Fisher Scientific 3431-11 
25 cm2 Cell Culture Flask Corning CLS3056 
4 mm disposable biopsy punch Kai Medical 21058KA 
5 ml Pipette LP Italiana Spa 160510 
50 ml Tube BD Falcon 352070 
75 cm2 Cell Culture Flask Corning CLS430641 
ELISA 96 well EIA/RIA clear flat bottom 
Microplate 
Corning 3590 
Neptune Tips10 µl  Pathtech NEP2340 
Eclipse pipet tips 200 µl  Labcon 1017-260-000 
Neptune Tips 1000 µl  Pathtech NEP2160 
Hypodermic 20 Gauge Needles Terumo Medical SKU#V00044 
LightCycler® 480 Multiwell 96 Plates Roche Applied Science 4729692001 
LightCycler® 480 Sealing Foil Roche Applied Science 4729757001 
Lithium Heparin Anticoagulant Tubes VWR 95057-407 
TC-Treated Microplate 96-Well Round 
Bottom 
Corning CLS3799 
TC-Treated Multiwell Plate 12-Well Corning CLS3513 
TC-Treated Multiwell Plate 24-Well Corning CLS3527 
TC-Treated Multiwell Plate 6-Well Corning CLS3516 
TC-Treated Multiwell Plate 96-Well Flat 
Bottom 
Corning CLS3628 
NuncTM Cell Scraper Thermo Fisher Scientific 12-565 
NuncTM Petri Dish Thermo Fisher Scientific 08-757-100 
Opaque white flat bottom TC-treated 96-
well plate 
Corning CLS3362 
Plastic Syringe Terumo Medical SKU#V00089 
Round bottom flow cytometry tubes Corning 14-959-5 
Serum Clot Activator Tubes VWR 95057-391 
ZAP filter tips sterile 10 µl Labcon 1151-965-008 
ZAP filter tips sterile 200 µl  Labcon 1059-965-008 
ZAP filter tips sterile 1000 µl  Labcon 1057-965-018 
Sterile Transfer Pipettes  SAMCO 225 1S 
Sterile Transfer Pipettes Extra-long SAMCO 262 1S 
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2.1.8. Equipment 
Table 2.7. Laboratory equipment used for experimentation 
Equipment Supplier 
Catalogue 
Number 
2100 BioAnalyser Agilent Technologies G2939BA 
37⁰C Incubator Binder 142489 
Allegra Centrifuge Beckman Coulter 21R 
Biological Safety Cabinet Class II Email Air Handling Mk5 
Centrifuge  Eppendorf 5424 
Eclipse Ti confocal microscope  Nikon Instruments - 
FACSCantoTM II Flow Cytometer  BD Biosciences - 
Fumehood Condionarie HC-05 
Heatblock Labline 2002-LC8 
Heraeus Multifuge  Thermo Scientific 1S-R 
Hot Plate Magnetic Stirrer Analite 135593-38 
Illumina Hiseq-2000 platform Illumina - 
Image Station Carestream 4000MM  
Improved Neubauer Haemocytometer Hawksley 748 
Inverted Microscope Olympus BX40 
Light Microscope  Leica DM IRB 
LightCycler® 480  Roche Applied Science 5015278001 
LTQ-Orbitrap Mass Spectrometer with 
nanospray flex ion 
Thermo Fisher Scientific - 
Mini-beadbeater-24 BioSpec Products 112011 
Mini-Sub Cell GT Bio-Rad 35597 
MoFlo Astrios Cell Sorter Beckman Coulter - 
NanoDrop® 1000 Spectrophotometer NanoDrop Technologies - 
Platform Mixer Ratek RPM5 
PowerPacTM 300  Bio-Rad 164-5052 
S@femate Class II Biological Safety 
Cabinet  
Laftech Bio-Cabinets 1.2 
SpectraMax Plus 384 Plate Reader  Molecular Devices - 
Rotary tube mixer Ratek RSM7DC 
Ultimate 3000 nanoRSLC system Thermo Fisher Scientific - 
Ultrasonic Cell Disruptor Misonix Inc. 04711-81 
Varian Clinac 23-EX Linear Accelerator Varian Medical Systems Inc. - 
Veriti 96-well Thermal Cycler  Applied Biosystems 4375786 
Waterbath Ratek WB7D 
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2.2. General experimental procedures 
2.2.1. Tasmanian devils and biological samples  
Samples were obtained from captive and wild Tasmanian devils (Appendix 1) cared for in 
accordance with the Tasmanian Department of Primary Industries, Parks, Water and 
Environment (DPIPWE) guidelines. All procedures were approved by the University of 
Tasmania Animal Ethics Committee (permit numbers A0011436, A0012513, A0013685, 
A0014976 and A0014599). For blood collection, devils were anaesthetised with 5 % 
Isofluorane® (Abbot Australasia Pty Ltd., Botany, Australia) in oxygen at a rate of 2 L/min. 
Approximately 10 ml of blood was collected from the jugular vein into lithium heparin 
anticoagulant tubes (Greiner Bio-One, Kremsmunster, Austria) for PBMNC isolation within 24 
h, as described below. For serum analysis, blood was collected into serum clot activating tubes 
(Greiner Bio-one, Kremsmunster, Austria) and centrifuged at 1000 g for 10 minutes. Serum 
was removed from blood clots following centrifugation and stored at -80°C. DFTD biopsies 
were collected from diseased devils using a 4 mm disposable biopsy punch (Kai Medical, 
Singen, Germany). Other primary tissue samples were obtained from Tasmanian devils 
ethically euthanised for disease or age-related health reasons. Primary tissue samples were cut 
into 2 mm2 pieces and immediately placed in RNAlater (Thermo Fisher Scientific, Waltham, 
USA). For storage, RNAlater was removed and tissues were snap frozen in liquid nitrogen. 
Frozen tissues were stored for extended periods at -80 °C.  
2.2.2. Mononuclear cell isolation 
Mononuclear cells (MNCs) were isolated from peripheral blood diluted with an equal volume 
of RPMI 1640 medium (Thermo Fisher Scientific, Waltham, USA). A volume of 8 ml of diluted 
blood was layered onto 4 ml of Histopaque-1077 (Sigma-Aldrich, St Louis, USA), and 
density gradient centrifugation was performed at room temperature for 30 min at 400 g. The 
deceleration function of the centrifuge was inactivated to prevent disruption of the separation 
during slowing of the centrifuge. Separated PBMNCs were removed and washed two times in 
PBS (section 2.1.6.)/0.25% FCS, centrifuging at 250 g for 10 m between each wash to remove 
platelets. PBMNCs were resuspended in 1 ml of RPMI/10FCS or PBS and cell counts were 
performed on an improved neubauer haemocytometer (Hawksley, London, UK) by trypan blue 
dye exclusion.  
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2.2.3. DFTD cell cultures 
DFT1 cell lines were provided by A.-M. Pearse and K. Swift of DPIPWE. These cell lines were 
previously established from DFT1 biopsies obtained under the approval of the Animal Ethics 
Committee of the Tasmanian Parks and Wildlife Service (permit numbers 33/2004-5, 32/2005-
6). DFT2 cell lines were established by A. Kreiss and R. Pye of the Menzies Institute for 
Medical Research. These cell lines were established from single cell suspensions of DFT2 
biopsies obtained as described in section 2.2.1., and cultured in RPMI/10FCS (section 2.1.6.) 
and 10 % amnioMAXTM-II complete medium (Thermo Fisher Scientific, Waltham, USA). 
Frozen stocks of DFT1 and DFT2 cell lines stored in cell culture freezing medium (section 
2.1.6.) were thawed when required by adding 10 ml of pre-warmed RMPI/10FCS in a drop-
wise manner. Cells were centrifuged at 500 g for 5 min and washed twice in PBS (section 
2.1.6.). Cells were resuspended in 5 ml of RPMI/10FCS and 10% amnioMAXTM-II complete 
medium and transferred to a 25 cm2 cell culture flask (Corning, New York, USA). Cultures 
were maintained at 35 °C and 5 % CO2 in a humidified incubator. When they had reached 90% 
confluency, cells were transferred to a 75 cm2 cell culture flask (Corning, New York, USA), 
and the medium was gradually replaced with RPMI/10FCS, as required. Cells were monitored 
daily using light microscopy, and cultures at greater than 90% confluency were split by flushing 
cells from the flask surface and transferring approximately 50% of the volume to a new flask. 
When required for experimentation, cells were collected and centrifuged at 500 g for 5 min. 
Collected cells were washed twice in 10 ml of PBS, with centrifugation at 500 g for 5 min 
between each wash. Cells were resuspended in 1 ml of either RPMI/10FCS or PBS, and cell 
counts were performed on an improved neubauer haemocytometer (Hawksley, London, UK) 
by trypan blue dye exclusion. Cells were cultured for experimentation as described in each 
chapter. 
2.2.4. RNA extraction  
Primary tissue sections stored in RNA later were roughly chopped into 1 mm2 sections. 
Approximately 20 mg of material was transferred to a 2 ml screw-top tube (Corning, New York, 
USA) containing approximately 1 ml of 2.3 mm zirconia beads (BioSpec Products, Bartlesville, 
USA) and 1 ml of TriReagent (Sigma-Aldrich, St Louis, USA). The tissue was homogenised 
by 5 consecutive 30 s rounds of bead-beating using a Mini-Beadbeater-24 (BioSpec Products, 
Bartlesville, USA), with a 30 s incubation on ice between each round. The homogenate was 
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removed from the beads for RNA extraction. Cell lines were homogenised in 1 ml of 
TriReagent by repetitive pipetting. A 200 l volume of chloroform (Merck Millipore, Billerica, 
USA) was added to each homogenate and samples were shaken vigorously for 15 s. The 
samples were let to sit at room temperature for 10 min, then centrifuged at 12 000 g and 4 C 
for 15 min to allow complete phase separation. The upper aqueous phase was removed from 
the sample and added to a 500 l volume of 100% isopropanol (Merck Millipore, Billerica, 
USA). The samples were incubated at room temperature for 1 h to allow RNA precipitation to 
occur. The RNA precipitate was pelleted by centrifugation at 12 000 g and 4 C for 20 min. 
The supernatant was discarded and the RNA pellet was washed twice in 1 ml of 75% ethanol 
(Fronine, Riverstone, Australia), centrifuging at 7500 g for 5 min after each wash. After the 
final wash, the supernatant was discarded and the RNA pellet was air-dried for approximately 
10 min. The RNA was resuspended in 50 l of TE buffer (pH 8.0) (Thermo Fisher Scientific, 
Waltham, USA) and dissolved at 60 C for 15 min. Extracted RNA was DNase treated with the 
TURBO DNA-freeTM kit (Thermo Fisher Scientific, Waltham, USA), according to the 
instructions of the manufacturer (Appendix 2). Briefly, 5 l of TURBO DNase buffer and 1 l 
of TURBO DNase was added to each sample and incubated for 30 min at 37 C. A 5 l volume 
of TURBO DNase inactivation reagent was added and the samples were incubated at room 
temperature for 5 min, flick mixing regularly. The sample was centrifuged at 10 000 g for 90 s 
and the RNA suspension was removed into a new tube. The concentration and integrity of the 
RNA was assessed using a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, USA). Samples with an A260/A280 ratio of 1.8 or greater were stored at -80 C 
for downstream application. 
2.2.5. Reverse transcription  
RNA samples were reverse transcribed to complementary deoxyribonucleic acid (cDNA) using 
the GoScriptTM Reverse Transcription System (Promega, Madison, USA), according to the 
instructions of the manufacturer (Appendix 2). Briefly, a 9 l volume of RNA (< 2 g) from 
each sample was transferred to a 200 l thin-walled PCR tube. A reaction master mix for n+1 
samples was created using the following reagents: 
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o 0.5 L x n Random Primer 
o 0.5 L x n Oligo(dT)15 Primer 
o 1.5 L x n Nuclease-Free Water 
o 4 L x n GoScript 5X Reaction Buffer 
o 2 L x n MgCl2, 25mM 
o 1 L x n PCR Nucleotide Mix, 10mM   
o 0.5 L x n Recombinant RNasin Ribonuclease Inhibitor 
o 1 L x n GoScript Reverse Transcriptase 
An 11 l volume of master mix was added to each tube of RNA, and samples were incubated 
on a Veriti 96-well thermal cycler (Applied Biosystems, Foster City, USA) with heated lid at 
25 C for 5 min, followed by 42 C for 60 min and 72 C for 15 min. A control with no reverse 
transcriptase (no-RT control) was included to identify contaminating genomic DNA.  
2.2.6. Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the ImmoMix Red master mix (Bioline, London, UK), according 
to the instructions of the manufacturer (Appendix 2). Briefly, a reaction master mix for n+1 
samples was created using the following reagents: 
o 12.5 L x n ImmoMix Red 
o 9.5 L x n UltraPureTM distilled water (Thermo Fisher Scientific, Waltham, 
USA)  
o 0.5 L x n Forward primer (10 M) 
o 0.5 L x n Reverse primer (10 M) 
A 23 L volume of reaction master mix was combined with 2 l of cDNA in a 200 l thin-
walled PCR tube. Water was used in place of cDNA for a no-template control, and reactions 
with no-RT control cDNA were included. Thermo-cycling was performed on a Veriti 96-well 
thermal cycler (Applied Biosystems, Foster City, USA) and consisted of an initial melt of 95 
C for 10 min, followed by 35 cycles of 95 C for 1 min, 62 C for 1 min and 72 C for 18 s. A 
final extension at 72 C for 10 min was included. The reference gene ribosomal protein S18 
(RPS18) was amplified in parallel with experimental genes for all experiments. 
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A 1.5 % agarose gel (section 2.1.6.) was poured and allowed to set for 30 min. The gel was 
placed in a Mini-Sub Cell (Bio-Rad, Hercules, USA) and covered with 1X TAE buffer (Bio-
Rad, Hercules, USA). A 5 L volume of Quick-Load 100 base-pair DNA ladder (New England 
Biolabs, Ipswich, USA) was pipetted into the first lane of the gel. A 10 L volume of each PCR 
product was pipetted into remaining lanes of the gel. Gel electrophoresis was performed at 100 
V for 40 min using a PowerPacTM 300 (Bio-Rad, Hercules, USA). Gels were imaged using the 
Carestream Image Station 4000MM (Carestream, Rochester, USA). 
2.2.7. Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) 
RNA was reverse transcribed to cDNA according to section 2.2.6. Quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR) was performed using the LightCycler® 480 
SYBR Green I Master (Roche Applied Sciences, Penzberg, Germany), according to the 
instructions of the manufacturer (Appendix 2). Briefly, a reaction master mix for n+1 samples 
was created using the following reagents: 
o 5.0 L x n LightCycler® 480 SYBR Green I Master 
o 1.8 L x n UltraPureTM Distilled water (Thermo Fisher Scientific, Waltham, 
USA) 
o 0.6 L x n Forward primer (5 M) 
o 0.6 L x n Reverse primer (5 M) 
Reactions were set up in LightCycler 480 96-well plates (Roche Applied Sciences, Penzberg, 
Germany) and consisted of 8 L of reaction master mix and 2 L of cDNA. Water was used in 
place of cDNA for a no-template control, and reactions were included using the no-RT control. 
All reactions were set up in triplicate, and the reference gene RPS18 was amplified in parallel 
with experimental genes. Thermo-cycling was performed in a LightCycler® 480 (Roche 
Applied Sciences, Penzberg, Germany) and consisted of an initial melt step at 95 C for 10 min, 
followed by 40 cycles of 95 C for 15 s, 60 C for 1 min and 72 C for 1 min. A melt curve was 
performed with temperature ramped from 50 C to 95 C at a rate of 0.11 C per second. 
Crossing point (Cp) values were calculated using the LightCycler 480 software (Roche Applied 
Sciences, Penzberg, Germany). The comparative Ct method (Livak et al. 2001) was used for 
calculation of expression levels relative to control samples or reference genes. This method of 
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quantification was validated through standard curve analysis of serially diluted cDNA standards 
by qRT-PCR. A reaction efficiency was calculated for each primer pair by the formula E=10(-
1/slope), and was required to be between 1.9 and 2.1 for method validation. Statistical significance 
was calculated from log2-converted expression levels using a one-way ANOVA and Dunnett’s 
multiple comparisons test. Statistical significance was defined as *p<0.05, **p<0.01, 
***p<0.001, ***p<0.0001. 
2.2.8. Flow cytometry 
DFTD cells and PBMNCs were harvested and washed in PBS (section 2.1.6.) as described in 
section 2.2.3. Cells were labelled with antibodies (described in each chapter) diluted in FACS 
buffer (section 2.1.6.). Where appropriate, isotype and fluorescence minus one (FMO) controls 
were included. Between each labelling step, cells were washed three times in FACS buffer with 
centrifugation at 500 g and 4 C. Cells were kept on ice where possible during the labelling 
procedure. After a final wash, cells were analysed on the BD FACSCanto II flow cytometer 
(BD biosciences, San Jose, USA). The basic gating strategy provided below was used for 
analysis of flow cytometry data (Fig. 2-1). 
 
 
54 
 
 
 
Figure 2-1. General gating strategy used for analysis of flow cytometry data in this thesis. (A) Cells analysed 
by flow cytometry and visualised by forward scatter (FSC) and side scatter (SSC). (B) Exclusion of doublet cells 
based on FSC-area and FSC-height. (C) Cells visualised by FSC and SSC after doublet exclusion. (D) Exclusion 
of non-viable cells (orange) based on dead cell stain (PI, DAPI or LIVE/DEAD near IR stain). Exclusion of early 
apoptotic cells (red) by annexin V-FITC staining (only some experiments). (D) Binding of antibody of interest to 
live, singular cells after gating. 
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3.1. Introduction 
The development of a successful vaccine against DFTD is challenged by gaps in knowledge of 
various aspects of the Tasmanian devil’s immune system. Previous studies have demonstrated 
that the Tasmanian devil has the full complement of cells, tissues and organs required for an 
immune response against DFTD cells (Howson et al. 2014; Kreiss et al. 2008; Kreiss et al. 
2009a; Woods et al. 2007). Furthermore, devils are capable of recognising allogeneic skin grafts 
(Kreiss et al. 2011). In rare cases, devils have also demonstrated immune-mediated rejection of 
naturally-occurring DFTD tumours (Pye et al. 2016a). While these findings suggest that the 
devil’s natural immune response is capable of targeting DFTD cells, little is known about the 
pathways required for the activation of these responses. In vivo, established DFTD tumours 
demonstrate little evidence of immune cell infiltration (Howson et al. 2014), suggesting that 
the tumour cells are non-immunogenic. An improved understanding of immune activation in 
the Tasmanian devil will reveal strategies for stimulation of a response against these cells 
during DFTD vaccination.  
TLR signalling is an ancient and highly conserved critical immune defence against pathogenic 
infection (Buchmann 2014). Conserved TLR paralogues have been identified across countless 
animal species from invertebrate sponges, molluscs and insects, to higher order mammals, birds 
and reptiles (Elvitigala et al. 2013; Lemaitre et al. 1996; Roach et al. 2005; Wiens et al. 2007). 
In mammalian species, TLRs play key roles in the activation of the immune system through 
recognition of damage- and pathogen-associated molecules and activation of genes required for 
innate and adaptive responses (Hornung et al. 2002; Medzhitov et al. 1997). Particularly in 
combination, ligands of TLRs have generated much interest in the development of human 
vaccines for their ability to activate potent immune responses via co-stimulation of MyD88 and 
TRIF-dependent signalling pathways (Galluzzi et al. 2012a; Vacchelli et al. 2013). Recently, 
full-length sequences for ten TLR genes were characterised in the genomes of marsupials 
including the Tasmanian devil (Cui et al. 2015a). These genes included homologues to 
mammalian TLRs 2-5, 7-10 and 13 (Table 3-1). A single gene with high homology for human 
TLRs 1 and 6 was also present (denoted TLR6 in this thesis), and represents an evolutionary 
precursor of both of these TLRs. Similar TLR genes have been identified in the genome of the 
koala and opossum, suggesting a common TLR repertoire across all marsupial species (Cui et 
al. 2015b; Roach et al. 2005). As TLR genes are highly conserved in the Tasmanian devil, a 
DFTD vaccine could potentially target TLR signalling to improve the immune response 
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Table 3-1. Comparison of toll-like receptor homologues in the genomes of placental and marsupial species 
Homologue 
Homo sapiens 
(human) 
Mus musculus 
(mouse) 
Monodelphis 
domestica 
(opossum) 
Sarcophilus harrisii 
(Tasmanian devil) 
TLR1 Present Present Present* Present* 
TLR2 Present Present Present Present 
TLR3 Present Present Present Present 
TLR4 Present Present Present Present 
TLR5 Present Present Present Present 
TLR6 Present Present Present* Present* 
TLR7 Present Present Present Present 
TLR8 Present Present Present Present 
TLR9 Present Present Present Present 
TLR10 Present Pseudogene Present Present 
TLR11 Pseudogene Present Absent Absent 
TLR12 Absent Present Absent Absent 
TLR13 Absent Present Present Present 
*A single precursor to mammalian TLR1 and TLR6 is present, denoted TLR6 in text.  
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generated. Investigation of TLR signalling in the Tasmanian devil is required to confirm that 
these pathways are functional, as TLR function has not yet been investigated in any marsupial 
species.  
In this chapter, I analysed the function of TLRs in the immune system of the Tasmanian devil 
to confirm that these signalling pathways are intact. To perform this analysis, MNCs obtained 
from the peripheral blood of Tasmanian devils were stimulated ex vivo with conventional TLR 
ligands and qRT-PCR and flow cytometry were performed to measure the production of down-
stream TLR signalling products. These experiments have also been completed using 
combinations of TLR ligands in order to co-stimulate MyD88 and TRIF-dependent pathways 
for improved immune responses. This analysis will provide an insight into innate immune 
function in the Tasmanian devil and will reveal potential TLR ligands for use as adjuvants in 
DFTD immunisations. As one of the most ancient extant mammalian lineages, this analysis will 
also have direct implications for our understanding of marsupial and evolutionary immunology.  
3.2. Experimental Procedures 
3.2.1. Biological samples  
Spleen and skin samples were obtained from Tasmanian devils euthanised for ethical reasons 
according to section 2.2.1. Peripheral blood was obtained from anaesthetised captive or wild 
Tasmanian devils according to section 2.2.1. MNCs were isolated on Histopaque-1077 
(Sigma-Aldrich, St Louis, USA) according to section 2.2.2. For isolation of monocyte 
populations, 1 x 107 peripheral blood MNCs (PBMNCs) in 5 ml of RPMI/10FCS (section 
2.1.6.) were seeded into a plastic NuncTM petri dish (Thermo Fisher Scientific, Waltham, USA) 
and incubated at 35 °C and 5 % CO2 in a humidified incubator for either 40 min or overnight, 
as stated for each experiment. After incubation, the dish was gently agitated to remove non-
adherent cells and the medium was transferred into a tube. Remaining non-adherent cells were 
gently flushed from the plastic dish containing adherent monocytes using pre-warmed 
RPMI/10FCS. Adherent cells were then removed from the dish using a NuncTM cell scraper 
(Thermo Fisher Scientific, Waltham, USA). Non-adherent and adherent cell populations were 
centrifuged at 500 g for 5 min to form a pellet and washed twice in 10 ml of PBS (section 2.1.6.) 
with centrifugation between each wash. For identification of B cells based on immunoglobulin 
(Ig) expression, non-adherent cells were labelled with polyclonal rabbit anti-Tasmanian devil 
Ig (section 2.1.4.) diluted 1000 x with FACS buffer (section 2.1.6.), then AF488 goat anti-rabbit 
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IgG (section 2.1.4.) diluted to 5 g/ml with FACS buffer for 30 m each, as described in section 
2.2.8. Cells were resuspended in 1 ml of PI (Sigma-Aldrich, St Louis, USA) diluted to 1 g/ml 
with FACS buffer. Ig+ and Ig- MNCs were separated by FACS using the MoFlo Astrios Cell 
Sorter (Beckman Coulter, Brea, USA). Total MNC populations, adherent MNC populations, 
non-adherent Ig- MNC populations and non-adherent Ig+ MNC populations were directly lysed 
for RNA extraction in 1 ml of TriReagent (Sigma-Aldrich, St Louis, USA).  
3.2.2. Gene expression analysis 
For analysis of baseline TLR and cell marker gene expression, RNA was directly extracted 
from spleen, skin and PBMNC samples, according to section 2.2.4. For analysis of 
inflammatory gene expression, total PBMNC populations were cultured at 1 x 106 cells/ml in 1 
ml of RPMI/10FCS (section 2.1.6.) in 12-well cell culture plates (Corning, New York, USA). 
PBMNCs were stimulated with TLR ligands (section 2.1.2.) for 6 h at the concentrations 
specified in table 3-2. These TLR ligands were chosen to represent all known mammalian TLR 
subfamilies. Untreated controls were included and all cultures were maintained at 35°C in a 
humidified 5% CO2 incubator for the duration of the TLR stimulation. After stimulation, 
PBMNC samples were lysed directly in TriReagent (Sigma-Aldrich, St Louis, USA). RNA was 
extracted from all samples according to section 2.2.4. Expression of experimental genes was 
measured relative to the reference gene RPS18 according to section 2.2.7. Heat maps were 
created from relative expression data clustered by column means (PBMNC sample) using the 
heatmaps.2 function from the gplots_3.0.1. package in R version 3.3.2. 
3.2.3. Analysis of interferon-gamma (IFNγ) production by flow cytometry 
Total PBMNC populations were cultured at 2 x 106 cells/ml in 200 μl of TCM (section 2.1.6.) 
in a round bottom 96-well cell culture plate (Corning, New York, USA). PBMNCs were 
stimulated with TLR ligands (section 2.1.2.) at the specified concentrations for 21 h. 
Recombinant devil IL-2 (Walter and Eliza Hall Institute of Medical Research, Melbourne, 
Australia) (Brown et al. 2016), was used at 3 μg/ml as a positive control for IFN production. 
BD GolgiStopTM (BD Biosciences, Franklin Lakes, USA) was added for the final 6 h of 
stimulation to prevent IFN release. All cultures were maintained at 35°C in a humidified 5% 
CO2 incubator for the duration of TLR stimulation. After stimulation, cells were harvested and 
washed in FACS buffer (section 2.1.6.) as described in section 2.2.3. Cells were then labelled 
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Table 3-2. Concentrations of TLR ligands used for experimentation in chapter 3 
TLR Ligand TLR Figures 3-2. and 3-4. 
Figures 3-6., 3-7., 3-8., 
3-9. and 3-10. 
Poly-IC/Poly-ICLC TLR3 20 g/ml 10 g/ml 
LPS TLR4 20 g/ml 10 g/ml 
Flagellin TLR5 100 ng/ml NA 
Imiquimod TLR7 20 g/ml 10 g/ml 
CpG-1585 TLR9 20 g/ml 5 g/ml 
CpG-2395 TLR9 20 g/ml 5 g/ml 
Profilin TLR11 100 ng/ml NA 
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as described in section 2.2.8. Extracellular staining was performed with Alexa Fluor-647 mouse 
anti-devil CD4 (section 2.1.4.) diluted with FACS buffer to 0.25 g/ml and LIVE/DEAD® 
Fixable Near-IR Dead Cell Stain diluted 600 x in PBS (section 2.1.6.) (Thermo Fisher 
Scientific, Waltham, USA), for 30 min each. The PBMNCs were then fixed and permeabilised 
for 20 min with 100 l of BD Cytofix/CytopermTM Plus Fixation/Permeabilisation solution (BD 
Biosciences, Franklin Lakes, USA), and washed twice in 250 l of BD Perm/Wash buffer (BD 
Biosciences, Franklin Lakes, USA). Fixed PBMNCs were intracellularly stained with rabbit 
anti-human CD3 (3 g/ml) /0.5% Normal Goat Serum (Thermo Fisher Scientific, Waltham, 
USA), followed by R-phycoerythrin goat anti-rabbit IgG (2 g/ml) and FITC mouse anti-IFNγ 
(2 g/ml) diluted in BD Perm/Wash buffer, for 30 min each (section 2.1.4.). Samples were 
analysed on the BD FACSCanto II flow cytometer (BD biosciences, San Jose, USA) within 1 
h. Flow cytometry data were analysed using FlowJo® v9.9 (FlowJo LLC, Ashland, USA), 
according to the gating strategy described (section 2.2.8.). Percentages of IFN positive cells, 
and mean fluorescence intensity (MFI) were calculated in TLR-stimulated samples and 
compared to untreated and IL-2-treated samples by ordinary one-way ANOVA and Dunnett’s 
multiple comparisons test. Statistical significance was defined as *p<0.05, **p<0.01, 
***p<0.001, ***p<0.0001. 
3.3. Results 
3.3.1. Expression of TLR genes in Tasmanian devil tissues 
Previous studies have determined that a range of TLR genes are present in the genome of the 
Tasmanian devil, including paralogues of human/mouse TLRs 2, 3, 4, 5, 6, 7, 8, 9, 10 and 13 
(Cui et al. 2015a). To determine if these TLR genes are expressed in the Tasmanian devil 
immune system, qRT-PCR analysis was performed using PBMNC populations and splenic 
tissue from three Tasmanian devils. TLR expression was also measured in the skin, a reservoir 
of tissue-resident DCs. This analysis revealed that Tasmanian devil tissues expressed all 
measured TLR genes at the mRNA level (Fig. 3-1). Relative to the reference gene RPS18, 
PBMNC samples demonstrated moderate to high expression of TLRs 2, 3, 4, 5, 6, 7, 8, 10 and 
13L (Fig. 3-1A). In comparison, only low expression of TLR9 was detected in these samples. 
Splenic tissue demonstrated the highest relative expression of TLRs, with all genes expressed 
at moderate to high levels (Fig. 3-1B). In comparison, skin tissue demonstrated the lowest  
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Figure 3-1. Expression of TLR genes in Tasmanian devil tissues. Expression of the TLR genes 1-10 and 13L 
was analysed by qRT-PCR in (A) MNCs isolated from peripheral blood, (B) primary spleen tissue and (C) primary 
skin tissue collected from Tasmanian devils. Gene expression was calculated relative to the reference gene RPS18. 
No-cDNA and no-RT controls were included and did not show any amplification of product. Results are the mean 
and standard error of three biological replicates. 
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relative expression of TLRs, with moderate levels of TLRs 2, 3, 4, 5, 6, 7, 8 and 13L and low 
levels of TLRs 9 and 10 (Fig. 3-1C). Together these findings reveal that TLR genes are 
functionally transcribed to mRNA in the Tasmanian devil, and that expression of these genes 
is varied among different tissues. 
3.3.2. Activation of Tasmanian devil PBMNCs by TLR ligands 
As immune-enriched tissues from the Tasmanian devil express TLRs at the mRNA level, the 
role of these TLRs in the activation of immune responses was next analysed. Studies in the 
Tasmanian devil are limited by the availability of species-specific and cross-reactive antibodies 
that can be used to study protein expression, and as such functional assays were performed to 
demonstrate the function of TLRs in the Tasmanian devil. In particular, the response of 
PBMNCs from four Tasmanian devils to treatment with the TLR ligands poly-IC (TLR3), LPS 
(TLR4), flagellin (TLR5), imiquimod (TLR7), CpG-1585 (TLR9), CpG-2395 (TLR9) and 
profilin (TLR11) was measured through qRT-PCR analysis of downstream TLR signalling 
molecule expression. This included analysis of the cytokines interleukin-1α (IL1α), interleukin-
6 (IL6), interleukin-12A (IL12A) and interferon-β (IFNβ), and the costimulatory molecule 
CD86. High concentrations of TLR ligands were required to stimulate these responses, as 
Tasmanian devils and other marsupials are typically poor responders to immunostimulatory 
agents, including LPS (Brozek et al. 1992; Kreiss et al. 2008; Wilkinson et al. 1992b). This 
analysis demonstrated that TLR ligands increase the expression of pro-inflammatory genes in 
Tasmanian devil PBMNCs (Fig. 3-2). The inflammatory cytokines IL-1α and IL6 displayed the 
greatest change, with significant increases of between 30-fold and 126-fold for IL1α and 43-
fold and 262-fold for IL6 after treatment with poly-IC (IL1α p<0.01, IL6 p<0.05), LPS (IL1α 
p<0.001, IL6 p<0.001), flagellin (IL1α p<0.001, IL6 p<0.05) or profilin (IL1α p<0.01), but not 
imiquimod, CpG-1585 or CpG-2395 (Fig. 3-2A-B). These results indicate that Tasmanian devil 
PBMNCs respond to treatment with a range TLR ligands, suggesting that TLRs are functional 
in these cells. In comparison, changes to IL12A, IFNβ and CD86 expression did not reach 
statistical significance after any treatment at the ligand concentrations tested (Fig. 3-2C-E). 
High variation in the measured response to TLR stimulation between biological replicates likely 
contributed to the insignificance of these results. 
Analysis of gene expression in a mixed cell PBMNC population is challenging, as qRT-PCR 
measures net gene expression across all cell types. In order to analyse the response of 
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Figure 3-2. Expression of inflammatory genes in Tasmanian devil PBMNCs after stimulation with TLR 
ligands. MNCs isolated from the peripheral blood of four Tasmanian devils were stimulated for 6 h with either 
poly-IC (20 g/ml), LPS (20 g/ml), flagellin (100 ng/ml), imiquimod (20 g/ml), CpG-1585 (20 g/ml), CpG-
2395 (20 g/ml) or profilin (T. gondii) (100 ng/ml). Expression of the downstream TLR signalling products (A) 
IL1, (B) IL6, (C) IL12A, (D) IFN or (E) CD86 was measured by qRT-PCR. RPS18 was amplified as a reference 
gene. No-cDNA and no-RT controls were included and did not show any amplification of product. Gene 
expression relative to the untreated sample is shown, with each point representing PBMNCs from an individual 
Tasmanian devil. Results are the mean and standard error of four biological replicates. Statistical significance 
relative to the untreated control was measured by one-way ANOVA and is defined as ns>0.05, *p<0.05, **p<0.01, 
***p<0.001. 
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Tasmanian devil PBMNCs to TLR stimulation in more detail, PBMNC subsets were isolated 
for TLR stimulation. As antibodies against T cell markers in the Tasmanian devil were 
unavailable at the time of these experiments, monocytes were separated from lymphocytes by 
plastic adherence as previously described in the Tasmanian devil (Brown et al. 2011). Serum 
from rabbits immunised with devil Ig was also used to separate B cells from remaining 
lymphocytes (presumably NK cells and T cells). The purity of these populations was assessed 
through qRT-PCR analysis of gene expression of the T cell marker CD3e, the B cell marker 
CD19 and the monocytic marker colony-stimulating factor 1 receptor (CSF1R). These analyses 
revealed that relative expression of CD3e, CD19 and CSF1R in the monocytic population was 
similar to the mixed PBMNC population, suggesting that this monocytic population was not 
pure (Fig. 3-3A). Furthermore, non-adherent cells exhibited moderate to high CFS1R 
expression, indicating that monocytes were not completely depleted by plastic adherence. 
Sorting based on Ig expression greatly decreased expression of CD19 in the non-adherent Ig- 
population, indicating that this technique was effective at depleting B cells. In comparison, high 
expression of CD3e, CD19 and CSF1R in the non-adherent Ig+ population suggests that the 
rabbit serum non-specifically binds to other cell types during the isolation. 
In order to improve the isolation technique, the length of plastic adherence was increased from 
40 m to overnight. This technique dramatically decreased the expression of CFS1R in non-
adherent populations, suggesting that more effective depletion of monocytes had occurred (Fig. 
3-3B). As a result, a purer non-adherent Ig- population was also generated, with much greater 
expression of CD3e than CD19 and CSF1R in this population. Although this isolation was 
improved, the adherent population and the non-adherent Ig+ population remained impure. As 
such, these experiments demonstrate that it is difficult to obtain pure immune cell subsets from 
Tasmanian devil PBMNCs in the absence of devil specific antibodies. Although analysis of 
inflammatory gene expression in TLR stimulated devil immune cell subsets was unable to be 
performed, results generated from the mixed PBMNC population confirm that TLR signalling 
is functional in the Tasmanian devil. These findings support the use of TLR ligands for immune 
activation by a DFTD vaccine. 
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Figure 3-3. Isolation of immune cell subsets from Tasmanian devil blood. MNCs were isolated from the 
peripheral blood of two Tasmanian devils. Monocytes were separated from the total PBMNC population by plastic 
adherence for (A) 40 m or (B) overnight. Non-adherent cells were separated by surface immunoglobulin 
expression using FACS. Purity of each immune cell subset was assessed through measurement of CD3e (non-
adherent Ig- T cells), CD19 (non-adherent Ig+ B cells), and CSF1R (adherent monocytes) expression using qRT-
PCR. Gene expression was calculated relative to the reference gene RPS18. No-cDNA and no-RT controls were 
included and did not show any amplification of product. Results are the mean and standard error of three technical 
replicates.  
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3.3.3. Enhancement of PBMNC responses through stimulation with multiple 
TLR ligands 
Tasmanian devil PBMNCs respond to TLR stimulation, suggesting that TLR ligands could act 
as effective vaccine adjuvants in the Tasmanian devil. To identify TLR ligands with potential 
as immune adjuvants, qRT-PCR was used as previously described to measure changes to the 
expression of IL1a, IL6, and IL12A in PBMNCs stimulated with TLR ligands. To engage 
synergic interactions between TRIF- and MyD88-dependent pathways, PBMNCs were co-
stimulated with poly-IC (TLR3) in combination with LPS (TLR4), flagellin (TLR5), 
imiquimod (TLR7), CpG-1585 (TLR9), CpG-2395 (TLR9) or profilin (TLR11). As a large 
number of PBMNCs were required for these stimulations, sufficient volumes of blood were 
obtained from three Tasmanian devils ethically euthanised for disease-related reasons. qRT-
PCR analysis of these cells revealed only small and non-significant increases in the expression 
of IL1a, IL6, and IL12A after stimulation with any TLR ligand (Fig. 3-4). In addition, no further 
increase in cytokine expression was measured when MyD88 and TRIF-dependent pathways 
were co-stimulated by multiple TLR ligands. To determine whether this lack of additive 
response to TLR stimulation could be explained by the diseased status of these devils, baseline 
expression of the inflammatory cytokines IL1a, IL6, and IL12A relative to the reference gene 
RPS18 was compared between 16 previously assessed Tasmanian devils. Analysis of the 
difference in expression of these genes between healthy devils and devils suffering from DFT1 
or DFT2 at the time of PBMNC isolation revealed a mean baseline expression of IL1a, IL6, and 
IL12A that was as much as 32-fold higher in DFTD-affected devils (Fig. 3-5A-C). As such, this 
finding suggests that immune cells in diseased Tasmanian devils are active prior to isolation, 
explaining the reduced response to TLR stimulation in these cells. 
As diseased devils did not respond well to TLR stimulation, the responses were re-measured 
using samples from healthy Tasmanian devils. Only a limited volume of blood was available 
from these devils, and as such a smaller number of TLR stimulations were performed. Poly- IC 
(TLR3), LPS (TLR4), imiquimod (TLR7) and CpG (ODN-1585 combined with ODN-2395) 
(TLR9) were chosen for these stimulations based on literature describing their efficacy for 
activation of tumour-specific immune responses in human studies (Galluzzi et al. 2012a; 
Vacchelli et al. 2012). The concentrations of TLR ligands used for these stimulations were also 
halved in order to more easily detect the activation of synergic responses. This analysis  
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revealed varied patterns of gene expression across the TLR ligands and cytokines measured. 
Relative to untreated cells, Tasmanian devil PBMNCs exhibited significantly higher expression 
of IL6 and IL12A after stimulation with poly-IC (IL6 p<0.01, IL12A p<0.05) or LPS (IL6 
p<0.01) (Fig. 3-6A). In comparison, CpG and imiquimod gave varied responses across all 
samples. Expression of IL1a, IL6, and IL12A was also significantly increased after stimulation 
with combinations of poly-IC and LPS (IL1a p<0.05, IL6 p<0.001, IL12A p<0.01) or poly-IC 
and imiquimod (IL1a p<0.05, IL6 p<0.0001). These increases in cytokine expression were not 
significantly greater than changes in expression stimulated by poly-IC alone due to high 
variation in the responses. To demonstrate this variation, data were visualised as heat maps 
clustered by column means (PBMNC sample) (Fig. 3-6B). These heat maps demonstrate 
inconsistent trends across genes and samples, which were likely due to biological variation in 
an outbred population. Nonetheless, most PBMNC samples responded more effectively to a 
combination of TLR ligands. Together these results suggest that combining TLR ligands may 
be a promising strategy for enhancement of immune responses in Tasmanian devils. 
3.3.4. Production of interferon- by TLR stimulated Tasmanian devil 
PBMNCs 
TLR ligands in combination may act as effective adjuvants in the Tasmanian devil. To further 
analyse the response of Tasmanian devil PBMNCs to TLR stimulation, production of IFNγ, a 
hallmark of cell-mediated responses and anti-tumour immunity, was measured by flow 
cytometry after TLR stimulation. Poly-IC was exchanged for poly-ICLC (Hiltonol®) in these 
experiments, as this exhibits similar biological activity to poly-IC but with much greater 
stability in the presence of RNases (Levy et al. 1975). Specific antibodies for Tasmanian devil 
CD3 and CD4 were also available for these experiments, allowing T cell populations to be 
distinguished from other immune cell populations. Analysis of a representative Tasmanian 
devil PBMNC sample revealed an absence of IFNγ production from PBMNCs stimulated with 
TLR ligands only, suggesting that alone these are not sufficient to activate T cell immunity 
(Fig. 3-7A-G). To improve these responses, IL-2 was included in the stimulations as an 
activator of T cell immunity. In the absence of stimulation, there was no IFNγ production (Fig. 
3-8A). In comparison, IL-2 alone (Fig. 3-8B) and combined with TLR ligands (Fig. 3-8C-2I) 
induced IFNγ production from CD3+ PBMNCs. Further analysis revealed that most IFNγ-
producing cells were CD3+CD4- (likely CD8+ T cells and NKT cells), with very few 
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Figure 3-7. Production of IFNγ from Tasmanian devil PBMNCs stimulated with TLR ligands. MNCs 
isolated from Tasmanian devil peripheral blood samples were stimulated for 21 h with Poly-ICLC (10 μg/ml), LPS 
(10 μg/ml), imiquimod (10 μg/ml), or CPG-1585 (5 μg/ml) plus CpG-2395 (5 μg/ml) alone or in combination. 
Production of IFNγ from CD3- and CD3+ cells was measured by intracellular flow cytometry. (A-G) Scatter plots 
generated from a representative PBMNC sample (Joffrey) demonstrate little IFNγ production from TLR stimulated 
PBMNCs. A percentage of IFNγ-positive events is given. Plots are representative of results generated from two 
other PBMNC samples. 
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Figure 3-8. Production of IFNγ from Tasmanian devil PBMNCs stimulated with TLR ligands and IL-2. 
MNCs isolated from Tasmanian devil peripheral blood samples were stimulated for 21 h with Poly-ICLC (10 
μg/ml), LPS (10 μg/ml), imiquimod (10 μg/ml), CPG-1585 (5 μg/ml) plus CpG-2395 (5 μg/ml) or IL-2 (3 μg/ml), 
alone or in combination. Production of IFNγ from CD3-CD4-, CD3+CD4- and CD3+CD4+ cells was measured 
by intracellular flow cytometry. (A-I) Scatter plots generated from a representative PBMNC sample (Joffrey) show 
IFNγ production from the total PBMNC population (left plot) and from CD3+ PBMNCs only (right plot). A 
percentage of total events for each quadrant is given. Plots are representative of results generated from two other 
PBMNC samples.  
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CD3-CD4- or CD3+CD4+ cells staining positive for the cytokine. Comparison of three 
stimulated PBMNC samples demonstrated that a combination of IL-2, poly-ICLC and 
imiquimod was most effective at stimulating IFNγ production, with a significant increase of 
around 2 to 4-fold in both the number of IFNγ-positive cells and the MFI, relative to IL-2 alone 
(Fig. 3-9A-B). IL-2 combined with LPS, or a combination of poly-ICLC and LPS also increased 
IFNγ production in all tested samples, however these did not reach statistical significance. In 
comparison, responses to IL-2 in combination with imiquimod or poly-ICLC and CpG were 
varied among the biological replicates, while IL-2 in combination with poly-ICLC or CpG 
alone produced no detectable increase in IFNγ production. Together these results demonstrate 
that poly-ICLC and imiquimod in combination with IL-2 most effectively stimulate functional 
responses in Tasmanian devil PBMNCs that will be required for effective anti-tumour 
immunity. 
3.3.5. Efficacy of TLR ligand mixtures for PBMNC stimulation  
A combination of the TLR3 ligand poly-ICLC and the TLR7 ligand imiquimod stimulates 
significant pro-inflammatory gene expression and IFNγ production from Tasmanian devil 
PBMNCs in vitro. Together these findings highlight the potential of poly-ICLC and imiquimod 
as immune adjuvants in the Tasmanian devil. Immunisation comprising these ligands will be 
more easily administered to wild Tasmanian devils if pre-prepared in the laboratory prior to the 
immunisation. To determine whether pre-mixed adjuvant exhibits the same biological activities 
as freshly mixed adjuvant, Tasmanian devil PBMNCs were stimulated with adjuvant mixtures 
and responses were assessed through measurement of IL1α and IL6 expression by qRT-PCR. 
The saponin-based adjuvant ISCOMATRIX was also included in these adjuvant mixtures to 
accurately reflect the current immunisation protocol given to Tasmanian devils (Tovar et al. 
2017). Comparison of inflammatory cytokine expression from stimulated PBMNCs revealed 
that the cells responded more effectively to adjuvant pre-mixed four days prior to the 
experiment, with levels of cytokine expression that were approximately 16-fold higher in these 
cells relative to PBMNCs stimulated with freshly mixed adjuvant (p < 0.05) (Fig. 3-10). These 
results suggest that pre-mixing adjuvants for DFTD immunisation does not decrease the 
efficacy of immune stimulation, and could even improve the immune responses generated. 
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Figure 3-9. Production of IFNγ from Tasmanian devil CD3+CD4- lymphocytes stimulated with TLR ligands 
and IL-2. MNCs isolated from the peripheral blood of three Tasmanian devils were stimulated for 21 h with Poly-
ICLC (10 μg/ml), LPS (10 μg/ml), imiquimod (10 μg/ml), CPG-1585 (5 μg/ml) plus CpG-2395 (5 μg/ml) or IL-2 
(3 μg/ml), alone or in combination. Production of IFNγ from CD3+CD4- cells was measured by intracellular flow 
cytometry. (A) The percentage of IFNγ positive CD3+CD4- cells was measured after stimulation with IL-2 and 
TLR ligands and is given as a ratio relative to IL-2 treatment alone (dashed line). (B) The mean fluorescence 
intensity (MFI) of IFNγ labelling was measured after stimulation with IL-2 and TLR ligands and is given as a 
ration relative to IL-2 treatment alone (dashed line). Statistical significance was measured by one-way ANOVA 
and Dunnett’s multiple comparisons test and is defined as ns>0.05, *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 3-10. Expression of inflammatory genes in Tasmanian devil PBMNCs stimulated with previously 
mixed adjuvant. MNCs isolated from the peripheral blood of three Tasmanian devils were stimulated for 6 h with 
poly-IC (10 g/ml), imiquimod (10 g/ml) and ISCOMATRIX® combined together either on the day of the 
experiment, or four days prior to the experiment, Expression of the downstream TLR signalling products IL1 and 
IL6 was measured by qRT-PCR. No-cDNA and no-RT controls were included and did not show any amplification 
of product. Gene expression was calculated relative to the reference gene RPS18 and is given as a ratio between 
cells treated with 4 day old and freshly mixed adjuvant. Results are the mean and standard error of three biological 
replicates. Statistical significance between the treatment groups was measured by unpaired t-test and is defined as 
ns>0.05, *p<0.05, **p<0.01, ***p<0.001. 
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3.4. Discussion 
The development of a prophylactic DFTD vaccine is priority for conservation of the Tasmanian 
devil. Adequate priming of the immune response will be critical to the generation of robust 
antigen-specific immune memory in response to these DFTD immunisations. TLR ligands have 
been included as adjuvants in countless human trials (Galluzzi et al. 2012a), and may provide 
the necessary immune stimulation for a DFTD vaccine to be successful. In support of this, 
examination of sequenced genomes demonstrates that TLR genes are well conserved across 
invertebrate and vertebrate species, including marsupials (Cui et al. 2015a; Cui et al. 2015b; 
Roach et al. 2005). Expression of TLR genes in the tissues of wild mammals such as the spotted 
hyena, black flying fox, water buffalo and goat has been confirmed using PCR (Cowled et al. 
2011; Flies et al. 2014; Tirumurugaan et al. 2010; Vahanan et al. 2008). A similar study has not 
been performed in any marsupial species. Analysis of TLR signalling in the Tasmanian devil 
immune system will reveal whether TLRs are potential targets for a DFTD vaccine, and will 
provide the first functional evidence for TLR signalling in any marsupial species. 
Analysis of TLR gene expression in immune-enriched tissues from Tasmanian devils revealed 
expression of all ten TLR genes that are present in the Tasmanian devil genome. Most TLR 
genes exhibited moderate to high expression levels across all tissues, suggesting that a variety 
of cells constitutively express these TLRs. In comparison, low levels of TLR9 in the peripheral 
blood and skin likely reflects selective expression of this receptor to cell subsets such as pDCs 
that are represented in low baseline numbers in these tissues (Hornung et al. 2002; Kassianos 
et al. 2010). Skin samples, which contain a reservoir of tissue-resident DCs, expressed many 
TLRs. Although skin is not a direct target of subcutaneous immunisation, CD301+ dermal DCs 
play a critical role in the activation of adaptive responses upon vaccination via this route (Apte 
et al. 2013; King et al. 2010). As such, this result supports the use of TLR ligands in a 
subcutaneous DFTD vaccine. Notably, skin samples also did not express TLR10, which has 
recently demonstrated immunoregulatory functions via inhibition of MyD88- and TRIF-
dependent signalling pathways (Jiang et al. 2016b). Low expression of this receptor may 
promote the pro-immune effects of DCs in response to TLR stimulation at peripheral sites. 
TLRs regulate MyD88 dependent and independent pathways to control inflammatory gene 
expression (Yamamoto et al. 2003). Increased expression of TLR signalling products such as 
cytokines and co-stimulatory molecules can be detected as a surrogate measure of TLR 
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function. In this chapter, genes expressed by APCs during immune responses including IL1α, 
IL6, IL12A, IFNβ and CD86 were measured to confirm that TLR signalling is functional in 
Tasmanian devil PBMNCs. To represent a cross section of the Tasmanian devil population, 
gene expression was analysed using blood samples of captive and wild devils from different 
environments. Consequently, background immune activation varied with each devil, creating 
differences in responsiveness to TLR stimulation among samples. The strongest response was 
the activation of the pro-inflammatory cytokine genes IL1α and IL6. These cytokines were 
increased in response to stimulation with poly-IC (TLR3), LPS (TLR4), flagellin (TLR5) and 
profilin (TLR11), suggesting that these TLRs are functional. Unexpectedly, Tasmanian devil 
PBMNCs responded to stimulation with profilin (T. gondii), a ligand of mouse TLR11. While 
there is no gene denoted TLR11 in the genome of the Tasmanian devil, marsupials express a 
gene with homology for the TLR11 subfamily (denoted TLR13L). Although TLR13 is a 
receptor for bacterial 23S ribosomal RNA in mice (Li et al. 2012), devil TLR13L arose from 
the same evolutionary precursor as TLRs 11, 12 and 13 (Cui et al. 2015a; Roach et al. 2005), 
suggesting that it could exhibit specificity for profilin. Further investigation is required to 
determine the ligand specificity of TLR13L in the Tasmanian devil and other marsupial species.  
The responses of Tasmanian devil PBMNCs to stimulation with imiquimod (TLR7), CpG-1585 
(TLR9) and CpG-2395 (TLR9) were non-significant and low in comparison to other TLR 
ligands. This finding could reflect low expression of TLR7 and TLR9 in the blood cell 
populations that are responsible for production of IL1α and IL6 in the Tasmanian devil. 
Furthermore, TLR7 and TLR9 are potent inducers of anti-viral immune responses in human 
studies (Ito et al. 2005; Kawai et al. 2004), suggesting that a different cytokine profile is induced 
by these TLRs. Expression of the anti-viral cytokine IFNβ was measured alongside the Th1 
cytokine IL12A and the costimulatory molecule CD86 in this study, but these were not 
significantly altered by TLR stimulation. While biological variation played a role in the 
insignificance of these results, low levels of gene expression also hampered the measurement 
of these genes. In order to improve the detection of IFNβ, IL12A and CD86, a protocol was 
developed for the separation of MNC subsets from the total PBMNC population. This 
experiment was challenged by the lack of specific antibodies available for identification of 
Tasmanian devil immune cell populations. As such, monocytes were separated using their 
plastic adherent properties, and B cells were separated from the remaining MNC population 
(presumably T cells and NK cells) using serum from rabbits immunised with devil Ig. 
Validation of this method through detection of the monocyte marker CFS1R, the B cell marker 
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CD19 and the T cell marker CD3e by qRT-PCR revealed that only pure populations of T 
cells/NK cells could be obtained. As a result, it was concluded that analysis of TLR-stimulated 
immune cell subsets in the Tasmanian devil was not feasible in the absence of specific 
antibodies. Although functional TLR analyses could only be performed with mixed MNC 
populations, findings from these experiments support the concept that TLRs are functional in 
Tasmanian devil immune cells. This is the first evidence of functional TLRs in any marsupial 
species, contributing to our understanding of marsupial immunology and the evolution of TLR 
signalling.  
The identification of functional TLRs in the Tasmanian devil immune system supports the use 
of TLR ligands as DFTD vaccine adjuvants. In human studies, the use of multiple TLR ligands 
in combination as adjuvants is a promising strategy for improving TLR-mediated responses 
both in vitro and in vivo (Hu et al. 2016; Kreutz et al. 2015). In particular, simultaneous 
stimulation of MyD88 and TRIF-dependent signalling pathways activates synergistic pathway 
interactions that produce significantly heightened immune responses (Bagchi et al. 2007; 
Ouyang et al. 2007; Suet Ting Tan et al. 2013). In this chapter, stimulation of diseased 
Tasmanian devil PBMNCs with individual and combinations of TLR ligands generated changes 
in IL1α, IL6 and IL12A expression that were low in magnitude compared to the responses to 
TLR stimulation that were generated in section 3.3.2. In addition, no increase in expression was 
evident when ligands were used in combination rather than as individual agents. The lack of 
response to TLR stimulation may be explained by the disease status of the devils used for these 
experiments, which had all been euthanised with disease related ailments at the time of blood 
collection. In support of this, significantly higher baseline expression of IL1α, IL6 and IL12A 
was measured in DFTD-infected devils, suggesting that constitutively active inflammatory 
responses in these PBMNCs prevented further responses to TLR stimulation. In human disease, 
systemic inflammation is frequently associated with cancer (Diakos et al. 2014; McAllister et 
al. 2014; Roxburgh et al. 2014). This systemic inflammation promotes a shift in immune 
balance towards the differentiation of MDSCs, Tregs, M2 macrophages and neutrophils, which 
inhibit protective anti-tumour responses and favour tumour-promoting inflammation. Systemic 
inflammation during cancer also induces production of growth factors that promote 
proliferation, survival and angiogenesis at the tumour site, thereby inferring poor prognosis 
(McAllister et al. 2014; Roxburgh et al. 2014). As such, the finding that devils suffering from 
DFTD exhibit higher baseline inflammatory gene expression than healthy devils highlights a 
potential role for tumour-promoting inflammation in the survival of DFTD. Comparison of the 
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immune profile of diseased and healthy devils is required to understand these mechanisms in 
detail.  
In order to overcome the challenges arising from the use of PBMNC samples from diseased 
devils in TLR-stimulation assays, blood was obtained from healthy devils for further 
experimentation. As a smaller volume of blood was available from these healthy devils, poly-
IC, LPS, imiquimod and CpG were selected for further stimulations based on literature 
describing their efficacy for activation of anti-tumour responses in human studies (Galluzzi et 
al. 2012a; Vacchelli et al. 2012). Results from these analyses reflected earlier findings that poly-
IC (TLR3) and LPS (TLR4), but not imiquimod (TLR7) or CpG (TLR9), are potent stimulators 
of inflammatory cytokines such as IL6 and IL12A. Combinations of poly-IC with LPS or 
imiquimod were also effective at inducing expression of these cytokines. As previously, these 
responses exhibited high biological variation with different devils responding optimally to 
different TLR ligands. Importantly, the majority of devils responded most effectively to a 
combination of TLR ligands, suggesting that this is an effective strategy for improving immune 
responses in the Tasmanian devil.  
An effective DFTD vaccine will require activation of potent anti-tumour immune responses. 
Recent studies in Tasmanian devils have demonstrated that DFTD tumour regression correlates 
with significant infiltration of MHCII+ cells (presumably DCs), CD4+ T cells and CD8+ T 
cells (Tovar et al. 2017), demonstrating the importance of cellular immunity for effective anti-
DFTD responses. Recently, improved availability of specific antibodies in the Tasmanian devil 
has allowed for identification of IFN in CD3+ and CD4+ T cell populations after TLR 
stimulation, allowing cellular immunity to be measured. IL-2, which induces IFN production 
in combination with TLR ligands in other mammalian species (Cottalorda et al. 2009), was 
necessary for this IFN production. This analysis revealed synergistic IFN production from 
devil CD3+CD4- lymphocytes in response to stimulation with the combination of poly-ICLC 
(TLR3) and imiquimod (TLR7), suggesting that these ligands favour cell-mediated responses. 
Unexpectedly, IFNγ was produced only by the CD3+CD4- T cell population, which were likely 
CD8+ T cells. This population could also include NKT cells, but as these make up only a small 
proportion of total PBMNCs in other species, it is unlikely that they account for the total IFNγ 
effect that was detected. The ability of poly-ICLC and imiquimod in combination to non-
specifically stimulate IFNγ production from CD8+ T cells will be beneficial to the development 
of potent cellular immunity in response to DFTD immunisation. In other studies, synergy 
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between TLR3 and TLR7 signalling also occurs in DC subsets, and enhances both cytokine 
production and antigen presentation for improved adaptive responses (Hu et al. 2016; Kreutz et 
al. 2015). Factors such as IL-12, which are released by TLR-stimulated DCs, can synergise 
with TLR ligands and IL-2 to promote IFNγ production from T cells in an antigen-independent 
manner (Freeman et al. 2012; Rubtsova et al. 2016; Song et al. 2009). This cooperation of 
immune cell subsets could account for the TLR synergy that was detected in devil PBMNCs, 
with poly-ICLC a potent activator of inflammatory cytokine expression, and imiquimod a 
superior inducer of T cell IFNγ.  
In human studies, TLR ligands stimulate IFNγ production from a number of cell populations 
including NK cells, CD4+ T cells and CD8+ T cells (Caron et al. 2005; Sawaki et al. 2007; 
Sivori et al. 2004). Unexpectedly, TLR-stimulated Tasmanian devil NK cells and CD4+ T cells 
did not produce IFNγ in this study. This may be a unique feature of marsupial immune systems 
and could have consequences for immune stimulation in the Tasmanian devil. NK cells are an 
integral component of the innate cellular response to viruses and tumour cells (Della Chiesa et 
al. 2014). Furthermore, IFNγ production from NK cells and CD4+ T cells is important for the 
development of potent Th1 immunity (Martin-Fontecha et al. 2004; Wakil et al. 1998). Further 
studies are required to understand why these cells do not produce IFNγ in response to TLR 
stimulation, and whether other anti-viral or Th1 cytokines can promote this response. 
Nonetheless, an inability of NK cells and CD4+ T cells to produce IFNγ in response to TLR 
stimulation and IL-2 could reduce their efficacy for stimulation of Th1 immunity during both 
immunisation and infection.  
Co-stimulation of TLR3 and TLR7 signalling in Tasmanian devil PBMNCs resulted in effective 
stimulation of both inflammatory cytokine expression and IFNγ production. As a result, ligands 
of these receptors are potential candidate adjuvants for immunisation trials in Tasmanian devils. 
In human studies, poly-ICLC (Hiltonol) has reached human clinical trials as a cancer 
immunotherapy for its ability to activate potent Th1 immunity via stimulation of type-1 IFN 
production (Cho et al. 2013; Galluzzi et al. 2012a). Similarly, imiquimod has been approved as 
a therapeutic agent for the treatment of superficial basal cell carcinoma since 2004 and is known 
for its ability to induce CD8+ T cell cytotoxicity against tumour cells via stimulation of IFNγ 
production (Huang et al. 2009; Vacchelli et al. 2012). Although few clinical studies have 
examined the combined use of TLR3 and TLR7 ligands as adjuvants in humans (Galluzzi et al. 
2012a), in vitro studies have provided convincing evidence of synergistic interactions between 
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TLR3 and TLR7. In particular, these TLRs are expressed in DCs and can synergise via co-
stimulation of TRIF and MyD88-dependent pathways to improve phagocytosis, antigen 
presentation and cytokine production (Kreutz et al. 2015; Liu et al. 2015). In vivo, generation 
of antigen-specific CD4+ and CD8+ T cells was increased in mice immunised with TLR3 and 
TLR7 ligands and antigen (Hu et al. 2016), supporting the use of these ligands in a DFTD 
vaccine. Studies in Tasmanian devils demonstrating successful activation of immune responses 
by poly-ICLC and imiquimod will support similar use of these ligands for human application.  
The ability of poly-ICLC and imiquimod to activate devil immune cells in culture warrants in 
vivo trials to determine the efficacy of these ligands as vaccine adjuvants in the Tasmanian 
devil. A limitation of performing immunisation trials in wild Tasmanian devils involves the 
requirement for these immunisations to be prepared days in advance. As such, it was necessary 
to compare the efficacy of freshly mixed and previously mixed adjuvant for activation of 
Tasmanian devil PBMNCs. The saponin-based adjuvant ISCOMATRIX was also used in 
these stimulations, as this is included in current DFTD immunisation protocols as a potent 
stimulator of T cell immunity in combination with TLR ligands (Silva et al. 2015; Tovar et al. 
2017). Unexpectedly, four-day old mixtures of poly-ICLC, imiquimod and ISCOMATRIX 
were more effective at stimulating inflammatory cytokine expression from devil PBMNCs than 
freshly mixed adjuvant. While the mechanism by which this occurs remains unconfirmed, it is 
possible that during storage these adjuvants form aggregates. This could result in co-delivery 
of the adjuvants to immune cells, thereby increasing the likelihood of a synergistic response 
being stimulated within each immune cell. While this concept has not been reported in the 
literature, a similar phenomenon is responsible for increases in immune reactivity that are 
evident when adjuvant-antigen conjugations are used for immunisation. These conjugates 
ensure co-delivery of adjuvant and antigen to APCs, ensuring that antigen-presentation is 
effectively stimulated (Kreutz et al. 2012). These findings suggest that it may be beneficial to 
pre-mix poly-ICLC, imiquimod and ISCOMATRIX for DFTD immunisation. 
In summary, in this chapter I have expanded the current knowledge of the Tasmanian devil’s 
immune system by verifying that devils have functional TLRs that respond to a range of 
prototypic TLR ligands. This is the first description of functional TLRs in a marsupial species, 
contributing to our understanding of marsupial immunology and the evolution of TLR 
signalling. In addition, this analysis has demonstrated a lack of IFNγ-production from NK cells 
and CD4+ T cells in response to TLR stimulation, highlighting a difference in the Tasmanian 
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devil immune system that could potentially impede anti-tumour and anti-viral responses. 
Nonetheless, poly-ICLC and imiquimod were demonstrated to be effective immune stimulants 
in vitro through their ability to induce potent inflammatory cytokine expression and IFNγ-
production from CD8+ T cells. Together these results suggest that TLR ligands are potential 
immune adjuvants in the Tasmanian devil. Poly-ICLC and imiquimod will be included in 
further immunisation trials to determine their efficacy for activation of DFTD-specific immune 
responses. 
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Chapter 4: Poly-ICLC and imiquimod 
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4.1. Introduction 
Tasmanian devil populations have experienced local declines as great as 95% since the arrival 
of DFT1 in the mid-1990s (Hollings et al. 2014). With DFT1 continuing to threaten populations 
state-wide, and DFT2 now posing a threat to devil populations in the south, strategies are 
required to ensure the long-term survival of the species (Hollings et al. 2014; Pye et al. 2016b). 
A prophylactic DFTD vaccine will allow for conservation of Tasmanian devils in the wild. This 
vaccine will be distributed among insurance population devils destined for release into areas of 
mainland Tasmania with endemic DFTD. Opportunistic vaccination of wild devils captured 
during routine trapping expeditions could also contribute to the establishment of herd DFTD 
immunity in these areas. Development of a successful DFTD vaccine is challenging, as DFT1 
cells successfully evade immune recognition through down-regulation of surface MHCI (Siddle 
et al. 2013). In culture, MHCI down-regulation can be reversed by IFNγ treatment, providing a 
source of potentially immunogenic cells for DFTD immunisation (Siddle et al. 2013; Tovar et 
al. 2017). An effective immune adjuvant will be required for these immunisations to promote 
robust and long-lived DFTD-specific immunity against few doses of antigen. TLR ligands are 
effective adjuvants in human and animal studies and could provide the necessary immune 
stimulation for a successful DFTD vaccine (Galluzzi et al. 2012a; Vacchelli et al. 2012). 
Previous DFTD immunisation trials used the TLR ligands poly-IC (TLR3) and CpG (TLR9) as 
adjuvants, alongside the water-in-oil adjuvant Montanide ISA-71VG or the saponin-based 
adjuvant ISCOMATRIX® (Kreiss et al. 2015; Tovar et al. 2017). These adjuvant combinations 
induced effective antigen-specific immune responses in mouse tumour models (Silva et al. 
2015; Valmori et al. 2007), but their efficacy for immune stimulation in the Tasmanian devil 
had not been verified in the presence of appropriate negative controls. In captive Tasmanian 
devils, immunisation with killed DFT1 cells and these adjuvants induced DFTD-specific 
immune responses that were detectable by analysis of antibody production and cytotoxicity 
(Kreiss et al. 2015; Tovar et al. 2017). In the first of these studies, four immunisations and a 
booster at six months protected one devil from immune challenge with live DFTD cells for a 
year after immunisation (Kreiss et al. 2015). In a second study, Tasmanian devils immunised 
three or four times with killed IFNγ-treated DFT1 cells were not protected from immune 
challenge, but did respond with full tumour regression to subsequent immunotherapeutic 
vaccinations (Tovar et al. 2017). In this study, tumour regression correlated with substantial 
IgG production and CD4+ and CD8+ T cell infiltration, demonstrating the importance of 
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humoral and cell-mediated immunity (CMI) for successful anti-DFTD responses (Tovar et al. 
2017). While these studies suggest that DFTD immunisations can prime protective immune 
responses in Tasmanian devils, a protocol of four immunisations is unlikely to be feasible in a 
wild devil population. Further improvement of DFTD immunisations is required for refinement 
of these protocols.  
In chapter 3, TLR signalling was demonstrated to be functional in immune cells of the 
Tasmanian devil, suggesting that TLR ligands are appropriate DFTD vaccine adjuvants. The 
TLR3 ligand poly-ICLC in combination with the TLR7 ligand imiquimod was the most 
effective at activating Tasmanian devil PBMNCs in vitro, suggesting that these ligands may be 
potent adjuvants in vivo. In this chapter, the efficacy of poly-ICLC and imiquimod as adjuvants 
in the Tasmanian devil has been assessed through in vivo immunisation trials. Devils were 
immunised using the model antigen keyhole limpet haemocyanin (KLH) to analyse the 
adjuvant-specific response, followed by DFTD to determine the efficacy of the adjuvants for 
activation of tumour-specific responses. These analyses will improve the current understanding 
of TLR-mediated immune activation in the Tasmanian devil and allow for improved 
formulation of future DFTD vaccinations. 
4.2. Experimental Procedures 
4.2.1. KLH Immunisations 
Captive Tasmanian devils (section 2.2.1.) were immunised in the left shoulder by subcutaneous 
injection with endotoxin-free KLH (Merck Millipore, Billerica, USA) alone or with adjuvants 
(Table 4-1). All devils received two immunisations, 42 days apart. Devils were aged from 3 to 
6 years and included a mix of males and females. Due to the endangered status and limited 
availability of Tasmanian devils, group size was n=2. Blood samples were collected 0, 14 and 
42 days after each immunisation. Serum and PBMNCs were isolated for analysis according to 
sections 2.2.1. and 2.2.2. Two devils were monitored at 42-day intervals for 388 days after 
immunisation, receiving a recall immunisation of KLH alone at day 304. 
4.2.2. Enzyme-linked immunosorbent assay (ELISA) 
KLH (5 μg/ml) (EMD Millipore, Billerica, USA) diluted in 50 μL of carbonate coating buffer 
(section 2.1.6.) was coated onto wells of a 96-well ELISA plate (Corning, New York, USA)  
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Table 1-4. Summary of KLH immunisation protocols 
Devil Age Sex 
First Immunisation 
(Day 0) 
Second Immunisation 
(Day 42) 
Antigen Recall 
(Day 304) 
Serum Samples 
Peaches 5 F 100 μg KLH 200 μg KLH - 
Days 0, 14, 42, 
56, 84 
Aurora 3 M 100 μg KLH 200 μg KLH - 
Days 0, 14, 42, 
56, 84 
Kakapo 3 M 
100 μg KLH, 100 μg 
Imiquimod 
200 μg KLH, 200 μg 
Imiquimod 
- 
Days 0, 14, 42, 
56, 84 
Joffrey 3 M 
100 μg KLH, 100 μg 
Imiquimod 
200 μg KLH, 200 μg 
Imiquimod 
- 
Days 0, 14, 42, 
56, 84 
Gwen 6 F 
100 μg KLH, 100 μg 
Poly-ICLC 
200 μg KLH, 200 μg 
Poly-ICLC 
- 
Days 0, 14, 42, 
56, 84 
Adam 4 M 
100 μg KLH, 100 μg 
Poly-ICLC 
200 μg KLH, 200 μg 
Poly-ICLC 
100 μg KLH  
Days 0, 14, 42, 
56, 84, 126, 168, 
220, 262, 304, 
318, 332, 388 
November 
Rain 
6 F 
100 μg KLH, 100 μg  
Poly-ICLC, 100 μg  
Imiquimod 
200 μg KLH, 200 μg 
Poly-ICLC, 200 μg 
Imiquimod 
- 
Days 0, 14, 42, 
56, 84 
Sparrow 4 M 
100 μg KLH, 100 μg 
Poly-ICLC, 100 μg 
Imiquimod 
200 μg KLH, 200 μg 
Poly-ICLC, 200 μg 
Imiquimod 
100 μg KLH 
Days 0, 14, 42, 
56, 84, 126, 168, 
220, 262, 304, 
318, 332, 388  
M, male; F, female;  
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overnight at 4°C. Plates were washed once with 200 μl of ELISA wash buffer (section 2.1.6.), 
and blocked in 200 μl of ELISA blocking buffer (section 2.1.6.) for 1 h at room temperature. 
Blocked plates were washed three times with 200 μl of ELISA wash buffer and incubated with 
50 μl of Tasmanian devil serum diluted with blocking buffer 5 000 x, 10 000 x or 100 000 x for 
2 h at room temperature. Plates were washed with ELISA wash buffer as previously then 
incubated with 50 μl of mouse anti-Tasmanian devil IgG (section 2.1.4.) diluted 200 x for 2 h 
at room temperature. Plates were again washed as previously and then incubated with 50 μl of 
goat anti-mouse immunoglobulin-HRP diluted 2000 x for 1 h at room temperature (section 
2.1.4.). After a final three washes, 50 μl of TMB Peroxidase substrate (Rockland 
Immunochemicals Inc., Limerick, USA) was added to each well and developed for 10 to 15 
min. The reaction was stopped with 50 μl of 1 M hydrochloric acid (VWR, Radnor, USA). 
ELISAs were read on the SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, 
USA) at 450 nm within 1 h.  
4.2.3. Antigen recall assays 
For gene expression analysis, Tasmanian devil PBMNCs isolated according to section 2.2.2. 
were plated at 2 x 106 cells/ml in 1 ml of TCM (section 2.1.6.). Cells were stimulated with KLH 
at 10 μg/ml for 72 h in a 37°C humidified 5% CO2 incubator. After incubation cells were 
harvested and washed in PBS (section 2.1.6.) as described in section 2.2.3. RNA extraction and 
gene expression analysis were performed according to sections 2.2.4. and 2.2.7. For lymphocyte 
proliferation analysis, Tasmanian devil PBMNCs washed in PBS/0.1% BSA were resuspended 
at 4 x 106 cells/ml in CellTraceTM violet (CTV) (Thermo Fisher Scientific, Waltham, USA) 
diluted 1000 x in PBS. The cells were incubated in the dark for 20 min, mixing frequently. 
After incubation, the reaction was quenched with at least five times the volume of RPMI 
medium (Thermo Fisher Scientific, Waltham, USA). The CTV labelled cells were centrifuged 
at 500 g for 5 min and resuspended in TCM. Cells were plated at 3.75 x 105 cells/ml in 200 μl 
of TCM in round-bottom cell culture plates (Corning, New York, USA). Cells were stimulated 
with KLH at 10 μg/ml, or IL-2 at 12.5 μg/ml as a positive control. Plates were incubated at 
37°C in a humidified 5% CO2 incubator for 5.5 days. 
4.2.4. Lymphocyte proliferation assay 
CTV labelled PBMNCs in 96-well round bottom cell culture plates were pelleted by 
centrifugation at 500 g for 3 min and washed three times in 200 μl of FACS buffer (section 
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2.1.6). Cells were resuspended in 50 μl of rabbit anti-Tasmanian devil IgG (section 2.1.4.) 
diluted 15 000 x in FACS buffer/0.5% normal goat serum (Thermo Fisher Scientific, Waltham, 
USA). The plate was incubated for 30 min on ice, then washed three times in FACS buffer as 
previously. Cells were resuspended in 50 μl of goat anti-rabbit IgG PE (section 2.1.4.) and 
mouse anti-Tasmanian devil CD4 AF-647 (section 2.1.4.), diluted 1000 x and 4000 x in FACS 
buffer, respectively. The plate was incubated for 30 min on ice and then washed in FACS buffer 
twice as previously. A third wash was performed using PBS (section 2.1.6 ). Cells were 
resuspended in 100 μl of live/dead fixable near IR dead cell stain (Thermo Fisher Scientific, 
Waltham, USA) diluted 600 x in PBS and incubated 30 min on ice. Cells were washed three 
times in FACS buffer as previously. Cells were resuspended in 150 μl of FACS buffer/5 mM 
EDTA (Thermo Fisher Scientific, Waltham, USA). Proliferation of CD4-IgG+, CD4+IgG- and 
CD4-IgG- lymphocytes was measured by CTV fluorescence on the BD FACS CANTO II (BD 
Biosciences, Franklin Lakes, USA). The percentage of dividing cells (% divided) and number 
of divisions made by each proliferating cell (proliferation index) were calculated using FlowJo 
V9 software. Statistical significance was measured by two-way ANOVA with Dunnett’s 
multiple comparisons test using Prism GraphPad V6. 
4.2.5. Stony Head DFTD immunisation trial 
Tasmanian devils selected from several captive and wild insurance populations were housed 
across two eleven-hectare free-range enclosures for immunisation. Devils were aged from 1 to 
4 years and included both males and females (Table 4-2). DFTD immunisations were pre-
prepared by treating C5065 DFT1 cells with recombinant devil IFNγ (Walter and Eliza Hall 
Institute of Medical Research, Melbourne, Australia) diluted 5000 x in RPMI/10FCS culture 
medium (section 2.1.6) for 24 h. After treatment, MHC positive DFT1 cells were inactivated 
by either four ultra-sonic cycles at 50% power on an ultrasonic cell disruptor (sonication) 
(Misonix Inc., Farmingdale, USA), or by two doses of 40 Gy gamma radiation 24 h apart using 
a Varian Clinac 23-EX linear accelerator (irradiation) (Varian Medical Systems Inc., Palo Alto, 
USA). On the day of immunisation, prepared cells were thawed and mixed with 50 μl 
ISCOMATRIX® (CSL Ltd, Victoria, Australia), 100 μg of poly-ICLC (Hiltonol; Oncovir, 
Washington DC, USA) and 100 μg of imiquimod (Sigma-Aldrich, St Louis, USA). Devils 
handled according to section 2.2.1 were immunised by subcutaneous injection between the 
scapulae with 2 x 107 sonicated cells and adjuvants at day 0, followed by 2 x 106 irradiated cells 
and adjuvants at day 28 (protocol A). Not all devils were trapped on each trip and as such  
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Table 4-2. Summary of Tasmanian devils immunised for release at Stony Head 
Tasmanian devil 
Insurance 
population 
Age (years) at 
immunisation 
Sex 
Immunisation 
protocol 
Three-month 
follow-up 
Blake Cressy 2 M A serum 
Podrick Cressy 2 M A serum 
Akaroa Cressy 3 M A not trapped 
Khal Cressy 3 M A serum 
Myrtle Cressy 3 M A deceased 
Tarkine Cressy 3 M A serum 
Weka Cressy 3 M A not trapped 
Grumble Cressy 3 F A not trapped 
Moretti Dubbo 4 F B serum 
Zoe Dubbo 4 F A deceased 
Penelope Stroman  Freycinet 3 F A deceased 
Melisandre Freycinet 3 F A deceased 
Prudence Stroman Freycinet 3 F C deceased 
Brienne Freycinet 4 F A deceased 
Flash Gordon Maria Island 1 M A not trapped 
Ventoux Maria Island 2 F A serum 
Frosty Maria Island 2 M A not trapped 
Geysir Maria Island 2 M A serum 
Machin Maria Island 2 M B serum 
Moffett Maria Island 2 M A serum 
Rotorua Maria Island 2 M A serum 
Taranaki Maria Island 2 M A deceased 
Ararat Maria Island 2 M C serum 
Askja Maria Island 2 M A not trapped 
Bosavi Maria Island 2 M A serum 
Fraser Maria Island 2 M C serum 
Savo Maria Island 2 M A serum 
Guernsey Maria Island 3 F B not trapped 
Macca Maria Island 3 M A serum 
Rapa Nui Maria Island 3 M A serum 
Nutella Maria Island 4 F A serum 
Rueben Monarto 3 M A not trapped 
Mindi Trowunna 3 F A not trapped 
M, male; F, female. 
 
92 
several individuals received their second immunisation at day 42 or day 70 (protocol B and C) 
(Table 4-3). Blood samples were collected at days 0, 28 and 70 (post-immunisation) in clot 
activator tubes (Corning, New York, USA) for serum analysis according to section 2.2.1. No 
post-immunisation sample was collected for devils receiving protocol B or C. All devils were 
released at Stony Head on the northern coast of Tasmania approximately 7 weeks after their 
second immunisation (1 week for protocol B or C). Devils were released wearing GPS collars, 
allowing their movements post-release to be monitored. Further serum samples were collected 
from 17 devils trapped during follow-up monitoring approximately four months post-release. 
4.2.6. Flow cytometric detection of DFTD-specific IgG 
C5065 DFT1 cells were treated for 24 h with recombinant devil IFNγ (Walter and Eliza Hall 
Institute of Medical Research, Melbourne, Australia) diluted 5000 x in RPMI/10FCS culture 
medium (section 2.1.6.) to up-regulate surface MHCI expression. MHCI-positive and MHCI-
negative C5065 DFT1 cells were harvested as described in section 2.2.3., washed in PBS and 
resuspended in ice-cold FACS buffer (section 2.1.6.). A total of 2 x 105 cells were plated per 
well into round-bottom 96-well cell culture plates (Corning, New York, USA) and centrifuged 
at 500 g for 5 min. FACS buffer was removed from cell pellets by suction and cells were 
resuspended in 100 μl of Tasmanian devil serum diluted 50 x in FACS buffer. Cells were 
incubated in serum for 30 min on ice. After incubation, cells were washed three times in FACS 
buffer, centrifuging at 500 g for 5 min between each wash. Cells were resuspended in 100 μl of 
mouse anti-Tasmanian devil IgG (section 2.1.4.) diluted 200 x in FACS buffer. After 30 min of 
incubation on ice cells were washed in FACS buffer as previously and then resuspended in 100 
μl of goat anti-mouse IgG AF-647 (section 2.1.4.) diluted 1000 x in FACS buffer. Cells were 
again incubated 30 min on ice and washed as previously in FACS buffer. Cells were 
resuspended in DAPI (Sigma-Aldrich, St Louis, USA) diluted to 200 ng/ml with FACS buffer. 
Binding of Tasmanian devil serum IgG to DFT1 cells was analysed using the BD FACSCanto 
II flow cytometer (BD Biosciences, Franklin Lakes, USA) and FlowJo version 9 software, using 
the gating strategy described (section 2.2.8). Response to immunisation was calculated as the 
ratio of median fluorescence intensity (MFI) between post-immune and pre-immune (day 0) 
samples (MFIR). A MFIR of >1.5 was chosen as a threshold for distinguishing responders from 
non-responders to immunisation. Statistical significance was measured by one-way ANOVA 
or t-test using Prism GraphPad version 6. 
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4.3. Results 
4.3.1. Activation of antigen-specific immune responses in Tasmanian devils 
by poly-ICLC and imiquimod 
An effective prophylactic DFTD vaccine will require a potent immune adjuvant. Ligands of 
TLRs are frequently used in animal and human studies to activate antigen-specific responses 
(Galluzzi et al. 2012a; Vacchelli et al. 2012). It was demonstrated in chapter 3 that TLRs are 
expressed as functional receptors in Tasmanian devil immune cells, and that they respond to a 
range of conventional TLR ligands. In particular, treatment of Tasmanian devil PBMNCs in 
vitro with the TLR ligands poly-ICLC (Hiltonol) (TLR3) and imiquimod (TLR7) effectively 
stimulated expression of a range of cytokines including IFNγ, a marker of cell-mediated 
responses and anti-tumour immunity. To determine whether these ligands are effective immune 
adjuvants in the Tasmanian devil, immunisation trials were performed in eight captive devils 
using poly-ICLC and imiquimod as adjuvants. In order to specifically examine the adjuvant-
mediated response and to reduce the potential for unpredictable antigen-mediated effects on the 
immune response, endotoxin-free KLH was used as a model antigen in place of DFTD cells for 
these immunisations.  
Analysis of KLH-specific IgG in the serum of immunised devils by ELISA demonstrated 
considerable increases in antigen-specific immunity in response to poly-ICLC and imiquimod 
(Fig. 4-1A). Two control devils (Peaches and Aurora), receiving an immunisation of KLH 
without TLR ligands, exhibited a small increase in specific IgG levels only after a second 
immunisation at day 42. Imiquimod alone (Kakapo and Joffrey) produced responses similar to 
Table 4-3. Summary of Stony Head immunisation protocols  
Protocol Description No. Devils 
A Two immunisations with 28 day interval 27 
B Two immunisations with 42 day interval* 3 
C Two immunisations with 70 day interval* 3 
*no serum sample collected after second immunisation  
 
94 
  
Figure 4-1. Antibody responses of Tasmanian devils immunised with KLH and TLR ligands. Tasmanian 
devils were immunised at day 0 and 42 (black arrows) with KLH only (n=2, orange), KLH and imiquimod (n=2, 
green), KLH and poly-ICLC (n=2, red) or KLH, poly-ICLC and imiquimod (n=2, blue). Serum samples were 
analysed by ELISA for KLH-specific IgG at dilutions of (A) 10 000 x, (B) 5000 x or (C) 100 000 x. Absorbance 
was measured at 450 nm and the mean and standard error of three technical replicates is given. 
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the antigen-only control. In comparison, devils receiving poly-ICLC (Gwen and Adam) or poly-
ICLC and imiquimod (November Rain and Sparrow) exhibited a greater primary response to 
first immunisation, followed by a sizeable secondary response to re-immunisation at day 42. 
Further analysis of the primary response at a lower serum dilution of 5000 x (Fig. 4-1B), and 
the secondary response at a greater serum dilution of 100 000 x (Fig. 4-1C), confirmed that the 
highest IgG response to immunisation was generated by the adjuvant combination of poly-
ICLC and imiquimod (Sparrow). The IgG response of November Rain, an older devil that also 
received these adjuvants in combination, was lower, while the devils that received poly-ICLC 
alone (Gwen and Adam) fell within the range of November Rain and Sparrow. Together these 
results indicate that poly-ICLC, with and without imiquimod, effectively activates antigen-
specific humoral immunity in Tasmanian devils. 
4.3.2. Ex vivo antigen recall responses of PBMNCs from immunised 
Tasmanian devils 
To further analyse the immune response activated by poly-ICLC and imiquimod in KLH-
immunised Tasmanian devils, PBMNCs taken at days 0, 14, 42 and 56 from Tasmanian devils 
were exposed to KLH ex vivo and analysed for cytokine expression and T cell proliferation. 
Adequate blood samples were available from only three immunised devils for these 
experiments (Peaches, Adam and Sparrow). Gene expression of the inflammatory cytokine IL6, 
the Th1 cytokines IL2, IL12A and IFNγ and the Th2/suppressive cytokines IL4, IL10 and TGFβ 
were monitored by qRT-PCR. Relative to RPS18, expression of all cytokines in unstimulated 
and KLH-stimulated PBMNCs was low and variable across the 56-day immunisation schedule 
(Fig. 4-2A-F). Analysis of cytokine expression as a ratio between unstimulated and stimulated 
samples revealed trends in gene expression that were small in magnitude but different across 
the three Tasmanian devils (Fig. 4-2G-I). In particular, PBMNCs from Peaches (immunised 
with KLH only) exhibited cytokine expression that was largely unchanged at any time-point 
after KLH re-exposure (Fig. 4-2G). PBMNCs taken from Adam (immunised with KLH and 
poly-ICLC) exhibited greater variation in cytokine expression after KLH stimulation, with 
numerous cytokines displaying a slight upward trend until day 42 and a decrease at day 56 after 
a second immunisation (Fig. 4-2H). PBMNCs from Sparrow (immunised with KLH, poly-
ICLC and imiquimod) also exhibited variation in cytokine expression after KLH stimulation, 
with most cytokines displaying a slight decrease following first immunisation, an increase of 
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2 to 8-fold between day 14 and 42, and another slight decrease following second immunisation 
(Fig. 4-2I).  
To further analyse these responses, T cell proliferation was measured using CTV labelled 
Tasmanian devil PBMNCs after 5 days of ex vivo KLH re-exposure. Additional cells were 
stimulated with IL-2 as a positive control. CD4+ T cells (Fig. 4-3) and CD4- T cells 
(presumably CD8+ T cells) (Fig. 4-4) taken at day 0 (pre-immune) and day 56 of the 
immunisation schedule demonstrated only a small amount of ex vivo proliferation in the absence 
of stimulation. In comparison, both cell subsets underwent considerable proliferation when 
stimulated with IL-2. Similarly to unstimulated samples, KLH stimulated CD4+ and CD4- T 
cells displayed only a small amount of proliferation, with no observed differences between cells 
taken at day 0 and day 56 of the immunisation schedule. Analysis of three technical replicates 
confirmed that there were no significant difference in the percentage of dividing CD4+ or CD4-
T cells between unstimulated and KLH-stimulated samples at day 0 or 56 (Fig 4-5A and Fig 4-
5B). Analysis of the proliferation index of each sample also demonstrated that there was no 
significant increase in the number of times each proliferating T cell divided after KLH 
stimulation (Fig 4-5C and Fig 4-5D). In comparison, IL-2 significantly increased the percentage 
of dividing T cells, but not proliferation index, by as much as 4-fold for CD4+ T cells and 100-
fold for CD8+ T cells. Together these results demonstrate that while peripheral blood T cells 
are capable of ex vivo proliferation, responses to KLH re-stimulation are undetectable through 
this analysis. 
4.3.3. In vivo antigen recall responses in immunised Tasmanian devils  
To determine whether immunological memory of KLH was maintained after immunisation, 
KLH-specific IgG levels in the serum of Adam (immunised with KLH and poly-ICLC) and 
Sparrow (immunised with KLH, poly-ICLC and imiquimod) were monitored for 8 months after 
immunisation. Levels of KLH-specific IgG in the serum of the immunised devils decreased 
post-immunisation and plateaued at a similar level to the primary response after approximately 
6 months (Fig. 4-6). Re-exposure of the devils to KLH without adjuvants resulted in a rapid 
increase in IgG production, with a magnitude greater than their original primary response to 
immunisation. This result suggests that poly-ICLC alone and in combination with imiquimod 
induces robust immunological memory in Tasmanian devils. 
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Figure 4-6. Post-immunisation IgG levels in Tasmanian devils immunised with KLH and TLR ligands. 
Tasmanian devils previously immunised at day 0 and 42 (black arrows) with KLH and poly-ICLC (n=1, red) or 
KLH, poly-ICLC and imiquimod (n=1, blue) were monitored for 8 months following immunisation, then re-
exposed to KLH without adjuvants by immunisation at 10 months. Serum samples were collected at 6 week 
intervals and analysed by ELISA for KLH-specific IgG at a 10 000 x dilution. Results were measured by 
absorbance at 450 nm and are the mean and standard error of three technical replicates. 
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4.3.4. Activation of DFTD-specific immune responses in Tasmanian devils 
immunised with poly-ICLC and imiquimod 
As poly-ICLC and imiquimod successfully activate antigen-specific immune responses against 
KLH in Tasmanian devils, these TLR ligands were next tested as adjuvants in DFTD 
vaccinations. A cohort of 33 insurance Tasmanian devils destined for release at Stony Head 
(SH), an area of mainland Tasmania with endemic DFT1, were available for immunisation with 
inactivated IFNγ-treated (MHCI positive) DFT1 cells and poly-ICLC and imiquimod as 
adjuvants. As with previous immunisation trials in captive Tasmanian devils (Tovar et al. 
2017), the saponin-based adjuvant ISCOMATRIX® was included alongside TLR ligands in 
these vaccines. The immunisation protocols given to the devils prior to release was previously 
summarised in section 4.2.5. Serum samples collected during the immunisation trial were 
analysed for levels of DFT1-specific IgG by flow cytometry.  
As Tasmanian devils were immunised with MHCI-positive DFT1 cells, the reactivity of 
collected serum against live MHCI-negative and positive DFT1 cells in vitro was first assessed 
to determine whether immunisation induces responses against both cells. There was no 
significant difference in serum reactivity against these cells at day 28 or day 70 (Fig. 4-7A, Fig. 
4-7B). As a result, further analyses of responses to immunisation were assessed against MHCI-
negative cells. The protocol used for serum analysis was also optimised to improve the 
sensitivity of DFTD-specific IgG detection. Tasmanian devils demonstrated responses of varied 
magnitude to DFTD immunisations comprising poly-ICLC and imiquimod as adjuvants (Fig. 
4-8A, Fig. 4-8B). Overall, devils receiving immunisation protocol A exhibited a significant 
increase in DFT1-specific IgG levels four weeks after the first immunisation (day 28) and again 
six weeks after the second immunisation (day 70) (Fig 4-8C). Devils receiving protocol B and 
C were not included in this analysis as no sample was available for these devils after their 
second immunisation. In total, 79% of devils (26/33) were classified as responders at day 28 by 
a MFIR of at least 1.5 times higher than the pre-immune response, while 100% (27/27) of devils 
were classified as responders at day 70 (Table 4-3). After day 70, immunised Tasmanian devils 
were released at SH and trapped and monitored at regular intervals. An additional serum sample 
was obtained from 17 devils that were trapped four months post release. Analysis of antibody 
in 13 of these samples (receivers of protocol A) demonstrated that levels of DFT1-specific IgG 
were effectively maintained post-release. One devil demonstrated a large increase in IgG post-
release, while only slight decreases in IgG were recorded (Fig. 4-9A, Fig 4-9B, Fig 4-9C). As  
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Figure 4-7. Comparison of antibody responses against MHCI positive and negative DFT1 cells after 
immunisation. Tasmanian devils were immunised at day 0 and 28 with inactivated MHCI+ C5065 DFT1 cells, 
ISCOMATRIX, poly-ICLC and imiquimod. Serum samples collected at day 0 (n=33), 28 (n=33) and 70 (n=27) 
were analysed by flow cytometry for specific IgG against (A) MHCI- and (B) MHCI+ live C5065 DFT1 cells. 
Magnitude of response in each devil was measured at day 28 and day 70 by MFI relative to pre-immune (day 0, 
dotted line) (MFIR). Mean and standard deviation are shown. Statistical significance between groups was 
measured by paired t-test and is given by ns >0.05, *<0.05, **<0.01, ***<0.001, ****<0.0001. 
Figure 4-8. Antibody responses of Tasmanian devils immunised with inactivated DFTD cells and TLR 
ligands. Tasmanian devils (n=27) were immunised at day 0 and 28 with inactivated MHCI+ C5065 DFT1 cells, 
ISCOMATRIX, poly-ICLC and imiquimod. Serum samples collected at day 0, 28 and 70 were analysed by flow 
cytometry for specific IgG against live C5065 DFT1 cells. Representative histograms demonstrate (A) a poor 
responder and (B) a good responder to immunisation. (C) Magnitude of response in each devil was measured at 
day 28 and day 70 by MFI relative to pre-immune (day 0, dotted line) (MFIR). Mean and standard deviation are 
shown. Statistical significance relative to day 0 and between groups was measured by a repeated measures one-
way ANOVA and is given by ns >0.05, *<0.05, **<0.01, ***<0.001, ****<0.0001. 
0.5
1
2
4
8
16
M
F
IR
Day 28
MHCI- DFT1 MHCI+ DFT1
ns
0.5
1
2
4
8
16
M
F
IR
Day 70
MHCI- DFT1 MHCI+ DFT1
ns
A B
0.5
1
2
4
8
16
M
F
IR ****
****
Day 28 Day 70
****
0 10
2
10
3
10
4
10
5
IgG (AF647)
0
20
40
60
80
100
C
o
u
n
t
0 10
2
10
3
10
4
10
5
IgG (AF647)
0
20
40
60
80
100
C
o
u
n
t Pre-immune (day 0)
Day 28
Day 70
A B
C
 
104 
a cohort, no significant difference in DFT1-specific IgG levels was measured between day 70 
and four-month post-release in SH devils (Fig. 4-9D). Together these results indicate that poly-
ICLC, imiquimod and ISCOMATRIX® in combination activate effective DFT1-specific 
immune responses to immunisation in devils, and that these are maintained post-release for at 
least four months. 
As the SH immunisation cohort comprised both male and female devils of various ages, IgG 
responses to DFT1 immunisation were also grouped by these factors to determine whether they 
were predictive of the magnitude of response. A trend of decreasing responses with increasing 
age was observed at day 28 and 70, although this was not statistically significant (Fig. 4-10A, 
Fig. 4-10B). At day 28, males demonstrated significantly higher responses than females, 
however this may have been confounded by a greater average age of the female devils (3.3 
compared to 2.3 for males) (Fig. 4-10C, Fig. 4-10D). Together these results suggest that DFTD 
immunisations may be more effective in younger devils. 
4.3.5. Comparison of DFTD-specific immune responses generated in devils 
immunised with and without poly-ICLC and imiquimod 
To determine whether poly-ICLC and imiquimod improve DFT1-specific immune responses 
in immunised devils, the responses of the SH cohort were compared with the responses of a 
second cohort of insurance devils immunised in 2015 for wild release at Narawntapu National 
Park (NNP). In comparison to the SH cohort, the NNP cohort received four immunisations with 
MHC-positive DFT1 cells, and poly-IC, CpG and ISCOMATRIX® were included as adjuvants 
(Table 4-4). Samples taken four weeks after first immunisation (day 28), post- immunisation, 
and four months post-immunisation from both cohorts were compared for levels of DFT1-
specific IgG by flow cytometry. The IgG response after two immunisations could not be 
compared, as no equivalent serum samples were collected for NNP devils. 
DFT1-specific IgG responses to immunisation in the SH cohort were significantly higher than 
the NNP cohort after first immunisation (day 28) (Fig. 4-11A). In comparison, a significantly 
greater response was measured in NNP devils (received 3-4 immunisations) relative to the SH 
devils (received 2 immunisation) after the completion of each full immunisation protocol (Fig. 
4-11B). Four months post-immunisation, levels of DFT1-specific IgG in the serum of NNP 
devils had dramatically decreased to a level significantly lower than SH devils (Fig. 4-11C). Of 
a total of 8 NNP devils where a serum sample was available after their final immunisation, 
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Figure 4-9. Post-immunisation specific antibody levels in Tasmanian devils immunised with inactivated 
DFT1 cells and TLR ligands. Tasmanian devils were immunised at day 0 and 28 with inactivated MHCI+ C5065 
DFT1 cells, ISCOMATRIX, poly-ICLC and imiquimod. Serum samples collected at day 0, 70 and four months 
after immunisation (n=13) were analysed by flow cytometry for DFT1-specific IgG. Representative histograms 
demonstrate (A) a slight decrease in IgG four-months post-immunisation, (B) no post-immunisation decrease in 
IgG and (C) a post-immunisation increase in specific-IgG. (D) Magnitude of response in each devil was measured 
at day 70 and four-months post-immune by MFI relative to pre-immune (day 0, dotted line) (MFIR). Mean and 
standard deviation are shown. Statistical significance between groups was measured by paired t-test and is given 
by ns >0.05, *<0.05, **<0.01, ***<0.001, ****<0.0001. 
Table 4-3. Percentages of Tasmanian devils classified as responders to immunisation 
 First immunisation  
(day 28) 
Second immunisation  
(day 70) 
Four-months post-immune 
MFIR > 1.5 26/33 (79%) 27/27 (100%) 13/13 (100%) 
MFIR, mean fluorescence intensity ratio. 
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Figure 4-10. Comparison of immunisation-specific antibody responses by Tasmanian devil age and sex. 
Tasmanian devils were immunised at day 0 and 28 with inactivated MHCI+ C5065 DFT1 cells, ISCOMATRIX, 
poly-ICLC and imiquimod. Serum samples collected at day 0 (n=33), 28 (n=33) and 70 (n=27) were analysed by 
flow cytometry for specific IgG against live C5065 DFT1 cells. Magnitude of response in each devil was measured 
at day 28 and day 70 by MFI relative to pre-immune (day 0, dotted line) (MFIR) and grouped by (C, D) Tasmanian 
devil age and (E, F) Tasmanian devil sex. Mean and standard deviation are shown. Statistical significance between 
groups was measured by one-way ANOVA or unpaired t-test is given by ns >0.05, *<0.05, **<0.01, ***<0.001, 
****<0.0001. 
 
M, male; F, female. 
 
Table 4-4. Comparison of Stony Head and Narawntapu immunisation protocols 
Trial Year Devils Protocol Adjuvants 
Narawntapu  2015 
n=16  
(F=8, M=11) 
av. age = 3.4 
4 immunisations, 4 weeks apart: 
2 x sonicated IFNγ-treated DFT1 cells  
2 x irradiated IFNγ-treated DFT1 cells  
100 μg poly-IC, 100 μg 
CpG, 50 μl 
ISCOMATRIX 
Stony Head 2016 
n=33 
(F= 11, M= 
22) 
av. age = 2.8 
2 immunisations, 4 weeks apart: 
1 x sonicated IFNγ-treated DFT1 cells  
1 x irradiated IFNγ-treated DFT1 cells  
100 μg poly-ICLC, 100 
μg imiquimod, 50 μl 
ISCOMATRIX 
 
107 
 
 
 
 
 
0
.512481
6
3
2
MFIR
D
a
y
 2
8
**
**
S
H
(1
 im
m
u
n
is
a
tio
n
)
N
N
P
(1
 i
m
m
u
n
is
a
tio
n
)
0
.512481
6
3
2
MFIR
P
o
s
t-
Im
m
u
n
e
*
S
H
(2
 im
m
u
n
is
a
ti
o
n
s
)
N
N
P
(3
-4
 i
m
m
u
n
is
a
tio
n
s
)
0
.512481
6
3
2
MFIR
*
F
o
u
r-
M
o
n
th
s
 P
o
s
t-
Im
m
u
n
e
S
H
(2
 i
m
m
u
n
is
a
tio
n
s
)
N
N
P
(3
-4
 i
m
m
u
n
is
a
ti
o
n
s
)
A
B
C
F
ig
u
re
 4
-1
1
. 
C
o
m
p
a
ri
so
n
 o
f 
a
n
ti
b
o
d
y
 r
e
sp
o
n
se
s 
g
en
er
a
te
d
 d
u
ri
n
g
 S
to
n
y
 H
ea
d
 a
n
d
 N
a
ra
w
n
ta
p
u
 i
m
m
u
n
is
a
ti
o
n
 t
ri
a
ls
. 
T
as
m
an
ia
n
 d
ev
il
s 
w
er
e 
im
m
u
n
is
ed
 2
 
ti
m
es
 w
it
h
 i
n
ac
ti
v
at
ed
 M
H
C
I+
 C
5
0
6
5
 D
F
T
1
 c
el
ls
, 
IS
C
O
M
A
T
R
IX

, 
p
o
ly
-I
C
L
C
 a
n
d
 i
m
iq
u
im
o
d
 (
S
H
) 
o
r 
3
-4
 t
im
es
 w
it
h
 i
n
ac
ti
v
at
ed
 M
H
C
I+
 C
5
0
6
5
 D
F
T
1
 c
el
ls
, 
IS
C
O
M
A
T
R
IX

, 
p
o
ly
-I
C
 a
n
d
 C
p
G
 (
N
N
P
).
 S
er
u
m
 s
am
p
le
s 
co
ll
ec
te
d
 a
t 
d
ay
 0
, 
(A
) 
fo
u
r 
w
ee
k
s 
af
te
r 
fi
rs
t 
im
m
u
n
is
at
io
n
 (
d
ay
 2
8
),
 (
B
) 
4
-6
 w
ee
k
s 
af
te
r 
la
st
 
im
m
u
n
is
at
io
n
 (
p
o
st
-i
m
m
u
n
e)
 a
n
d
 (
C
) 
fo
u
r-
m
o
n
th
s 
p
o
st
-i
m
m
u
n
e 
w
er
e 
an
al
y
se
d
 b
y
 f
lo
w
 c
y
to
m
et
ry
 f
o
r 
D
F
T
1
-s
p
ec
if
ic
 I
g
G
. 
T
h
e 
re
sp
o
n
se
 o
f 
ea
ch
 d
ev
il
 t
o
 
im
m
u
n
is
at
io
n
 w
as
 m
ea
su
re
d
 b
y
 M
F
I 
re
la
ti
v
e 
to
 p
re
-i
m
m
u
n
e 
(d
ay
 0
, 
d
o
tt
ed
 l
in
e)
 (
M
F
IR
).
 M
ea
n
 a
n
d
 s
ta
n
d
ar
d
 d
ev
ia
ti
o
n
 a
re
 s
h
o
w
n
. 
S
ta
ti
st
ic
al
 s
ig
n
if
ic
an
ce
 b
et
w
ee
n
 
g
ro
u
p
s 
w
as
 m
ea
su
re
d
 b
y
 u
n
p
ai
re
d
 t
-t
es
t 
an
d
 i
s 
g
iv
e
n
 a
s 
n
s 
>
0
.0
5
, 
*
<
0
.0
5
, 
*
*
<
0
.0
1
, 
*
*
*
<
0
.0
0
1
, 
*
*
*
*
<
0
.0
0
0
1
. 
 
 
108 
75 % (6/8) had demonstrated a decrease in MFI of greater than half their post-immunisation 
MFI after four months (Table 4-5). In comparison, there were no SH devils that demonstrated 
a similar decline in DFT1-specific IgG within this time frame, while one devil demonstrated an 
increase in DFT1-specific IgG. These results suggest that the adjuvant combination of poly-
ICLC and imiquimod activates more rapid and long-lived responses against DFT1 
immunisation than the combination of poly-IC and CpG used in NNP immunisations.  
As NNP devils were older on average than SH devils (2.8 years for SH compared to 3.4 years 
for NNP), IgG responses to immunisation at day 28 were compared by age to confirm that there 
was no confounding effect on the difference in responses measured between SH and NNP 
cohorts. Levels of DFT1-specific IgG remained significantly higher in the SH cohort when 
devils were grouped by age (Fig. 4-12A, Fig. 4-12B). These results confirm that poly-ICLC 
and imiquimod are more effective adjuvants in Tasmanian devils than the combination of poly-
IC and CpG used in previous immunisation trials. 
4.4. Discussion 
A potent immune adjuvant will be crucial to the development of a successful DFTD vaccine. 
Current immunisation strategies use whole inactivated DFT1 cells, requiring robust immune 
stimulation to generate long-lived immunity (Kreiss et al. 2015; Tovar et al. 2017). As efficient 
inducers of immune responses in human studies (Galluzzi et al. 2012a), TLR ligands could 
provide the necessary immune stimulation for a DFTD vaccine to be successful. Previous 
DFTD immunisations used the TLR ligands poly-IC and CpG alongside ISCOMATRIX® as 
adjuvants (Tovar et al. 2017). ISCOMATRIX® is an adjuvant composed of plant-derived 
saponin, cholesterol and phospholipids. Under certain conditions, these molecules form cage-
like structures that are readily taken up by APCs, where they promote cell maturation, antigen 
presentation and potent cellular and humoral responses (Morelli et al. 2012; Wilson et al. 2012). 
In mouse studies, a combination of ISCOMATRIX®, poly-IC and CpG successfully induced 
tumour regression (Silva et al. 2015). Immunisation of Tasmanian devils with this adjuvant 
combination did not stimulate protective immunity (Tovar et al. 2017), and as such alternative 
adjuvant combinations could be considered to improve DFTD-specific responses. It was 
demonstrated in Chapter 3 that Tasmanian devil PBMNCs respond more effectively to poly-IC 
in combination with imiquimod than CpG. In addition, poly-IC is susceptible to RNase activity 
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Figure 4-12. Comparison of Stony Head and Narawntapu antibody responses by age. Tasmanian devils were 
immunised with inactivated MHCI+ C5065 DFT1 cells, ISCOMATRIX, poly-ICLC and imiquimod (SH) or 
inactivated MHCI+ C5065 DFT1 cells, ISCOMATRIX, poly-IC and CpG (NNP). Serum samples collected at 
day 0 and day 28 were analysed by flow cytometry for DFT1-specific IgG. Magnitude of response in each devil 
was measured by MFI relative to pre-immune (day 0, dotted line) (MFIR) and grouped by age. Mean and standard 
deviation are shown. Statistical significance between groups was measured by unpaired t-test and is given as ns 
>0.05, *<0.05, **<0.01, ***<0.001, ****<0.0001. 
Table 4-5. Change in DFT1-specific IgG levels four months post-immunisation  
Cohort Decrease (MIFR<0.5) 
No change 
(0.05<MIFR<1.5) 
Increase (MIFR>1.5) 
Stony Head (n=13) 0 (0%) 12 (92%) 1 (8%) 
Narawntapu (n=8) 6 (75%) 2 (25%) 0 (0%) 
MIFR, mean fluorescence intensity ratio 
0.5
1
2
4
8
16
M
F
IR
1, 2, 3 Years Old
**
SH NNP
0.5
1
2
4
8
16
M
F
IR
4 Years Old
**
SH NNP
A B
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and could easily become degraded during the preparation and administration of DFTD 
immunisations (Levy et al. 1975). As a result, imiquimod in combination with the stabilised 
poly-IC analogue poly-ICLC (Hiltonol®), was assessed for its efficacy for activation of antigen-
specific immunity in Tasmanian devils for this study.  
Both poly-ICLC and imiquimod have shown efficacy as adjuvants in human trials (Galluzzi et 
al. 2012a). Imiquimod is approved by the FDA for the topical treatment of superficial basal cell 
carcinoma (Galluzzi et al. 2012a; Vacchelli et al. 2012). In animal models, simultaneous TLR3 
and TLR7 engagement resulted in enhanced Th1 cytokine expression and antigen-presentation, 
suggesting that these ligands act effectively as adjuvants in combination (Hu et al. 2016; Liu et 
al. 2015; Napolitani et al. 2005). To determine whether imiquimod and poly-ICLC effectively 
activate immunisation-specific immune responses in Tasmanian devils, immunisation trials 
using the model antigen KLH were performed. In support of previous findings that humoral 
responses in the Tasmanian devil are competent (Kreiss et al. 2009b), antigen specific IgG 
production in response to poly-ICLC and imiquimod was substantial. Immune memory was 
also induced by these ligands, with devils responding effectively to antigen recall almost a year 
after immunisation. The role of imiquimod in these immunisations was unclear, with responses 
to imiquimod alone comparable to the responses of devils receiving KLH without adjuvants. In 
addition, responses to poly-ICLC and imiquimod in combination were not consistently better 
than poly-ICLC alone, with an older devil (November Rain) exhibiting a reduced response. 
With such limited numbers it cannot be ruled out that this was the result of age-related low 
immune-competence in this devil. As our in vitro results in chapter 3 suggest that in 
combination these ligands can favour cellular immunity via stimulation of CD8+ T cell IFNγ 
production, differences in the responses may also have not been detectable through total IgG 
analysis.  
To further analyse the immune responses to KLH immunisation, PBMNCs isolated from 
Tasmanian devil blood throughout the immunisation schedule were re-exposed to KLH ex vivo 
for analysis of cytokine expression and T cell proliferation. Results generated from these 
experiments were unclear, with only small changes in cytokine expression measured in 
response to KLH stimulation, and no change in T cell proliferation observed. Antigen recall 
assays with PBMNC samples can be challenging, as blood contains low proportions of both 
antigen-specific lymphocytes and professional APCs to present antigen and stimulate T cell 
activation. In addition, soluble antigens such as KLH lack immunogenic PAMPS, which aid 
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the generation of robust responses. Inclusion of a TLR ligand such as LPS at a low 
concentration could have increased the sensitivity of these assays for improved ex vivo detection 
of KLH-specific T cell activity. Although proliferation assays failed to demonstrate any 
difference in T cell proliferation after KLH re-exposure, small changes in cytokine expression 
were observed upon re-stimulation of PBMNCs from Adam and Sparrow, two devils 
immunised with KLH and TLR ligands. Unexpectedly, samples obtained two weeks after 
second immunisation in both devils exhibited decreased cytokine expression when re-exposed 
to KLH. Although these changes suggest a negative response to KLH stimulation, they may not 
be biologically significant, as expression of each cytokine at baseline was already low. In 
addition, accurate quantification of low abundance transcripts can be difficult due to the lack 
of PCR sensitivity, and measurements are more likely to be affected by experimental noise 
(Lekanne Deprez et al. 2002). Baseline cytokine expression for each devil was also variable 
throughout the immunisation trial, suggesting that PBMNCs had different levels of background 
immune activation at each time-point. These differences may have influenced the PBMNC 
response to antigen recall ex vivo. Analysis of further devils is required to confirm the changes 
in cytokine expression in response to KLH recall that were measured in these experiments.  
The inability of PBMNCs to respond to antigen recall ex vivo was a major limitation of this 
study, as the efficacy of poly-ICLC and imiquimod for activation of T cell immunity was unable 
to be determined. In chapter 3, it was demonstrated that these ligands were the most effective 
stimulators of IFNγ from CD8+ T cells in vitro, suggesting that they promote functional 
responses consistent with CMI. Potent IgG responses are also T cell dependent, and IgG levels 
can act as a surrogate measure of T cell immunity. In support of this, substantial IgG responses 
correlated with DFTD CD4+ and CD8+ T cell infiltration and tumour regression in previous 
studies in the Tasmanian devil (Tovar et al. 2017). The highly conserved nature of TLR 
signalling and function across mammalian species also suggests that poly-ICLC and imiquimod 
are likely to produce potent Th1-type responses in the Tasmanian devil. In human and animal 
studies, they promote these responses through the stimulation of multiple immune pathways. 
As well as a TLR3 ligand, poly-ICLC is an agonist of the retinoic acid-inducible gene-I-like 
receptor (RLR) melanoma differentiation-associated protein-5 (MDA5), which stimulates 
production of large amounts of type-1 IFN (Longhi et al. 2009). A noticeable characteristic of 
our measured antibody responses to KLH in Tasmanian devils was the highly substantial 
increase in specific IgG after a second immunisation with poly-ICLC. In mice immunised with 
poly-ICLC, similar sizeable secondary responses to booster immunisation occurred as a result 
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of MDA5-mediated type-1 IFN production, which enabled substantial increases in CD8+ T cell 
cytotoxicity via enrichment of TLR-primed cDC maturation (Cho et al. 2013; Kato et al. 2006). 
Imiquimod is also a potent stimulator of type-1 IFN via TLR7-dependent activation of pDCs 
(Gibson et al. 2002). In these cells, type-1 IFN acts in an autocrine manner to activate TLR3 
expression, allowing synergistic enhancement of type-1 IFN production in the presence of 
TLR3 ligands (Kreutz et al. 2015). As potent immune activation in response to poly-ICLC and 
imiquimod was detected in our study, it is likely that similar pathways are activated by these 
ligands in the Tasmanian devil. Improved DC priming in response to poly-ICLC and imiquimod 
will allow more potent activation of T cell responses upon DFTD immunisation. 
In 2016, an opportunity arose for the immunisation of thirty-three insurance devils destined for 
release at SH, an area of northern Tasmania with endemic DFT1. This DFTD immunisation 
trial followed a similar trial in 2015, where nineteen immunised insurance devils had been 
released at NNP, also in the north of the state. Devils from the NNP cohort were given a four-
immunisation protocol similar to previous immunisation trials in captive Tasmanian devils. 
Approximately 80% of the devils demonstrated DFTD-specific immune responses to 
immunisation (Pye 2016). Although these results were promising, the four-shot immunisation 
protocol given to these animals was lengthy and laborious, requiring improvements to be an 
effective strategy for DFTD prevention in the wild. For the SH trial, a greater understanding of 
TLR-mediated immune activation in Tasmanian devils allowed for poly-IC and CpG to be 
exchanged for poly-ICLC and imiquimod as adjuvants alongside ISCOMATRIX®. The 
protocol given to these devils was also shortened to a more feasible two-immunisation protocol. 
A successful vaccine adjuvant in the Tasmanian devil will overcome DFTD-specific immune 
tolerance to reduce the threshold of immune activation, allowing more rapid and robust immune 
responses to fewer or lower doses of antigen (Morelli et al. 2012). Devils in the SH cohort 
demonstrated significant responses to immunisation with 79% of devils classed as responders 
to first immunisation, and 100% of devils responders to a second immunisation. IgG responses 
were specific for both MHCI-positive and negative cells, suggesting that immune responses 
against DFTD surface antigens were generated. This antibody will be critical for recognition of 
MHCI-negative DFTD cells upon exposure to the disease in the wild, and will opsonise the 
cells for phagocytosis and antibody-dependent cellular cytotoxicity. DFTD-specific immune 
responses in SH devils were maintained post-immunisation with no significant decrease in IgG 
levels, suggesting that robust immune memory was generated. Unexpectedly, there was also a 
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single devil with increased IgG levels four months-post-immunisation relative to the post-
immune level. As post-immune samples were taken six weeks after the second immunisation, 
it seems unlikely that this further increase in IgG levels would have been the result of 
immunisation. One possible explanation is that this devil was exposed to DFT1 in the wild prior 
to being re-trapped, and had mounted an anti-tumour response against the tumour cells. Future 
trapping will determine the disease status of this and other Tasmanian devils post-release.  
In comparison to the NNP immunisation trial, SH devils exhibited more rapid responses to 
immunisation, as demonstrated by the increase in specific-IgG levels at day 28. A small number 
of individuals in the NNP cohort demonstrated high responses to the four-immunisation 
protocol, resulting in a significantly better response post-immunisation. Most other NNP devils 
had a comparable level of response to the two-immunisation SH cohort, suggesting that poly-
ICLC and imiquimod promote more robust responses requiring fewer doses of antigen. In 
support of this, 100% of re-trapped SH devils had maintained their post-immunisation IgG 
levels four months after the end of their immunisation protocol, compared to only 25% of NNP 
devils. This suggests that the combination of poly-ICLC and imiquimod in SH immunisations 
not only produced more rapid and robust immune responses, but stimulated superior immune 
memory in these devils compared to the combination of poly-IC and CpG used in NNP 
immunisations. Previous studies of adjuvant efficacy have demonstrated improved generation 
of T cell memory in response to poly-ICLC or imiquimod compared to other adjuvants 
(Goldinger et al. 2012; Martins et al. 2016). In one study, immunisations incorporating poly-
ICLC induced complete protection in mice against Ebola virus challenge. This compared to 
immunisations comprising CpG and MPL, which offered no greater protection than the antigen 
alone (Martins et al. 2016). Poly-ICLC-mediated immune memory in this study was associated 
with a Th1 skewed IgG response (IgG2c and IgG3) and robust CD4+ T cell responses, including 
significant differentiation of antigen-specific follicular helper T cells. Similar responses in 
Tasmanian devils against DFTD immunisations containing poly-ICLC could be sufficient for 
protection against DFTD. 
Future immunisation trials in Tasmanian devils will continue to use poly-ICLC and imiquimod 
as adjuvants alongside ISCOMATRIX®. Follow-up trapping of released devils will determine 
the efficacy of these immunisations for DFTD prevention, while laboratory investigation will 
continue to improve the antigenic component of DFTD immunisations for greater 
immunogenicity. The requirement for a two-immunisation protocol will be assessed, with a 
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one-shot immunisation likely to be of more benefit to vaccination of wild Tasmanian devil 
populations. Lastly, with the impending spread of DFT2 from the Channel region of southern 
Tasmania, a successful DFTD immunisation could be adapted to protect against both forms of 
the tumour.  
In summary, in this chapter I have demonstrated that TLR ligands effectively stimulate antigen-
specific immune responses in Tasmanian devils. In particular, poly-ICLC and imiquimod in 
combination are potent immunostimulatory agents in vivo, producing substantial primary and 
secondary responses to immunisation with a model antigen. These ligands are also successfully 
used as adjuvants in DFTD immunisations, producing more rapid, robust and long-lived 
responses than previously used vaccine adjuvants. This study provides the first thorough 
analysis of candidate vaccine adjuvants in the Tasmanian devil. Poly-ICLC and imiquimod will 
be included in future DFTD immunisations for improved immune stimulation. 
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5.1. Introduction 
As a transmissible cancer, DFTD employs sophisticated mechanisms of immune evasion to 
survive in new hosts. The most investigated of these mechanisms involves suppression of cell 
surface MHCI expression, which is down-regulated in DFT1 cells in response to epigenetic 
silencing of genes required for MHCI processing (Siddle et al. 2013). In mammalian species, 
the immune system targets and destroys tumour cells lacking MHCI through the cytotoxic 
functions of NK cells (Correa et al. 1995). As NK killing does not appear to occur in DFT1, it 
is likely that other mechanisms of immune evasion exist to ensure the survival of DFTD tumour 
cells. It was recently shown that DFTD cells significantly increase the expression of inhibitory 
checkpoint molecules including PDL1 upon stimulation with IFNγ (Flies et al. 2016). This 
finding provides a mechanism by which the tumour cells shut down an adaptive immune 
response upon recognition by the immune system. TLR signalling also contributes to immune 
evasion in many human cancers (Huang et al. 2005), and could provide a mechanism by which 
other immune cells, including NK cells, are suppressed in DFTD. In support of this, NK cell 
dysfunction has been associated with TGF signalling (Lee et al. 2014; Rouce et al. 2016), a 
cytokine that can be stimulated through TLR signalling in human cancer (Li et al. 2017). 
Investigation of the effects of TLR stimulation in DFTD cells is required to determine whether 
TLR signalling is involved in immune evasion or survival in DFTD. 
TLR signalling was initially identified in cells of the immune system as a potent stimulator of 
innate functions (Medzhitov et al. 1997). Further research determined that TLRs are expressed 
across almost all cell types, where they play fundamental roles in the stimulation of 
inflammatory factors to warn the innate immune system of impending threats (Faure et al. 2001; 
Kollisch et al. 2005; Nishimura et al. 2005). As such, it is not surprising that tumour cells inherit 
functional TLR expression from their cell of origin. Stimulation of these tumour cell TLRs can 
exert a range of pro- and anti-tumoural effects through modulation of proliferation, invasion 
and migration, angiogenesis, resistance to apoptosis and cell signalling (Killeen et al. 2009; 
Szczepanski et al. 2009; Tang et al. 2012). In addition, TLR signalling in tumour cells can 
create a microenvironment that favours cancer growth and survival through stimulation of 
cytokines involved in immunosuppression and tumour-promoting inflammation (Tang et al. 
2012; Yu et al. 2014). In chapters 3 and 4 of this thesis it was demonstrated that functional 
TLRs in the immune system of the Tasmanian devil can be stimulated by conventional TLR 
ligands to promote potent antigen-specific immune responses. Although current DFTD 
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immunisation protocols use non-viable DFTD cells (Tovar et al. 2017), an understanding of the 
effects of TLR ligands on DFTD growth survival will reveal any potentially undesirable 
outcomes associated with the use of these adjuvants in the Tasmanian devil. Furthermore, the 
use of live DFTD immunisations in Tasmanian devils is being considered for their increased 
immunomodulatory capacity (C. Ong, A. Flies, personal communication), and TLR ligands 
could be included in future DFTD immunotherapies to improve immune stimulation. 
Knowledge of TLR-mediated effects in DFTD cells will be required for the successful 
development of these preventative and therapeutic strategies. 
In this chapter, the response of DFT1 and DFT2 cells to stimulation in culture with conventional 
TLR ligands has been assessed. Expression of TLRs in DFTD cells has been measured by qRT-
PCR and functional assays have been performed to detect changes to proliferation, apoptosis 
and the expression of angiogenic and immunosuppressive cytokine genes after TLR 
stimulation. This analysis will determine the effects of candidate vaccine adjuvants in the 
Tasmanian devil on DFTD growth and survival. Furthermore, this analysis will reveal whether 
TLR signalling is involved in DFTD immune evasion and growth in the Tasmanian devil. 
Results generated from this chapter will allow for rational selection of adjuvants for future use 
in the Tasmanian devil. 
5.2. Experimental Procedures 
5.2.1. Cell lines and TLR stimulation 
The DFT1 cell lines C5065, 1426, 4906 and half-pea, the DFT2 cell lines RV and SN and the 
fibroblast (FBB) cell line TD344 were cultured and harvested as described in section 2.2.3. 
Cells were plated as described for each experiment in RPMI/10FCS medium (section 2.1.6.). 
Unless otherwise stated, cells were treated with the following TLR ligands (section 2.1.2.) as 
described: 1. FSL-1 (TLR2/6) at 100 ng/ml; 2. poly-IC (TLR3) at 30 μg/ml; 3. LPS (TLR4) at 
30 μg/ml; 4. flagellin (TLR5) at 100 ng/ml; 5. imiquimod (TLR7) at 60 μg/ml; 6. CpG-1585 
(TLR9) at 30 μg/ml; 7. CpG-2395 (TLR9) at 30 μg/ml; 8. profilin (TLR11) at 100 ng/ml. 
Cultures were maintained in a 35 °C, 5% CO2 humidified incubator for the experiment duration. 
Untreated controls were included for all experiments.  
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5.2.2. Gene expression analysis 
For baseline gene expression analysis, RNA was extracted directly from DFTD cell lines or 
tissue samples. For differential gene expression analysis, DFTD and FBB cell lines were 
stimulated with TLR ligands at 1 x 106 cells/ml in 1 ml of RPMI/10FCS medium (section 2.1.6.) 
in 12-well cell culture plates (Corning, New York, USA). Untreated controls were included, 
and all cultures were maintained at 35°C in a humidified 5% CO2 incubator for the duration of 
the TLR stimulation. Prior to RNA extraction, DFTD cells were washed in PBS (section 2.1.6.) 
according to section 2.2.3., and lysed directly in 1 ml of TriReagent (Sigma-Aldrich, St Louis, 
USA). RNA was extracted according to section 2.2.4. Non-quantitative expression of 
experimental genes was measured according to sections 2.2.5. and 2.2.6. Quantitative 
expression of experimental genes was measured relative to the reference gene RPS18 according 
to section 2.2.7.  
5.2.3. WST-8 cell proliferation assay 
DFTD and FBB cell lines were seeded into flat-bottom 96-well cell culture plates (Corning, 
New York, USA) at a concentration of 1 x 105 cells/ml in 100 l of RPMI/10FCS (section 
2.1.6.). Cells were treated in triplicate with TLR ligands and maintained at 35°C in a humidified 
5% CO2 incubator for the duration of the TLR stimulation. Cell proliferation was measured 
after each treatment using the Cell Counting Kit-8 (water-soluble tetrazolium-8 assay (WST-
8)) (Sigma-Aldrich, St Louis, USA), according to the manufacturer’s directions (Appendix 2). 
Briefly, 10 μl of WST-8 reagent was added to each experimental well for the final 4 h of TLR 
stimulation. Relative cell number was measured as OD570-OD650 using the SpectraMax Plus 
384 plate reader (Molecular Devices, Sunnyvale, USA). Baseline metabolic rate was 
determined by absorbance at the 0 h time point. For absolute cell quantification, a standard 
curve of known cell numbers was prepared for each cell line on a separate plate during the 
seeding of each experiment and analysed immediately using the WST-8 assay. Experimental 
values were interpolated into the standard curve to approximate exact cell number in each 
culture. Cell numbers were compared to an untreated sample to identify changes to the rate of 
cell proliferation after treatment.  
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5.2.4. Annexin V apoptosis assay 
DFTD and FBB cell lines were seeded into round-bottom 96-well cell culture plates (Corning, 
New York, USA) at a concentration of 5 x 105 cells/ml in 200 l of RPMI/10FCS (section 
2.1.6.). Cells were treated in triplicate with TLR ligands and maintained at 35°C in a humidified 
5% CO2 incubator for the duration of the TLR stimulation. Analysis of cell death was performed 
after treatment using an Annexin V cell death assay (Miltenyi Biotec, Bergusch Gladbach, 
Germany). Briefly, cells were harvested and washed as described in section 2.2.3., then re-
suspended in 100 μl of annexin V binding buffer. Each sample was labelled with 2 μl of annexin 
V and 1 μl of PI (1 μg/ml). The samples were incubated at room temperature for 15 min and 
analysed on the BD FACSCanto II flow cytometer (BD Biosciences, San Jose, USA). The 
percentages of cells labelled with annexin V and PI were calculated using the Kaluza Flow 
Analysis Software (Beckman Coulter, Pasadena, USA). Statistical analysis was performed 
using an ordinary one-way ANOVA and Dunnett’s multiple comparisons test. Statistical 
significance was defined as *p<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
5.2.5. Cell cycle analysis 
DFTD and FBB cell lines were seeded into round-bottom 96-well cell culture plates (Corning, 
New York, USA) at a concentration of 5 x 105 cells/ml in 200 l of RPMI/10FCS (section 
2.1.6.). Cells were treated with TLR ligands and maintained at 35°C in a humidified 5% CO2 
incubator for the duration of the stimulation. Cell cycle analysis was performed according to 
the methods of Riccardi & Nicoletti (Riccardi et al. 2006). Briefly, cells were harvested and 
washed as described in section 2.2.3., then suspended in 500 l of PBS (section 2.1.6.). A 4.5 
ml volume of ice-cold 70% ethanol (Fronine, Riverstone, Australia) was added to each sample 
drop-wise to fix the cells. The fixed cells were centrifuged at 500 g for 5 min, washed once in 
5 ml of PBS and centrifuged again to pellet. The fixed cells were suspended in 1 ml of DNA 
extraction buffer (section 2.1.6.) for 5 min, followed by 1 ml of DNA staining solution (section 
2.1.6.) for 30 min. DNA content was analysed by flow cytometry using the BD FACSCanto II 
flow cytometer (BD biosciences, San Jose, USA). The Kaluza Flow Analysis Software 
(Beckman Coulter, Pasadena, USA) was used to visualise DNA content as histograms and 
hypodiploid and diploid DNA peaks were measured. A hypodiploid peak represents DNA 
fragmentation and suggests that apoptotic cells are present. 
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5.2.6. Caspase assay 
DFTD cell lines were seeded into opaque white flat-bottom 96-well cell culture plates (Corning, 
New York, USA) at a concentration of 5 x 105 cells/ml in 100 l of phenol red free Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific, Waltham, USA). Cells were 
treated in triplicate with TLR ligands and maintained at 35°C in a humidified 5% CO2 incubator 
for the duration of the stimulation. Caspase activity was measured after treatment using the 
Apo-ONE Homogeneous Caspase 3/7 Assay (Promega, Madison, USA), according to the 
directions of the manufacturer (Appendix 2). Briefly, 100 l of Apo-ONE Caspase-3/7 reagent 
was added to each sample and plates were incubated on a plate shaker for 30 min. Fluorescence 
of the cultures was measured at an excitation of 485 nm and an emission of 530 nm using the 
SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, USA). Changes in caspase 
activity between untreated and treated samples were measured using an ordinary one-way 
ANOVA and Dunnett’s multiple comparisons test. Statistical significance was defined as 
*p<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
5.2.7. Flow cytometry analysis of 2-microglobulin 
DFTD cell lines were plated at 5 x 105 cells/ml in 1 ml of RPMI/10FCS in 12-well cell culture 
plates (Corning, New York, USA) and treated with TLR ligands in combination with IFN at 5 
ng/ml for 48 h. Untreated controls were included. Cultures were maintained in a 37°C 
humidified 5% CO2 incubator. After incubation, cells were harvested and washed in FACS 
buffer (section 2.1.6.) as described in section 2.2.3, and labelled as described in section 2.2.8. 
Primary labelling was performed with mouse anti-Tasmanian devil 2M (section 2.1.4.) diluted 
200 x with FACS buffer. Cells were incubated for 1 h at room temperature. Secondary labelling 
was performed with alexa fluor-647 goat anti-mouse IgG (section 2.1.4.), diluted 1000 x in 
FACS buffer. Cells were incubated in the dark for 1 h at room temperature. Cells were 
resuspended in 200 μl of FACS buffer and analysed on the BD FACSCanto II flow cytometer 
(BD biosciences, San Jose, USA) within 1 h. Flow cytometry data was analysed using Kaluza 
Flow Cytometry Analysis Software version 1 (Beckman Coulter, Brea, USA), according to the 
gating strategy described (section 2.2.8).  
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5.3. Results 
5.3.1. Expression of TLR genes in DFTD cells 
A variety of cancers express functional TLRs that signal to alter rates of tumour growth and 
survival (Basith et al. 2012). To determine whether DFTD might be responsive to stimulation 
with TLR ligands, expression of genes encoding TLRs 2, 3, 4, 5, 6, 7, 8, 9, 10 and 13L was 
detected in three DFT1 cell lines and three primary DFT1 tumours by RT-PCR and agarose gel 
electrophoresis. This analysis demonstrated expression of TLRs 2, 5, 6, and 13-like in DFT1 
cell lines (Fig. 5-1A). Primary DFT1 tumour samples expressed the same TLR genes, as well 
as TLRs 3, 4, 7, 8, 9 and 10. The expression of these additional genes may be attributable to 
other cells present in tumour biopsies, such as fibroblasts and immune cells. To quantify TLR 
gene expression in DFTD cells, qRT-PCR analysis was performed using representative DFT1 
and DFT2 cell lines. This analysis detected moderate expression of TLRs 2, 6 and 13L in both 
DFT1 and DFT2 (Fig. 5-1B-C). TLRs 4 and 5 were expressed at low levels in both cell lines, 
while TLR8 was detected only in the DFT2 cell line. These results confirm that DFTD cells 
constitutively express TLR genes at the mRNA level. 
To determine whether TLR genes can be switched on, or up-regulated, in DFTD cells by TLR 
signalling, expression of each TLR was measured in DFT1 cells by qRT-PCR after stimulation 
with the respective TLR ligand. As DFT1 and DFT2 shared a similar pattern of TLR expression, 
DFT1 cells were used as a model for this experiment. As above, expression of TLRs 3, 7 and 9 
was not detectable at baseline in DFT1 cells. These TLRs were also not up-regulated by 
stimulation with poly-IC (TLR3), imiquimod (TLR7) or CpG (TLR9), respectively (Fig. 5-2). 
Although expression of TLR4 and TLR5 was detected, stimulation of DFT1 cells with LPS 
(TLR4) or flagellin (TLR5) did not significantly alter the expression of these receptors. In 
comparison, stimulation of DFT1 cells with FSL-1 (TLR2/6) increased the expression of TLR2 
and TLR6 by greater than 16-fold (p < 0.01). This result suggests that TLR2/6 signalling could 
play a functional role in DFT1 tumours. 
5.3.2. Changes to the proliferation and viability of DFT1 cells after 
stimulation with TLR ligands 
As DFTD cells express TLRs, it is possible that they respond to stimulation with TLR ligands. 
To evaluate this possibility, changes to the proliferation of DFTD cell lines were measured after 
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Figure 5-1. Expression of TLR genes in DFTD cell lines. (A) Non-quantitative expression of the TLR genes 1-
10 and 13L was analysed by RT-PCR in three DFT1 cell lines (C5065, 1426, 4906) and three primary DFT1 
tumours. Gene expression was visualised by agarose gel electrophoresis. (B-C) Quantitative expression of TLR 
genes was analysed by qRT-PCR in (B) the representative DFT1 cell line C5065 and (C) the representative DFT2 
cell line RV. Gene expression was calculated relative to the reference gene RPS18. No-cDNA and no-RT controls 
were included and did not show any amplification of product. Results are the mean and standard error of three 
technical replicates. 
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Figure 5-2. Expression of TLR genes in DFT1 cells after stimulation with the respective TLR ligand. The 
DFT1 cell line C5065 was treated with FSL-1 (100 ng/ml), poly-IC (30 μg/ml), LPS (30 μg/ml), flagellin (100 
ng/ml), imiquimod (60 μg/ml), CpG-1585 (30 μg/ml) and CpG-2395 (30 μg/ml) for 8 h. Quantitative expression 
of TLR2/6, TLR3, TLR4, TLR5, TLR7 and TLR9 was analysed by qRT-PCR after stimulation with the respective 
TLR ligand. Gene expression was calculated relative to the reference gene RPS18 and is displayed as a fold-change 
relative to untreated samples. No-cDNA and no-RT controls were included and did not show any amplification of 
product. Results are the mean and standard error of three replicates. Statistical significance relative to the untreated 
sample was measured by one-way ANOVA and Dunnett’s multiple comparisons test and is represented as 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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treatment with TLR ligands. Cultures of the representative DFT1 cell line C5065 were treated 
for 24, 48 and 72 h with increasing concentrations of the TLR ligands FSL-1 (TLR2/6), poly-
IC (TLR3), LPS (TLR4), flagellin (TLR5), imiquimod (TLR7), CpG-1585 (TLR9), CpG-2395 
(TLR9) or profilin (TLR11). A WST-8 assay was performed to measure cell number in each 
culture as a determinant of proliferation. These analyses demonstrated that DFT1 cell number 
did not increase with increasing concentration of any TLR ligand (Fig. 5-3A-H). In contrast, 
the TLR ligands poly-IC, LPS and CpG-2395 inhibited the proliferation of DFT1 cells (Fig. 5-
3B-C, G), and imiquimod and CpG-1585 decreased the number of cells to less than the seeded 
amount (red line) (Fig. 5-3E-F). In imiquimod-treated cultures, high concentrations were 
required to reduce DFT1 cell number, with lower concentrations increasing cell number. There 
was no change in cell number after treatment with the TLR ligands flagellin and profilin (Fig. 
5-3D, H). These effects were visible at all time-points, suggesting that TLR ligands do not 
enhance DFTD cell proliferation.  
To confirm that all DFT1 cell lines respond to treatment with TLR ligands in a similar manner, 
proliferation assays were repeated with a further two DFT1 cell lines (1426 and 4906). Cultures 
were treated for 48 h with TLR ligands for these analyses. As previously, TLR ligands did not 
increase the number of cells in culture for any cell line, confirming that these ligands do not 
promote DFT1 proliferation (Fig. 5-4A-H). The slight inhibitory effect on proliferation that was 
observed after stimulation of C5065 cells with LPS and CpG-2395 was not observed in 1426 
or 4906 cultures, suggesting that this effect is specific to the C5065 cell line (Fig. 5-4C, G). 
Cell number in 1426 and 4906 cultures dramatically decreased after stimulation with poly-IC, 
CpG-1585 and imiquimod, as was observed for C5065 cultures (Fig. 5-4B, E-F). This finding 
confirms the suppressive effect of these ligands on DFT1 proliferation, warranting further 
investigation into mechanisms by which cell number was decreased in these cultures. 
The decrease in cell number that was detected in DFT1 cell lines after stimulation with poly-
IC (TLR3), imiquimod (TLR7) and CpG-1585 (TLR9) could have occurred as the result of 
activation of cell death pathways in these cultures. To assess this, C5065, 1426 and 4906 DFT1 
cell lines were stimulated for 48 hours with TLR ligands and labelled with annexin V and PI to 
distinguish early apoptotic and late apoptotic/necrotic cells from viable cells. These analyses 
demonstrated that TLR ligands such as LPS, flagellin, CpG-2395 and profilin, which had little 
or no effect on DFT1 proliferation, also had no effect on the viability of DFT1 cell lines (Fig. 
5-5). Similarly, the TLR3 ligand poly-IC did not alter the viability of DFT1 cells in any culture, 
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Figure 5-3. Proliferation of C5065 DFT1 cells after treatment with TLR ligands. The DFT1 cell line C5065 
was treated with increasing concentrations of (A) FSL-1, (B) poly-IC, (C) LPS, (D) flagellin, (E) imiquimod, (F) 
CpG-1585, (G) CpG-2395 and (H) profilin (T. gondii) for 24, 48 or 72 h. A WST-8 assay was performed to 
measure viable cell number in each culture after treatment. Cell number was compared to the original number of 
seeded cells (solid red line) to determine cell proliferation. Results are the mean and standard error of three 
technical replicates. 
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Figure 5-4. Proliferation of DFT1 cell lines after treatment with TLR ligands. The DFT1 cell lines C5065, 
1426 and 4906 were treated with increasing concentrations of (A) FSL-1, (B) poly-IC, (C) LPS, (D) flagellin, (E) 
imiquimod, (F) CpG-1585, (G) CpG-2395 and (H) profilin (T. gondii) for 48 h. A WST-8 assay was performed to 
measure viable cell number in each culture after treatment. Cell number was compared to the original number of 
seeded cells (solid red line) to determine cell proliferation. Results are the mean and standard error of three 
technical replicates. 
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suggesting that this ligand suppresses DFT1 proliferation but does not induce cell death. In 
contrast, the percentage of DFT1 cells in late stage apoptosis/necrosis (annexin V+PI+) 
increased from around 30% to 50% and 75% after treatment with imiquimod (p<0.01) and 
CpG-1585 (p<0.001), respectively. The percentage of early apoptotic cells (annexin V+PI-) did 
not significantly increase in any culture, but decreased from 20% to 5% after treatment with 
CpG-1585 (p<0.001). To confirm that these results were representative of additional time 
points, annexin V and PI labelling was monitored in C5065 DFT1 cells over a 72 h period. This 
analysis revealed a gradual increase in the percentage of cells in early and late apoptosis over 
the 72 h period after treatment with imiquimod (Fig. 5-6A). In comparison, PI labelling in 
cultures treated with CpG-1585 peaked at 48 h, before decreasing at 72 h (Fig. 5-6B). The 
percentage of early apoptotic cells in CpG-1585-treated C5065 cultures also decreased to its 
lowest point at 48 h, suggesting that the cells overcome the toxic effects of CpG-1585 treatment 
after this time point.  
In order to understand cell death pathways stimulated by TLR ligands in DFT1 cells in more 
detail, TLR stimulated C5065 cells were observed for DNA fragmentation and caspase activity, 
which are increased during activation of apoptotic pathways. DNA fragmentation was 
measured through flow cytometry analysis of the nuclear content of cells via PI staining (Fig. 
5-7A-H). This analysis revealed an increase in DNA fragmentation in imiquimod- treated DFT1 
cells, as shown by the presence of a hypo-diploid peak with lower fluorescence intensity than 
the diploid DNA peak (Fig. 5-7E). Other TLR ligands, including CpG-1585, did not induce 
DNA fragmentation and produced a histogram of DNA content that was similar to untreated 
cells (Fig. 5-7A-D, G-H). Analysis of caspase 3/7 activity in DFT1 cells revealed that cultures 
treated with imiquimod also displayed the highest caspase activity compared to untreated 
cultures (Fig. 5-8). After 24 hours of treatment, caspase activity in imiquimod treated cultures 
had increased by approximately 12-fold (p<0.001), but had decreased to 3-fold higher than the 
untreated culture after 48 hours (p<0.001). There was also a significant increase in caspase 
activity after 24 hours of treatment with CpG-1585 (p<0.01) and CpG-2395 (p<0.001), 
although these were only 3-fold higher than the untreated culture. In comparison, poly-IC 
exhibited no effect on DNA degradation or caspase activity, supporting findings that this ligand 
does not induce cell death in DFT1 cells. Together these results suggest that imiquimod induces 
apoptosis of DFT1 cells, based on the presence of annexin V+PI- cells, caspase activity and 
hypo-diploid DNA in these cultures. Although CpG-1585 increases the percentage of annexin  
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Figure 5-5. Activation of DFT1 cell death after treatment with TLR ligands. The DFT1 cell lines C5065, 1426 
and 4906 were treated with FSL-1 (100 ng/ml), poly-IC (30 μg/ml), LPS (30 μg/ml), flagellin (100 ng/ml), 
imiquimod (60 μg/ml), CpG-1585 (30 μg/ml), CpG-2395 (30 μg/ml), and profilin (T. gondii) (100 ng/ml) for 48 
h. Annexin V and PI labelling was analysed using flow cytometry to determine viable cells (A-PI-), early apoptotic 
cells (A+PI-) and late apoptotic/necrotic cells (A+PI+). Results are the mean and standard error of the three cell 
lines. Statistical significance was measured by two-way ANOVA and is defined as ns>0.05, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Figure 5-6. Cell death of DFT1 cells over a 72 h treatment period with imiquimod or CpG-1585. The DFT1 
cell line C5065 was treated with imiquimod (60 μg/ml) or CpG-1585 (30 μg/ml) for 24, 48 or 72 h. Annexin V 
and PI labelling was analysed using flow cytometry to determine early apoptotic cells (A+PI-) and late 
apoptotic/necrotic cells (A+PI+). Cell death relative to an untreated sample at each time point is shown. Results 
are the mean and standard error of the three technical replicates.  
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Figure 5-7. DNA fragmentation in DFT1 cells after treatment with TLR ligands. The DFT1 cell line C5065 
was cultured with (A) no treatment, (B) poly-IC (30 μg/ml), (C) LPS (30 μg/ml), (D) flagellin (100 ng/ml), (E) 
imiquimod (60 μg/ml), (F) CpG-1585 (30 μg/ml), (G) CpG-2395 (30 μg/ml), and (H) profilin (T. gondii) (100 
ng/ml) for 48 h. Fixed cells were stained with PI and DNA analysis was performed by flow cytometry. DNA 
content was plotted on histograms. A hypo-diploid peak, as can be seen in the imiquimod histogram, is indicative 
of DNA fragmentation. Results are representative of repeated experiments. 
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Figure 5-8. Caspase 3/7 activity in DFT1 cells after treatment with TLR ligands. The DFT1 cell line C5065 
was treated with poly-IC (30 μg/ml), imiquimod (60 μg/ml), CpG-1585 (30 μg/ml) and CpG-2395 (30 μg/ml) for 
10, 24 and 48 h. Caspase 3/7 activity was analysed as a measure of apoptosis and is represented by an increase in 
mean fluorescence compared to the corresponding untreated sample. Results are the mean and standard error of 
three technical replicates. Statistical significance was measured by two-way ANOVA and is defined as ns>0.05, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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V+PI+ DFT1 cells, the absence of annexin V+PI- cells, DNA fragmentation and low caspase 
activity in these cultures suggests that this TLR9 ligand may induce cell death via necrotic 
pathways. 
5.3.3. Regulation of tumour immunogenicity by TLR stimulation 
Although TLR ligands exhibited no direct stimulatory effect on DFT1 proliferation, other 
mechanisms may exist by which these ligands promote DFTD survival. In human cancers, TLR 
signalling has been linked to cancer progression through its ability to down-regulate anti-
tumour responses via stimulation of suppressive cytokines. To determine whether TLR ligands 
can promote immunosuppressive cytokine release in DFTD, qRT-PCR analysis of IL10 and 
TGFβ1 expression was performed in TLR-stimulated DFT1 cells. Expression of the 
inflammatory cytokine IL6, the angiogenic cytokine VEGFA and the immune checkpoint 
molecule PDL1 was also assessed to explore additional mechanisms of survival such as tumour-
promoting inflammation and T cell suppression. DFT1 cells did not express PDL1 at any stage 
of TLR stimulation, and as a result no data for this gene are shown. Analysis of 
immunosuppressive/angiogenic cytokine expression in DFT1 cells after TLR stimulation 
demonstrated that most TLR ligands exhibited no effect on the expression of these genes (Fig. 
5-9A-D). The exception was FSL-1 (TLR2/6), which increased the expression of IL6 and 
VEGFA in DFT1 cells by more than 64-fold (p<0.05) and 256-fold (p<0.001), respectively. 
Increasing trends in the expression of IL10 and TGFβ1 were also measured after treatment with 
FSL-1, imiquimod and CpG-1585. These changes did not reach statistical significance samples 
due to high variation between replicates. Nonetheless, these results suggest that certain TLR 
ligands can favour immunosuppressive/angiogenic cytokine expression in DFT1 cells, 
providing a novel mechanism by which DFTD tumours could evade immune detection in vivo. 
DFT1 also evades immune detection through epigenetic down-regulation of genes required for 
cell surface expression of MHCI molecules (Siddle et al. 2013). Treatment of DFT1 cells with 
IFNγ reverses suppression of MHCI expression, providing a mechanism by which the 
immunogenicity of DFT1 cells can be improved for DFTD immunisations. As TLR ligands will 
be used in combination with DFTD cells in the Tasmanian devil, it was necessary to determine 
whether TLR ligands exhibit any suppressive effect on MHCI expression. To measure MHCI 
expression, DFT1 cells were cultured with IFNγ and assessed by flow cytometry for surface  
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Figure 5-9. Expression of immunosuppressive cytokines in DFT1 cells after stimulation with TLR ligands. 
The DFT1 cell line C5065 was cultured with FSL-1 (100 ng/ml), poly-IC (30 μg/ml), LPS (30 μg/ml), flagellin 
(100 ng/ml), imiquimod (60 μg/ml), CpG-1585 (30 μg/ml), CpG-2395 (30 μg/ml), and profilin (T. gondii) (100 
ng/ml) for 8 h. Quantitative expression of IL6, IL10, TGF1 and VEGFA was analysed by qRT-PCR after TLR 
stimulation. Gene expression was calculated relative to the reference gene RPS18 and is displayed as a fold-change 
relative to untreated samples. No-cDNA and no-RT controls were included and did not show any amplification of 
product. Results are the mean and standard error of three RNA preparations. Statistical significance relative to the 
untreated sample was measured by one-way ANOVA and Dunnett’s multiple comparisons test and is represented 
as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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β2M expression, a marker of MHCI. This analysis demonstrated that the TLR ligands tested 
(excluding imiquimod) did not effect β2M expression on DFT1 cells, suggesting that they can 
be combined with live MHCI+ DFT1 cells with no impact on MHCI expression (Fig. 5-10A-
D, F-H). In comparison, imiquimod (TLR7) suppressed MHCI, as is evident by lower levels of 
β2M on the DFT1 surface than after treatment with IFNγ alone (Fig. 5-10E). This analysis 
suggests that imiquimod reverses the positive regulation of MHCI expression on DFT1 cells by 
IFNγ. 
5.3.4. Stimulation of DFT2 cells with TLR ligands 
In 2015, a second transmissible cancer was identified in Tasmanian devils (Pye et al. 2016b). 
Denoted DFT2, this tumour was shown to be genetically distinct and its origin was independent 
of DFT1. Little is understood about the differences and similarities between DFT1 and DFT2 
tumours. In order to assess whether DFT2 tumours respond to TLR stimulation in a manner 
similar to DFT1, an available DFT2 cell line (RV) was treated with TLR ligands and functional 
assays were repeated. As both DFT1 and DFT2 cells were demonstrated to express genes 
encoding TLR2/6 in section 5.3.1., expression of immunosuppressive cytokines after FSL-1 
stimulation was first assessed. This analysis revealed small but significant increases in IL10 
and TGF expression after TLR2/6 stimulation (Fig. 5-11). In comparison, IL6 and VEGFA 
demonstrated increasing trends in expression that were non-significant. Although these changes 
in expression were of a smaller magnitude than those detected after stimulation of DFT1 cells 
in section 5.3.3., these results suggest that DFT2 cells respond in a similar manner to FSL-1 
stimulation. Together these findings suggest that TLR2/6 signalling could also play a role in 
immune evasion in DFT2.  
Analysis of TLR stimulated DFT2 cells using the WST-8 assay did not reveal an increase in 
DFT2 cell number, suggesting that as with DFT1, TLR ligands do not have a stimulatory effect 
on DFT2 proliferation (Fig. 5-12A-H). Notably, the response of DFT2 cells to stimulation with 
the TLR7 ligand imiquimod was consistent with DFT1, with a decrease in the number of cells 
to less than the seeded amount (red line) at all time-points (Fig. 5-12E). In comparison, several 
TLR ligands that suppressed DFT1 proliferation including poly-IC and LPS demonstrated no 
suppressive effect on proliferation in DFT2 cells (Fig. 5-12B-C). Inhibitory effects on DFT2 
proliferation were instead evident after treatment with flagellin, CpG-1585 and CpG-2395 (Fig. 
5-12D, F-G). These effects were not visible until 72 h of treatment, perhaps due to a slower 
growth rate of DFT2 cells. Specifically, the number of DFT2 cells in untreated cultures tripled  
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Figure 5-10. Surface expression of 2-microglobulin in DFT1 cells after stimulation with IFN and TLR 
ligands. The DFT1 cell line C5065 was cultured with IFN (5 ng/ml) alone (blue histogram) or in combination 
with poly-IC (30 μg/ml), LPS (30 μg/ml), flagellin (100 ng/ml), imiquimod (60 μg/ml), CpG-1585 (30 μg/ml), 
CpG-2395 (30 μg/ml) or profilin (T. gondii) (100 ng/ml) (orange histogram) for 48 h. Surface 2M expression was 
measured after stimulation by flow cytometry as a marker of MHCI expression, and compared to untreated cells 
(grey histogram). Cells were gated according to section 2.2.8. Results are representative of repeat experiments. 
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Figure 5-11. Expression of immunosuppressive cytokines in DFT2 cells after stimulation with the TLR2/6 
ligand FSL-1. The DFT2 cell line RV was cultured with FSL-1 for 8 h. Quantitative expression of IL6, IL10, 
TGF1 and VEGFA was analysed by qRT-PCR after TLR stimulation. Gene expression was calculated relative to 
the reference gene RPS18 and is displayed as a fold-change relative to untreated samples. No-cDNA and no-RT 
controls were included and did not show any amplification of product. Results are the mean and standard error of 
three replicates. Statistical significance relative to the untreated sample was measured by one-way ANOVA and 
Dunnett’s multiple comparisons test and is represented as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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Figure 5-12. Proliferation of RV DFT2 cells after treatment with TLR ligands. The DFT2 cell line RV was 
treated with increasing concentrations of (A) FSL-1, (B) poly-IC, (C) LPS, (D) flagellin, (E) imiquimod, (F) CpG-
1585, (G) CpG-2395 and (H) profilin (T. gondii) for 24, 48 or 72 h. A WST-8 assay was performed to measure 
viable cell number in each culture after treatment. Cell number was compared to the original number of seeded 
cells (solid red line) to determine cell proliferation. Results are the mean and standard error of three technical 
replicates. 
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within the 72 h treatment period, compared to an increase in DFT1 cell numbers of around 5-6 
times in figure 5-3.  
Further analysis of TLR-stimulated DFT2 cells using the annexin V cell death assay supported 
findings from the WST-8 assay. This analysis revealed that imiquimod was the only TLR ligand 
to significantly increase DFT2 cell death after TLR stimulation (Fig. 5-13). Cell death in 
imiquimod-treated DFT2 cultures was characterised by an increase in early apoptotic cells from 
10% to 30% and late apoptotic/necrotic cells from 10% to 50% after 48 h of treatment. This 
finding suggests that imiquimod activates apoptotic pathways in both DFT1 and DFT2 cell 
lines.  
5.3.5. Pro-apoptotic effects of the TLR7 ligand imiquimod in DFTD cell lines 
In humans, imiquimod is approved by the FDA for the treatment of superficial basal cell 
carcinoma due to its ability to stimulate potent anti-tumour responses via TLR7 signalling. 
Studies have also demonstrated pro-apoptotic effects of imiquimod in a range of human tumour 
cell lines (Huang et al. 2010; Jiang et al. 2016a; Schon et al. 2003). As DFT1 and DFT2 cell 
lines undergo apoptosis in a concentration dependent manner after treatment with imiquimod, 
this small molecule could potentially be a successful therapy in DFTD. To investigate the 
effects of imiquimod in DFTD cells more thoroughly, cell death was monitored over time using 
a WST-8 assay. The DFT1 cell lines C5065, 1426 and 4906 and the DFT2 cell line RV were 
used for this analysis, and a vehicle control was included to control for levels of DMSO (0.5 
%) that were required for solubilisation of imiquimod for culture. At a high imiquimod 
concentration (60 μg/ml), cell number gradually decreased over a 120 h treatment period (Fig. 
5-14A). All DFTD cultures were sensitive to this change but responded at different rates, with 
the DFT2 cell line RV demonstrating the most rapid reduction in viable cell number. In 
comparison, no change in viable cell number was measured in the vehicle control, suggesting 
that 0.5% DMSO has no effect on DFTD viability. The rates at which DFTD cell lines 
responded to imiquimod treatment correlated with their baseline metabolic rate, which was 
highest in RV cultures, moderate in C5065 cultures and lowest in 1426 and 4906 cultures (Fig. 
5-14B). Further analysis of apoptosis in imiquimod-treated DFTD cell cultures was performed 
using the representative DFT1 cell line C5065 and the representative DFT2 cell line RV. 
Detection of annexin V and PI labelling in these cells confirmed findings from the WST-8 assay 
that induction of apoptosis occurred in these treated cultures over a 120 h period (Fig. 5-15A- 
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Figure 5-13. Activation of cell death in DFT2 cells after treatment with TLR ligands. The DFT2 cell line RV 
was treated with FSL-1 (100 ng/ml), poly-IC (30 μg/ml), LPS (30 μg/ml), flagellin (100 ng/ml), imiquimod (60 
μg/ml), CpG-1585 (30 μg/ml), CpG-2395 (30 μg/ml), and profilin (T. gondii) (100 ng/ml) for 48 h. Annexin V 
and PI labelling was analysed using flow cytometry to determine viable cells (A-PI-), early apoptotic cells (A+PI-
) and late apoptotic/necrotic cells (A+PI+). Results are the mean and standard error of the three technical replicates. 
Statistical significance was measured by two-way ANOVA and is defined as ns>0.05, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Figure 5-14. Relative viability of DFTD cell lines cultured with imiquimod over a 120 h period. (A) The 
DFT1 cell lines C5065, 1426 and 4906 and the DFT2 cell line RV were treated with imiquimod (60 g/ml) for 12, 
24, 48, 72, 96 or 120 h. A vehicle control (C5065 cells; DMSO, 0.5%) was included. A WST-8 assay was 
performed to measure cell number at each time point relative to an untreated culture. (B) Baseline metabolic rate 
of C5065, 1426, 4906 and RV cells was determined by WST-8 absorbance measures from untreated cells. All 
results are the mean and standard error of three technical replicates. 
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B). In both cell lines, the percentage of viable cells entering apoptotic pathways peaked at 72 
h, with complete apoptosis occurring after 120 h of treatment. 
Apoptotic pathways are regulated by a range of pro- and anti-apoptotic molecules. To analyse 
the regulation of these molecules in imiquimod-treated DFTD cultures, the expression of the 
anti-apoptotic genes BCL2, BCLXL, MCL1 and A20 and the pro-apoptotic genes BAD, BID, 
BIM, BAK and BOK was measured at various time points after imiquimod treatment using qRT-
PCR. As DFT1 and DFT2 cell lines responded to imiquimod treatment in a similar manner, 
they were grouped together for this analysis. Regulators of apoptosis had not previously been 
investigated in the Tasmanian devil, so their baseline expression was first measured in 
PBMNCs and peripheral nerve, a source of Schwann cells. Expression levels of these genes 
were compared to primary DFTD biopsies and DFT1 (C5065, 1426, 4906, Half-pea) and DFT2 
(RV) cell lines. Relative to RPS18, all anti-apoptotic genes were expressed at low to moderate 
levels, and were varied across the tested tissues (Fig.-5-16A). Expression of anti-apoptotic 
genes in DFTD primary tumours and cell lines was within the range of PBMNC and peripheral 
nerve samples, suggesting that these genes are not overexpressed beyond normal levels. In 
response to imiquimod treatment, only BCL2 and BCLXL were down-regulated significantly 
over the 72 h period (Fig. 5-16B). In comparison, A20 and MCL1 were significantly up-
regulated at 24 h, before decreasing as the cells entered apoptosis. The peak in expression 
occurred earlier for MCL1 when compared to A20, a negative regulator of extrinsic apoptosis.  
Similarly to anti-apoptotic genes, pro-apoptotic genes were expressed in Tasmanian devil 
tissues at low to moderate levels relative to RPS18, and were varied across the tested tissues 
(Fig. 5-17A). The exception was BOK, which was not detectable in DFTD cell lines and as a 
result has not been included in this analysis. Expression of pro-apoptotic genes in DFTD 
primary tumours and cell lines was within the range of both PBMNC and peripheral nerve 
samples, suggesting that these genes were not abnormally expressed in DFTD. In response to 
imiquimod treatment, expression of BAD was significantly decreased after 16 h of treatment, 
while BIM was up-regulated from 8 h (Fig. 5-17B). In comparison, expression of the pro-
apoptotic genes BAK and BID remained unchanged. Together these results indicate that 
imiquimod-induced apoptosis in DFTD cells is associated with regulation of anti-apoptotic 
BCL2 and BCLXL, and pro-apoptotic BIM. 
Although imiquimod is a TLR7 ligand, induction of apoptotic pathways in DFT1 and DFT2 
cell lines may be TLR7-independent, as DFTD cells did not express TLR7 (section 5.3.1). To  
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Figure 5-15. Induction of apoptosis in DFTD cell lines cultured with imiquimod over a 120 h period. (A) 
The DFT1 cell line C5065 and (B) the DFT2 cell line RV were treated with imiquimod (60 μg/ml) for 24, 48, 72, 
96 or 120 h. Annexin V and PI labelling was analysed using flow cytometry to determine early apoptotic cells 
(AV+PI-), late apoptotic/necrotic cells (AV+PI+) and total apoptosis (AV+). Results are the mean and standard 
error of the three technical replicates. 
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confirm this, TLR7 expression was analysed in DFT1 and DFT2 cells throughout a 72 h course 
of imiquimod treatment and qRT-PCR products were visualized by agarose gel electrophoresis. 
This analysis confirmed that neither DFT1 nor DFT2 cell lines express detectable levels of 
TLR7 prior to or during imiquimod treatment (Fig. 5-18). These results indicate that TLR7 is 
absent from DFTD cell lines and does not play a role in the activation of apoptotic pathways 
after imiquimod treatment. 
To investigate whether TLR7-independent responses to imiquimod treatment were specific to 
tumour cells, a non-transformed Tasmanian devil fibroblast cell line (TD344) with no 
detectable expression of TLR7 was treated with imiquimod. The response of the fibroblast cell 
line to imiquimod treatment was compared with DFTD cultures using apoptosis, proliferation 
and gene expression assays. This analysis demonstrated that DFT1 and DFT2 cells, but not 
fibroblasts, undergo apoptosis after treatment with imiquimod (Fig. 5-19). Co-binding of 
annexin V and PI demonstrates a significant difference in the percentage of non-viable cells 
between untreated and imiquimod-treated samples for DFT1 and DFT2 cell lines (Fig. 5-19A). 
This trend is not replicated in fibroblast cultures, suggesting that apoptotic pathways are not 
activated in these cells. To confirm this finding, DNA fragmentation was analysed using cell 
cycle analysis. Large hypo-diploid peaks were detected in imiquimod treated DFT1 and DFT2 
cultures, but not fibroblast cultures, confirming that imiquimod does not activate apoptosis in 
these cells (Fig. 5-19B). To understand whether imiquimod had any effect on the growth of 
Tasmanian devil fibroblasts, WST-8 assays were performed. High imiquimod concentrations 
(60 μg/ml) reduced cell number in fibroblast cultures by around 50% after 48 h of treatment, 
suggesting that imiquimod suppresses their growth without activating apoptotic pathways (Fig. 
5-19C). This effect was not replicated in vehicle controls, suggesting that suppression of 
proliferation in fibroblasts is imiquimod- specific. Expression analysis of the pro-apoptotic 
gene BIM and anti-apoptotic gene BCL2 over a 72 h treatment period revealed that BCL2 
expression was heightened for the treatment duration, while BIM remained unchanged (Fig. 5-
19D). As we previously demonstrated that BCL2 was down-regulated and BIM up-regulated by 
imiquimod treatment in DFTD cells, these results suggest that alternative regulation of pro- and 
anti- apoptotic proteins prevents imiquimod-induced apoptosis in Tasmanian devil fibroblasts. 
Together these results suggest that imiquimod induces TLR7-independent, tumour-specific 
apoptosis in DFTD cell lines. 
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Figure 5-18. Expression of TLR7 in DFTD cells during imiquimod treatment. The DFT1 cell line C5065 and 
the DFT2 cell line RV were treated with imiquimod (60 μg/ml) for 0, 8, 16, 24, 48 or 72 h. TLR7 expression was 
analysed using qRT-PCR. PBMNCs were analysed as a positive control. RPS18 was amplified as a reference gene. 
PCR products were visualised on a 2% agarose gel with a 100 bp ladder for size comparison. No-template and no-
RT controls are included and do not show any amplification of product. 
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Figure 5-19. Response of Tasmanian devil fibroblasts to imiquimod treatment. The DFT1 cell line C5065, 
the DFT2 cell line RV and the non-transformed Tasmanian devil fibroblast cell line (TD344) were treated with 
imiquimod (60 g/ml). (A) Cells were treated for 48 h and annexin V and PI labelling was analysed using flow 
cytometry to determine viable cells (AV-PI-), necrotic cells (AV-PI+), early apoptotic cells (AV+PI-) and late 
apoptotic cells (AV+PI+). (B) Cells were treated for 48 h, fixed and stained with PI. DNA analysis was performed 
by flow cytometry and DNA content was plotted on histograms. A hypo-diploid peak is indicative of DNA 
fragmentation and suggests that cells are apoptotic. (C) Cells were treated with the indicated concentrations of 
imiquimod for 48 h and a WST-8 assay was performed to measure relative cell number compared to an untreated 
culture. Cells were treated with 0.5 % DMSO as a vehicle control. (D) Fibroblasts were treated over a 72 h time 
period and expression of pro-apoptotic BIM and anti-apoptotic BCL2 was measured by qRT-PCR. Gene expression 
was measured relative to RPS18. All results are the mean and standard error of the three replicates. Statistical 
significance was measured by ANOVA and is defined as *<0.05, **<0.01, ***<0.001. 
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5.3.6. Effects of intermittent imiquimod treatment on tumour cell survival 
In chapters 3 and 4 of this thesis I demonstrated that imiquimod is a potent immune-modifier 
in the Tasmanian devil. As DFT1 and DFT2 cells are sensitive to the direct anti-tumoural effects 
of imiquimod, this small molecule could potentially be a successful therapy in DFTD. As DFTD 
cells require up to 120 h to undergo apoptosis after imiquimod treatment, it was necessary to 
determine whether the tumour cells survive brief or intermittent imiquimod treatments. To 
perform this analysis, DFT1 cell lines C5065, 1426 and 4906 were treated with imiquimod for 
48 hours, washed and recovered in culture for 96 h. WST-8 assays were performed to compare 
cell death in these cultures with continuously treated DFT1 cultures. This analysis demonstrated 
that continuous imiquimod treatment is required for activation of apoptosis in treated DFT1 
cells (Fig. 5-20A). Cells treated for 48 h with imiquimod exhibited only a small loss of viability 
at 72 h, and were able to recover and resume proliferation within the 96 h recovery period. 
Analysis of the expression of pro- and anti-apoptotic genes in these recovering cells 
demonstrated up-regulation of BCL2, BCLXL and MCL1 expression, but not A20, to levels that 
were significantly higher than untreated cultures (Fig. 5-20B). Similarly, expression of BAD, 
BAK and BID was increased after imiquimod treatment was removed, while BIM expression 
was decreased (Fig. 5-20C). These results support a role for anti- and pro-apoptotic genes in 
controlling the fate of DFTD cells during imiquimod treatment. 
As DFTD cells recover from brief imiquimod treatments in vitro, it was next necessary to 
determine whether recovering cells could become resistant to further imiquimod therapy. To 
assess this possibility, C5065 DFT1 cells were exposed to five repeat cycles of 48 h of 
imiquimod treatment with washout and 48 h of recovery between each cycle. Sensitivity of the 
cells to imiquimod-induced effects was assessed after each recovery period using a WST-8 
assay. This analysis demonstrated that there was no decrease in the sensitivity of DFT1 cells to 
imiquimod treatment, with each cycle producing a similar curve (Fig. 5-21A). To confirm that 
imiquimod treatment cannot confer resistance in DFT1 cells, C5065 cultures were next exposed 
to increasing imiquimod concentrations from 1.875 g/ml to 15 g/ml over 8 days. At this point 
cells were harvested, and their sensitivity to imiquimod-induced apoptosis was compared 
immediately and after 48 h of recovery. This analysis again demonstrated no evidence for 
induction of imiquimod resistance in DFT1 cell lines, with treated cells demonstrating the same 
sensitivity as untreated cells (Fig. 5-21B). These results suggest that intermittent treatments do 
not induce imiquimod resistance in DFTD cells, supporting the use of this molecule in DFTD. 
 
148 
 
 
Figure 5-20. Recovery of DFT1 cell lines after 48 h of treatment with imiquimod. The DFT1 cell lines C5065, 
1426 and 4906 and the DFT2 cell line RV were treated with imiquimod (60 g/ml) for 48 h. After treatment, cells 
were washed and recovered in culture with no treatment. (A) A WST-8 assay was performed to measure relative 
cell number in culture every 24 h during and after imiquimod treatment. Results were compared to continuously 
treated DFTD cells. Results are the mean and standard error of the four DFTD cell lines (B-C) Expression levels 
of (B) anti-apoptotic genes and (C) pro-apoptotic genes were measured in all four cell lines by qRT-PCR every 24 
h after imiquimod washout and compared to an untreated sample. Gene expression was measured relative to 
RPS18. Box-and-whisker plots represent minimum and maximum expression values relative to RPS18, with the 
upper quartile, median and lower quartile indicated by the horizontal lines of the box.. Statistical significance was 
measured by one-way ANOVA and Dunnett’s multiple comparisons test and is defined as *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 5-21. Sensitivity of C5065 DFT1 cells to imiquimod-induced apoptosis after intermittent or ramped 
pre-treatments with imiquimod. (A) The DFT1 cell line C5065 was exposed to five repeated cycles consisting 
of 48 h of imiquimod treatment (60 g/ml), and 48 h of recovery (no treatment). After each recovery period, a 
subset of the cells were re-treated with increasing concentrations of imiquimod for 48 h and a WST-8 assay was 
performed to measure sensitivity to imiquimod treatment. Results were compared to a previously untreated DFT1 
sample (black line). (B) The DFT1 cell line C5065 was exposed to imiquimod ramped in concentration every 24 
h from 1.875 g/ml to 15 g/ml in 1.875 g/ml increments. After treatment, the cells were re-treated either 
immediately or after 48 h of recovery (no treatment) with increasing concentrations of imiquimod. A WST-8 assay 
was performed to measure sensitivity to imiquimod treatment. Results were compared to a previously untreated 
DFT1 sample (black line). All results are the mean and standard error of three technical replicates. 
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5.4. Discussion 
Many human tumours express TLRs, which signal to alter a range of cell functions including 
proliferation, invasion and migration, apoptotic resistance and production of immune-
modulatory factors (He et al. 2007; Song et al. 2011; Xie et al. 2009). These functions are 
increased or decreased by TLR stimulation to promote or inhibit tumour survival. As a result, 
TLR signalling in cancer is frequently described as a double-edged sword (Dajon et al. 2017). 
The outcome of TLR stimulation in cancer depends on the tumour type and the TLR stimulated. 
In DFTD, identification of TLR ligands with stimulatory effects on growth may have 
implications for their use as adjuvants, particularly for immunotherapy of diseased animals. In 
contrast, TLRs with suppressive effects on DFTD growth could have potential as therapeutic 
agents. Analysis of the response of DFTD cells to TLR stimulation will reveal roles for TLR 
signalling in the modulation of DFTD growth and survival. 
Consistent with many other cancers, TLR expression was detected in DFTD cell lines and 
primary tumours. Both DFT1 and DFT2 cell lines expressed moderate levels of TLRs 2, 6 and 
13, receptors that detect bacterial components including lipopeptide and 23S ribosomal RNA 
(Li et al. 2012; Takeuchi et al. 1999). TLR2 can function as a heterodimer in combination with 
TLR6 (Ozinsky et al. 2000), suggesting that this receptor complex is present in DFTD cells. 
Expression of TLR2/6 in DFTD may reflect expression of these genes in Schwann cells, which 
are the cellular origin of DFT1. In support of this, human Schwann cells express moderate 
levels of TLR1, TLR2 and TLR6 (homologues of devil TLR2 and TLR6) (Goethals et al. 2010). 
These genes were up-regulated in response to external stimuli, suggesting that they are 
inducible (Goethals et al. 2010). This was also the case in DFT1, which exhibited heightened 
expression of TLR2 and TLR6 after stimulation with the TLR2/6 ligand FSL-1. In vivo, this 
positive feedback mechanism could amplify TLR2/6 signalling for an improved response upon 
bacterial exposure. An understanding of the functional changes to TLR2/6-stimulated DFTD 
cells will determine how this signalling may influence DFTD growth.  
Primary DFT1 tumour samples expressed a greater repertoire of TLRs than DFTD cell lines. 
This additional TLR expression may be attributable to supporting cells in the tumour 
microenvironment, such as fibroblasts, epithelial cells and immune cells. Expression of TLRs 
in supporting cells of the tumour may have implications for the use of TLR ligands as 
immunotherapeutic agents in DFTD. The role of the tumour microenvironment in tumour 
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survival is becoming better known, with many cells producing a range of molecules including 
cytokines and growth factors to modulate immune function and increase tumour survival (Hui 
et al. 2015). Particularly in response to TLR stimulation, these supporting cells can produce 
inflammatory and pro-survival factors that could promote DFTD growth (Grimmig et al. 2016; 
Tang et al. 2012). The response of these supportive cells in the tumour microenvironment to 
TLR stimulation will need to be considered prior to the use of TLR ligands as 
immunotherapeutic agents in DFTD.  
The response of DFTD cells to TLR stimulation was measured using functional assays such as 
proliferation assays, apoptosis assays and gene expression assays. DFT1 cells exhibited 
increased proliferation only after treatment with low concentrations of imiquimod, suggesting 
that most TLR ligands do not directly accelerate DFT1 growth. This ability of imiquimod to 
increase proliferation could be an artefact of decreased metabolic activity in the untreated 
cultures as a result of overcrowding, or a consequence of increased glycolysis to overcome mild 
hypoxic stress. In contrast, a decrease in proliferation was measured across multiple DFT1 cell 
lines treated with the poly-IC (TLR3), imiquimod (high concentrations; TLR7) and CpG-1585 
(TLR9). The pathways responsible for this decreased proliferation are unclear. As TLR3, TLR7 
and TLR9 are expressed at low levels in DFT1 cells, the decrease in DFTD cell proliferation 
might not involve TLR pathways, but could potentially be mediated by indirect toxic effects. 
C5065 DFT1 cells also displayed minor decreases in proliferation after stimulation with LPS 
(TLR4) and CpG-2395 (TLR9). These results may be reflective of the metabolic rate of C5065 
cells, which is higher than the metabolic rate of 1426 and 4906 DFT1 cell lines. The WST-8 
proliferation assay measures dehydrogenase activity, which is proportional to the number of 
cells in culture. As a result this assay exhibits less sensitivity in a cell line with lower metabolic 
activity.  
TLR ligands can suppress tumour growth through the activation of cell death pathways 
including apoptosis and programmed necrosis (Kaiser et al. 2013; Luo et al. 2012; Paone et al. 
2008). Poly-IC, imiquimod and CpG-1585 all suppressed proliferation of DFT1 cells, but only 
imiquimod increased characteristics of apoptosis such as annexin V/PI labelling, DNA 
degradation and caspase 3/7 activity. In comparison, DFTD cultures treated with poly-IC did 
not show any of these features. Labelling with the dead cell marker PI was unchanged in poly-
IC treated DFT1 cells, suggesting that this ligand suppresses DFT1 cell cycle without inducing 
cell death. In contrast, DFT1 cells treated with the TLR9 ligand CpG-1585 demonstrated 
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increases in annexin V/PI labelling, but not DNA degradation. Consequently, a cell death 
pathway more similar to necrosis is likely to have been activated in these cells. This finding is 
supported by results from the annexin V assay that demonstrated a significant decrease in early 
annexin V labelling after CpG-1585 treatment, suggesting that the cells were not entering 
apoptotic pathways at 48 h. Unexpectedly, a small increase in caspase activity was measured 
in these CpG treated cells at 24 h. As necrosis is usually caspase independent (Galluzzi et al. 
2012b), this finding suggests that apoptosis or caspase-dependent necrosis (pyroptosis) may 
have been activated in these cells. Analysis of cell death in at 24 h in CpG-1585 treated DFT1 
cells does not support this, with increases in cell death occurring only between 24 and 48 h. 
Instead, it is possible that the toxic effects of CpG-1585 stimulated induction of apoptosis in a 
small number of damaged cells at 24 h, with necrotic pathways over-riding apoptosis by 48 h 
to become the dominant form of cell death in these cultures. 
TLR ligands did not stimulate DFT1 cell proliferation in culture, suggesting that these ligands 
do not directly promote tumour growth. In humans, TLR ligands can promote tumour survival 
through indirect modulation of the surrounding tumour microenvironment (Ridnour et al. 
2013). In particular, TLR stimulated tumour cells have been shown to release a range of factors 
that hijack immune cells to produce a pro-survival suppressive or inflammatory tumour 
microenvironment (Tang et al. 2012). TLR-stimulated tumour cells can also release growth 
factors that increase survival through modulation of angiogenesis (Grimmig et al. 2016). 
Expression of genes encoding the suppressive cytokines IL-6, IL-10 and TGF, as well as the 
angiogenic cytokine VEGFA, was increased in DFT1 cells after stimulation with the TLR2/6 
ligand FSL-1. While this finding highlights a potential role for the TLR2/6 receptor in DFTD 
survival, analysis of protein expression is required to confirm that these cytokine genes are 
increased to sufficient levels for production as a functional protein, as baseline expression was 
low. Analysis of protein expression is challenging in DFTD cells due to a lack of specific and 
cross-reactive antibodies with devil tissues. Nonetheless, this finding confirms that DFT1 cells 
can respond to FSL-1 stimulation, suggesting that TLR2/6 stimulation could represent a novel 
mechanism of immune evasion in DFTD.  
TLR2/6 is a cell surface receptor of mycoplasma, while TLR2 can also function as a homodimer 
that recognises a variety of gram-positive bacteria and yeast (Ozinsky et al. 2000; Takeuchi et 
al. 1999). In vivo, DFTD cells are transmitted directly into bite wounds, which would frequently 
become infected. In addition, established DFTD tumours often ulcerate (Loh et al. 2006a), and 
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would likely harbour a range of bacterial species. As such, DFTD tumour cells are continuously 
exposed to ligands of TLR2/6 and TLR2 in vivo, providing a mechanism by which anti-tumour 
immune responses could be suppressed upon DFTD transmission and during established 
tumour growth. A similar role for TLR2/6 in the suppression of anti-tumour immune responses 
has been demonstrated in a mouse model of hepatocarcinoma (Huang et al. 2012b). This model 
demonstrated significantly reduced tumour growth and decreased pro-survival inflammatory 
cytokine production after genetic knockdown of TLR2/6 expression, revealing a role for 
TLR2/6 signalling as a therapeutic target. Comprehensive studies are warranted to fully 
understand the role of TLR2/6 signalling in DFTD survival. 
The finding that TLR2/6 stimulation promotes expression of immunosuppressive cytokines in 
DFTD has implications for the use of TLR2/6 ligands in the Tasmanian devil. In particular, use 
of these ligands would be limited to applications involving only inactivated DFTD cells, 
preventing their use in DFTD therapies or live DFTD immunisations. The TLR7 ligand 
imiquimod and TLR9 ligand CpG-1585 also induced slight increases in TGF1 in DFT1 cells. 
While this finding suggests that these ligands may also play roles in promoting DFTD immune 
evasion, TGF1 expression can be involved in activation of cell death pathways (Roberson et 
al. 1997; Yoo et al. 2003). As a result, this increase in expression may be a consequence of cell 
death in imiquimod and CpG-1585 treated cultures, rather than a direct response to TLR 
stimulation. Other TLR ligands demonstrated no pro-tumoural effects in these studies, 
suggesting that they are appropriate adjuvants for use in the Tasmanian devil. In support of this, 
poly-IC and imiquimod, which were shown to be effective adjuvants in the Tasmanian devil in 
chapters 3 and 4 of this thesis, exhibited anti-tumour effects in DFTD through suppression of 
proliferation and induction of apoptosis. One potential pitfall of the use of imiquimod in a 
DFTD immunisation involved the down-regulation of surface 2M expression (and therefore 
MHCI expression) when this ligand was combined with MHCI+ DFT1 cells. While this finding 
would not affect cells in an inactivated DFTD vaccine, the effects of imiquimod on MHCI 
expression would need to be taken into account if it were to be used as an immunotherapeutic 
agent or in combination with live MHCI+ DFTD cells. MHCI suppression in imiquimod-treated 
DFT1 cells in vitro is likely an indirect outcome of the activation of apoptotic pathways in these 
cells. Apoptosis induced by imiquimod has previously been linked to ER stress responses, 
which can suppress MHCI expression via attenuation of normal protein translation (Granados 
et al. 2009). Further studies in Tasmanian devils are required to confirm that these pathways 
are activated by imiquimod treatment in vivo.  
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Recently, a second transmissible tumour was discovered in Tasmanian devils (Pye et al. 2016b). 
Denoted DFT2, this tumour exhibits a distinct karyotype and was demonstrated to be of 
independent origin to DFT1 tumours. Although DFT2 is transmitted in a similar manner to 
DFT1, little is currently understood of the survival mechanisms used by these DFT2 tumours. 
As such, it was necessary to repeat previously performed functional assays using DFT2 cells, 
to determine whether this tumour exhibits similar responses to TLR ligands. One of the striking 
similarities between DFT1 and DFT2 cells involved the moderate expression of genes encoding 
the TLR2/6 receptor in both cell lines. Trends in increasing immunosuppressive cytokine 
expression after stimulation of DFT2 cells with FSL-1 (TLR2/6) were also detected, although 
these changes were much smaller than were measured in FSL-1 treated DFT1 cells. Assessment 
of the response of DFT2 cells to stimulation with FSL-1 was challenging, as the cells 
spontaneously form large spheres in culture. The reduced effect that was detected in FSL-1 
treated DFT2 cells may be attributable to an inability of the drug to effectively penetrate these 
spheres. As increasing trends in immunosuppressive cytokine expression were still observed, 
TLR2/6 stimulation remains a potential mechanism of immune evasion in both DFT1 and DFT2 
tumours. 
Similarly to DFT1 cells, TLR ligands did not directly promote DFT2 cell proliferation. Some 
differences in the responses to TLR ligands in DFT2 cells were measured, with flagellin 
(TLR5), CpG-1585 (TLR9) and CpG-2395 (TLR9), but not poly-IC (TLR3) or LPS (TLR4), 
exhibiting inhibitory effects on proliferation. As previously, it is likely that these inhibitory 
effects occur due to toxicity of the TLR ligands in vitro, as expression of TLR5 and TLR9 was 
either low or absent in DFT2 cells. Responses of DFT2 cells to stimulation with imiquimod 
(TLR7) were consistent with the responses of DFT1 cells to this small molecule. Analysis of 
DFT2 cell death using the annexin V assay confirmed that imiquimod was the only TLR ligand 
to significantly increase the percentage of early apoptotic and late apoptotic/necrotic cells in 
these cultures. This finding confirms that imiquimod is also a potent inducer of apoptosis in 
DFT2 cells, and warrants further investigation of this ligand as a therapeutic agent in DFTD.  
Imiquimod is known for its ability to selectively induce apoptosis in tumour cells (Schon et al. 
2003). In vivo, these effects may combine with the immunomodulatory properties of imiquimod 
to promote anti-tumour responses. Indeed, topical treatment of skin carcinomas with imiquimod 
leads to tumour clearance via mechanisms involving immune infiltration and cytotoxic 
activation (Adams et al. 2012; Hemmi et al. 2002; Schon et al. 2003; Schon et al. 2004; Sohn 
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et al. 2014). Tasmanian devil immune cells express functional TLR7 that can be stimulated by 
imiquimod to induce immune activation. As a result, imiquimod could be a potential 
immunotherapeutic agent in DFTD. Only two previous studies have investigated the use of 
therapeutic agents in DFTD. These studies analysed the chemotherapeutic drugs doxorubicin, 
carboplatin and vincristine, and found none of these to be effective in the treatment of DFTD 
tumours (Phalen et al. 2013; Phalen et al. 2015). As DFTD is transmitted as a foreign allograft 
(Pearse et al. 2006; Pye et al. 2016b), immunotherapy may be a more effective treatment 
strategy, with stimulation of an anti-tumour immune response perhaps sufficient to break 
immune tolerance and promote regression of the DFTD allograft. If imiquimod could produce 
an allogeneic response against DFTD with minimal treatments, it would be feasible to 
opportunistically treat wild diseased devils captured during routine trapping expeditions with 
this drug. A thorough understanding of apoptosis activated by imiquimod in DFTD cells will 
reveal whether this drug could be an effective DFTD therapy. 
In human studies, imiquimod directly modulates tumour cells via activation of apoptotic 
pathways (Almomen et al. 2016; El-Khattouti et al. 2015; Huang et al. 2010; Schon et al. 2003; 
Schon et al. 2004; Sohn et al. 2014). In vivo, the growth of xenograft tumours in athymic mice 
was completely suppressed by imiquimod therapy, highlighting roles for imiquimod-induced 
effects in the absence of an adaptive immune response (Almomen et al. 2016). To gain a better 
understanding of the effects of imiquimod in DFTD, in vitro studies were performed to 
investigate changes to DFT1 and DFT2 tumour cell lines after treatment. Although DFT1 and 
DFT2 tumours arose independently (Pye et al. 2016b), both underwent time dependent growth 
inhibition and activation of apoptosis after imiquimod treatment. Consistent with previous in 
vitro studies, high concentrations were required for the initiation of these effects (El-Khattouti 
et al. 2015; Schon et al. 2003; Schon et al. 2004; Sohn et al. 2014). These findings reflect the 
high amounts of imiquimod required for the immunotherapy of superficial basal carcinoma in 
humans, with FDA guidelines suggesting topical application of 0.5 – 2 mg of imiquimod almost 
daily (Graceway Pharmaceuticals. 2007). 
Although imiquimod is a ligand of TLR7, expression of this gene could not be detected in 
DFTD cell lines prior to or during imiquimod treatment. As previous studies have reported 
TLR7 independent activation of apoptosis in imiquimod treated tumour cell lines (Huang et al. 
2016; Huang et al. 2014; Schon et al. 2003; Sohn et al. 2014; Wang et al. 2015), imiquimod 
likely induces apoptotic pathways in DFTD cells via alternative mechanisms. It has been 
suggested that apoptotic pathways in imiquimod treated tumour cells are activated as a result 
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of ROS accumulation, which enhances ASK-1 stimulation of JNK and p38 apoptotic pathways 
(El-Khattouti et al. 2015; Huang et al. 2016; Huang et al. 2014; Ichijo et al. 1997; Matsuzawa 
et al. 2002; Tobiume et al. 2001). Imiquimod-induced ROS production may occur as a result of 
calcium induced deregulation of oxidative phosphorylation (El-Khattouti et al. 2015), and rapid 
accumulation is likely due to the elevated metabolic activity of tumour cells. This hypothesis is 
supported by our results, which show a faster response to imiquimod treatment in cell lines with 
a higher baseline metabolic rate.  
The regulation of pro- and anti-apoptotic proteins in imiquimod treated tumour cells has been 
well established, with several studies measuring changes to BCL2, MCL1, A20 and Noxa after 
treatment (Almomen et al. 2016; El-Khattouti et al. 2015; Huang et al. 2012a; Schon et al. 2003; 
Schon et al. 2004; Sohn et al. 2014; Vidal et al. 2004). Recently, El-Khattouti et al. suggested 
that localization of pro-apoptotic Noxa to mitochondria is required for a loss of mitochondrial 
membrane potential, cytochrome C release and subsequent apoptosis of imiquimod-treated 
melanoma cell lines. Activity of Noxa was controlled through ER-stress mediated activation of 
PERK signalling and ROS-mediated JNK activation (El-Khattouti et al. 2015). Noxa 
expression was not able to be measured in this study due to incomplete annotation of the 
Tasmanian devil genome, but up-regulation of BIM was detected, a pro-apoptotic protein also 
activated through ER-stress pathways (Puthalakath et al. 2007). Significant down-regulation of 
genes encoding anti-apoptotic BCL2, but not MCL1 or A20, was also detected. It remains 
possible that A20 and MCL2 were further down-regulated after 72 h of imiquimod treatment, 
but quality RNA could not be extracted for PCR after this time due to low cell viability.  
MCL1 and A20 are involved in suppression of apoptosis through interactions with Noxa and 
BIM, and degradation of ASK1, respectively (Thomas et al. 2010; Won et al. 2010). Transient 
up-regulation of MCL1 and A20 was detected immediately after treatment, suggesting that there 
may be early activation of pathways protective against Noxa and BIM-mediated apoptosis in 
response to imiquimod. This could explain the prolonged survival of tumour cells in culture for 
96 to 120 h after treatment, and the ability of pulsed cultures to fully recover from treatment. 
In vivo, frequent application of imiquimod may be required to overcome these pathways and 
induce tumour cell apoptosis. Human cancer therapies utilize daily topical treatments with 
imiquimod as a normal practice (Telfer et al. 2008), but a repetitive protocol of treatment is less 
feasible in a wild species such as the Tasmanian devil. In vivo studies are required to determine 
how many treatments are required for rejection of the DFTD allograft. Repetitive patterns of 
drug application can also lead to the development of drug-resistant cells and tumour relapse. 
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Experiments aimed at inducing imiquimod resistant DFTD cells in this study were 
unsuccessful, supporting the use of imiquimod as an anti-tumour drug.  
Although imiquimod is a potent inducer of apoptosis in tumour cells, these effects do not extend 
to normal tissues. In vivo, this may restrict imiquimod-induced effects to the tumour site, 
preventing substantial damage of surrounding tissue. These findings align with previous 
research where primary keratinocyte cultures were resistant to imiquimod-induced effects, but 
treated tumour cells and transformed keratinocyte cultures underwent apoptosis (Schon et al. 
2003). The uncontrolled nature of tumour cell growth and metabolism may allow imiquimod-
induced cellular stressors such as ROS to accumulate at a greater rate in these cells, 
overwhelming defences against cellular damage. In addition, neoplastic cells cope with ROS 
and other stressors at heightened baseline levels relative to normal cells, suggesting that 
homeostatic mechanisms may be more easily exhausted by additional stressors (Schumacker 
2006; Szatrowski et al. 1991). Although imiquimod did not activate apoptosis of Tasmanian 
devil fibroblasts, there was a decrease in cell number after treatment, suggesting an inhibitory 
effect on growth. Cell cycle arrest has been documented in response to imiquimod treatment, 
and could allow resolution of cellular stress in normal cells (Han et al. 2013).  
The ability of imiquimod to deregulate DFTD survival could allow for more effective tumour 
targeting by the immune system. Immune cells were traditionally thought to be tolerant of 
apoptotic cells, however, forms of ICD have been described whereby apoptotic and necrotic 
cancer cells were potent activators of the immune response, and in some cases acted as cancer 
vaccines without additional adjuvants (Casares et al. 2005; Inoue et al. 2014; Obeid et al. 2007). 
Analysis of the pathways activated by imiquimod in DFTD cells in chapter 6 of this thesis will 
reveal whether this small molecule can modulate DFTD cells in a manner consistent with 
increased immunogenicity. 
In summary, in this chapter I have demonstrated that both DFT1 and DFT2 tumour cells express 
TLRs. Although ligands of these TLRs did not directly promote DFTD proliferation, TLR2/6 
ligands were able to promote expression of immunosuppressive and angiogenic cytokines. As 
these cytokines are involved in the modulation of the tumour microenvironment to a pro-tumour 
state, caution should be taken when using TLR2/6 ligands in combination with live DFTD cells. 
Importantly, poly-ICLC and imiquimod, which were shown in chapters 3 and 4 to be potent 
immune-stimulatory agents in the Tasmanian devil, exhibited no pro-tumoural effects in DFTD. 
In contrast, the direct and targeted anti-tumour effects of imiquimod in DFT1 and DFT2 cell 
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lines could be useful for a DFTD therapy. Findings from these analyses will be integrated with 
data from chapters 3 and 4 of this thesis to select appropriate adjuvants for future DFTD 
vaccinations and immunotherapies.  
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Chapter 6: Anti-tumour effects of the 
TLR7 agonist imiquimod in DFTD
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6.1. Introduction 
Imiquimod (R-837), an imidazoquinoline analogue of guanosine, is a potent immune modifier 
(Lee et al. 2003b). Primarily known as an agonist of the viral single stranded RNA sensor TLR7, 
imiquimod has attracted interest in clinical immunotherapy trials for its anti-viral and anti-
tumour properties (Hemmi et al. 2002; Lee et al. 2003b; Vacchelli et al. 2012). Currently, it is 
approved by the FDA as a topical immunotherapy against external genital and perianal warts, 
actinic keratosis and superficial basal cell carcinoma (Vacchelli et al. 2012). Successful 
imiquimod immunotherapy against these and other lesions leads to extensive immune 
infiltration and subsequent regression via TLR7-dependent cytotoxic mechanisms (Barnetson 
et al. 2004; Fehres et al. 2014; Huang et al. 2009; Soong et al. 2014). TLR7 is expressed at high 
levels by pDCs. These cells play key roles in the recruitment and activation of cytotoxic 
immune cells via cytokine and chemokine production (Liu et al. 2008). More recently, 
imiquimod-stimulated pDCs in mouse models have also been demonstrated to directly suppress 
tumour growth and activate apoptosis through TLR7-dependent TNF-related apoptosis-
inducing ligand (TRAIL) and granzyme B release (Drobits et al. 2012; Wu et al. 2017b). 
Imiquimod may also inhibit immune-regulatory pathways via antagonism of adenosine receptor 
signalling (Schon et al. 2006), and activate NLRP3-mediated inflammasome signalling via 
stimulation of ROS production (Gross et al. 2016). This ability of imiquimod to act on the 
immune response at multiple levels could account for its success as an anti-cancer drug (Fehres 
et al. 2014; Huang et al. 2009; Ooi et al. 2006; Soong et al. 2014). 
It has previously been demonstrated that imiquimod has direct effects on tumour cell function 
in vitro and in vivo. Studies in vitro have demonstrated direct activation of intrinsic apoptosis 
in cell lines from a range of cancers including malignant melanoma, basal cell carcinoma, 
squamous cell carcinoma, gastric cancer and endometrial cancer (Almomen et al. 2016; Huang 
et al. 2010; Jiang et al. 2016a; Schon et al. 2003; Schon et al. 2004). These apoptotic pathways 
are activated via mechanisms involving oxidative and ER stress, and regulation of the BCL2 
family of proteins (El-Khattouti et al. 2015; Huang et al. 2016; Nyberg et al. 2016; Schon et al. 
2003; Schon et al. 2004; Wang et al. 2015). Autophagic pathways have also been implicated in 
this process and may contribute to imiquimod-induced death (Huang et al. 2010; Jiang et al. 
2016a; Yi et al. 2009). In vivo, tumour growth was directly arrested by topical imiquimod 
treatment in an immune-compromised mouse model of endometrial cancer (Almomen et al. 
2016). In another study, imiquimod synergised with radiotherapy to enhance tumour regression 
 
162 
via mechanisms dependent on the activation of autophagic pathways (Cho et al. 2017). Together 
these results suggest that these direct anti-tumour effects may play roles in imiquimod-induced 
tumour regression in cancer patients. This is the case for many other anti-cancer drugs, which 
deregulate oncogenic pathways and alter the expression of silenced and overexpressed genes, 
allowing for enhanced targeting by the immune system (Bracci et al. 2014). Further 
investigation of the molecular changes that occur in imiquimod-treated tumour cells is required 
to understand pathway regulation in response to this small molecule.  
In chapter 5, it was determined that cell lines established from DFTD tumours, which are 
resistant to many anti-cancer agents, are sensitive to cell death induced by imiquimod. In 
addition, TLR7 was shown to be functional in the immune system of the Tasmanian devil in 
chapters 3 and 4, suggesting that imiquimod could be an effective DFTD immunotherapy. 
Thorough investigation of the effects of imiquimod in DFTD are required to understand the 
mechanisms by which imiquimod deregulates DFTD cell survival. As these analyses are 
challenged by a lack of Tasmanian devil specific reagents, the effects of imiquimod in DFTD 
have been explored in this chapter at the whole mRNA and protein level using RNA sequencing 
(RNA-seq) and proteomic mass spectrometry (MS). This study will improve the current 
understanding of DFTD tumourigenesis and will reveal new targets for DFTD therapy. As a 
natural tumour model with established mechanisms of immune evasion and survival, DFTD 
also provides an ideal model for studying the mechanisms of imiquimod action for human 
application. 
6.2. Experimental Procedures 
6.2.1. Cell lines and imiquimod treatment 
The DFT1 cell line C5065 was cultured and harvested as described in section 2.2.3. A total of 
1 x 106 cells were plated per well of a 12-well cell culture plate (Corning, New York, USA) in 
1 ml of RPMI/10FCS medium (section 2.1.6.). Cells were treated with imiquimod (section 
2.1.2.) at 60 μg/ml in a 35 °C, 5% CO2 humidified incubator for 24 h for RNA-seq or 48 h for 
proteomic MS. Untreated controls were included. After incubation, cells were harvested as 
described in section 2.2.3. and washed three times in PBS prior to RNA or protein extraction.  
6.2.2. RNA extraction 
RNA was extracted from untreated and imiquimod-treated C5065 DFT1 samples in duplicate 
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using the RNeasy Mini Kit (QIAGEN Bioinformatics, Hilden, Germany), according to the 
manufacturer’s instructions (Appendix 2). Briefly, cells were lysed in 350 μl of buffer RLT by 
passing the lysate through a hypodermic 20-gauge needle (Terumo Medical, Somerset, USA) 
with sterile plastic syringe (Terumo Medical, Somerset, USA) 5 times. 350 μl of 70% ethanol 
was mixed with the lysate to precipitate the RNA. The lysate was added to an RNeasy spin 
column and centrifuged at 8000 g for 15 s to remove the supernatant. The RNA precipitate was 
washed in 700 μl of buffer RW1, followed by two washes in 500 μl of buffer RPE. 
Centrifugation at 8000 g for 15 s was performed between each wash. To ensure purity of the 
sample, the RNA precipitate was centrifuged for a further 2 min at 8000 g after the final wash. 
The RNA was eluted from the spin column membrane in 50 μl RNase-free water by 
centrifugation at 8000 g for 1 min. RNA integrity was assessed using the 2100 BioAnalyser 
(Agilent Technologies, Santa Clara, USA). An RNA integrity number (RIN) of greater than 8 
was required for mRNA sequencing.  
6.2.3. Next generation mRNA sequencing 
Single-read mRNA sequencing was performed on the Illumina Hiseq-2000 platform (Illumina, 
San Diego, USA). Sequence quality was assessed using fastqc 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Cleaned sequence reads were 
aligned to the Tasmanian devil reference genome (7.0.82) using subread (Liao et al. 2013), and 
counts were summarised into genes using featureCounts (Liao et al. 2014) (Appendix 3-1). 
Differential expression analysis of gene counts was performed using R version 3.3.2 (Appendix 
3-2). Technical replicates were combined and genes with less than 20 aligned reads across all 
samples were removed. Expression levels were normalised by upper quartile normalisation 
using EDAseq (Bullard et al. 2010; Risso et al. 2011) (Appendix 3-3). Differential expression 
analysis was performed using limma/voom (Law et al. 2014) (Appendix 3-4). Volcano plots of 
differential gene expression data were created using the R plot function, and heat maps were 
produced using heatmap.2/gplots (https://CRAN.R-project.org/package=gplots). Gene 
ontology (GO) analysis of genes up and down-regulated greater than 2-fold (FDR < 0.001) was 
performed using limma/goana (Ritchie et al. 2015; Young et al. 2010) (Appendix 3-5). To 
remove general and repetitive GO terms, those with a gene size of greater than 200 were filtered 
from the analysis, and where possible child terms were paired with parent terms post-analysis. 
Differential gene expression data was further analysed using Ingenuity Pathway Analysis 
(IPA) (QIAGEN Bioinformatics, Hilden, Germany). A stringent FDR cut-off of 10-7 was 
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applied and canonical pathways associated with differentially expressed genes were generated 
(Appendix 3-6). 
6.2.4. Protein extraction and trypsin digestion 
Untreated and imiquimod-treated C5065 DFT1 samples in triplicate were lysed in 700 μl of 
protein extraction lysis buffer (section 2.1.6.) by repetitive pipetting, and incubated on a tube 
rotator (Ratek, Boronia, Australia) for 2 h at 4 °C. The lysate was centrifuged at 13 000 g for 
10 m and the supernatant was transferred to a new tube. Proteins were precipitated from the 
lysate with 9 x the volume of 100% ethanol (Fronine, Riverstone, Australia) overnight at -20 
°C. Precipitated proteins were pelleted by centrifugation at 13 000 g for 10 min and the 
supernatant was discarded. Protein pellets were air-dried and reconstituted in 100 μl of protein 
extraction digest buffer (section 2.1.6.). Protein concentration was determined using the EZQ 
Protein Quantification Kit (Thermo Fisher Scientific, Waltham, USA), according to the 
instructions of the manufacturer (Appendix 2). Briefly, 1 μl of each protein sample was spotted 
onto filter paper alongside serially diluted ovalbumin standards. Proteins were fixed in 
methanol (Merck Millipore, Billerica, USA) for 5 min and stained with EZQ protein 
quantification reagent for 30 min with gentle agitation. Proteins were rinsed twice in protein 
quantification rinse buffer (section 2.1.6.), and fluorescence was measured using the 
SpectraMax Plus 384 Plate Reader (Molecular Devices, Sunnyvale, USA). Protein 
concentration was determined from the standard curve of known ovalbumin concentrations. 
After quantification, 10 μl of dithiothreitol (DTT) (100 mM ) (Bio-Rad, Hercules, USA) was 
mixed with 90 μl of protein at a concentration of 1 mg/ml. Samples were incubated overnight 
at 4 °C. 11 μl of iodoacetemide (500 mM) (Sigma-Aldrich, St Louis, USA) was then added to 
each sample and incubated for 2 h at room temperature. Proteins were digested by pipetting 1 
μl of trypsin from porcine pancreas (1 mg/ml) (Sigma-Aldrich, St Louis, USA) to the tube wall 
and flushing into the protein sample with 1 ml of chilled methanol. Proteins were digested 
overnight at -20 °C. The peptide precipitate was collected by centrifugation at 13 000 g for 5 
min. Pellets were air-dried and reconstituted in 100 μl of ammonium bicarbonate (100 mM) 
(Sigma-Aldrich, St Louis, USA) for 2 h at 37 °C.  
6.2.5. Proteomic Mass Spectrometry 
Tryptic peptides equivalent to ~ 1 g of digested protein were separated using an Ultimate 3000 
nano RSLC system (Thermo Fisher Scientific, Waltham, USA). Peptides were first 
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concentrated on a 20 mm x 75 m PepMap 100 trapping column (3 m C18) at a flow rate of 
5 l/min, using 98% water, 2% acetonitrile and 0.05% TFA. Peptides were separated after 
elution from the pre-column onto on a 250 mm x 75 m PepMap 100 RSLC column (2m C18) 
at a flow rate of 300 nL/min. A 180 minute gradient from 98% mobile phase A (0.1% formic 
acid in water) to 50% mobile phase B (0.08% formic acid in 80% acetonitrile and 20 % water) 
comprised the following steps: 2-10% B over 10 min, 10-40% B over 120 min, 40-50% B over 
10 min, holding at 95% B for 10 min then re-equilibration in 2% B for 15 min. The nanoHPLC 
system was coupled to an LTQ-Orbitrap mass spectrometer equipped with nanospray Flex ion 
source (Thermo Fisher Scientific, Waltham, USA) and controlled using Xcalibur 2.1 software. 
MS scans were acquired from 460-2000 m/z at a resolution of 30,000 and MS/MS spectra were 
acquired in data-dependent mode using a Top8 method and 30-second dynamic exclusion of 
fragmented peptides, as described (Wilson et al. 2016).  
6.2.6. Protein identification and analysis 
Data files were imported into MaxQuant version 1.5.1.2 (http://maxquant.org/) and MS/MS 
spectra were searched using the Andromeda search engine against the complete Sarcophilus 
harrisii UniProt reference proteome (ID 0000007648; updated on 11/02/2016) comprising 
22,388 protein entries. Default settings for protein identification by LTQ-Orbitrap MS/MS and 
label-free quantitation (LFQ) included a maximum of two missed cleavages, mass error 
tolerances of 20 ppm then 4.5 ppm for initial and main peptide searches, respectively, 0.5 Da 
tolerance for fragment ions, variable methionine oxidation and fixed carbamidomethylation. A 
default false discovery rate (FDR) of 0.01 was used for peptide-spectrum matches and protein 
identification. The MaxQuant peptides.txt and proteinGroups.txt output files are presented in 
Appendix 4-1. The MaxQuant algorithm MaxLFQ was used for peptide intensity determination 
and normalization (Cox et al. 2014), using pair-wise comparison of unique and razor peptide 
intensities and a minimum ratio count of 2. The proteinGroups output file generated by 
MaxQuant analysis was processed as follows: The normalised label-free quantification (LFQ) 
intensity values, MS/MS counts and the numbers of razor and unique peptides for each of the 
identified proteins were imported into Perseus software version 1.5.031 (http://perseus-
framework.org/). Protein groups identified either as potential contaminants (prefixed with 
CON_), identified by modified site only, by reverse database matching or on the basis of a 
single matching peptide were removed. LFQ intensity values were then log2–transformed and 
then a filter applied to include only proteins detected in a minimum of the three untreated or 
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imiquimod treated replicates. Missing values were replaced with random intensity values for 
low-abundance proteins based on a normal distribution of protein abundances using default 
MaxQuant parameters. To determine proteins that were significantly altered in abundance 
between treatments a two-sided t-test with a permutation-based FDR of 0.05 was applied, using 
250 randomizations and a minimum fold-change cut-off of 1.5. The data was exported from 
Perseus into Excel after each data processing step (Appendix 4-2). Volcano plots of protein 
expression data were created using the plot function in R (Appendix 4-3). Gene set testing of 
significantly up and down-regulated proteins was performed using the Functional Annotation 
Clustering tool of the DAVID Bioinformatic Database version 6.8 (https://david.ncifcrf.gov/) 
(Huang da et al. 2009) (Appendix 4-4). As little functional information is available for the 
Tasmanian devil, protein lists were analysed using the Homo sapiens species database, with 
medium stringency. Protein-protein interactions between up-regulated proteins were identified 
using the STRING Database version 10.5 (https://string-db.org) (Szklarczyk et al. 2017). Only 
interactions predicted with high confidence (interaction score ≥ 0.700) were included in the 
analysis. 
6.2.7. qRT-PCR Analysis 
DFT1 cells were plated at 1 x 106 cells/ml in 1 ml of RPMI/10FCS (section 2.1.6.). For analysis 
of ER stress gene expression, cells were stimulated with imiquimod at 60 μg/ml for 8, 16, 24, 
48 or 27 h. For analysis of genes in the MHC processing pathway, cells were stimulated with 
either imiquimod at 30 μg/ml or 60 μg/ml, or IFN (Walter and Eliza Hall Institute of Medical 
Research, Melbourne, Australia) at 5 ng/ml, for 24 h. Untreated controls were included. 
Cultures were maintained in a 37°C humidified 5% CO2 incubator for the treatment duration. 
After incubation, cells were harvested and washed in PBS as described in section 2.2.3. RNA 
extraction, cDNA conversion and qRT-PCR were performed according to sections 2.2.4. and 
2.2.7. Relative gene expression was analysed by one-way ANOVA and Dunnett’s multiple 
comparison test using PRISM GraphPad version 6. 
6.2.8. Flow cytometry 
C5065 DFT1 cells were plated at 1 x 106 cells/ml in 1 ml of RPMI/10FCS and treated with 
imiquimod at 60 μg/ml for 24, 48, 72 or 96 h, IFN at 5 ng/ml for 24, 48, 72 or 96 h, digoxin 
(GlaxoSmithKline, Brentford, UK) at 1 mM for 6 h, or camptothecin (BioVision, Milpitas, 
USA) at 2 mM for 6 h. Untreated controls were included. Cultures were maintained in a 37°C 
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humidified 5% CO2 incubator. After incubation, cells were harvested and washed in FACS 
buffer as described in section 2.2.3, and labelled as described in section 2.2.8. Primary labelling 
was performed with 200 μl of rabbit anti-calreticulin antibody (section 2.1.4.) diluted to 1.58 
μg/ml with FACS buffer (section 2.1.6.) or mouse anti-Tasmanian devil 2M (section 2.1.4.) 
diluted 200 x with FACS buffer. Alternatively, cells were resuspended in mouse or rabbit Ig 
(Dako, Santa Clara, USA) diluted to an equal concentration as the primary antibody as an 
isotope control, or FACS buffer alone as an FMO control. Cells were incubated for 1 h at room 
temperature. Secondary labelling was performed with PE goat anti-rabbit IgG (section 2.1.4.) 
or alexa fluor-647 goat anti-mouse IgG (section 2.1.4.), diluted to 2 μg/ml in FACS buffer. 
Cells were incubated in the dark for 1 h at room temperature. Cells were resuspended in 100 μl 
of annexin V binding buffer (Merck Millipore, Billerica, USA) containing 2 μl of annexin V 
(Merck Millipore, Billerica, USA) and 1 μl of PI (Sigma-Aldrich, St Louis, USA) in the 
appropriate samples. Samples were analysed on the BD FACSCanto II flow cytometer (BD 
biosciences, San Jose, USA) within 1 h. Flow cytometry data was analysed using Kaluza Flow 
Cytometry Analysis Software version 1 (Beckman Coulter, Brea, USA), according to the gating 
strategy described (section 2.2.8).  
6.3. Results 
6.3.1. Molecular changes to DFT1 cells after imiquimod treatment 
Previous studies have determined that imiquimod decreases tumour cell survival by inducing 
cell stress and activating apoptotic and autophagic cell death pathways (El-Khattouti et al. 2015; 
Wang et al. 2015). These effects are thought to be independent of TLR7 signalling (Nyberg et 
al. 2016), but the mechanisms involved remain poorly understood in mammalian species 
including the Tasmanian devil. To understand the molecular pathways regulated by imiquimod 
in DFT1, the transcriptome and proteome of untreated and imiquimod-treated cells were 
generated using RNA-seq and proteomic MS. As it was determined in chapter 5 that DFT1 cells 
require anywhere from 24 to 96 h to undergo imiquimod-mediated cell death, transcriptional 
changes were analysed at 24 h to ensure mRNA quality for RNA-seq. A later time-point of 48 
h was chosen for analysis of the proteome to understand the changes occurring as many cells 
enter apoptotic pathways. In total, there were 13559 different gene transcripts detected by RNA-
seq and 1057 proteins detected by MS in DFT1 cells (Fig. 6-1A, Fig. 6-1B). The molecular 
landscape of imiquimod-treated and untreated DFTD cells was vastly different, with 2655 
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(19.58%) mRNA transcripts significantly up-regulated and 4188 (30.89%) mRNA transcripts 
significantly down-regulated (FDR < 0.05, FC = ±2.0). In comparison, there were 136 (12.87%) 
proteins significantly up-regulated and 163 (15.42%) proteins significantly down-regulated in 
the proteome by imiquimod (FDR < 0.05, FC = ±1.5) (Fig. 6-1B). Comparison of the measured 
fold-changes of genes that were detected at both 24 h by RNA-seq and 48 h by MS demonstrates 
a low but significant correlation of expression trends between the two datasets (R2 = 0.10, p < 
0.0001) (Fig. 6-1C). In total there were 18 genes that demonstrated opposing regulation 
between the transcriptome and proteome, with many other genes significantly regulated in only 
one dataset. All 18 of these genes were down-regulated at 24 h in the transcriptome and up-
regulated at 48 h in the proteome (Table 6-1). Together these results suggest that molecular 
changes to imiquimod-treated DFT1 cells were substantial, and continued to occur throughout 
48 h of treatment. 
6.3.2. Functional changes to DFT1 cells after imiquimod treatment 
To determine the functional changes occurring in DFT1 cells after imiquimod treatment, up 
and down-regulated genes detected through RNA-seq were analysed by GO analysis. As more 
than 50% of the DFT1 transcriptome was regulated greater than 2-fold after imiquimod 
treatment, the threshold of significance was adjusted to a more stringent FDR of less than 0.001 
for this analysis. The most significant biological process GO terms associated with up and 
down-regulated genes in the DFT1 transcriptome are shown (Table 6-2A-B). Genes up-
regulated by imiquimod are associated with terms such as ‘response to topologically incorrect 
protein’, ‘intrinsic apoptosis pathway in response to ER stress’ and ‘response to unfolded 
protein’, suggesting that ER stress responses were activated. Other functions with known roles 
in ER homeostasis including ‘phosphatidylinositol-mediated signalling’, ‘steroid biosynthetic 
process’ and ‘negative regulation of cell growth’ were also positively regulated. Terms 
associated with genes down-regulated by imiquimod included ‘DNA-dependent DNA 
replication’, ‘sister chromatid cohesion’ and ‘DNA strand elongation involved in DNA 
replication’, suggesting that DNA replication and cell cycle were arrested. Other negatively 
regulated terms were associated with the Schwann cell origin of DFT1 cells and included ‘glial 
cell differentiation’ and ‘peripheral nervous system development’. To determine whether 
similar molecular changes occur at the protein level, proteins regulated by imiquimod were 
analysed by functional annotation clustering using the online bioinformatic database DAVID. 
Analysis of up-regulated proteins demonstrated significant regulation of mRNA splicing (Table 
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Table 6-1. Genes with opposing regulation between transcriptome and proteome datasets 
Symbol Name 
Fold-Change 
Function 
mRNA protein 
AK2 Adenylate Kinase 2 0.23 1.56 
Catalyses transfer of phosphate group from ATP to 
AMP to form 2ADP 
CTSC Cathepsin C 0.06 2.26 Lysosomal cysteine protease involved in apoptosis 
ERP29 ER resident protein 29 0.26 1.47 Protein chaperone involved in protein folding 
GNB1 
Guanine nucleotide-
binding protein beta-1 
0.30 1.50 
Required for GTPase activity, GTP synthesis and G-
protein interactions 
HDGF 
Hepatoma-derived 
growth factor 
0.16 1.55 Transcriptional repressor 
HNRNPA3 
Heterogeneous 
nuclear 
ribonucleoprotein A3 
0.07 1.54 
Involved in cytoplasmic trafficking of RNA and pre-
mRNA splicing 
HNRNPD 
Heterogeneous 
nuclear 
ribonucleoprotein D 
0.16 1.53 Involved in pre-mRNA processing and transcription 
HNRNPH3 
Heterogeneous 
nuclear 
ribonucleoprotein H3 
0.33 1.66 
Involved in heat-shock induced splicing arrest and 
mRNA splicing 
LMNA Prelamin A/C 0.31 1.62 
Component of lamin on the inner nuclear membrane. 
Interacts with chromatin 
LMNB2 Lamin B2 0.16 1.91 
Component of lamin on the inner nuclear membrane. 
Interacts with chromatin 
PHB Prohibitin 0.28 2.01 Inhibits DNA synthesis 
S100A6 Protein S100-A6 0.06 1.78 Calcium sensor and modulator 
SLC26A6 
Solute carrier family 
26 member 6 
0.23 14.74 Anion exchanger, pH buffering 
SNRPE 
Small nuclear 
ribonucleoprotein E 
0.32 1.74 Component of the splicosome. Pre-mRNA splicing 
SNRPF 
Small nuclear 
ribonucleoprotein F 
0.17 2.63 Component of the splicosome. Pre-mRNA splicing 
SRM Spermidine synthase 0.14 1.99 Catalyses spermidine production 
SRSF1 
Serine/arginine rich 
splicing factor 1 
0.33 1.65 Regulates accuracy of splicing and alternative splicing 
VIM Vimentin 0.17 1.56 Component of class-III intermediate filaments 
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Table 6-2. Most significant biological process GO terms associated with genes regulated greater than 2-fold in 
imiquimod-treated DFT1 cells 
GO ID GO term Term size 
No. up-
regulated 
p-value 
A. Up-regulated genes    
GO:0048015 phosphatidylinositol-mediated signaling 199 44 5.1357E-08 
> GO:0014068 > positive regulation of phosphatidylinositol 3-kinase signaling 64 18 1.51008E-05 
> GO:0014066 > regulation of phosphatidylinositol 3-kinase signaling 141 35 5.82505E-08 
> GO:0014065 > phosphatidylinositol 3-kinase signaling 159 38 4.7709E-08 
GO:0035966 response to topologically incorrect protein 181 40 2.07826E-07 
GO:0070059 
intrinsic apoptotic signaling pathway in response 
to endoplasmic reticulum stress 
56 19 3.70339E-07 
> GO:1902235 
> regulation of endoplasmic reticulum stress-induced intrinsic 
apoptotic signaling pathway 
29 11 3.2923E-05 
> GO:1902041 
> regulation of extrinsic apoptotic signaling pathway via death 
domain receptors 
55 15 0.000112357 
> GO:0008625 
> extrinsic apoptotic signaling pathway via death domain 
receptors 
84 19 0.000225944 
GO:0006986 response to unfolded protein 166 37 4.68813E-07 
> GO:0035967 > cellular response to topologically incorrect protein 141 26 0.000589794 
> GO:0036499 > PERK-mediated unfolded protein response 20 8 0.000260795 
> GO:0036500 > ATF6-mediated unfolded protein response 10 6 0.000100485 
> GO:0006983 > ER overload response 11 6 0.00020347 
> GO:0034620 > cellular response to unfolded protein 128 24 0.000735699 
GO:0006694 steroid biosynthetic process 151 34 1.0539E-06 
> GO:0016125 > sterol metabolic process 135 25 0.00069775 
> GO:0016126 > sterol biosynthetic process 56 16 3.59253E-05 
GO:0030308 negative regulation of cell growth 163 35 2.36592E-06 
> GO:0061387 > regulation of extent of cell growth 99 22 9.90148E-05 
> GO:0030516 > regulation of axon extension 86 19 0.000311745 
> GO:0048588 > developmental cell growth 188 33 0.00030318 
> GO:0048640 > negative regulation of developmental growth 81 19 0.000135894 
> GO:0048675 > axon extension 111 24 7.75532E-05 
> GO:1990138 > neuron projection extension 143 28 0.000130377 
GO:0006984 ER-nucleus signaling pathway 43 15 4.20436E-06 
GO:0017157 regulation of exocytosis 155 32 1.48047E-05 
> GO:0045921 > positive regulation of exocytosis 76 20 1.53886E-05 
> GO:1903305 > regulation of regulated secretory pathway 103 21 0.000493174 
GO:1902653 secondary alcohol biosynthetic process 51 15 4.30923E-05 
> GO:1902652 > secondary alcohol metabolic process 126 25 0.000235776 
> GO:0008203 > cholesterol metabolic process 121 24 0.000312896 
> GO:1901617 > organic hydroxy compound biosynthetic process 163 29 0.000544127 
> GO:0006695 > cholesterol biosynthetic process 50 15 3.32736E-05 
GO:0048016 inositol phosphate-mediated signaling 35 12 4.68598E-05 
> GO:0019722 > calcium-mediated signaling 146 28 0.000188408 
> GO:0070884 > regulation of calcineurin-NFAT signaling cascade 17 7 0.000519757 
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GO ID GO term Term size 
No. up-
regulated 
p-value 
B. Down-regulated genes    
GO:0006261 DNA-dependent DNA replication 135 58 1.34E-13 
GO:0010001 glial cell differentiation 175 65 1.37E-11 
> GO:0048708 > astrocyte differentiation 62 23 5.46E-05 
> GO:0048709 > oligodendrocyte differentiation 79 32 2.04E-07 
> GO:0014013 > regulation of gliogenesis 90 31 1.71E-05 
> GO:0021782 > glial cell development 78 27 5.30E-05 
> GO:0014037 > Schwann cell differentiation 32 14 0.000210591 
GO:0007062 sister chromatid cohesion 124 46 1.33E-08 
GO:0061647 histone H3-K9 modification 38 21 3.94E-08 
> GO:0051567 > histone H3-K9 methylation 28 16 9.09E-07 
> GO:0051573 > negative regulation of histone H3-K9 methylation 9 6 0.000961254 
GO:0007422 peripheral nervous system development 69 30 7.39E-08 
GO:0006271 
DNA strand elongation involved in DNA 
replication 
23 15 1.76E-07 
> GO:0006270 > DNA replication initiation 39 24 1.96E-10 
> GO:0044786 > cell cycle DNA replication 33 14 0.000311625 
GO:0007266 Rho protein signal transduction 151 50 2.16E-07 
> GO:0035023 > regulation of Rho protein signal transduction 110 38 1.86E-06 
GO:0032392 DNA geometric change 81 32 4.01E-07 
> GO:0032508 > DNA duplex unwinding 76 30 9.36E-07 
> GO:0006268 > DNA unwinding involved in DNA replication 10 8 1.54E-05 
> GO:0003678 > DNA helicase activity 50 22 3.14E-06 
GO:0022616 DNA strand elongation 30 17 4.86E-07 
GO:0007224 smoothened signaling pathway 119 41 8.03E-07 
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3A). Other terms such as ‘protein folding’, ‘mitochondrion’, ‘ER lumen’ and ‘cell redox 
homeostasis’ provide further evidence that stress responses were activated by imiquimod in 
DFT1 cells. In comparison, many down-regulated term clusters were associated with protein 
translation (Table 6-3B). Together these findings suggest that functional changes in imiquimod-
treated DFT1 cells are related to the onset of cellular stress and are controlled at both the 
transcriptional and translational level. 
6.3.3. Stress responses in imiquimod-treated DFT1 cells 
GO analysis of the DFT1 transcriptome and proteome indicates that stress responses are 
activated by imiquimod treatment. To further understand these responses, proteins up-regulated 
by imiquimod were examined for protein-protein interactions using the online proteomic 
database STRING. This analysis demonstrated regulation of distinct protein networks in 
response to imiquimod treatment (Fig. 6-2). In support of findings from GO analysis, stress-
responsive proteins involved in protein re-folding and degradation, protein transport and 
calcium homeostasis in the ER are present (calnexin (CANX), lectin mannose-binding 1 
(LMAN1), binding immunoglobulin protein (BiP or HSPA5), DnaJ homolog subfamily B 
member 11 (DNAJB11), hypoxia up-regulated protein 1 (HYOU1), calreticulin (CALR), 
protein disulphide-isomerase (P4HB), protein disulphide-isomerase A3 (PDIA3)). 
Mitochondrial proteins were also up-regulated by imiquimod, including the stress-inducible 
chaperones mitochondrial HSP70 (HSPA9), HSP10 (HSPE1), HSP60 (HSPD1) and HSP105 
(HSPH1), and the mitochondrial voltage-dependent anion channels VDAC1, VDAC2 and 
VDAC3. In addition, essential components of the mitochondrial respiratory chain, including 
critical subunits of complex I (NADH dehydrogenase ubiquinone iron-sulphur protein 3 
(NDUFS3)), complex III (ubiquinol-cytochrome c reductase, rieske iron-sulphur polypeptide 1 
(UQCRFS1)), complex IV (cytochrome c oxidase subunit 4 isoform 1 (COX4I1)) and complex 
V (ATP synthase subunits alpha and beta (ATP5A1 and ATB5B)), were up-regulated. Proteins 
associated with cellular responses to oxidative stress such as catalase (CAT) and thioredoxin 
reductase 1 (TXNRD1) were also present, as were the lysosomal proteins cathepsin B (CTSB) 
and lysosomal-associated membrane protein 1 (LAMP1). A key role of the spliceosome in post-
transcriptional regulation in response to imiquimod treatment is evident with a large network 
of proteins involved in mRNA splicing and processing. These include all three members of the 
apoptosis and splicing associated protein (ASAP) complex, which is involved in alternative 
splicing of regulators of apoptosis (apoptotic chromatin condensation inducer in the nucleus  
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Table 6-3. Representative enriched ontological terms associated with proteins regulated greater than 1.5-fold 
in imiquimod-treated DFT1 cells 
Category Term 
No. 
proteins 
Enrichment 
Score 
p-Value FDR 
(A) Up-regulated proteins         
GOTERM_MF_DIRECT poly(A) RNA binding 60 18.53 3.69E-31 5.08E-28 
GOTERM_BP_DIRECT 
mRNA spicing, via 
spliceosome 
29 16.71 7.28E-25 1.13E-21 
GOTERM_CC_DIRECT nucleoplasm 58 12.71 8.30E-12 1.09E-08 
GOTERM_CC_DIRECT spliceosomal complex 10 9.54 7.99E-08 1.05E-04 
GOTERM_BP_DIRECT protein folding 19 9.18 4.72E-06 2.95E-11 
GOTERM_CC_DIRECT 
intracellular ribonucleoprotein 
complex 
15 6.26 6.37E-12 8.36E-09 
UP_KEYWORDS mitochondrion 29 6.18 8.83E-09 1.14E-05 
GOTERM_CC_DIRECT endoplasmic reticulum lumen 17 4.74 4.90E-12 6.43E-09 
GOTERM_BP_DIRECT cell redox homeostasis 8 4.35 4.49E-06 6.98E-03 
GOTERM_BP_DIRECT 
negative regulation of mRNA 
splicing, via spliceosome 
6 3.71 8.16E-07 1.27E-03 
            
(B) Down-regulated proteins         
GOTERM_BP_DIRECT translational initiation 51 45.75 1.62E-67 2.58E-64 
GOTERM_CC_DIRECT cell-cell adherens junction 30 18.55 4.01E-21 5.31E-18 
GOTERM_BP_DIRECT 
tRNA aminoacylation for 
protein translation 
7 3.91 2.15E-06 3.43E-03 
INTERPRO actin/actin-like conserved site 5 3.81 3.13E-05 4.51E-02 
INTERPRO armadillo-type fold 16 3.57 5.43E-07 7.83E-04 
GOTERM_BP_DIRECT 
regulation of translational 
initiation 
7 3.34 1.13E-06 1.79E-03 
GOTERM_MF_DIRECT 
translation initiation factor 
activity 
7 3.23 2.83E-05 3.81E-02 
UP_KEYWORDS Neurodegeneration 11 3.08 1.32E-04 1.68E-01 
GOTERM_BP_DIRECT vesicle mediated transport 8 2.27 6.85E-04 1.09E+0 
UP_KEYWORDS ATP binding 24 2.63 7.46E-04 9.47E-01 
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Figure 6-2. Interactions of proteins up-regulated by imiquimod in DFT1 cells. C5065 DFT1 cells were treated 
with imiquimod at 60 μg/ml for 48 h. The proteome of treated and untreated cells was analysed by proteomic MS. 
Proteins significantly up-regulated greater than 1.5-fold (FDR < 0.05) were analysed for protein-protein 
interactions using the STRING database. Only interactions predicted with high confidence were included in the 
analyses, and proteins with no predicted interactions were removed. Functional groups were assigned based on 
scientific literature. 
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(ACIN1), histone deacetylase complex subunit SAP18 (SAP18) and RNA-binding protein with 
serine-rich domain (RNPS1)) Together these findings confirm that imiquimod induces stress 
responses at both the ER and mitochondria in DFT1 cells, and suggest that these molecular 
changes are associated with significant post-transcriptional gene modification. 
6.3.4. Endoplasmic reticulum stress responses 
Previous studies have determined that ER stress pathways control the activation of apoptosis in 
response to imiquimod treatment (El-Khattouti et al. 2015). As the imiquimod treated DFT1 
proteome includes molecular changes consistent with onset of ER stress, expression of the key 
ER stress genes BiP (HSPA5), XBP1 and CHOP (DDIT3) was analysed by qRT-PCR across a 
72 h course of imiquimod treatment. Samples were not available for gene expression analysis 
beyond 72 h due to substantial mRNA degradation in apoptotic cells. Analysis of these genes 
demonstrated consistent activation of ER stress responses after imiquimod treatment (Fig. 6-
3). Expression of HSPA5, a master regulator of stress responses in the ER, gradually increased 
over the first 24 h of treatment and peaked at an expression magnitude of 6-fold higher than 
RPS18 at 48 h (Fig. 6-3A). In comparison, X-box binding protein 1 (XBP1), which controls 
protein refolding and degradation of terminally misfolded proteins, was significantly up-
regulated from 16 h of treatment, and persisted at high levels for the remainder of the 72 h 
treatment period (Fig. 6-3B). Pro-apoptotic C/EBP homologous protein (CHOP, DDIT3) was 
significantly up-regulated from 24 h of treatment, and peaked at 72 h as cells were entering 
apoptosis (Fig. 6-3C). Together these results suggest that ER stress is continuously activated 
throughout 72 h of imiquimod treatment. 
To further explore the ER stress pathways activated by imiquimod in treated DFT1 cells, 
molecular changes measured by RNA-seq analysis were explored in more detail using 
Ingenuity Pathway Analysis (IPA). Analysis of canonical pathways revealed that ‘Unfolded 
protein response’ (p = 4.07 x10-09) and ‘Endoplasmic reticulum stress pathway’ (p = 1.22 x10-
06) were two of the most over-represented and significantly modulated pathways associated 
with the imiquimod-treated dataset (Appendix 3-6). Analysis of the canonical pathway 
‘Unfolded protein response’ confirmed that BiP (HSPA5) was positively regulated in response 
to treatment (Fig. 6-4). Genes involved in protein refolding alongside XBP1 were also up-
regulated, including activating transcription factor 6 (ATF6) and several HSP chaperones. 
Protein kinase R-like ER kinase (PERK, EIF2AK3), a stress-induced regulator of translation 
attenuation via eukaryotic translation initiation factor 2A (EIF2A), was up-regulated at the gene 
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level, as was the downstream transcription factor activating transcription factor 4 (ATF4). 
Increased ATF4 expression corresponded with strong up-regulation of downstream genes 
encoding both CHOP and the pro-survival protein growth arrest and DNA damage-inducible 
protein (GADD34, PPP1R15A), demonstrating a role for these pathways in the control of DFT1 
survival after imiquimod treatment. 
As HSPs can be exposed at extracellular membranes during certain forms of ER stress-mediated 
apoptosis to increase the immunogenicity of tumour cells (Obeid et al. 2007), surface 
expression of the pro-phagocytic HSP calreticulin (CALR) was assessed in imiquimod-treated 
DFT1 cells by flow cytometry. Although CALR expression was up-regulated at the mRNA and 
protein level (Appendix 3-4 and Appendix 4-2), no detectable increase in surface CALR was 
measured in pre-apoptotic DFT1 cells at any time (Fig. 6-5A-D). In comparison, digoxin, a 
known inducer of ICD in tumour cells, induced a slight shift in antibody binding after 6 h of 
treatment, suggesting that surface CALR exposure was increased (Fig. 6-5E). These findings 
suggest that although DFT1 cells are capable of releasing immunogenic HSPs in response to 
treatment with anti-cancer agents, imiquimod does not stimulate these pathways. 
6.3.5. Regulation of DFT1 tumourigenesis  
ER stress regulates a range of molecular functions through modulation of protein translation 
(Harding et al. 2000a; Harding et al. 2000b). To determine how these translational changes 
altered the DFT1 landscape after imiquimod treatment, canonical pathways predicted by IPA 
to be regulated were further analysed. Investigation of these pathways confirmed that many 
cellular processes were significantly altered in imiquimod-treated DFT1 cells (Fig. 6-6A and 
Fig. 6-6B). Many of these pathways play known roles in tumorigenic processes and were 
negatively regulated in response to imiquimod treatment. Examples of these included ‘Integrin 
Signalling’ (p = 3.39x10-10), ‘STAT3 Pathway’ (p = 1.17x10-08) and ‘Protein Kinase A 
Signalling’ (p = 1.99x10-08). The canonical pathway most significantly associated with the 
RNA-seq dataset was ‘Molecular Mechanisms of Cancer’ (p = 6.31x10-13) (Fig. 6-7). Analysis 
of this pathway in detail revealed networks by which imiquimod influenced tumour growth, 
with deregulation of cyclin signalling and strong up-regulation of cyclin-dependent kinase 
inhibitor 1 (p21-CIP1, CDKN1A), an inducer of replicative senescence. Genes encoding 
pathways that promote cell cycle, DNA repair and proliferation were also negatively regulated,
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Figure 6-4. Regulation of the unfolded protein response in DFT1 cells by imiquimod. C5065 DFT1 cells were 
treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated and untreated cells was analysed by 
RNA-seq and IPA was used to predict canonical pathways regulated by imiquimod treatment. The significantly 
regulated canonical pathway ‘Unfolded protein response’ is shown. Up-regulated genes are coloured red and 
down-regulated proteins are coloured blue. 
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Figure 6-5. Analysis of surface CALR expression in DFT1 cells after imiquimod treatment. C5065 DFT1 
cells were treated with imiquimod at 60 μg/ml for (A) 6 h, (B) 12 h, (C) 24 h or (D) 48 h, or (E) digoxin at 1 mM 
for 6 h. Surface CALR expression was measured on live non-apoptotic (PI-, annexin V-) treated cells by flow 
cytometry (red) and compared to untreated cells (grey). FMO and isotype controls were included and were negative 
for antibody binding. 
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Figure 6-6. IPA canonical pathways regulated in DFT1 cells by imiquimod treatment. C5065 DFT1 cells 
were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated and untreated cells was analysed 
by RNA-seq and IPA was used to predict canonical pathways regulated by imiquimod treatment. (A) The 15 most 
significantly regulated canonical pathways by p-value are shown. (B) The 15 pathways with the highest gene 
enrichment (ratio of represented genes compared to total number of genes in pathway) are shown. Pathways 
predicted to be up-regulated are coloured red (z-score > 0) and pathways predicted to be down-regulated are 
coloured blue (z-score < 0). Pathways with no consistent regulation are coloured grey. 
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including Ras, p53, breast cancer 1 (BRCA1), integrin, phospholipase C and Hedgehog 
signalling pathways. Other pathways, such as NFκB, p38 MAPK and neurogenic locus notch 
homolog protein 1 (NOTCH1) signalling pathways were positively regulated, and may play 
roles in the stress response to imiquimod treatment. 
In addition to regulation of pathways associated with cell cycle and tumour growth, genes 
involved in tumour immune evasion were also regulated by imiquimod. Notably, the canonical 
pathway ‘Molecular mechanisms of cancer’ demonstrated strong up-regulation of the death 
receptor FAS, which is involved in immune-mediated activation of tumour apoptosis. Genes 
associated with the MHCI processing pathway such as β2M and TAP proteins were also up-
regulated by imiquimod (Appendix 3-4). In comparison, numerous immunosuppressive 
molecules were negatively regulated at the gene level. These included genes encoding the anti-
phagocytic molecules CD200 and CD47, the angiogenic cytokine VEGFA and the immune 
checkpoint inhibitor CD276 (B7-H3) (Appendix 3-4). Other immunoregulatory molecules such 
as PDL1 exhibited low or no expression at baseline and were not up-regulated by imiquimod. 
As silencing of genes in the MHCI processing pathway is a well-established mechanism of 
DFT1 immune evasion (Siddle et al. 2013), the expression of these genes after imiquimod 
treatment was analysed in more detail by qRT-PCR and flow cytometry. For qRT-PCR analysis, 
two DFT1 cell lines were treated with imiquimod or IFNγ as a positive control. In support of 
results generated via RNA-seq, imiquimod-treated DFT1 cells demonstrated increased gene 
expression of β2M, TAP1 and TAP2, but not MHCI, in a dose-related manner (Fig. 6-8A-D). In 
comparison, IFNγ significantly increased the expression of all four genes to levels 
approximately 2-fold higher than imiquimod. To determine whether MHCI processing 
pathways are intact after imiquimod treatment, flow cytometry was performed using an anti-
β2M antibody as a marker of surface MHCI expression. Although this analysis revealed an 
increase in binding of anti-β2M to imiquimod treated cells, analysis of the isotype and FMO 
controls revealed a similar increase in fluorescence intensity (Fig. 6-9A). To determine whether 
the primary or secondary antibodies used for this analysis bind non- specifically to dying 
imiquimod-treated cells, annexin V was included in the analysis to detect phosphatidylserine, 
a marker of early apoptosis. Exclusion of annexin V+ PI+ cells from the analysis (blue 
histograms) did not change fluorescence intensity of IFN treated cells (Fig. 6-9B). In 
comparison, exclusion of annexin V+ PI+ cells from imiquimod treated cells resulted in a  
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Figure 6-7. Regulation of ‘Molecular mechanisms of cancer’ canonical pathway in DFT1 cells by 
imiquimod. C5065 DFT1 cells were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated 
and untreated cells was analysed by RNA-seq and IPA was used to predict canonical pathways regulated by 
imiquimod treatment. The canonical pathway most significantly associated with genes regulated by imiquimod 
treatment is shown. Up-regulated genes are coloured red and down-regulated proteins are coloured blue.  
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Figure 6-8. Expression MHCI processing pathway genes in DFT1 cells after imiquimod treatment. C5065 
and 1426 DFT1 cells were treated with imiquimod at 30 μg/ml, imiquimod at 60 μg/ml or IFNγ at 5 ng/ml for 24 
h. Expression of the genes (A) MHCI, (B) B2M, (C) TAP1 and (D) TAP2 was measured by qRT-PCR. Expression 
of RPS18 was measured as a reference gene. Gene expression levels relative to an untreated control are shown. 
The standard error and mean of three technical replicates are given. No cDNA and no-RT controls were included 
and did not show any amplification of product. 
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Figure 6-9. Analysis of surface β2M expression in DFT1 cells after imiquimod treatment. (A) C5065 DFT1 
cells were treated with imiquimod at 60 μg/ml for 72 h. Surface β2M expression was measured on live (PI-) 
imiquimod-treated cells by flow cytometry (orange) and compared to untreated cells (grey). FMO and isotype 
controls are also shown (green). (B) C5065 DFT1 cells were treated with IFNγ at 5 ng/ml for 24 h. Surface β2M 
expression was measured on live imiquimod-treated cells (PI-) (orange) and live non-apoptotic imiquimod-treated 
cells (PI-, annexin V-) (blue) by flow cytometry and compared to untreated cells (grey). (C) C5065 DFT1 cells 
were treated with imiquimod at 60 μg/ml for 24, 48, 72 or 96 h. Surface β2M expression was measured on live 
imiquimod-treated cells (PI-) (orange) and live non-apoptotic imiquimod-treated cells (PI-, annexin V-) (blue) by 
flow cytometry and compared to untreated cells (grey). (D) C5065 DFT1 cells were treated with camptothecin at 
2 mM for 6 h. Surface β2M expression was measured on live imiquimod-treated cells (PI-) (orange) by flow 
cytometry and compared to untreated cells (grey). 
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histogram with a fluorescence intensity similar to untreated cells (Fig. 6-9C). These results 
suggest that non-specific binding of antibody to cells in the early stages of apoptosis creates a 
low fluorescence peak, producing a result that appears positive when cells are treated with 
imiquimod. In support of this, a similar pattern of non-specific binding was observed when 
DFT1 cells were treated with camptothecin, an inducer of apoptosis (Fig. 6-9D). Together, these 
findings suggest that although imiquimod up-regulates MHCI processing genes, it does not 
reinstate MHCI expression at the cell surface prior to imiquimod-induced cell death. 
6.3.6. Suppression of cell cycle 
Previous studies in animal models have observed immune-independent suppression of tumour 
growth in response to imiquimod treatment in vivo (Almomen et al. 2016). In support of this, 
genes demonstrated to be positively regulated in DFT1 cells by imiquimod treatment in section 
6.3.5. included p21-CIP1, an inducer of replicative senescence at the G1/S phase. Consistent 
with these findings, IPA analysis of the DFT1 transcriptome revealed that the canonical 
pathway ‘Cell cycle control of chromosomal replication’ was the second most significantly 
associated pathway with imiquimod-treated DFT1 cells (p = 2.51x10-11). Analysis of this 
pathway revealed strong suppression of genes encoding necessary components of chromosomal 
replication machinery (Fig. 6-10). These included the minichromosome maintenance protein 
complex (MCM), replication protein A (RPA), DNA replication factor Cdt1 (CDT1) and DNA 
polymerase (DNA pol). Cyclin dependent kinases (CDKs), which are required for cell cycle 
progression, were also highly suppressed. In comparison, checkpoint kinase 2 (CHK2), an 
upstream negative regulator of CDK activity, was up-regulated. Together these results suggest 
that imiquimod suppresses DFT1 cell cycle at the G1/S phase. 
6.3.7. Activation of autophagic and apoptotic pathways 
The ability of imiquimod to promote tumour cell death in vitro via autophagy and apoptosis is 
well established (Huang et al. 2010; Jiang et al. 2016a). In chapter 5 it was demonstrated that 
imiquimod induces death of DFT1 cells over a 96 h period via mechanisms associated with 
down-regulation of anti-apoptotic genes and up-regulation of the pro-apoptotic gene BIM. To 
further understand the apoptotic and autophagic pathways activated in these cells, genes in the 
DFT1 transcriptome that are involved in the regulation and execution of cell death were 
visualised using a heat map. Many autophagic genes were highly expressed in both untreated 
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Figure 6-10. Regulation of ‘Cell cycle control of chromosomal replication’ canonical pathway in DFT1 cells 
by imiquimod. C5065 DFT1 cells were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated 
and untreated cells was analysed by RNA-seq and IPA was used to predict canonical pathways regulated by 
imiquimod treatment. The highly regulated pathway ‘Cell cycle control of chromosomal replication’ is shown. 
Up-regulated genes are coloured red and down-regulated proteins are coloured blue.  
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and imiquimod-treated DFT1 cells (Fig. 6-11A). Phosphatidylinositol 3-kinase catalytic 
subunit type 3 (PIK3C3, class III PI3K), the activator of autophagy, was moderately expressed 
in both the untreated and treated DFT1 transcriptome. Phosphatidylinositol 3-kinase regulatory 
subunit 4 (PIK3R4) (p150), which is required for stabilisation and correct function of the class 
III PI3K complex, was also positively regulated in response to imiquimod treatment. Other 
critical genes required for formation of the autophagosome (beclin-1 (BECN1), autophagy 
related protein 9A (ATG9A), autophagy related protein 2A (ATG2A)), autophagosome and 
lysosome fusion (Ras-related protein Rab-7a (RAB7A)) and lysosomal protein degradation 
(lysosome-associated membrane proteins 1 and 2 (LAMP1, LAMP2), cathepsin A (CTSA)) were 
either highly expressed in both untreated and treated cells, or were up-regulated in response to 
imiquimod treatment. These results suggest that autophagic pathways are active in imiquimod 
treated DFT1 cells. 
Genes associated with stress-induced apoptosis were also regulated in response to imiquimod 
treatment (Fig. 6-11B). As described in section 6.3.4., CHOP, an ER-stress inducible inhibitor 
of anti-apoptotic BCL2, was highly up-regulated at the gene level in imiquimod-treated DFT1 
cells. Other pro-apoptotic genes associated with ER and oxidative stress were also highly 
expressed after imiquimod treatment, including JNK, BCL2L11 (BIM), diablo homolog 
(DIABLO) and endonuclease G (ENDOG). Isoforms of the calcium-dependent activator of 
apoptosis calpain were differentially regulated, with the μ-calpain isoform (CAPN1) strongly 
suppressed and the m-calpain isoform (CAPN2) up-regulated. High expression of the anti-
apoptotic gene MCL1 was also observed in untreated and treated cells, while the inhibitor of 
apoptosis family members X-linked inhibitor of apoptosis protein (XIAP) and baculoviral IAP 
repeat-containing protein 2 (BIRC2) were up-regulated by imiquimod treatment. No negative 
regulation of anti-apoptotic genes was demonstrated at the 24 h time point of RNA-seq analysis, 
suggesting that these genes play a role in prolonging cell survival in response to imiquimod 
treatment at this time point.  
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Figure 6-11. Relative expression of genes associated with autophagy and apoptosis in DFT1 cells after 
imiquimod treatment. C5065 DFT1 cells were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome 
of treated and untreated cells was analysed by RNA-seq. Relative expression of genes associated with (A) 
autophagic pathways and (B) apoptotic pathways in untreated (UT) and imiquimod-treated (IM) cells was 
visualised on heat maps generated by Euclidean clustering. High gene expression is represented in red and low 
gene expression is represented in blue. 
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6.4. Discussion 
As a potent TLR7 agonist, imiquimod effectively activates anti-tumour immunity via 
stimulation of cytotoxic responses. Many studies in human cell lines have also demonstrated 
direct activation of tumour apoptosis in response to imiquimod treatment (Huang et al. 2010; 
Jiang et al. 2016a; Schon et al. 2003). A thorough understanding of these pathways in vivo has 
been impeded by an inability to distinguish the effects of imiquimod from immune-mediated 
cytotoxicity. Recently, imiquimod was demonstrated to inhibit tumour growth and progression 
in an athymic mouse xenograft model (Almomen et al. 2016). Although induction of apoptosis 
was not detected, this study provided the first evidence that imiquimod exhibits anti-tumour 
properties in vivo in the absence of a T cell response. An improved understanding of these 
effects is required to determine how they may influence tumour regression during imiquimod 
therapy. Chapter 5 of this thesis demonstrates that imiquimod exhibits direct anti-tumour effects 
in DFTD. In this chapter, these effects have been explored in more detail using RNA-seq and 
proteomic MS to understand the anti-tumour properties of imiquimod, and to assess the 
therapeutic potential of this small molecule in the Tasmanian devil. This analysis has 
demonstrated the considerable impact of imiquimod treatment on numerous cellular functions, 
including the UPR, production of ROS, cell cycle regulation, tumourigenesis, autophagy and 
apoptosis. The roles of these functions in imiquimod-induced DFT1 effects are detailed below. 
The unfolded protein response (UPR) 
Investigations in tumour cell lines have determined that imiquimod is a strong inducer of 
oxidative and ER stress responses (El-Khattouti et al. 2015; Nyberg et al. 2016; Wang et al. 
2015). The UPR is a stress inducible network of proteins that is responsible for restoration of 
ER and mitochondrial homeostasis upon activation of this cellular stress. The results from my 
thesis are consistent with stimulation of the UPR in imiquimod-treated DFT1 cells. In 
particular, imiquimod up-regulated BiP (HSPA5), which is a master regulator of the UPR in 
other species (Hetz 2012). BiP regulates the function of three key UPR pathways that were also 
positively regulated by imiquimod treatment (IRE1-XBP1, ATF6 and PERK-EIF2α-ATF4 
pathways). These pathways reduce protein damage and overload at the ER through increased 
protein folding (IRE1-XBP1 and ATF6 pathways), removal of terminally misfolded proteins 
via ER-associated degradation (ERAD) (IRE1-XBP1 and ATF6 pathways) and attenuation of 
protein translation (PERK-EIF2α-ATF4 pathway) (Harding et al. 2000b; Lee et al. 2003a; Wu 
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et al. 2007). Continued stimulation of PERK-EIF2α-ATF4 and IRE1-XBP1 pathways by 
unresolved stress can also activate CHOP and JNK1, which regulate pro and anti-apoptotic 
proteins such as BIM, BCL2 and XIAP to stimulate apoptosis (Hiramatsu et al. 2014; Lei et al. 
2003; Puthalakath et al. 2007). Chapter 5 demonstrated that DFT1 cells recovered after short 
treatment with imiquimod. These results suggest that prolonged cell stress is a key determinant 
of imiquimod-induced apoptosis in tumour cells. 
The UPR is also involved in protein maintenance at the mitochondria, where protein damage 
can have deleterious effects on metabolic processes (Zhao et al. 2002). Consistent with a role 
of the mitochondria in imiquimod-induced cell stress, mitochondrial chaperones such as HSP60 
and its co-chaperone HSP10 were up-regulated by imiquimod treatment in DFT1 cells. These 
chaperones can be activated by disruptions to oxidative phosphorylation that produce an excess 
of unassembled respiratory chain components in the mitochondria (Jovaisaite et al. 2014). Key 
subunits of respiratory chain complexes I, III, IV and V were up-regulated in DFT1 cells, 
demonstrating involvement of oxidative phosphorylation in the response to imiquimod 
treatment.  
Production of reactive oxygen species (ROS) 
Disruptions to oxidative phosphorylation result in production of ROS, which can shuttle 
between the ER and mitochondria to alter protein homeostasis and induce stress responses 
(Malhotra et al. 2007). Calcium released from the ER during this stress also deregulates 
oxidative phosphorylation to further stimulate ROS production (Cao et al. 2014). Tumour cells 
treated with imiquimod demonstrated heightened levels of intracellular ROS and ER calcium 
depletion, suggesting a similar mechanism of action (Huang et al. 2014; Nyberg et al. 2016). In 
imiquimod-treated DFT1 cells, alterations to oxidative homeostasis were evident by an increase 
in the expression of proteins associated with redox homeostasis, such as CAT and TXNRD1. 
TXNRD1 catalyses the reduction of thioredoxin, a key antioxidant protein involved in the 
stabilisation of AMP-activated protein kinase (AMPK) during oxidative stress (Shao et al. 
2014). Increased AMPK activity has been measured in imiquimod-treated tumour cells, and 
increases glycolysis in an attempt to restore homeostasis (Huang et al. 2016; Huang et al. 2014). 
 The involvement of ROS in the stress response to imiquimod could explain why tumour cells 
are more susceptible to the effects of imiquimod than healthy cells. ROS accumulates at a faster 
rate in highly metabolic tumour cells, leading to detrimental conditions that promote apoptotic 
 
192 
pathways (Schumacker 2006). Pro-survival mechanisms such as the UPR are also constitutively 
active in tumours to cope with high metabolic demands, and additional production of stressors 
including ROS is more likely to overwhelm these mechanisms and promote a pro-apoptotic 
state (Feldman et al. 2005). Stress responses have been explored as potential therapeutic targets 
in cancer, and could provide a target for treatment of DFTD tumours (Verfaillie et al. 2010). 
Indeed, pathways involved in reinstating cellular homeostasis including autophagy, the UPR 
and antioxidant signalling were positively regulated in DFT1 cells prior to cell death, 
demonstrating that these pro-survival mechanisms can be overwhelmed by stress-inducing 
drugs. These pathways may also act as drug targets in tandem with imiquimod treatment to 
improve its anti-tumour effects. Consistent with this, Huang and colleagues have shown that 
knockdown of the antioxidant regulator hypoxia-inducible factor 1α (HIF1α) increases the rate 
of apoptosis in an imiquimod-treated tumour cell line (Huang et al. 2014). 
Cell cycle regulation 
Activation of the UPR by cellular stress leads to cell cycle arrest, allowing time for damage to 
be repaired prior to cell division. This cell cycle arrest is controlled by PERK, which 
phosphorylates the translational regulator EIF2a to preferentially produce stress-related 
proteins and attenuate normal protein translation (Harding et al. 2000a; Harding et al. 2000b). 
The RNA-seq results from my thesis are consistent with activation of cell cycle arrest in 
imiquimod-treated DFT1 cells. In particular, the G1/S phase cyclin/CDK inhibitors p21CIP1 and 
CHK2 were highly up-regulated at the mRNA level in DFT1 cells. Critical components of DNA 
replication machinery including DNA polymerase, CDT1, MCM and RPA were also 
suppressed. In comparison, the G2/M cyclin/CDK inhibitor CHK1 was down-regulated in 
DFT1 cells after 24 h of imiquimod treatment. These findings indicate that imiquimod-induced 
cell cycle arrest occurs at the G1/S phase after 24 h of treatment.  
G1/S cell cycle arrest during ER stress is controlled through PERK-dependent preferential 
translation of p53 (Thomas et al. 2013). Unexpectedly, p53 was down-regulated in imiquimod-
treated DFT1 cells, opposing its role in imiquimod-induced G1/S arrest. In studies by Huang 
and colleagues, expression of p53 was up-regulated by imiquimod in tumour cells at 24 h and 
was required for more rapid onset of apoptosis when compared to p53 knockdown cells (Huang 
et al. 2016). As such, the down-regulation of p53 in imiquimod-treated DFT1 cells could 
represent a difference in the DFT1 response to imiquimod, or p53 signalling in the Tasmanian 
devil. p53-independent activation of p21CIP1 via mechanisms involving CHK2 has been 
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reported in other models and could play a role in G1/S cell cycle arrest in DFT1 cells (Aliouat-
Denis et al. 2005).  
Regulation of tumourigenesis 
Regulation of protein translation through the UPR results in attenuation of normal cellular 
function during ER stress. In imiquimod treated DFT1 cells, these changes lead to the 
suppression of pathways with known roles in tumorigenic processes such as proliferation, 
resistance to apoptosis, angiogenesis, immune evasion, migration and invasion (e.g. Rho, 
integrin, STAT3 and hedgehog signalling pathways) (Bianconi et al. 2016; Li et al. 2014; Wu 
et al. 2017a; Yu et al. 2014). With such potent effects on tumourigenesis, imiquimod may 
increase the ability of immune cells to mount anti-tumour responses in vivo. In support of this, 
the death receptor FAS was present at only low levels in the transcriptome of untreated DFT1 
cells and was up-regulated by imiquimod treatment. FAS expression is frequently suppressed 
in tumour cells to evade immune-mediated cytotoxicity and is functionally up-regulated in an 
immune-independent manner in response to other anti-cancer drugs such as cisplatin and 
doxorubicin (Micheau et al. 1997). Up-regulation of FAS expression in imiquimod-treated 
DFT1 cells could increase their susceptibility to immune-mediated cytotoxicity. In addition, 
genes encoding the anti-phagocytic molecules CD200 and CD47 and the checkpoint inhibitor 
CD267 were down-regulated in DFT1 cells by imiquimod treatment. As these molecules 
suppress immune responses, their down-regulation provides further evidence for increased 
immunogenicity of imiquimod-treated DFT1 cells. 
DFT1 cells evade immune responses via epigenetic down-regulation of genes required for the 
expression of MHCI at the tumour cell surface (Siddle et al. 2013). Following imiquimod 
treatment, genes of the MHCI processing pathway including β2M, TAP1 and TAP2 were up-
regulated in DFT1 cells. Consequently, imiquimod reverses the histone deacetylase activity 
required for the silencing of these genes. Although genes of the MHCI processing pathway 
were up-regulated in DFT1 cells, MHCI was not present at the cell surface after imiquimod 
treatment. Previous studies have demonstrated down-regulation of surface MHC1 during ER 
stress due to UPR-induced attenuation of protein translation (Granados et al. 2009). Inhibition 
of overall protein synthesis during this time produces a shortage of peptides for MHCI 
presentation, and prevents expression of the MHCI-peptide complex at the cell surface. A 
similar mechanism may explain the absence of MHCI from the DFT1 cell surface after 
imiquimod treatment. 
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Autophagic pathways 
It is well established that tumour cells treated in vitro with imiquimod undergo cell death (El-
Khattouti et al. 2015; Schon et al. 2003). In addition to apoptosis, autophagy has been 
implicated in these cell death pathways (El-Khattouti et al. 2015; Huang et al. 2010; Wang et 
al. 2015). Genes critical to autophagic process were highly expressed in imiquimod-treated 
DFT1 cells, confirming that these pathways were active. During ER stress, autophagic gene 
expression is stimulated by PERK-ATF4-mediated transcriptional activity (B'Chir et al. 2013). 
In comparison, autophagic pathways are activated via the IRE1-JNK axis (Ogata et al. 2006). 
JNK likely mediates phosphorylation of anti-apoptotic BCL2, which leads to its dissociation 
from the autophagy inducer beclin-1 (Wei et al. 2008). Although autophagic pathways have the 
potential to induce cell death, in most cases they are activated early in the stress response as a 
protective mechanism by which apoptosis is inhibited and damaged proteins and organelles are 
degraded and recycled to minimise cellular stress (Ogata et al. 2006). In support of this, key 
inhibitors of apoptosis including MCL1, XIAP and BIRC2 were highly expressed in tandem 
with autophagic genes at 24 h of imiquimod treatment.  
Apoptotic pathways 
Continued stimulation of the UPR by unresolved cellular stress leads to activation of apoptotic 
pathways. This can occur via direct UPR stimulation of CHOP (PERK-EIF2a-ATF4 pathway) 
and JNK1 (IRE1-ASK1 pathway) activity, or through stimulation of the calcium-dependent 
protein calpain via ER calcium depletion (Sano et al. 2013; Tan et al. 2006). The results from 
my thesis demonstrate up-regulation of CHOP and high constitutive expression of JNK1 in 
DFT1 cells, suggesting that both pathways could be involved in imiquimod-induced apoptosis. 
Isoforms of calpain were differentially regulated, with up-regulation of the m-calpain isoform 
(CAPN2) and down-regulation of the μ-calpain isoform (CAPN1). Although m-calpain can 
directly activate apoptosis via cleavage of caspase 12, it also interacts with the IRE1-ASK1 
pathway during ER stress to promote JNK1-mediated apoptosis (Tan et al. 2006). In a previous 
study, individual inhibition of JNK1, CHOP and calpain pathways slowed but did not prevent 
imiquimod-induced cell death (El-Khattouti et al. 2015). This finding suggests that cooperation 
of these pathways is required for activation of apoptosis after imiquimod treatment. 
Mitochondrial pro-apoptotic genes such as BIM, DIABLO and ENDOG were also positively 
regulated by imiquimod in DFT1 cells and could play roles in the activation of apoptotic 
pathways. In support of this, ENDOG is a key inducer of caspase-independent apoptosis and 
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DNA fragmentation during sustained endogenous oxidative stress (Li et al. 2001; van Loo et 
al. 2001). 
Many anti-cancer drugs activate tumour apoptosis via an ER/oxidative stress-mediated form of 
apoptosis resulting in increased cellular immunogenicity. These apoptotic pathways involve 
cell surface exposure or release of DAMPs such as CALR (a pro-phagocytic HSP), high 
mobility group box 1 (HMGB1) and ATP (Krysko et al. 2012). Although immunogenic 
DAMPs were up-regulated in imiquimod-treated DFT1 cells, surface exposure of CALR was 
not detected. This suggests that non-immunogenic forms of apoptosis were activated in DFT1 
cells by imiquimod. Conventional apoptotic pathways can promote immune tolerance, an 
outcome that could be detrimental to imiquimod-induced tumour regression (Birge et al. 2016). 
The ability of tumour cells to withstand imiquimod-induced effects for several days could 
provide a window during which a competent immune system could target and destroy the 
compromised tumour cells. Analysis of immune cell killing of tumour cells at different stages 
of imiquimod treatment is required to determine how activation of apoptotic pathways may 
influence the immune response generated against imiquimod-treated tumour cells. 
Mechanism of imiquimod action 
Although many pathways by which imiquimod influences tumour survival have been 
elucidated, little is understood as to how these mechanisms are activated. As a potent agonist 
of TLR7, it is tempting to hypothesise that imiquimod induces ER stress and apoptosis in 
tumour cells via TLR7 signalling. In support of this, Cho and colleagues reported that MyD88 
knockdown cell lines were resistant to imiquimod-induced autophagy, suggesting that TLR7 
signalling was necessary (Cho et al. 2017). In contrast, tumour cell lines lacking TLR7 were 
sensitive to imiquimod-induced autophagy and apoptosis in other studies (Huang et al. 2014; 
Nyberg et al. 2016; Wang et al. 2015). As shown in chapter 5, DFTD cells do not express TLR7 
at any stage of imiquimod treatment. One possible explanation for the dependence of 
imiquimod-induced autophagy on MyD88 is that interaction of DAMPs with alternate TLRs is 
required for activation of these pathways. In particular, TLR2 was highly expressed in 
imiquimod-treated DFT1 cells and could induce autophagy through DAMP recognition (Ma et 
al. 2012; Sanjuan et al. 2007).  
In support of a TLR7-independent mechanism of imiquimod action in tumour cells, myeloid 
cells treated with imiquimod undergo a ROS burst that is activated via direct inhibition of 
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NAD(P)H quinone dehydrogenase 2 (NQO2) and complex I of the respiratory chain (Gross et 
al. 2016). Similar direct inhibition of complex I in highly metabolic tumour cells would shift 
oxidative homeostasis, leading to the activation of the mitochondrial and ER stress responses. 
This is the case for other known inhibitors of complex I, which demonstrate anti-cancer effects 
involving substantial ROS production and ER stress (Fato et al. 2009; Goswami et al. 2016). 
Decreased oxidative respiration and ATP depletion have been measured in imiquimod-treated 
tumour cells, providing further evidence for respiratory chain inhibition (Huang et al. 2014; 
Wang et al. 2015). In contrast, key subunits of complexes I, III, IV and V were up-regulated at 
the mRNA level in imiquimod-treated DFT1 cells. These complexes may have been up-
regulated as a compensatory mechanism for ATP depletion, and could add to proteomic and 
oxidative stress at the mitochondria in a vicious stress cycle. Further studies are required to 
confirm the mechanism of imiquimod action in tumour cells. These studies are challenging in 
the Tasmanian devil due to lack of reagents that are cross-reactive with the species. 
Summary 
The potent anti-tumour effects of imiquimod in DFT1 have highlighted the potential of cellular 
stress responses in the Tasmanian devil as therapeutic targets for the deregulation of DFTD 
survival. Imiquimod was also demonstrated to be an effective immune adjuvant in the 
Tasmanian devil in chapter 3 and chapter 4 of this thesis, supporting its potential as a DFTD 
immunotherapy. Although imiquimod would be difficult to distribute among a wild Tasmanian 
devil population, the drug could be available as an intra-tumoural or topical agent for 
opportunistic treatment of captured Tasmanian devils affected by the disease. As DFTD 
tumours are allografts (Pearse et al. 2006), it is possible that only a short period of imiquimod 
treatment would be required to break immune tolerance and induce allogeneic immunity. 
Captive trials are required to determine whether imiquimod is an effective immunotherapy in 
the Tasmanian devil. 
In conclusion, in this chapter I have analysed the transcriptome and proteome of imiquimod-
treated DFT1 cells to improve the current understanding of the direct anti-tumour effects of this 
small molecule in cancer. This analysis has demonstrated that imiquimod activates significant 
oxidative and ER stress responses in DFT1 tumour cells via TLR7-independent mechanisms, 
resulting in a myriad of molecular changes including cell cycle arrest, suppression of 
tumorigenic pathways, stimulation of autophagic pathways and positive regulation of apoptosis 
(Fig. 6-12). Activation of numerous pro-survival pathways was also detected, many of which 
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could pose as potential drug targets to enhance the direct effects of imiquimod in vivo. This 
study has provided the first whole transcriptome and proteome analysis of any imiquimod-
treated tumour cell. Findings from this analysis will allow for improved mechanistic use of 
imiquimod as a cancer immunotherapy in both human and Tasmanian devil cancer trials. 
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Figure 6-12. Proposed mechanism of imiquimod action in DFTD cells. 1. Induction of cell stress (red arrows): 
Imiquimod enters the cell and disrupts oxidative phosphorylation at the mitochondria via a TLR7-independent 
mechanism. ROS is produced and shuttles between the ER and mitochondria to disrupt cellular homeostasis and 
activate the UPR. Ca2+ is depleted from the ER upon activation of ER stress, and is taken up by the mitochondria 
where it further disrupts oxidative phosphorylation in a stress-induced cycle. 2. Attenuation of protein translation 
and cell cycle arrest (Orange arrows): PERK is activated by the UPR and phosphorylates EIF2a, resulting in 
attenuation of regular protein translation and suppression of oncogenic pathways. EIF2a induces cell cycle arrest 
through preferential translation of cyclin inhibitors such as p21CIP1. 3. Activation of autophagy (Green arrows): 
PERK stimulates the expression of genes required for stress responses via ATF4, including autophagic genes. 
IRE1 is activated via the UPR and stimulates JNK via ASK1. Increased cytoplasmic Ca2+ activates m-calpain, 
which further stimulates JNK activity via ASK1. JNK phosphorylates BCL2, resulting in its dissociation from 
beclin-1, and allowing beclin-1 to induce autophagy. 4. Inhibition of apoptosis (Blue arrows): Activation of 
autophagy inhibits apoptosis, in part through the release of BCL2. BCL2 inhibits the XIAP inhibitor DIABLO and 
cytochrome C release. DFTD cells survive in this state for up to 72 h. 5. Activation of apoptosis (Purple arrows): 
Prolonged cell stress induces the expression of pro-apoptotic CHOP via the PERK-ATF4 axis. JNK activates pro-
apoptotic members of the BCL2 family such as BIM. CHOP, JNK and BIM cooperated to inhibit anti-apoptotic 
molecules including BCL2. Inhibition of BCL2 activates DIABLO, which inhibits anti-apoptotic XIAP. 
Cytochrome C is released from the mitochondria, and stimulates the caspase cascade. M-calpain supports the 
activation of this pathway through cleavage of caspase 12. ENDOG is also released from the mitochondria in 
response to prolonged oxidative stress and promotes DNA degradation in a caspase-independent manner. DFTD 
cells undergo apoptosis. 
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7.1. Final Discussion 
Devil facial tumour disease: The plight of the Tasmanian devil 
The Tasmanian devil is imperative to the Tasmanian ecosystem and is an important Tasmanian 
icon. As the top mammalian predator in Tasmania and the world’s largest surviving marsupial 
carnivore, this unique species plays an important role in the control of native herbivores and 
introduced predators in Tasmania (Hawkins et al. 2006). The Tasmanian devil is also a draw-
card for the thousands of tourists that visit Tasmania each year, and is renowned worldwide as 
the inspiration for the Warner Bros. Looney Tunes character Taz. As a result, there is both 
national and international interest in protecting the Tasmanian devil from threats, including 
disease. Since 1996, the survival of the Tasmanian devil has been threatened by DFTD, which 
now includes two genetically distinct transmissible cancers (DFT1 and DFT2) (Hawkins et al. 
2006; Pye et al. 2016b). DFT1 is usually fatal and has resulted in an estimated total population 
decline of greater than 80% across the geographical range of the Tasmanian devil (McCallum 
et al. 2009). In comparison, the potential impact of DFT2 remains unknown, as this disease 
only recently emerged in 2015 (Pye et al. 2016b). Both DFT1 and DFT2 are clonal cell lineages 
transmitted as foreign allografts through contact-dependent biting behaviour of the Tasmanian 
devil (Pearse et al. 2006; Pye et al. 2016b). In order to successfully be transmitted, DFTD cells 
must effectively evade immune detection in hosts. In DFT1, this immune evasion is achieved 
through down-regulation of cell surface MHCI, which allows the tumour cells to go unnoticed 
by the devil’s adaptive immune system (Siddle et al. 2013). The identification of strategies to 
overcome these mechanisms of immune evasion will be important to the development of 
effective therapeutic and preventative strategies against DFTD in the Tasmanian devil.  
Recent investigation has identified several wild Tasmanian devils with evidence of immune-
mediated rejection of DFT1 tumours (Pye et al. 2016a). Although most devils remain 
susceptible to DFTD, this finding suggests that the devil’s immune system is capable of 
rejecting the tumour cells and highlights the potential for stimulation of these responses by an 
effective DFTD vaccine. Previous immunisations of Tasmanian devils with DFTD cells 
produced immune responses characterised by heightened levels of DFT1-specific IgG and 
cytotoxicity (Kreiss et al. 2015; Tovar et al. 2017). Although promising, in most cases these 
responses failed to protect devils from further immune challenge with live DFTD cells. 
Improvements to these immunisations are required for DFTD vaccination to be a viable strategy 
for protection of Tasmanian devils in the wild.  
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In this thesis, I have investigated the function of TLRs in the Tasmanian devil to determine the 
potential of these receptors as adjuvant targets in a DFTD vaccine. TLRs are highly conserved 
among mammalian species and are known for their potent immune-modulatory activities 
(Roach et al. 2005). In human studies, TLR ligands have demonstrated much promise alone and 
in combination with other drugs as immunotherapies and vaccine adjuvants (Galluzzi et al. 
2012a; Vacchelli et al. 2012). As such, investigation of TLR responses in the Tasmanian devil 
will identify effective adjuvants for a DFTD vaccine. My research required preliminary 
investigation into TLR function in the Tasmanian devil immune system, as this had not 
previously been analysed in any marsupial species. As a result, the findings presented in this 
thesis also have implications for our current understanding of marsupial and evolutionary 
immunology.  
TLR signalling also plays important roles in cancer suppression and progression (Dajon et al. 
2017). As mechanisms of immune evasion have not yet been fully elucidated in DFT1 or DFT2, 
I have also explored the role of TLRs in the survival of these tumours. This research not only 
improves our understanding of DFTD survival, but also reveals potential off-target effects of 
TLR ligands in a DFTD vaccine or immunotherapy. In this discussion, these results have been 
integrated with analyses of TLR function in the devil’s immune system to recommend effective 
TLR ligands for use as adjuvants the Tasmanian devil. 
Understanding the immune system of the Tasmanian devil: The toll roads to improved 
preventative strategies in DFTD  
An understanding of the mechanisms by which immune responses are activated in the 
Tasmanian devil is required for the successful development of a DFTD vaccine. Vaccines 
usually require adjuvants, which potently stimulate the immune system to improve antigen 
recognition and response (Lee et al. 2015). In this thesis, ligands of TLRs were chosen as 
potential adjuvants in the Tasmanian devil for their highly conserved nature among mammalian 
species and their efficacy as adjuvants in human studies (Galluzzi et al. 2012a; Roach et al. 
2005). Indeed, genes encoding ten TLRs (TLRs 2, 3, 4, 5, 6, 7, 8, 9, 10, 13L) had been identified 
in the Tasmanian devil genome (Cui et al. 2015a), supporting the use of TLR ligands as 
adjuvants in a DFTD vaccine. It was necessary to analyse the proficiency of TLR signalling in 
the Tasmanian devil prior to the inclusion of TLR ligands in DFTD vaccines, as marsupials 
were typically thought of as exhibiting poor immune systems in comparison to eutherian 
mammals. This theory had been supported by experiments demonstrating that marsupial species 
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exhibited poor mixed lymphocyte reactions and weak antigenic responses to immunisation, 
suggesting that they lacked immune proficiency (Croix et al. 1989; Stone et al. 1998; Wilkinson 
et al. 1992a). Many subsequent studies have revealed that this is not the case in the Tasmanian 
devil, with functions including neutrophil phagocytosis, NK cell-like cytotoxicity, lymphocyte 
proliferation, humoral responses, allogeneic responses and immunological memory all 
demonstrating competency (Brown et al. 2011; Kreiss et al. 2011; Kreiss et al. 2008; Kreiss et 
al. 2009b). The analysis presented in this thesis further supported the hypothesis that immune 
systems are competent in the Tasmanian devil, by revealing that devil PBMNCs respond to 
stimulation with a range of conventional TLR ligands. High concentrations of TLR ligands 
were required in vitro for effective stimulation of inflammatory cytokine expression, a finding 
that could be perceived as a poor response to TLR stimulation. Despite this, Tasmanian devils 
responded to immunisation with TLR ligands and the model antigen KLH with highly 
significant increases in IgG production, confirming that the TLR response is indeed sufficient 
for effective immunity. A perceived lack of sensitivity to TLR stimulation in vitro could instead 
represent a more delayed, drawn-out response than is typically seen in other mammalian 
species. 
Analysis of immune responses activated by TLR ligands in Tasmanian devil PBMNCs 
highlighted the potential of a combination of the TLR3 ligand poly-ICLC and the TLR7 ligand 
imiquimod as DFTD vaccine adjuvants. These TLR ligands have attracted interest in human 
studies for their ability to stimulate potent anti-tumour immunity (Galluzzi et al. 2012a). In 
addition, the use of TLR ligand combinations in vaccines effectively improves immune 
activation by stimulating synergistic interactions between MyD88 dependent and TRIF 
dependent pathways (Bagchi et al. 2007; Ouyang et al. 2007). In human studies and animal 
models, the efficacy of poly-ICLC and imiquimod for activation of anti-tumour responses is 
likely attributable to the ability of these ligands to co-stimulate DCs and induce potent cellular 
immunity (Huang et al. 2009; Kreutz et al. 2015; Matsumoto et al. 2008). In support of this, 
poly-ICLC and imiquimod were the most effective ligand combination at stimulating 
production of IFN, a marker of cellular immunity, from devil PBMNCs. This suggests that 
poly-ICLC and imiquimod modulate the Tasmanian devil immune system in a manner similar 
to eutherian mammals. These findings support the notion that TLRs are highly conserved 
among mammalian species, and highlight the potential of poly-ICLC and imiquimod as 
adjuvants in a DFTD vaccine. 
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The efficacy of poly-ICLC and imiquimod for stimulation of immunisation-specific immune 
responses in Tasmanian devils was assessed in vivo using the pure and immunogenic model 
antigen KLH. This was necessary as it allowed the response generated by the TLR ligands to 
be analysed in the context of a ‘clean’ antigen with little effect on the immune response. As 
poly-ICLC and imiquimod were able to induce effective IgG responses against KLH 
immunisation, they were next trialled alongside inactivated MHCI+ DFT1 cells as DFTD 
vaccine adjuvants. A cohort of 33 insurance Tasmanian devils destined for re-wilding into an 
area of Tasmania with endemic DFT1 were chosen for these immunisations, as this allowed for 
testing of larger numbers of animals than would be possible in captivity. In addition, these 
animals would receive ‘natural’ exposure to DFT1 after immunisation, thereby generating a 
definitive assessment of protection against wild-type disease. All 33 Tasmanian devils 
immunised with poly-ICLC and imiquimod exhibited immune responses to DFTD, suggesting 
that these TLR ligands were effective adjuvants. In addition, comparison of these responses to 
a previous re-wilding trial demonstrated that poly-ICLC and imiquimod were able to induce 
more rapid and long-lasting immune response to DFTD immunisation. Importantly, this finding 
has reduced the previous DFTD immunisation protocol from four immunisations to two 
immunisations, a more feasible protocol for administration to a wild Tasmanian devil 
population. Although promising, future monitoring of these devils in the wild will be required 
to determine whether the vaccine is fully protective against DFTD. 
Effects of TLR ligands in DFTD: Potential implications for tumour survival 
Transmissible cancers are rare, with CTVT and a recently discovered transmissible leukaemia 
in soft-shell clams the only other naturally occurring transmissible cancers in animal species 
(Metzger et al. 2015; Murgia et al. 2006). The factors predisposing Tasmanian devils to these 
rare cancers are currently undefined. One of the most distinctive behaviours of Tasmanian 
devils involves physical displays of dominance between one another through fighting, 
particularly during mating season (Hamede et al. 2008). Devils frequently exhibit numerous 
bite wounds in and around their mouths as a result of this fighting. As DFTD is rarely observed 
in areas other than the face, it was hypothesised early on that it was this biting behaviour that 
allowed the transmission of DFTD cells as an allograft from one individual to another (Pearse 
et al. 2006). In humans, it is well accepted that conditions resulting in chronic and repetitive 
inflammation favour cancer. Established associations between inflammation and cancer include 
Crohn’s disease and colon cancer, alcoholism and a variety of oral, liver and gastrointestinal 
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cancers, and reflux and oesophageal cancer (Bagnardi et al. 2015; Canavan et al. 2006; Spechler 
2013). Recognised as one of Hanahan and Weinberg’s next generation hallmarks of cancer, 
tumour-promoting inflammation provides a pro-tumour microenvironment analogous to wound 
healing by inhibiting anti-tumour responses and stimulating the growth of a highly vascularised 
tumour stroma (Hanahan et al. 2011). As a result, repeated inflammation and tissue damage in 
the facial areas of the Tasmanian devil could explain the susceptibility of this species to cancer. 
Bite wounds on the face of Tasmanian devils also provide an ideal inflammatory niche into 
which cancer cells can be transferred, perhaps contributing to the transmissibility of DFTD 
tumours.  
A striking similarity between DFT1 and DFT2 cells was their expression of TLR2 and TLR6 
genes, which encode subunits of the bacterial TLR2/6 receptor in mammalian species (Takeuchi 
et al. 1999). In humans, exogenous and endogenous TLR ligands released during infection or 
tissue damage can favour tumour-promoting inflammation through stimulation of 
immunomodulatory and growth factor expression (Grimmig et al. 2016; He et al. 2007; 
Hernandez et al. 2016). In support of a role for tumour-promoting inflammation in enhancing 
DFTD survival, stimulation of TLR2/6 in DFTD cells induced the expression of 
immunosuppressive and angiogenic cytokines. In vivo, DFTD tumours are exposed to a range 
of bacteria that could stimulate this TLR2/6 signalling. In addition, TLR2/6 is a ligand of the 
endogenous DAMP versican, a proteoglycan component of the extracellular matrix produced 
by fibroblasts and involved in cell-matrix interactions during wound healing (Kim et al. 2009; 
Smith et al. 2015). As a result, DFTD cells are exposed to ligands of TLR2/6 during initial 
transmission into bite wounds and during established tumour growth. Cytokines such as IL-6 
and TGFβ that are produced through this TLR2/6 stimulation would be capable of suppressing 
NK cell responses against DFTD (Cifaldi et al. 2015; Viel et al. 2016), thereby allowing 
immune evasion in the absence of MHCI. These mechanisms would also have implications for 
tumour growth, with increased VEGFA production allowing improved angiogenesis (Carmeliet 
2005). The association between tumour-promoting inflammation, TLR2/6 signalling and 
tumour survival is deserving of thorough investigation in DFTD, and will be explored as an 
individual project as a part of future DFTD research. 
The identification of adjuvants with no stimulatory effects on DFTD growth was of importance 
to a DFTD vaccine. Although current DFTD vaccines use inactivated DFTD cells (Tovar et al. 
2017), an adjuvant with no pro-tumoural effect would be safer for use in Tasmanian devils and 
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could also be applied to a DFTD therapy. Furthermore, the use of live DFTD immunisations is 
currently being considered in the Tasmanian devil for their improved immunostimulatory 
capabilities (A. Flies, C. Ong, personal communication), and would require an adjuvant with 
no pro-tumoural properties. Ligands of TLR2/6 were excluded as adjuvants in the Tasmanian 
devil for their potential involvement in the survival of DFTD cells. Other TLR ligands exhibited 
either no effects or only anti-tumour effects in DFTD and would be safe to use as adjuvants in 
a DFTD vaccine. In particular, several TLR ligands suppressed proliferation or induced cell 
death in DFT1 and DFT2 cell lines. Although many previous studies have reported TLR-
mediated induction of programmed cell death in tumour cells (Huang et al. 2010; Liang et al. 
2010; Paone et al. 2008), a lack of expression of the respective TLRs in DFTD suggests that 
the effects were likely a result of TLR-independent toxicities. The best example of this was the 
TLR7 ligand imiquimod, which induced apoptosis in DFTD cultures despite an absence of 
TLR7 expression. Imiquimod is an FDA approved therapy against superficial basal cell 
carcinoma (Vacchelli et al. 2012), and is known to exhibit TLR7-independent anti-cancer 
effects in a range of tumour types (Almomen et al. 2016; Jiang et al. 2016a; Schon et al. 2003).  
As DFTD cells are resistant to many anti-cancer agents, investigation into the mechanisms by 
which imiquimod deregulates DFTD survival was warranted. This analysis has not only 
improved the current understanding of imiquimod action, but has generated a greater 
understanding of DFTD tumourigenesis. Importantly, this analysis demonstrated that DFTD 
survival can be overwhelmed by potentiation of constitutively active ROS and ER stress 
responses, revealing a novel mechanism by which DFTD cells could be therapeutically 
targeted. Indeed, numerous anti-cancer drugs are known to act via similar mechanisms (Farooqi 
et al. 2015). Many of these drugs represent a class of therapeutic drugs known as inducers of 
ICD, a mode of ER stress-induced apoptosis characterised by release of immunogenic DAMPs 
and increased tumour immunogenicity (Inoue et al. 2014). Although imiquimod-treated DFTD 
cells did not display characteristics of ICD, the finding that DFTD cells are sensitive to drugs 
that induce ER stress reveals ICD-inducers as potential therapeutic agents in DFTD. In support 
of future research into a role for ICD-inducing drugs in DFTD, tumour cells modified by ICD 
inducers have acted alone as cancer vaccines in mouse models, offering complete protection 
against subsequent tumour challenge (Casares et al. 2005). 
Another important finding from the analysis of imiquimod-induced effects in DFTD involved 
the suppression of tumourigenic processes. While the effects of imiquimod on stress responses 
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and apoptosis in tumour cells are known (El-Khattouti et al. 2015; Nyberg et al. 2016), no 
previous studies had demonstrated modulation of oncogenic pathways in response to 
imiquimod treatment. Molecules with established roles in immune evasion including anti-
phagocytic molecules and immune checkpoint inhibitors were also suppressed. Furthermore, 
FAS, an important death receptor for NK and CD8+ T cell cytotoxicity, was increased from 
low constitutive expression levels by imiquimod treatment. Importantly, these findings 
highlight molecules that could be involved in immune evasion in DFTD. The ability of 
imiquimod to reverse immunosuppressive gene expression patterns in DFTD also reveals the 
potential of using this small molecule to modify DFTD cells for immunisation. Although these 
changes could allow for improved targeting of DFTD by the immune system, surface MHCI, 
which would be required for T cell responses, was suppressed by imiquimod treatment. Immune 
cells are generally also tolerant of apoptotic cells, and as a result targeted methods of 
modification would likely be more advantageous to a DFTD vaccine. Imiquimod would 
perhaps be more beneficial as a DFTD therapy, as this is where the drug has demonstrated 
promise in human trials (Vacchelli et al. 2012). As a topical or intra-tumoural therapy, 
imiquimod could stimulate cellular immune responses via TLR7 signalling, and deregulate 
tumourigenesis in DFTD cells to allow for anti-tumour immunity. In vivo studies would need 
to be performed if the use of imiquimod as a therapeutic agent in DFTD was considered. 
Nonetheless, analysis of pathway regulation in response to imiquimod treatment has provided 
useful information regarding molecular targets for deregulation of DFTD survival and 
improvement of DFTD immunogenicity. This information will be of use to the development of 
new strategies for DFTD prevention and treatment in the Tasmanian devil. 
Toll-like receptor ligands: Applications for protection against DFTD  
A potent DFTD vaccine will offer the Tasmanian devil protection from DFTD. In particular, 
this vaccine will be of use to the re-population of areas that have been decimated by DFTD, as 
it will allow devils from valuable insurance populations to be protected and re-wilded. The 
overall aim of this thesis was to identify TLR ligands that could be included as adjuvants in 
DFTD vaccines to improve their efficacy. Studies of TLR function in both the Tasmanian devil 
immune system and DFTD have revealed advantages and disadvantages of the use of each TLR 
ligand in a DFTD vaccine, which are summarised in Table 7.1. The integration of these findings 
have highlighted two adjuvants in particular, poly-ICLC (TLR3) and imiquimod (TLR7), which 
in combination stimulate effective immune responses both in vitro and in vivo, and have 
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Table 7.1. Advantage and disadvantages of TLR ligands as adjuvants in the Tasmanian devil 
TLR ligand TLR Advantages  Disadvantages  
Poly-IC or 
Poly-ICLC 
TLR3 - Potent stimulator of anti-tumour immunity 
in other mammalian species 
- Signals via TRIF-dependent pathways, 
inducing synergistic responses in 
combination with MyD88-dependent TLRs 
- Stimulates potent inflammatory cytokine 
expression in devil PBMNCs 
- Combines superiorly with imiquimod to 
induce production of IFNγ, a marker of 
cellular immunity, from devil PBMNCs 
- Exhibits anti-proliferative effects in DFTD 
- Susceptible to RNase degradation 
(improved by using poly-ICLC instead of 
poly-IC) 
LPS TLR4 - Potent stimulator of anti-tumour immunity 
in other mammalian species 
- Stimulates potent inflammatory cytokine 
expression in devil PBMNCs 
- Induces production of IFNγ, a marker of 
cellular immunity, from devil PBMNCs 
- No effect on DFTD growth 
- Highly toxic in mammalian species 
(endotoxic shock) 
Flagellin TLR5 - Stimulates potent inflammatory cytokine 
expression in devil PBMNCs 
- No effect on DFTD growth 
- Ability to activate anti-tumour responses is 
not well explored in mammalian species 
FSL-1 TLR2/6 
 
- TLR2/6 signalling is frequently implicated 
in cancer survival and immune evasion 
- Induces immunosuppressive and angiogenic 
cytokine expression in DFTD cells 
Imiquimod TLR7 - Potent stimulator of anti-tumour immunity 
in other mammalian species 
- Stimulates potent inflammatory cytokine 
expression in devil PBMNCs in combination 
with poly-ICLC 
- Combines superiorly with poly-ICLC to 
induce production of IFNγ, a marker of 
cellular immunity, from devil PBMNCs 
- Induces stress responses and apoptosis in 
DFTD cells 
- Inhibits oncogenic pathways and molecules 
in DFTD cells 
- Down-regulates MHCI expression in live 
DFTD cells 
- Apoptosis can be immunosuppressive 
CpG-1585 
or CpG-
2395 
TLR9 - Potent stimulator of anti-tumour immunity 
in other mammalian species 
- Combines with poly-ICLC to induce 
production of IFNγ, a marker of cellular 
immunity, from devil PBMNCs 
- Exhibits toxic effects in DFTD cells 
- As an individual agent, induces weak 
Inflammatory cytokine expression from devil 
PBMNCs 
Profilin TLR13L? - Stimulates potent activation of 
inflammatory cytokine expression in devil 
PBMNCs 
- No effect on DFTD growth 
- Ability to activate anti-tumour responses is 
not well explored in mammalian species 
- Mechanism of immune stimulation in devil 
cells via TLR13L is not proven 
- TLR13L is highly expressed in DFT1 and 
DFT2 cells and may also play an undefined 
role in tumour survival 
 
209 
no pro-tumour effects in DFT1 or DFT2. Two potential pitfalls of the use of imiquimod as an 
adjuvant in a DFTD vaccine involved the ability of this ligand to down-regulate MHCI in IFN-
treated DFT1 cells and to induce apoptotic pathways, which can generate immune tolerance. 
Down-regulation of MHCI by imiquimod is of particular concern, as MHCI is a key 
immunogenic target during the activation of adaptive immune responses. MHCI suppression 
and apoptosis occur subsequently to the onset of ER stress in imiquimod-treated DFTD cells. 
ER stress responses inhibit normal protein translation to prevent protein overload, resulting in 
a reduced supply of MHCI-associated peptides (Granados et al. 2009). In return, MHCI 
processing is reduced, resulting in lower surface expression of MHCI-peptide complexes. 
While the effects of imiquimod on MHCI expression would not be applicable to an inactivated 
DFTD vaccine, they may need to be taken into account if imiquimod were to be used in a 
vaccine with live cells. Imiquimod could be combined with live cells immediately before 
immunisation to avoid modulation of MHCI expression in these vaccines. 
The use of poly-ICLC and imiquimod in DFTD vaccines has reduced the current immunisation 
protocol from four to two immunisations. This has improved the feasibility of immunising 
Tasmanian devils, which are usually held in captivity over the course of the immunisation 
schedule. As holding large numbers of devils in captivity for immunisation is expensive, 
strategies are being investigated to overcome the need for this holding. One strategy is to 
develop a one-shot DFTD vaccine that can promote a protective response without the need for 
a follow-up immunisation. It is likely that DFTD immunisations will need to be further 
improved for such a strategy to be feasible. Experiments using KLH as a model antigen in the 
Tasmanian devil demonstrated that poly-ICLC and imiquimod act as highly effective adjuvants 
in the presence of immunogenic antigen. As a result, enhancement of DFTD immunogenicity 
could provide the necessary improvement for a one-shot immunisation to be successful. Indeed, 
it is known that DFT1 cells modified with IFN to express MHCI also up-regulate PDL1, a 
potent immune checkpoint inhibitor that promotes T cell exhaustion upon recognition by the 
immune system. Blockade of PDL1 and other inhibitory molecules using monoclonal 
antibodies could improve the immune response generated by TLR ligands upon DFTD 
vaccination, therefore increasing the likelihood that a one-shot vaccine could be successful. 
Other strategies that are being considered for DFTD immunisation include the use of DFTD 
membrane vesicles or immunogenic tumour peptides. As vaccine antigens, vesicles and 
peptides are more readily taken up by APCs, and can be modified as appropriate to improve 
immune stimulation. Future trials will be required to determine whether any of these strategies 
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will be more effective at inducing DFTD-specific immune responses in combination with poly-
ICLC and imiquimod. 
Although the development of a prophylactic DFTD vaccine is a priority for the protection of 
the Tasmanian devil, investigation into potential DFTD therapies is also warranted. 
Immunisation of Tasmanian devils produced specific immune responses against DFTD cells in 
this study, but it is not yet known whether these responses will be protective. In contrast, DFTD 
immunotherapies have induced tumour regression in several Tasmanian devils (Tovar et al. 
2017). Although devils needed to be previously immunised for this treatment to be successful, 
these findings revealed the potential of immunotherapy for treatment of Tasmanian devils with 
DFTD. In human studies TLR ligands have been used as stand-alone and combinatorial 
immunotherapies for their ability to shift the immune balance towards an anti-tumour 
inflammatory response. Poly-ICLC and imiquimod have demonstrated proficiency at activating 
these responses as intra-tumoural or topical agents, and imiquimod is approved by the FDA for 
the treatment of superficial basal cell carcinoma in amounts that surpass the concentrations 
required to induce DFTD apoptosis in our study (Salazar et al. 2014; Vacchelli et al. 2012). If 
topical or intra-tumoural poly-ICLC or imiquimod could break immune tolerance against the 
DFTD allograft with limited treatments, these ligands could be effective therapeutic agents in 
DFTD. This immunotherapy could be distributed among diseased devils captured during 
routine trapping expeditions, and could aid the protection of wild populations until a successful 
and feasible DFTD vaccine is developed. Trials in diseased Tasmanian devils are required to 
determine whether poly-ICLC or imiquimod are effective and safe therapeutic agents in DFTD. 
The Tasmanian devil and TLRs: a model for human cancer research  
Although the use of TLR ligands as adjuvants and therapeutic agents in humans has been 
thoroughly investigated, today only three TLR ligands are approved by the FDA and other 
national regulatory organisations for human application (Vacchelli et al. 2012). While two of 
these ligands are approved as immunotherapeutic agents in cancer (BCG – non-invasive bladder 
cancer, imiquimod – superficial basal cell carcinoma), only the TLR4 ligand MPL is approved 
as a vaccine adjuvant (approved in 2009). Concerns of vaccine safety in recent years have 
hampered progress in the development of new adjuvants. Although rare, many individuals fear 
adverse events that can develop in response to immunisation (Salmon et al. 2015). As such, 
regulatory organisations such as the FDA are under much pressure to only approve adjuvants 
that have been passed through considerable scrutiny and are deemed safe. MPL was the first 
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vaccine adjuvant to gain FDA approval since the implementation of aluminium salts in the 
1930s. Aluminium salts are taken up by DCs and stimulate production of DAMPs such as uric 
acid, which go on to activate immune responses via mechanisms including TLR signalling 
(Crisan et al. 2016; Kool et al. 2008). While aluminium salts have been effectively used as 
vaccine adjuvants for many decades, it is debatable as to whether this crude adjuvant would 
have ever been used if today’s strict criteria had applied when these vaccines were developed. 
As a result, the use of more tested adjuvants in new vaccines could increase their safety, thereby 
improving public confidence in immunisation.  
Although the immunostimulatory capabilities of TLRs are well defined, there has been some 
question of the efficacy of TLR ligands as adjuvants. While often not effective alone, it is now 
becoming more widely accepted that in combination with other TLR ligands and adjuvants, 
TLR ligands can promote highly robust and effective immune responses (Bayyurt et al. 2017; 
Hu et al. 2016; McCluskie et al. 2013). Further human clinical trials are required to demonstrate 
the full potential of TLR ligands as vaccine adjuvants, however studies using animal models 
can provide robust indications of adjuvant safety and efficacy. The Tasmanian devil prevents a 
unique opportunity for studying adjuvant efficiency in an animal model. Unlike most animal 
models, Tasmanian devils represent an outbred population, meaning they respond with similar 
variation to a human population. In addition, DFTD is a naturally occurring disease in an 
immune-competent host, meaning that responses to immunisation closely reflect those that 
would be seen in human disease. The results generated from immunisation trials demonstrate 
that poly-ICLC and imiquimod in combination produce highly effective and long-lived antigen-
specific responses in the Tasmanian devil. As a result, this thesis supports the use of these 
ligands in combination as human vaccine adjuvants. There were also no adverse events or 
abnormal behaviour observed after immunisation of Tasmanian devils with these ligands, 
providing evidence for the safety of poly-ICLC and imiquimod in combination as adjuvants. 
Results generated through the analysis of the effects of imiquimod in DFTD cells were also 
valuable to human cancer research. Imiquimod has been approved as a topical immunotherapy 
for the treatment of superficial basal cell carcinoma in humans since 2004 (Vacchelli et al. 
2012), but the mechanisms by which this small molecule induces tumour regression have not 
been fully elucidated. It is well known that imiquimod stimulates immune infiltration and anti-
tumour cytotoxicity via stimulation of TLR7 signalling (Hemmi et al. 2002; Huang et al. 2009). 
It has also been known for some time that imiquimod directly induces apoptosis in tumour cells 
(Schon et al. 2003), but a role for these effects in tumour regression was not defined. By 
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providing the first whole transcriptome and proteome analysis of any imiquimod treated tumour 
cell line, this study has identified molecular changes in imiquimod-treated tumour cells that 
likely allow for improved targeting by the immune system during imiquimod therapy. This 
analysis also highlights a role for imiquimod in altering oncogenic pathways and 
immunosuppressive molecules for the first time, and as such these findings could have 
implications for the use of imiquimod across a variety of therapeutic applications. In humans, 
combination immunotherapies are becoming more popular due to increased efficacy and 
reduced chances of drug resistance in the presence of multiple drugs (Ott et al. 2017). As 
identification of potential drug combinations is based on the mechanisms by which the drugs 
induce tumour regression, thorough analyses of drug interactions is of particular importance. 
The results presented in this thesis have led to a greater mechanistic understanding of 
imiquimod action, which may in turn allow this drug to be applied in new ways to human cancer 
treatment. 
7.2. Conclusions 
DFTD has threatened the survival of the Tasmanian devil for more than twenty years. With 
declines in Tasmanian devil numbers of greater than 80% and a second transmissible cancer 
now threatening the survival of some populations (McCallum et al. 2009; Pye et al. 2016b), 
protection of the Tasmanian devils from these cancers has never been more important. A 
prophylactic vaccine remains one of the most feasible strategies for protection of the Tasmanian 
devil. This vaccine could be distributed among insurance devils prior to their release into the 
wild, and wild devils during routine trapping expeditions. Success in the immunisation of 
Tasmanian devils with DFTD had been limited prior to this project, and strategies were required 
to improve the immune responses generated by these vaccinations. TLRs were selected as 
potential immunostimulatory targets in the Tasmanian devil immune system for their high 
evolutionary conservation and efficacy for immune activation across mammalian species 
(Galluzzi et al. 2012a; Roach et al. 2005).  
At the start of this thesis I hypothesised that TLRs are functional in the Tasmanian devil and 
that these can be stimulated by conventional TLR ligands to enhance DFTD vaccinations. The 
results presented in this thesis have proved this hypothesis by demonstrating that the Tasmanian 
devil expresses a wide repertoire of functional TLRs. I have also demonstrated efficacy of the 
TLR3 ligand poly-ICLC and the TLR7 ligand imiquimod in combination as 
immunostimulatory agents in vitro. Furthermore, these ligands in combination act as highly 
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effective vaccine adjuvants in the Tasmanian devil, both in combination with the model antigen 
KLH and inactivated DFTD cells. Inclusion of poly-ICLC and imiquimod in DFTD vaccines 
has reduced the current immunisation protocol from four to two immunisations by stimulating 
more rapid and long-lived anti-DFTD immunity. Poly-ICLC and imiquimod will be used in 
future DFTD vaccines to allow for more feasible and effective protection of Tasmanian devils 
from DFTD.  
Through analysis of the effects of TLR ligands in DFTD, I have advanced the field of immune 
escape in DFTD by highlighting a novel immune evasion strategy. The observation that DFTD 
cells respond to TLR2/6 stimulation by increasing expression of suppressive and angiogenic 
cytokines implicates tumour-promoting inflammation in the survival of DFTD for the first time, 
improving the current understanding DFTD tumourigenesis. This finding warrants thorough 
investigation of the role of the tumour microenvironment in DFTD, a project that would likely 
reveal new strategies for DFTD therapy and prevention in the Tasmanian devil. In addition, 
studies into the effects of imiquimod in DFTD have highlighted stress responses as potential 
targets for deregulation of DFTD survival. This analysis also revealed a role for imiquimod in 
regulating oncogenic pathways in DFTD cells, suggesting that this small molecule could have 
therapeutic potential in the Tasmanian devil. This improved understanding of the mechanisms 
by which imiquimod directly targets tumour cells not only has implications for our 
understanding of DFTD, but can be applied to human research for improved mechanistic use 
of imiquimod in cancer therapy. 
In summary, this thesis has provided the first thorough analysis of TLR function in any 
marsupial species. Importantly, this analysis will allow for rational selection of adjuvants for 
application in the Tasmanian devil, and also supports the use of TLR ligands as adjuvants in 
human cancer research. Future DFTD vaccines will include the TLR3 ligand poly-ICLC and 
the TLR7 ligand imiquimod as adjuvants to ensure rapid and robust stimulation of long-lived 
antigen-specific immunity in the Tasmanian devil. 
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Appendix 1. Tasmanian devils  
Tasmanian devils sampled for experiments presented in this thesis 
Tasmanian Devil Age* (years) Sex Experiment 
Alex 6 M Cytokine expression stimulations (Fig. 3-2)_ 
Maydim 7 F Cytokine expression stimulations (Fig. 3-2)_ 
TD423 Adult+ F Cytokine expression stimulations (Fig. 3-2)_ 
Finn 4 M Cytokine expression stimulations (Fig. 3-2 and 3-4) 
expression stimulations (Fig. 3-4)_ 
Melaleuca 5 M MNC population separations (Fig. 3-3) 
Morey 8 M MNC population separations (Fig. 3-3) 
Angelica 5 F Cytokine expression stimulations (Fig. 3-4)_ 
TD500 4 M Cytokine expression stimulations (Fig. 3-4)_ 
Froddo Adult+ M Cytokine expression stimulations (Fig. 3-6)_ 
Prince 4 M Cytokine expression stimulations (Fig. 3-6)_ 
Ziggy 5 M Cytokine expression stimulations (Fig. 3-6)_ 
Blue-Jean 5 M Cytokine expression stimulations (Fig. 3-6)_ 
Merrick 4 M Cytokine expression stimulations (Fig. 3-6)_ 
Stinky 8 F Cytokine expression stimulations (Fig. 3-6)_ 
Tip 7 M Cytokine expression stimulations (Fig. 3-6)_ 
Melanie 7 F IFNγ stimulations (Fig. 3-9) 
Aurora 3 M IFNγ stimulations (Fig. 3-9), KLH Immunisations 
Joffrey 3 M IFNγ stimulations (Fig. 3-9), KLH Immunisations 
Peaches 5 F KLH Immunisations 
Kakapo 3 M KLH Immunisations 
Gwen 6 F KLH Immunisations 
Adam 3 M KLH Immunisations 
November Rain 6 F KLH Immunisations 
Sparrow 3 M KLH Immunisations 
Blake 2 M Stony Head Immunisations 
Podrick 2 M Stony Head Immunisations 
 
III 
Akaroa 3 M Stony Head Immunisations 
Khal 3 M Stony Head Immunisations 
Myrtle 3 M Stony Head Immunisations 
Tarkine 3 M Stony Head Immunisations 
Weka 3 M Stony Head Immunisations 
Grumble 3 F Stony Head Immunisations 
Moretti 4 F Stony Head Immunisations 
Zoe 4 F Stony Head Immunisations 
Penelope Stroman  3 F Stony Head Immunisations 
Melisandre 3 F Stony Head Immunisations 
Prudence Stroman 3 F Stony Head Immunisations 
Brienne 4 F Stony Head Immunisations 
Flash Gordon 1 M Stony Head Immunisations 
Ventoux 2 F Stony Head Immunisations 
Frosty 2 M Stony Head Immunisations 
Geysir 2 M Stony Head Immunisations 
Machin 2 M Stony Head Immunisations 
Moffett 2 M Stony Head Immunisations 
Rotorua 2 M Stony Head Immunisations 
Taranaki 2 M Stony Head Immunisations 
Ararat 2 M Stony Head Immunisations 
Askja 2 M Stony Head Immunisations 
Bosavi 2 M Stony Head Immunisations 
Fraser 2 M Stony Head Immunisations 
Savo 2 M Stony Head Immunisations 
Guernsey 3 F Stony Head Immunisations 
Macca 3 M Stony Head Immunisations 
Rapa Nui 3 M Stony Head Immunisations 
Nutella 4 F Stony Head Immunisations 
Rueben 3 M Stony Head Immunisations 
 
IV 
Mindi 3 F Stony Head Immunisations 
Beau 4 M Narawntapu Immunisations 
Boots 4 M Narawntapu Immunisations 
Bruce 4 M Narawntapu Immunisations 
Cory 4 M Narawntapu Immunisations 
Floyd 4 M Narawntapu Immunisations 
Jackson 4 M Narawntapu Immunisations 
Monty 4 M Narawntapu Immunisations 
Jorah 1 M Narawntapu Immunisations 
Gendry 1 M Narawntapu Immunisations 
Andrea 4 F Narawntapu Immunisations 
Cindy 5 F Narawntapu Immunisations 
Heidi 3 F Narawntapu Immunisations 
Irry 2 F Narawntapu Immunisations 
Isla 4 F Narawntapu Immunisations 
Janice 4 F Narawntapu Immunisations 
Mystique 3 F Narawntapu Immunisations 
*Age at time of experimentation; +Age unknown; M, male; F, female.  
  
 
V
 
A
p
p
en
d
ix
 2
. M
a
n
u
fa
ctu
rer’s p
ro
to
co
ls 
A
p
o
-O
N
E
 H
o
m
o
g
en
eo
u
s C
a
sp
a
se 3
/7
 A
ssa
y
 (P
r
o
m
eg
a
, M
a
d
iso
n
, U
S
A
): 
E
x
cerp
t fro
m
 m
an
u
factu
rer’s p
ro
to
co
l 
          
3. Reagent Preparation
P l ea s e  r ea d  th e  p r o to c o l  th o r o u g h l y  b e f o r e  b eg i n n i n g .  D i r ec t i o n s  a r e  g i v en  f o r
p e r fo r m i n g  th e  a s s a y  i n  a  to ta l  v o l u m e  o f  2 0 0μl  u s i n g  9 6 -w e l l  p l a te s  a n d  a
f l u o r es c en c e  p l a te  r ea d er .  H o w ev er ,  th e  a s s a y  c a n  b e  ea s i l y  a d a p ted  to  d i f f e r en t
v o l u m es  p r o v i d i n g  th a t th e  1 :1  r a t i o  o f  H o m o g en eo u s  C a s p a s e-3 / 7  R ea g en t
v o l u m e  to  s a m p l e  v o l u m e i s  p r es er v ed  ( e .g . ,  2 5μl  o f  s a m p l e  +  2 5μl  A p o -O N E ®
C a s p a s e-3 / 7  R ea g en t) .  T h i s  a s s a y  i s  ea s i l y  a d a p ta b l e  to  a  3 8 4 -w e l l  f o r m a t .
Materials to be Supplied by the User
• 96- o r  384-w el l  op a q u e w h i te o r  b l a ck  p l a te su i ta b le fo r  cel l  cu l tu r e  ( N a lg e  
N u n c I n ter n a tio n a l  h a s  F lu o r o N u n c™  P r od u cts  fo r  su ch  a p p l i ca tion s )
• f l u o r escen t p l a te r ea d er  (e .g . ,  L a b S y s tem s  C a t.#  9502887 o r  eq u i v a l en t)
• s in g le  a n d  m u l ti ch a n n el  p ip etto r s
• p la te sh a k er
T h a w  th e 1 0 0 X  S u b s tr a te  a n d  B u f f e r  to  r o o m  tem p er a tu r e .  M i x  b y  i n v e r s i o n  o r
v o r tex i n g .  D i l u te  th e  S u b s tr a te  1 :1 0 0  w i th  th e  B u f f e r  to  o b ta i n  th e  d es i r ed
v o l u m e  o f  A p o -O N E ® C a s p a s e-3 / 7  R ea g en t ( e .g . ,  1 0 0μl  o f  1 0 0 X  S u b s t r a te  to
9 ,9 0 0μl  B u f f e r ) .  S to r e  th e  A p o -O N E ® H o m o g en eo u s  C a s p a s e-3 / 7  R ea g en t ,
p r o tec ted  f r o m  l i g h t ,  a t  4 °C  f o r  u p  to  2 4  h o u r s  u n t i l  u s e .  D o  n o t  f r eez e  a n d  s to r e
th e A p o -O N E ® C a s p a s e-3 / 7  R ea g en t .  A v o i d  m u l t i p l e  f r eez e-th a w  c y c l es  o f  th e
S u b s tr a te  a n d  B u f f e r .
4. Detection of Caspase-3/7 Activity in Cell Culture
4.A. Assay Conditions
P r ep a r e  th e  f o l l o w i n g  r e a c t i o n s  to  d e te c t  c a s p a s e -3 / 7  a c t i v i ty  i n  c e l l  c u l tu r e :
• Blank. A p o -O N E ® C a sp a s e-3/ 7  R ea g en t +  c el l  c u l tu r e  m ed iu m  w i th o u t c e l l s .
• Negative Control. A p o -O N E ® C a s p a se-3/ 7  R ea g en t +  v eh i c l e-tr ea ted  ce l l
cu l tu r e .
• Assay. A p o -O N E ® C a sp a s e-3/ 7  R ea g en t +  tr ea ted  c el l  cu l tu r e .
T h e  b l a n k  c o n tr o l  i s  u s ed  a s  a  m ea s u r e  o f  b a c k g r o u n d  f l u o r es c e n c e  a s s o c i a te d
w i th  th e  c u l tu r e  s y s tem  a n d  A p o -O N E ® C a s p a s e -3 / 7  R ea g e n t a n d  s h o u l d  b e
s u b t r a c te d  f r o m  e x p e r i m en ta l  v a l u es .  N e g a t i v e  c o n t r o l  r ea c t i o n s  a r e  u s e f u l  f o r
d e te r m i n i n g  th e  b a s a l  c a s p a s e  a c t i v i ty  o f  th e  c e l l  c u l tu r e  s y s tem .  A n  e x a m p l e
o f  th e  a n a l y s i s  o f  tr ea ted  a n d / o r  i n d u c ed  c e l l s  i s  g i v e n  i n  S e c t i o n  6 .  “ V eh i c l e ”
r e f e r s  to  th e  s o l v en t  u s ed  to  d i s s o l v e  th e  d r u g  o r  p r o te i n  o f  i n te r e s t .
Notes:
1 . P r i o r  to  s ta r t i n g  th e  a s s a y ,  p r ep a r e  th e  A p o -O N E ® C a s p a s e -3 / 7  R ea g en t  
a s  d es c r i b e d  i n  S ec t i o n  3 ,  a n d  m i x  th o r o u g h l y .
2 . F o r  b es t  r e s u l ts ,  em p i r i c a l  d e te r m i n a t i o n  o f  th e  o p t i m a l  c e l l  n u m b er ,
a p o p to s i s  i n d u c t i o n  t r ea tm en t a n d  i n c u b a t i o n  p e r i o d  f o r  th e  c e l l  c u l tu r e
s y s tem  m a y  b e  n ec e s s a r y .
Promega Corporation · 2 8 0 0  W o o d s  H o l l o w  R o a d  · M a d i s o n ,  W I  5 3 7 1 1 -5 3 9 9  U S A  
T o l l  F r e e  i n  U S A  8 0 0 -3 5 6 -9 5 2 6 · P h o n e  6 0 8 -2 7 4 -4 3 3 0  · F a x  6 0 8 -2 7 7 -2 5 1 6  · www.promega.com
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3. Use identical cell numbers and volumes for the assay and the negative
control samples.
4. Do not mix Apo-ONE® Caspase-3/7 Reagent and samples by manual
pipetting. Mixing in this manner is unnecessary and may create bubbles
that interfere with fluorescence readings or cross-contaminate the samples.
Gentle mixing may be performed using a plate shaker.
5. Total incubation time for the assay depends upon the amount of 
caspase- 3/7 present in the sample. Minimal apoptotic induction and 
low cell number may require an extended incubation period. Maximum
recommended incubation time is 18 hours.
6. The Apo-ONE® Caspase-3/7 Reagent was formulated to mediate cellular
lysis and support optimal caspase-3/7 activity. In rare instances, the
reagent does not affect complete lysis of cultured cells. In such cases, lysis
is enhanced by a freeze-thaw cycle. For best results, freeze at –70°C, then
thaw at room temperature. After equilibration, mix to homogeneity and
incubate until measurable fluorescence is achieved.
4.B. Standard Assay (96-well, 200μl final reaction volume)
1. Add 100μl of Apo-ONE® Caspase-3/7 Reagent to each well of a white or
black 96-well plate containing 100μl of blank, control or cells in culture. If
reusing tips, be careful not to touch pipette tips to the wells containing
samples to avoid cross-contamination. Perform blank and negative controls
in triplicate. Cover the plate with a plate sealer if incubating for extended
periods (>4 hours).
Note: To perform this assay in a 384-well plate, simply maintain the 1:1
volume ratio of Apo-ONE® Caspase-3/7 Reagent to sample. Adjust the
total reaction volume such that the bottom of the well is covered but liquid 
does not splash out of the well during the assay.
2. Gently mix contents of wells using a plate shaker at 300–500rpm from 
30 seconds up to read time. Incubate at room temperature for 30 minutes 
to 18 hours depending upon expected level of apoptosis (and thus 
caspase-3/7 activity) in the cells analyzed. The optimal incubation 
period should be determined empirically.
3. Measure the fluorescence of each well. The optimal excitation wavelength
for detection is 499nm with emission maximum at a wavelength of 521nm
(10). This protocol was developed using a spectrofluorometer configured to
detect caspase-3/7 activity at an excitation wavelength range of 485 ± 20nm
and an emission wavelength range of 530 ± 25nm. Fluorescence
measurements should be determined empirically and should be 
completed within 18 hours.
Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA 
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Printed in USA. Part# TB295
Revised 5/09 Page 9
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4.A. First-Strand cDNA Synthesis (continued)
4. Add 15µ l aliquots of the reverse transcription reaction mix to each reaction
tube on ice. Be careful to prevent cross-contamination. Add 5µ l of RNA and
primer mix to each reaction for a final reaction volume of 20µ l per tube. If
there is a concern about evaporation in subsequent steps, overlay the
reaction with a drop of nuclease-free mineral oil to prevent evaporation
and condensation.
5. Anneal: Place the tubes in a controlled-temperature heat block equilibrated
at 25°C, and incubate for 5 minutes.
6. Extend: Incubate the tubes in a controlled-temperature heat block at 42°C
for up to one hour. The extension temperature may be optimized between
37°C and 55°C.
The reactions may be stopped at this point for cDNA analysis as outlined in
Section 4.D. The reactions may be maintained frozen for long-term storage.
7. Inactivate Reverse Transcriptase: If the experimental goal is to proceed
with PCR, the reverse transcriptase must be thermally inactivated prior to
amplification. Incubate the reaction tubes in a controlled-temperature heat
block at 70°C for 15 minutes.
4.B. cDNA Quantification Using qPCR
cDNA synthesized using GoScript™ Reverse Transcriptase can be amplified
and quantified using the GoTaq® qPCR Master Mix or Plexor® qPCR Systems.
cDNA samples may be used directly or diluted prior to amplification. As a
starting point for dilution, dilute sample and reference standard cDNA
reactions 1:10, then add 5µ l of these diluted reactions to the reaction mix. For
additional information, refer to the GoTaq® qPCR Master Mix Technical Manual,
#TM318, or the Plexor® qPCR System Technical Manual, #TM262.
The synthesized cDNA may be added directly to PCR amplifications. Unlike
other first-strand systems, there will be no inhibitory effects encountered when
up to 20% of the reaction is added to a PCR amplification as long as the final
MgCl2 concentration is kept at an optimal level. The robust reaction conditions
of the GoScript™ Reverse Transcription System make many flexible
applications possible. The method outlined in Section 4.C describes two-step
RT-PCR using either 1µ l or 5µ l of the reverse transcription reaction in a 25µ l
PCR. The volumes of PCR components assembled take into account the
carryover of buffer, magnesium and dNTP from the reverse transcription
reaction to achieve the final concentration of each component.
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Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Part# TM316 Printed in USA.
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4.A. First-Strand cDNA Synthesis
The following procedure is designed to convert up to 5µg of total RNA or up
to 500ng of poly(A) RNA into first-strand cDNA.
1. Mix and briefly centrifuge each component before use. Combine the
following:
Component
Experimental RNA (up to 5µg/reaction) Xµ l
Primer [Oligo(dT)15 (0.5µg/reaction) and/or 
Random Primer (0.5µg/reaction) or 
gene-specific primer (10–20pmol/reaction)] Xµ l
Nuclease-Free Water Xµ l
Final volume 5µ l
2. Close each tube of RNA tightly. Place tubes into a preheated 70°C heat
block for 5 minutes. Immediately chill in ice-water for at least 5 minutes.
Centrifuge each tube for 10 seconds in a microcentrifuge to collect the
condensate and maintain the original volume. Keep the tubes closed and
on ice until the reverse transcription reaction mix is added.
3. Prepare the reverse transcription reaction mix by combining the following
components of the GoScript™ Reverse Transcription System in a sterile
microcentrifuge tube on ice. Prepare sufficient mix to allow 15µ l for each
cDNA synthesis reaction to be performed. Determine the volumes needed
for each component, and combine them in the order listed. Vortex gently to
mix, and keep on ice prior to dispensing into the reaction tubes.
Component Amount
Nuclease-Free Water (to a final volume of 15µ l) Xµ l
GoScript™ 5X Reaction Buffer 4.0µ l
MgCl2 (final concentration 1.5–5.0mM)1 1.2–6.4µ l
PCR Nucleotide Mix (final concentration 0.5mM each dNTP)2 1.0µ l
Recombinant RNasin® Ribonuclease Inhibitor (optional) 20u
GoScript™ Reverse Transcriptase 1.0µ l
Final volume 15.0µ l
1Mg2+ concentration should be optimized. We recommend 1.5–5.0mM. (MgCl2 is
provided at 25mM.)
2If isotopic or nonisotopic incorporation is desired to monitor this first-strand
cDNA synthesis, α[32P]-dCTP or other modified nucleotides may be
supplemented in the PCR Nucleotide Mix. See Section 4.D for analysis
suggestions.
TM316.0916_EIVD_TM.qxd  9/12/2016  1:47 PM  Page 7
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XIV 
Appendix 3. DFTD RNA sequencing raw data and analysis 
Appendix 3-1. RNA sequencing read counts aligned by subread and featureCounts 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis.  
 
Appendix 3-2. R script used for RNA sequencing analysis 
#Data normalisation and differential expression analysis  
 
library(limma) 
library(edgeR) 
library(EDASeq) 
library(GenomicFeatures) 
 
 
# Load gene symbols 
gene.symbols <- read.delim("gene_symbols.txt", as.is=TRUE) 
rownames(gene.symbols) <- gene.symbols$gene_id 
 
classIs <- read.delim("devil_classIs.txt", as.is=TRUE) 
classIs <- subset(classIs, gene_id!="None") 
rownames(classIs) <- classIs$gene_id 
 
# Load counts 
filename <- "counts.txt" 
counts <- read.delim(filename, comment="#") 
row.names(counts) <- counts$Geneid 
features <- data.frame(length=counts$Length, x=1, row.names=counts$Geneid) 
counts <- counts[,seq(-1, -6)] 
 
# Combine technical replicates 
counts <- counts[, seq(1, 20, by=2)] + counts[, seq(2, 20, by=2)] 
 
# Load sample names 
targets <- read.delim("targets.txt") 
targets <- targets[seq(1, 20, by=2), ] 
rownames(targets) <- targets$filename 
colnames(counts) <- targets[colnames(counts),]$sample.name 
rownames(targets) <- targets$sample.name 
 
# Library sizes 
par(mfrow=c(2,1), las=2, mai=c(0.3, 1.5, 1.0, 1)) 
barplot(colSums(im.counts), ylab= "Total Read Counts", ylim=c(0, 40000000), mgp=c(4,0.5,0), 
main="Barplot of library sizes") 
 
# Filter & normalisation 
dge <- DGEList(counts=im.counts) 
isexpr <- rowSums(dge$counts) > 20 
dge <- dge[isexpr, , keep.lib.size=FALSE] 
index <- rownames(dge$counts) 
features <- features[index,] 
dge <- calcNormFactors(dge) 
 
#MDS Plot 
par(mfrow=c(2,1), mai=c(0.4,2.2,0.4,2.2)) 
plotMDS(dge, xlim=c(-4, 4), labels=c('UT.1', 'UT.2', 'IM.1', 'IM.2'), ylim=c(-4, 4), 
ylab='Dimension 2', cex=0.7) 
mtext(text='Dimension 1', side=1, line=3, cex=1, las=1) 
mtext(text='Treatment', side=3, line=0.5, cex=1, las=1) 
 
#Normalisation 
exp.set <- newSeqExpressionSet(counts=dge$counts, featureData=features) 
 
XV 
within.set <- betweenLaneNormalization(exp.set, which="upper", offset=TRUE) 
 
#Comparison of unnormalised and normalised data 
par(mfrow=c(2,2), mai=c(0.2,0.7,0.2,0.7)) 
plotRLE(exp.set, outline=FALSE, las=2, ylim=c(-1.7, 1.7), col='light grey', main='Unnormalised 
data', ylab='Relative Log Expression') 
plotRLE(within.set, outline=FALSE, las=2, ylim=c(-1.7, 1.7), col='light grey', main='Normalised 
data',  ylab='Relative Log Expression') 
 
# design = model.matrix(~ 0+line+treatment, data=targets) 
design <- model.matrix(~ 0+factor(c(1,1,2,2))) 
colnames(design) <- c("G1", "G2") 
 
design2 <- contrastAsCoef(design,  
                          cbind( 
                            c(-1,1) 
                          ))$design 
 
par(mfrow=c(2,2)) 
v <- voom(counts(within.set), design2, plot=TRUE) 
mtext(text='log2(count size + 0.5)', side=1, line=3, cex=0.8, las=1) 
fit <- lmFit(v, design2) 
fit <- eBayes(fit) 
plotSA(fit) 
title(main="Final model: Mean-variance trend") 
mtext(text='Average log-expression', side=1, line=3, cex=0.8, las=1) 
 
 
tt1 <- topTreat(fit, number=Inf, coef=1) 
 
 
# Output RPKM 
index <- rownames(features) 
norm.counts <- within.set@assayData$normalizedCounts[index,] 
rpkm2 <- rpkm(norm.counts, gene.length=features$length) 
              
            output <- data.frame(gene_id=index, 
                                 symbol=gene.symbols[index,]$symbol, 
                                 FDR=tt1[index,]$adj.P.Val, 
                                 logFC=tt1[index,]$logFC, 
                                 log2.rpkm=log2(0.1+rpkm2),  
                                 counts=counts[index,] 
             ) 
              
             classI.index = subset(index, index %in% rownames(classIs)) 
             output$symbol = as.character(output$symbol)  
             output[classI.index,]$symbol = classIs[classI.index,]$symbol 
              
           
             write.table(output, "output.txt", append=TRUE, sep="\t",quote=FALSE, 
row.names=FALSE) 
       
 
# Volcano plot, GO analysis and heat maps 
 
library(gplots) 
library(org.Hs.eg.db) 
library(RColorBrewer) 
 
#volcano plot 
data <- read.table("output.txt", header=TRUE) 
data.plot <- data[,-c(1:2, 5:12)] 
data.plot$FDR <- -log10(data.plot$FDR) 
significant <- data.plot[which(data.plot$C1.FDR > (-log10(0.05)) & (data.plot$C1.logFC > 1 | 
data.plot$C1.logFC < -1)),] 
sum(data.plot$C1.FDR > (-log10(0.05)) & (data.plot$C1.logFC > 1)) 
sum(data.plot$C1.FDR > (-log10(0.05)) & (data.plot$C1.logFC < -1)) 
significant <- significant[,c(2,1)] 
plot(data.plot$C1.logFC, data.plot$C1.FDR, xlab=expression("log"[2]*"(fold-change)"), 
ylab=expression("-log"[10]*"(FDR)"),cex=0.4, pch=16) 
points(significant, col="royalblue4", cex=0.4, pch=16) 
abline(h=-log10(0.05), v=(c(1, -1)), lty=5) 
 
#Remove genes with no symbol  
Valid.Genes <- subset(data, substr(data$symbol, 1, 7) !="ENSSHAG" ) 
 
#Map Entrez IDs 
 
XVI 
Valid.Genes$symbol <- as.character(Valid.Genes$symbol) 
Enz.IDs <- as.vector(0) 
for(i in 1:length(Valid.Genes$symbol)) 
{ 
  try({ 
        Enz.IDs[i] <- unlist(mget(Valid.Genes$symbol[i], envir=org.Hs.egALIAS2EG)) 
    })   
} 
 
Data.Entrez <- cbind(Valid.Genes, Enz.IDs) 
Data.Entrez.unique <- Data.Entrez[!duplicated(Data.Entrez$symbol),] 
 
#Goana 
up.reg <- Data.Entrez.unique[which(Data.Entrez.unique$C1.FDR<0.001 & 
Data.Entrez.unique$C1.logFC>1),] 
down.reg <- Data.Entrez.unique[which(Data.Entrez.unique$C1.FDR<0.001 & 
Data.Entrez.unique$C1.logFC< -1),] 
up.reg.sorted <- up.reg[sort(up.reg$C1.logFC, decreasing = TRUE, index.return = TRUE)$ix,] 
down.reg.sorted <- down.reg[sort(down.reg$C1.logFC, decreasing = FALSE, index.return = 
TRUE)$ix,] 
goana.up = goana(de = as.character(up.reg.sorted$Enz.IDs)) 
goana.down = goana(de = as.character(down.reg.sorted$Enz.IDs)) 
goana.up.ord = goana.up[with(goana.up,order(P.DE)),] 
goana.up.ord.filt <- subset(goana.up.ord, goana.up.ord$P.DE <= 0.05) 
goana.up.ord.filt2 <- subset(goana.up.ord.filt, goana.up.ord.filt$N <= 200) 
goana.down.ord = goana.down[with(goana.down,order(P.DE)),] 
goana.down.ord.filt <- subset(goana.down.ord, goana.down.ord$P.DE <= 0.05) 
goana.down.ord.filt2 <- subset(goana.down.ord.filt, goana.down.ord.filt$N <= 200) 
 
#Heat map 
data <- read.table("genes.txt", header=TRUE, as.is=TRUE) 
rownames(data) <- data$GENE 
data <- data[,-1] 
data.numerical <- matrix(data=NA, nrow=dim(data)[1], ncol=dim(data)[2]) 
rownames(data.numerical) <- rownames(data) 
colnames(data.numerical) <- colnames(data) 
 
for (i in 1:dim(data)[2]) { 
  data.numerical[,i] <- c(as.numeric(data[[i]])) 
} 
 
colors <- c(seq(-3,3.99,length=25),seq(4,5,length=10),seq(5.01,10,length=25)) 
palette <- colorRampPalette(c("blue3", "aliceblue", "red"))(n=59) 
heatmap.2(data.numerical, rowsep=1:31, breaks=colors, colsep=1:3, lwid=c(0.07,0.3), 
lhei=c(0.04, 0.4), cexCol=0.8, cexRow=0.8, density.info = "none", sepwidth=c(0.025,0.05), 
trace="none", symbreaks= FALSE, symkey=FALSE, hclust=function(x) hclust(x,method="complete"), 
col=palette) 
  
 
XVII 
Appendix 3-3. Data normalisation and quality control 
1. Bar-plot of read count library sizes of each sequenced sample  
2. MDS plot demonstrating mRNA expression variation between each sample 
3. Box and whiskers plots demonstrating mean mRNA expression levels before and after 
normalisation 
4. Mean variance trend in expression data before and after transformation by voom 
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Appendix 3-4. Normalised read counts and differential expression 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis.  
 
Appendix 3-5. Complete GO analysis of genes up and down-regulated greater than 2-fold 
by imiquimod  
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis.  
 
Appendix 3-6. Complete list of IPA canonical pathways associated with imiquimod 
treatment 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis.  
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XIX 
Appendix 4. DFTD proteomic MS raw data and analysis 
Appendix 4-1. Proteomic MS peptide and protein group counts and intensities 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis.  
 
Appendix 4-2. Proteomic data set after filtering, imputation of missing values, calculation 
of differential expression and calculation of FDR  
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis.  
 
Appendix 4-3. R script used to create volcano plot of proteomic expression data 
#volcano plot 
data.prot <- read.table("proteome.txt", header=TRUE) 
significant.prot <- data.prot[which(data.prot$logpvalue > (-log10(0.05)) & (data.prot$Diff > 
0.584963 | data.prot$Diff < -0.584963)),] 
sum(data.prot$logpvalue > (-log10(0.05)) & (data.prot$Diff > 0.584963)) 
sum(data.prot$logpvalue > (-log10(0.05)) & (data.prot$Diff < -0.584963)) 
significant.prot <- significant.prot[,c(2,1)] 
plot(data.prot$Diff, data.prot$logpvalue, xlab=expression("log"[2]*"(fold-change)"), 
ylab=expression("-log"[10]*"(FDR)"),cex=0.4, pch=16) 
points(significant.prot, col="royalblue4", cex=0.4, pch=16) 
abline(h=-log10(0.05), v=(c(0.584963, -0.584963)), lty=5) 
 
 
 
 
 
Appendix 4-4. Complete DAVID functional annotation clustering analysis of proteins up 
and down-regulated greater than 1.5-fold by imiquimod 
This data is available in Microsoft Excel 2011 format as a supplementary electronic file to this 
thesis. 
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Page XXI 
Toll-like receptor signalling is functional in immune cells of the endangered Tasmanian devil. 
Developmental and Comparative Immunology, vol. 53, no. 1, pp. 123-133. 
 
Page XXXII 
The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial 
Tumour Cell Lines. PLoS One, vol. 11, no. 12, p. e0168068. 
 
Page XLIX 
The toll-like receptor ligands Hiltonol and imiquimod effectively activate antigen-specific 
immune responses in Tasmanian devils (Sarcophilus harrisii). Developmental and 
Comparative Immunology, vol. 76, pp. 352-360. 
 
Page LVIII 
Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial 
Tumour Disease in the Majority of Tasmanian Devils Destined for Wild Release, Frontiers in 
Immunology, vol. 9, no. 259, https://doi.org/10.3389/fimmu.2018.00259. 
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